Tokushima University / Educator and Researcher Directory --- Matsuhisa, Munehide

Field of Study

○	Diabetology

Subject of Study

○	糖の流れの調節因子の解明

Book / Paper

Book:

1.	Munehide Matsuhisa : 糖尿病のある方へ口腔の健康を保つためのご提案, Mar. 2024.
2.	Munehide Matsuhisa : 重症副作用疾患別対応マニュアル低血糖, Ministry of Health, Labour and Welfare, 2023.
3.	Munehide Matsuhisa and Akio Kuroda : 糖尿病専門医研修ガイドブック, 診断と治療者, Aug. 2023.
4.	Munehide Matsuhisa and Akio Kuroda : 内分泌代謝・糖尿病内科領域専門医研修ガイドブック, 診断と治療者, May 2023.
5.	Akio Kuroda and Munehide Matsuhisa : ライフキャリアから診る1型糖尿病, 株式会社中外医学社, Tokyo, May 2023.
6.	Munehide Matsuhisa : ORGON必携内科医のための臓器移植診療ハンドブックTRANSPLANT(各論執筆者:膵臓・膵島移植), ぱーそん書房, Mar. 2023.
7.	Munehide Matsuhisa : 高齢者肥満の特徴と治療, メディカルビュー社, 2022.
8.	Munehide Matsuhisa : 肥満症診療ガイドライン2022, ライフサイエンス出版株式会社(肥満学会編集), Dec. 2022.
9.	Akio Kuroda and Munehide Matsuhisa : ガイドラインにないリアル糖尿病薬物療法をガイドする坂根直樹編, 新興医学出版社, Tokyo, Nov. 2022.
10.	Munehide Matsuhisa : COVID-19での糖尿病診療, 株式会社振興医学出版社, Nov. 2022.
11.	Munehide Matsuhisa : 糖尿病治療の関連する低血糖の疫学―重症低血糖を中心にー特集:低血糖, 科学評論社, Apr. 2022.
12.	Munehide Matsuhisa : 内科総合誌M.P.マイナーエマージェンシー外来診療・一人当直に強くなる!いざというときの対処法 2022臨時増刊号, 文光堂, Tokyo, Apr. 2022.
13.	Munehide Matsuhisa : 包括的治療のポイント, 文光堂, 2021.
14.	Munehide Matsuhisa : TODAYS THERAPY, IGAKU-SHOIN Ltd.Tokyo,Japan, 2021.
15.	Munehide Matsuhisa : 糖尿病患者の手術, Nankodo, Nov. 2021.
16.	Munehide Matsuhisa : 低血糖, 総合医学社, Sep. 2021.
17.	Munehide Matsuhisa : GLP-1RAの副作用と使用上の注意点は?, Nankodo, Sep. 2021.
18.	Munehide Matsuhisa : 低血糖のときに糖尿病患者の体で起こっていること, MCメディカ出版, Jan. 2021.
19.	Akio Kuroda and Munehide Matsuhisa : 追加インスリン注入法の決定法, Nankodo, 2020.
20.	Munehide Matsuhisa : 日本糖尿病学会専門医取得のための研修必携ガイド, 株式会社診断と治療社, Nov. 2020.
21.	Akio Kuroda and Munehide Matsuhisa : 高齢発症の1型糖尿病患者, MCメディカ出版, Sep. 2020.
22.	Munehide Matsuhisa : 序, Medical Review Co.,Ltd, 2017.
23.	Munehide Matsuhisa : クローズドループ型人工膵臓による血糖自動制御, Feb. 2017.
24.	Munehide Matsuhisa : 低血糖, Jan. 2017.
25.	Munehide Matsuhisa : 注射薬の種類を間違えた?, Nankodo, 2016.
26.	Munehide Matsuhisa : 注射部位にしこり?, Dec. 2016.
27.	Munehide Matsuhisa : 低血糖時の対処法, Oct. 2016.
28.	Munehide Matsuhisa : Q74インスリン製剤のエビデンスを教えてください, May 2016.
29.	Munehide Matsuhisa : 1，5アンヒドロ-D-グルシトール, May 2016.
30.	Munehide Matsuhisa : グルコース, May 2016.
31.	Munehide Matsuhisa : 糖尿病治療の最前線:Q低血糖を起こさないようにするSU薬，インスリンの使い方の工夫を教えてください, 文光堂, Mar. 2016.
32.	Munehide Matsuhisa : インスリンとインクレチンって何?∼糖尿病にまつわるホルモン∼, MCメディカ出版, Mar. 2016.
33.	Munehide Matsuhisa : Q50 ビグアナイド薬の高用量処方のコツを教えてください, Nankodo, Oct. 2015.
34.	Munehide Matsuhisa : Q49 ビグアナイド薬の標準的な処方例について教えてください, Nankodo, Oct. 2015.
35.	Akio Kuroda and Munehide Matsuhisa : インスリンポンプ療法の適応と用量調節方法, Nakayama-Shoten Co., Ltd., May 2015.
36.	Munehide Matsuhisa : 精神疾患(うつ病など), Nakayama-Shoten Co., Ltd., May 2015.
37.	Akio Kuroda and Munehide Matsuhisa : インスリンポンプ療法の心構え, Ishiyaku Publishers,Inc., May 2015.
38.	Munehide Matsuhisa : 糖尿病について知ってほしいこと, Ishiyaku Publishers,Inc., May 2015.
39.	Munehide Matsuhisa : 膵臓移植・膵島移植, Iyaku Journal Co., Ltd., Mar. 2015.
40.	Akio Kuroda and Munehide Matsuhisa : 糖代謝異常妊娠の管理:食事療法, KINPODO, INC., 2014.
41.	Akio Kuroda and Munehide Matsuhisa : 補正インスリン注入量の決定法, Jun. 2014.
42.	Akio Kuroda and Munehide Matsuhisa : 追加インスリン注入量の決定法, Nankodo, Jun. 2014.
43.	Motoyuki Tamaki and Munehide Matsuhisa : 糖尿病, May 2014.
44.	Munehide Matsuhisa : 代謝疾患とは, May 2014.
45.	Motoyuki Tamaki and Munehide Matsuhisa : 脂質異常症と高血圧には関連があるのでしょうか?, Mar. 2014.
46.	Munehide Matsuhisa : 泌尿器科, Mar. 2014.
47.	Akio Kuroda and Munehide Matsuhisa : 強化インスリン療法中の患者における1型糖尿病と2型糖尿病の違いとは, Jan. 2014.
48.	Akio Kuroda and Munehide Matsuhisa : 強化インスリン療法中の患者に対して応用カーボカウントを教える, Jan. 2014.
49.	Akio Kuroda and Munehide Matsuhisa : カーボカウントの基礎∼血糖応答から食品を考える視点を持つ∼, Jan. 2014.
50.	Munehide Matsuhisa : 1,5アンヒドログルシトール, 株式会社診断と治療社, 2014.
51.	Akio Kuroda and Munehide Matsuhisa : インスリンポンプ療法における食事療法, Nankodo, 2014.
52.	Munehide Matsuhisa : 糖尿病の病態生理, Iyaku Journal Co., Ltd., 2014.
53.	Munehide Matsuhisa : GLP-1 タキフィラシーとは?, 株式会社中外医学社, May 2013.
54.	Munehide Matsuhisa : 糖尿病昏睡 diabetic coma, Nankodo, Mar. 2013.
55.	Akio Kuroda and Munehide Matsuhisa : 移植医療ー膵臓移植・膵島移植, Nakayama-Shoten Co., Ltd., 2012.
56.	Munehide Matsuhisa : 療養指導士の育成と今後の課題糖尿病地域医療連携ー絆の紡ぎ方実相ガイド, 医歯薬出版株式会社, Sep. 2012.
57.	Munehide Matsuhisa : 脳梗塞:チャートで学ぶ糖尿病と合併症, Medicus SHUPPAN, Sep. 2012.
58.	Munehide Matsuhisa : 糖尿病治療の新しい展開ーインクレチン関連薬ー, 医学図書出版, Apr. 2012.
59.	伊藤壽記, Munehide Matsuhisa, Akio Kuroda and 宮下和幸 : 膵臓移植の血糖管理, 医学図書出版, 2012.
60.	Munehide Matsuhisa : 最新インスリン療法, Nakayama-Shoten Co., Ltd., 2011.
61.	Munehide Matsuhisa : どの経口血糖降下薬を使うか, Nankodo, Oct. 2011.
62.	Munehide Matsuhisa : その他の合併症(高血圧，糖尿病，脂質異常症等), シュプリンガー・ジャパン株式会社, May 2011.
63.	Munehide Matsuhisa : インスリン製剤2011, 有限会社フジメディカル出版, May 2011.
64.	Akio Kuroda and Munehide Matsuhisa : 糖尿病臨床のすべて, Nakayama-Shoten Co., Ltd., 2011.
65.	Munehide Matsuhisa : 基礎知識すいすい見直しドリル100, Sep. 2010.

Academic Paper (Judged Full Paper):

1.	Tomoyo Hara, Takeshi Watanabe, Hiroki Yamagami, Kosuke Miyataka, Saya Yasui, Takahito Asai, Yohsuke Kaneko, Yukari Mitsui, Shiho Masuda, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Soichi Honda, Akira Kondo, Munehide Matsuhisa and Ken-ichi Aihara : Development of Liver Fibrosis Represented by the Fibrosis-4 Index Is a Specific Risk Factor for Tubular Injury in Individuals with Type 2 Diabetes, Biomedicines, Vol.12, No.8, 1789, 2024. (Summary) Although hyperglycemia and hypertension are well-known risk factors for glomerular injury in individuals with type 2 diabetes (T2D), specific risk factors for tubular injury remain unclear. We aimed to clarify the differences between risk factors for glomerular injury and risk factors for tubular injury in individuals with T2D. We categorized 1243 subjects into four groups based on urinary biomarkers, including the albumin-to-creatinine ratio (uACR) and L-type fatty acid-binding protein-to-creatinine ratio (uL-ABPCR) as a normal (N) group (uACR < 30 mg/gCr and uL-FABPCR < 5 μg/gCr; n = 637), a glomerular specific injury (G) group (uACR ≥ 30 mg/gCr and uL-FABPCR < 5 μg/gCr; n = 248), a tubular specific injury (T) group (uACR < 30 mg/gCr and uL-FABPCR ≥ 5 μg/gCr; n = 90), and a dual injury (D) group (uACR ≥ 30 mg/gCr and uL-FABPCR ≥ 5 μg/gCr; n = 268). Logistic regression analysis referencing the N group revealed that BMI, current smoking, and hypertension were risk factors for the G group, creatinine (Cr) and Fibrosis-4 (FIB-4) index were risk factors for the T group, and BMI, hypertension, HbA1c, Cr, and duration of diabetes were risk factors for the D group. While hypertension was a distinct specific risk factor for glomerular injury, the FIB-4 index was a specific contributor to the prevalence of tubular injury. On the other hand, the logistic regression analysis revealed that the hepatic steatosis index (HSI) did not show any significant association with the G group, T group, or D group. Taken together, the development of liver fibrosis rather than liver steatosis is an inherent threat relating to tubular injury in individuals with T2D. (Link to Publication Site) ● Publication site (DOI): 10.3390/biomedicines12081789 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39200252 ● Summary page in Scopus @ Elsevier: 2-s2.0-85202596205 (DOI: 10.3390/biomedicines12081789, PubMed: 39200252, Elsevier: Scopus)
2.	Elizabeth Seaquist, Marga Giménez, Yu Yan, Munehide Matsuhisa, Yuting Christi Kao, Paul R Wadwa, Yukiko Nagai and Kamlesh Khunti : Nasal Glucagon Reverses Insulin-induced Hypoglycemia With Less Rebound Hyperglycemia: Pooled Analysis of Clinical Trials., Journal of the Endocrine Society, Vol.8, No.4, bvae034, 2024. (Summary) NCT03421379, NCT03339453, NCT01994746. (Link to Publication Site) ● Publication site (DOI): 10.1210/jendso/bvae034 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38444629 ● Search Scopus @ Elsevier (PMID): 38444629 ● Search Scopus @ Elsevier (DOI): 10.1210/jendso/bvae034 (DOI: 10.1210/jendso/bvae034, PubMed: 38444629)
3.	Minae Hosoki, HORI Taiki, KANEKO Yohsuke, Kensuke Mori, Saya Yasui, Seijiro Tsuji, Hiroki Yamagami, Saki Kawata, Tomoyo Hara, Shiho Masuda, Yukari Mitsui, Kiyoe Kurahashi, Takeshi Harada, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : Causes of In-Hospital Death and Pharmaceutical Associations with Age of Death during a 10-Year Period (2011-2020) in Individuals with and without Diabetes at a Japanese Community General Hospital., Journal of Clinical Medicine, Vol.13, No.5, 1283, 2024. (Summary) Since diabetes and its complications have been thought to exaggerate cardiorenal disease, resulting in a short lifespan, we investigated causes of death and lifespans in individuals with and without diabetes at a Japanese community general hospital during the period from 2011 to 2020. Causes of death and age of death in individuals with and those without diabetes were compared, and associations between medications used and age of death were statistically analyzed. A total of 2326 deaths were recorded during the 10-year period. There was no significant difference between the mean ages of death in individuals with and those without diabetes. Diabetic individuals had higher rates of hepato-pancreatic cancer and cardio-renal failure as causes of death. The prescription rates of antihypertensives, antiplatelets, and statins in diabetic individuals were larger than those in non-diabetic individuals. Furthermore, the use of sulfonyl urea or glinides and insulin was independently and inversely associated with the age of death. In conclusion, individuals with diabetes were treated with comprehensive pharmaceutical interventions and had life spans comparable to those of individuals without diabetes. This study's discovery of an inverse relationship between the use of insulin secretagogues or insulin and the age of death suggests that the prevention of life-threatening hypoglycemia is crucial for individuals with diabetes. (Tokushima University Institutional Repository) ● Metadata: 119252 (Link to Publication Site) ● Publication site (DOI): 10.3390/jcm13051283 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38592103 ● Search Scopus @ Elsevier (PMID): 38592103 ● Search Scopus @ Elsevier (DOI): 10.3390/jcm13051283 (Tokushima University Institutional Repository: 119252, DOI: 10.3390/jcm13051283, PubMed: 38592103)
4.	Daisuke Yabe, Munehide Matsuhisa, Yoko Takahashi, Yukiko Morimoto and Yasuo Terauchi : Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan., Diabetes Therapy, Vol.15, No.3, 705-723, 2024. (Summary) The real-world SPARTA Japan study confirmed the effectiveness and safety of the fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) once daily over 6 months in Japanese people with type 2 diabetes (T2D). This post hoc analysis examined the impact of participant characteristics on the achievement of age-defined glycaemic targets with iGlarLixi therapy. The retrospective, observational SPARTA Japan study included adults with T2D who initiated iGlarLixi. In this analysis, data from insulin-naïve and insulin-experienced participants were separately assessed to compare glycated haemoglobin (HbA1c), body weight and safety outcomes between those who achieved ('achieved' group) and those who did not achieve ('not-achieved' group) age-defined glycaemic targets after 6 months of iGlarLixi. The not-achieved group was further stratified by whether or not their iGlarLixi dose was increased during treatment. In total, 418 participants were included in this analysis (138 insulin naïve and 280 insulin experienced). Among both insulin-naïve and insulin-experienced participants, those in the achieved group were older and had lower baseline HbA1c than those in the not-achieved group. Compared with the not-achieved group, the achieved group showed significantly greater HbA1c reductions from baseline (in both insulin-naïve and insulin-experienced participants) and significantly greater body weight reductions (in insulin-naïve participants), despite some participants in the not-achieved group receiving significantly higher insulin glargine doses than those in the achieved group. In both insulin-naïve and insulin-experienced participants, the incidence of hypoglycaemia and gastrointestinal-related adverse events was similar in the achieved and not-achieved groups. In a multivariate analysis, glycaemic target achievement was significantly more likely in older individuals and those who lost weight during iGlarLixi treatment. Achievement of age-defined glycaemic targets with iGlarLixi treatment for 6 months was significantly affected by increased age and body weight loss, regardless of prior insulin exposure. UMIN-CTR Trials Registry, UMIN000044126; registered 10 May 2021. (Link to Publication Site) ● Publication site (DOI): 10.1007/s13300-024-01531-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38363541 ● Search Scopus @ Elsevier (PMID): 38363541 ● Search Scopus @ Elsevier (DOI): 10.1007/s13300-024-01531-8 (DOI: 10.1007/s13300-024-01531-8, PubMed: 38363541)
5.	Hiroyasu Mori, Satoshi Taniguchi, Yuu Tamaki, Motoyuki Tamaki, Yuko Akehi, Akio Kuroda and Munehide Matsuhisa : Telenutrition Education Is Effective for Glycemic Management in People with Type 2 Diabetes Mellitus: A Non-Inferiority Randomized Controlled Trial in Japan, Nutrients, Vol.16, No.2, 268, 2024. (Summary) This study examined the non-inferior efficacy of telenutrition education compared with face-to-face nutrition education in managing glycemic control in people with type 2 diabetes mellitus (T2DM). Participants had T2DM and a glycated hemoglobin (HbA1c) ranged 6.5-9.5%. Thirty participants were randomly assigned to either the telenutrition or face-to-face nutrition education group. During the 32-week intervention period, the participants received four sessions on nutrition education from a registered dietitian at the hospital. The telenutrition group received remote education via a videoconferencing platform. Face-to-face nutrition education was conducted using paper-based instructions. The main outcome measure was the non-inferiority of HbA1c levels in the telenutrition group compared to the face-to-face nutrition group. The non-inferiority of telenutrition education was considered valid if the intergroup difference in the mean values of the change in HbA1c had a bilateral 95% confidence interval (CI) upper limit below 0.40%. The intergroup difference in the mean HbA1c change from baseline to the fourth nutrition education session was -0.11 (95% CI -0.54-0.32) for both groups. The upper limit of the bilateral 95% CI was 0.32%, which was below the 0.40% non-inferiority margin (non-inferiority test; = 0.011). Telenutrition education was not inferior to face-to-face nutrition education for glycemic management in people with T2DM. (Keyword) Humans / Diabetes Mellitus, Type 2 / Educational Status / Glycated Hemoglobin / Health Education / Japan (Tokushima University Institutional Repository) ● Metadata: 119489 (Link to Publication Site) ● Publication site (DOI): 10.3390/nu16020268 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38257162 ● Search Scopus @ Elsevier (PMID): 38257162 ● Search Scopus @ Elsevier (DOI): 10.3390/nu16020268 (Tokushima University Institutional Repository: 119489, DOI: 10.3390/nu16020268, PubMed: 38257162)
6.	Rimei Nishimura, Akira Shimada, Norio Abiru, Munehide Matsuhisa, Yoko Takahashi and Hiroshi Ikegami : Association between glycemic control and patient-reported outcomes in adults with type 1 diabetes in Japan: the SAGE study subanalysis., Diabetology International, Vol.15, No.2, 212-222, 2023. (Summary) The online version contains supplementary material available at 10.1007/s13340-023-00668-4. (Link to Publication Site) ● Publication site (DOI): 10.1007/s13340-023-00668-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38524926 ● CiNii @ National Institute of Informatics (CRID): 1520018677364072576 ● Search Scopus @ Elsevier (PMID): 38524926 ● Search Scopus @ Elsevier (DOI): 10.1007/s13340-023-00668-4 (DOI: 10.1007/s13340-023-00668-4, PubMed: 38524926, CiNii: 1520018677364072576)
7.	Hiroki Yamagami, Tomoyo Hara, Saya Yasui, Minae Hosoki, Taiki Hori, Yousuke Kaneko, Yukari Mitsui, Kiyoe Kurahashi, Takeshi Harada, Sumiko Yoshida, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Cross-Sectional and Longitudinal Associations between Skin Autofluorescence and Tubular Injury Defined by Urinary Excretion of Liver-Type Fatty Acid-Binding Protein in People with Type 2 Diabetes., Biomedicines, Vol.11, No.11, 3020, 2023. (Summary) = 0.026). In conclusion, SAF is positively correlated with uL-FABP but not with uACR in people with T2D. Thus, there is a possibility that SAF can serve as a novel predictor for the development of diabetic tubular injury. (Keyword) skin autofluorescence / type 2 diabetes / diabetic kidney disease / albuminuria / tubular injury / L-FABP (Tokushima University Institutional Repository) ● Metadata: 119108 (Link to Publication Site) ● Publication site (DOI): 10.3390/biomedicines11113020 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38002020 ● CiNii @ National Institute of Informatics (CRID): 1050581224891895040 ● Summary page in Scopus @ Elsevier: 2-s2.0-85178346619 (Tokushima University Institutional Repository: 119108, DOI: 10.3390/biomedicines11113020, PubMed: 38002020, CiNii: 1050581224891895040, Elsevier: Scopus)
8.	Saya Yasui, Yousuke Kaneko, Hiroki Yamagami, Minae Hosoki, Taiki Hori, Akihiro Tani, Tomoyo Hara, Kiyoe Kurahashi, Takeshi Harada, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Hiroyasu Mori, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Takeshi Soeki and Ken-ichi Aihara : Dehydroepiandrosterone Sulfate, an Adrenal Androgen, Is Inversely Associated with Prevalence of Dynapenia in Male Individuals with Type 2 Diabetes., Metabolites, Vol.13, No.11, 1129, 2023. (Summary) Dehydroepiandrosterone sulfate (DHEAS) is thought to be associated with life expectancy and anti-aging. Although skeletal muscle disorders are often found in diabetic people, the clinical significance of DHEAS in skeletal muscle remains unclear. Therefore, we aimed to determine whether DHEAS is associated with the development of skeletal muscle disorders in individuals with type 2 diabetes (T2D). A cross-sectional study was conducted in 361 individuals with T2D. Serum DHEAS levels, skeletal muscle mass index (SMI), handgrip strength (HS), and gait speed (GS) were measured in the participants. Pre-sarcopenia, sarcopenia, and dynapenia were defined according to the definitions of the AWGS 2019 criteria. DHEAS level was positively associated with HS but not with SMI or GS after adjustment of confounding factors. Multiple logistic regression analyses in total subjects showed that DHEAS level had an inverse association with the prevalence of dynapenia but not with the prevalence of pre-sarcopenia or sarcopenia. Furthermore, a significant association between DHEAS level and dynapenia was found in males but not in females. ROC curve analysis indicated that cutoff values of serum DHEAS for risk of dynapenia in males was 92.0 μg/dL. Therefore, in male individuals with T2D who have low serum levels of DHEAS, adequate exercise might be needed to prevent dynapenia. (Tokushima University Institutional Repository) ● Metadata: 119107 (Link to Publication Site) ● Publication site (DOI): 10.3390/metabo13111129 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37999225 ● CiNii @ National Institute of Informatics (CRID): 1050862699868605952 ● Summary page in Scopus @ Elsevier: 2-s2.0-85178271509 (Tokushima University Institutional Repository: 119107, DOI: 10.3390/metabo13111129, PubMed: 37999225, CiNii: 1050862699868605952, Elsevier: Scopus)
9.	Toshiki Otoda, Akiko Sekine, Ryoko Uemoto, Seijiro Tsuji, Tomoyo Hara, Motoyuki Tamaki, Tomoyuki Yuasa, Toshiaki Tamaki, Munehide Matsuhisa and Ken-ichi Aihara : Albuminuria and Serum Tumor Necrosis Factor Receptor Levels in Patients with Type 2 Diabetes on SGLT2 Inhibitors: A Prospective Study., Diabetes Therapy, Vol.15, No.1, 127-143, 2023. (Summary) UMIN000031947. (Tokushima University Institutional Repository) ● Metadata: 119109 (Link to Publication Site) ● Publication site (DOI): 10.1007/s13300-023-01488-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37883001 ● CiNii @ National Institute of Informatics (CRID): 1050299749915184256 ● Summary page in Scopus @ Elsevier: 2-s2.0-85174952372 (Tokushima University Institutional Repository: 119109, DOI: 10.1007/s13300-023-01488-0, PubMed: 37883001, CiNii: 1050299749915184256, Elsevier: Scopus)
10.	Takafumi Masuda, Naoto Katakami, Hirotaka Watanabe, Naohiro Taya, Kazuyuki Miyashita, Mitsuyoshi Takahara, Ken Kato, Akio Kuroda, Munehide Matsuhisa and Iichiro Shimomura : Evaluation of changes in glycemic control and diabetic complications over time and factors associated with the progression of diabetic complications in Japanese patients with juvenile-onset type 1 diabetes mellitus., Journal of Diabetes, Vol.16, No.2, e13486, 2023. (Summary) In this retrospective observational study, glycemic control and albuminuria improved; however, renal function and arteriosclerosis worsened over time. HbA1c levels, glycemic excursion, and blood pressure are associated with nephropathy progression. HbA1c levels, glycemic excursion, lipid levels, and BMI are associated with the progression of atherosclerosis. (Keyword) Humans / Adolescent / Young Adult / Adult / Diabetes Mellitus, Type 1 / Glycated Hemoglobin / Diabetes Mellitus, Type 2 / Carotid Intima-Media Thickness / Ankle Brachial Index / Glycemic Control / Glycated Serum Albumin / Japan / Pulse Wave Analysis / Diabetes Complications / Cholesterol / Diabetic Nephropathies / Risk Factors (Link to Publication Site) ● Publication site (DOI): 10.1111/1753-0407.13486 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37853936 ● Search Scopus @ Elsevier (PMID): 37853936 ● Search Scopus @ Elsevier (DOI): 10.1111/1753-0407.13486 (DOI: 10.1111/1753-0407.13486, PubMed: 37853936)
11.	Hiroyasu Mori, 谷口諭, 玉木悠, 野村友美, 鈴木麗子, Akio Kuroda, 明比祐子, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, 白神敦久, 田蒔基行, 天満仁, 長島伸光, 比木武 and Munehide Matsuhisa : 2型糖尿病患者のPersonal Health Recordを用いたセルフモニタリングに自動支援メッセージが与える効果:探索的ランダム化比較試験, 日本糖尿病インフォマティクス学会誌, Vol.22, No.2, 7-18, 2023.
12.	Masao Toyoda, Takashi Murata, Yushi Hirota, Kiminori Hosoda, Ken Kato, Kunichi Kouyama, Ryuji Kouyama, Akio Kuroda, Yuka Matoba, Munehide Matsuhisa, Shu Meguro, Junnosuke Miura, Kunihiro Nishimura, Akira Shimada, Shota Suzuki, Atsuhito Tone and Naoki Sakane : Possible Relationship between the Deteriorated Accuracy of Intermittent-Scanning Continuous Glucose Monitoring Device and the Contact Dermatitis: Post-hoc analysis of the ISCHIA Study., The Tokai Journal of Experimental and Clinical Medicine, Vol.48, No.3, 83-90, 2023. (Summary) There was negative bias in the SG levels of isCGM compared to the BG levels. There is a possibility that the complication of the contact dermatitis during isCGM use may be related with deteriorated accuracy of the SG levels. (Keyword) Humans / Blood Glucose / Blood Glucose Self-Monitoring / Quality of Life / Glucose / Dermatitis, Contact (Tokushima University Institutional Repository) ● Metadata: 119488 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37635068 ● Search Scopus @ Elsevier (PMID): 37635068 (Tokushima University Institutional Repository: 119488, PubMed: 37635068)
13.	Marga Giménez, Kamlesh Khunti, Munehide Matsuhisa, Suresh Chenji, Kristen Syring and Yu Yan : Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia., Diabetes Therapy, Vol.14, No.11, 1757-1769, 2023. (Summary) Baqsimi, Gvoke and Zegalogue had comparable high proportions of treatment success in reversing insulin-induced hypoglycemia. Baqsimi achieved a lower mean maximum blood glucose value, which may have implications for the re-establishment of euglycemia. These findings may help support patients, caregivers and health care providers in their decision-making process when discussing various ready-to-use glucagon treatment options. (Link to Publication Site) ● Publication site (DOI): 10.1007/s13300-023-01466-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37707700 ● Search Scopus @ Elsevier (PMID): 37707700 ● Search Scopus @ Elsevier (DOI): 10.1007/s13300-023-01466-6 (DOI: 10.1007/s13300-023-01466-6, PubMed: 37707700)
14.	Takashi Murata, N Lise Lotte Husemoen, Satoko Nemoto and Munehide Matsuhisa : Safety and glycemic control with insulin degludec use in clinical practice: results from a 3-year Japanese post-marketing surveillance study., Diabetology International, Vol.15, No.1, 76-85, 2023. (Summary) The online version contains supplementary material available at 10.1007/s13340-023-00657-7. (Link to Publication Site) ● Publication site (DOI): 10.1007/s13340-023-00657-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38264229 ● Search Scopus @ Elsevier (PMID): 38264229 ● Search Scopus @ Elsevier (DOI): 10.1007/s13340-023-00657-7 (DOI: 10.1007/s13340-023-00657-7, PubMed: 38264229)
15.	Hiroyuki Yamasaki, Yoshiro Abe, Shunsuke Mima, Mayu Bando, Shinji Nagasaka, Yutaro Yamashita, Kazuhide Mineda, Akio Kuroda, Munehide Matsuhisa, Masahiro Takaiwa and Ichiro Hashimoto : Efect of joint limitation and balance control on gait changes in diabetic peripheral neuropathy, Diabetology International, Vol.14, 390-396, 2023. (Summary) This study analyzed the gait patterns of diabetic peripheral neuropathy (DPN) patients and changes in the center of mass sway to prevent the formation and recurrence of foot ulcers. Forty-two subjects were divided into the diabetes mellitus (DM), DPN, and diabetic foot ulcer (DFU) groups. We measured the range of motion (ROM) of the lower limb joints in the resting position and the center of mass sway in the standing position. Joint angles, ROM during walking, and distance factors were evaluated. In the DFU group, ROM limitation during walking was detected at the knee joint, and functional and ROM limitations were found at the ankle joint. The step length ratio and step width in the DFU group were significantly lower and higher than those in the DM group, respectively. The sway distances in the DFU group were greater than those in the DM and DPN groups. Functional joint limitations and gait changes due to the decreased ability to maintain the center of gravity were observed in the DFU group. As DPN progressed, the patients' gait became small, wide, and shuffled. Thus, supporting joint movement during walking may help reduce the incidence and recurrence of foot ulcers. The online version contains supplementary material available at 10.1007/s13340-023-00647-9. (Link to Publication Site) ● Publication site (DOI): 10.1007/s13340-023-00647-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37781462 ● Search Scopus @ Elsevier (PMID): 37781462 ● Search Scopus @ Elsevier (DOI): 10.1007/s13340-023-00647-9 (DOI: 10.1007/s13340-023-00647-9, PubMed: 37781462)
16.	Hiroyuki Yamasaki, Yoshiro Abe, Shunsuke Mima, Mayu Bando, Shinji Nagasaka, Yutaro Yamashita, Kazuhide Mineda, Akio Kuroda, Munehide Matsuhisa, Masahiro Takaiwa and Ichiro Hashimoto : Effect of joint limitation and balance control on gait changes in diabetic peripheral neuropathy., Diabetology International, Vol.14, No.4, 390-396, 2023. (Summary) The online version contains supplementary material available at 10.1007/s13340-023-00647-9. (Tokushima University Institutional Repository) ● Metadata: 118739 (Link to Publication Site) ● Publication site (DOI): 10.1007/s13340-023-00647-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37781462 ● Search Scopus @ Elsevier (PMID): 37781462 ● Search Scopus @ Elsevier (DOI): 10.1007/s13340-023-00647-9 (Tokushima University Institutional Repository: 118739, DOI: 10.1007/s13340-023-00647-9, PubMed: 37781462)
17.	Yuichi Saito, Atsushi Tanaka, Tomoko Ishizu, Hisako Yoshida, Yoshiaki Kubota, Mamoru Nanasato, Munehide Matsuhisa, Yusuke Ohya, Yoshio Kobayashi and Koichi Node : Factors associated with carotid intima-media thickness progression in patients with asymptomatic hyperuricemia: insights from the PRIZE study., Scientific Reports, Vol.13, No.1, 10927, 2023. (Summary) Hyperuricemia is reportedly associated with the progression of carotid intima-media thickness (IMT), a surrogate of cardiovascular risks and events. However, factors associated with carotid IMT progression in patients with asymptomatic hyperuricemia are largely unknown. In this post-hoc analysis of the multicenter, randomized PRIZE study, we analyzed data from a total of 326 patients who underwent carotid ultrasonography in a blind manner at baseline and 24 months to evaluate carotid IMT. Mean and maximum IMT at the common carotid artery (CCA) were measured at a central core laboratory. Factors related to the absolute change in mean and maximum IMT from baseline to 24 months were explored. Overall, the adjusted mean [0.0032 (- 0.0214 to 0.0278) mm] and maximum [0.0011 (- 0.0327 to 0.0351) mm] CCA-IMT increased numerically from baseline to 24 months. Multivariable analysis identified higher body mass index, history of atherosclerotic cardiovascular disease (ASCVD), and lower mean CCA-IMT at baseline as significant factors associated with the increase in mean CCA-IMT. In addition, older age and lower mean CCA-IMT at baseline were significant factors for an increased absolute change in the maximum CCA-IMT at 24 months. The present sub-analysis of the PRIZE study showed higher body mass index, history of ASCVD, and older age as significant factors associated with CCA-IMT progression in patients with asymptomatic hyperuricemia. These factors may be considered when identifying the possible risk of atherosclerotic progression in this specific patient population of hyperuricemia.Trial registration: UMIN000012911 and UMIN000041322. (Keyword) Humans / Carotid Intima-Media Thickness / Risk Factors / Hyperuricemia / Carotid Artery, Common / Atherosclerosis / Carotid Artery Diseases (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-023-37183-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37407666 ● Search Scopus @ Elsevier (PMID): 37407666 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-023-37183-0 (DOI: 10.1038/s41598-023-37183-0, PubMed: 37407666)
18.	Ryotaro Bouchi, Takehiro Sugiyama, Atsushi Goto, Mitsuru Ohsugi, Narihito Yoshioka, Hideki Katagiri, Tomoya Mita, Yushi Hirota, Hiroshi Ikegami, Munehide Matsuhisa, Eiichi Araki, Hiroki Yokoyama, Masae Minami, Katsuya Yamazaki, Hideaki Jinnouchi, Hiroki Ikeda, Hitomi Fujii, Miyuki Nogawa, Masahiro Kaneshige, Kengo Miyo and Kohjiro Ueki : Impact of COVID-19 pandemic on behavioral changes and glycemic control and a survey of telemedicine in patients with diabetes: A multicenter retrospective observational study., Journal of Diabetes Investigation, Vol.14, No.8, 994-1004, 2023. (Summary) Our data suggest that glycemic control did not deteriorate during the COVID-19 pandemic with appropriate intensification of diabetes treatment in patients with diabetes who continued to attend specialized diabetes care facilities, and that patients and physicians shared the same expectations and concerns about telemedicine. (Tokushima University Institutional Repository) ● Metadata: 118682 (Link to Publication Site) ● Publication site (DOI): 10.1111/jdi.14027 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37183588 ● CiNii @ National Institute of Informatics (CRID): 1050298201111287936 ● Summary page in Scopus @ Elsevier: 2-s2.0-85159195407 (Tokushima University Institutional Repository: 118682, DOI: 10.1111/jdi.14027, PubMed: 37183588, CiNii: 1050298201111287936, Elsevier: Scopus)
19.	Shiho Masuda, Tomoyo Hara, Hiroki Yamagami, Yukari Mitsui, Kiyoe Kurahashi, Sumiko Yoshida, Takeshi Harada, Toshiki Otoda, Tomoyuki Yuasa, Shingen Nakamura, Akio Kuroda, Itsuro Endo, Toshio Matsumoto, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Vascular Endothelial Function Is Associated with eGFR Slope in Female and Non-Smoking Male Individuals with Cardiovascular Risk Factors: A Pilot Study on the Predictive Value of FMD for Renal Prognosis., Journal of Atherosclerosis and Thrombosis, 2023. (Summary) In individuals with cardiovascular risk factors, evaluation of vascular endothelial function enables prediction of renal prognosis in females and non-smoking males. (Tokushima University Institutional Repository) ● Metadata: 118250 (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.63987 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37081616 ● Search Scopus @ Elsevier (PMID): 37081616 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.63987 (Tokushima University Institutional Repository: 118250, DOI: 10.5551/jat.63987, PubMed: 37081616)
20.	Taiki Hori, Shingen Nakamura, Hiroki Yamagami, Saya Yasui, Minae Hosoki, Tomoyo Hara, Yukari Mitsui, Shiho Masuda, Kiyoe Kurahashi, Sumiko Yoshida, Takeshi Harada, Akio Kuroda, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Phase angle and extracellular water-to-total body water ratio estimated by bioelectrical impedance analysis are associated with levels of hemoglobin and hematocrit in patients with diabetes., Heliyon, Vol.9, No.4, 2023. (Summary) PhA and ECW/TBW but not SMI were associated with levels of Hgb and Hct in patients with diabetes. Therefore, aberrant values of PhA and ECW/TBW suggest a risk of anemia in diabetic patients. (Tokushima University Institutional Repository) ● Metadata: 118251 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.heliyon.2023.e14724 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37057050 ● Search Scopus @ Elsevier (PMID): 37057050 ● Search Scopus @ Elsevier (DOI): 10.1016/j.heliyon.2023.e14724 (Tokushima University Institutional Repository: 118251, DOI: 10.1016/j.heliyon.2023.e14724, PubMed: 37057050)
21.	Hideaki Miyoshi, Munehide Matsuhisa, Daisuke Yabe, Yoko Takahashi, Yukiko Morimoto and Yasuo Terauchi : Use of iGlarLixi for the Management of Type2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study., Diabetes Therapy, Vol.14, No.4, 671-689, 2023. (Summary) UMIN-CTR Trials Registry, UMIN000044126; registered 10 May 2021. (Tokushima University Institutional Repository) ● Metadata: 118683 (Link to Publication Site) ● Publication site (DOI): 10.1007/s13300-023-01373-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36809494 ● Search Scopus @ Elsevier (PMID): 36809494 ● Search Scopus @ Elsevier (DOI): 10.1007/s13300-023-01373-w (Tokushima University Institutional Repository: 118683, DOI: 10.1007/s13300-023-01373-w, PubMed: 36809494)
22.	Ayuka Kawakami, Mika Bandou, Tomoe Takashi, Mizuki Sugiuchi, Mizusa Hyodo, Yuna Mishima, Masashi Kuroda, Hiroyasu Mori, Akio Kuroda, Hiromichi Yumoto, Munehide Matsuhisa, Hiroshi Sakaue and Rie Tsutsumi : Umami taste sensitivity is associated with food intake and oral environment in subjects with diabetes, The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 241-250, 2023. (Summary) Dysgeusia is a serious problem in patients with diabetes because it often leads to overeating, which is associated with disease progression. This study aimed to investigate the association between taste sensitivity, eating habits, and the oral environment. In this cross-sectional study of 75 subjects with diabetes, gustatory function was assessed using the whole-mouth method, and lingual taste receptor gene expression was measured by real-time PCR. Food intake was evaluated using a food frequency questionnaire based on food groups. The oral environment was assessed using xerostomia and periodontal comprehensive examination. In total, 45.3%, 28.0%, and 18.7% of subjects showed lower umami taste sensitivity, low sweet taste sensitivity, and low salt taste sensitivity, respectively. Lower umami sensitivity correlated with lower estimated glomerular filtration rate and higher energy-source food intake. Subjects with diabetes with higher plaque control record showed significantly higher T1R3 gene expression than those with lower plaque control record. Reduced umami taste sensitivity is associated with decreased renal function and high energy food intake in diabetes. Subjects with diabetes with higher plaque control record showed significantly higher T1R3 gene expression, suggesting that the oral environment affects taste gene expression. J. Med. Invest. 70 : 241-250, February, 2023. (Keyword) Humans / Taste / Cross-Sectional Studies / Taste Perception / Diabetes Mellitus / Eating (Tokushima University Institutional Repository) ● Metadata: 118208 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.241 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164729 ● Summary page in Scopus @ Elsevier: 2-s2.0-85158866092 (Tokushima University Institutional Repository: 118208, DOI: 10.2152/jmi.70.241, PubMed: 37164729, Elsevier: Scopus)
23.	Tomoharu Kawano, Motohiro Aiba, Masashi Ishizu, Hiroyasu Mori, Munehide Matsuhisa, Seiichi Hashida, Tracey Colpitts and Toshihiro Watanabe : Molecular composition of adiponectin in urine is a useful biomarker for detecting early stage of diabetic kidney disease., The Journal of Medical Investigation : JMI, Vol.70, No.3.4, 464-470, 2023. (Summary) We previously developed two immune complex transfer enzyme immunoassays (ICT-EIA) to measure total adiponectin (T-AN) and high molecular weight adiponectin (H-AN) in urine and have verified their usefulness as biomarkers for diabetic kidney disease. In this study, we developed T-AN and H-AN assays using the sandwich EIA (Sand-EIA). The reactivities of Sand-EIAs were compared with ICT-EIAs by measuring size exclusion chromatography (SEC) fractions of urine and adiponectin standard. As a result, ICT-EIAs showed higher macromolecular specificity. We then analyzed the molecular profile of adiponectin in the urine of 5 patients with different eGFR stages by measuring SEC fractions of urine. The results showed that smaller adiponectin correlated relatively well with eGFR stage. Finally, because SEC is time-consuming, we investigated that the ratio of T-ANs by Sand-EIA and ICT-EIA could be a good indicator of the monomer adiponectin. The ratio was evaluated using 77 urine samples from patients with diabetes and showed a significant decrease at an earlier stage compared with other biomarkers. In conclusion, we demonstrated a new index to estimate monomer adiponectin in urine by using Sand-EIA and ICT-EIA, and urinary monomer adiponectin can be a good early indicator of deterioration of renal function in diabetic patients. J. Med. Invest. 70 : 464-470, August, 2023. (Keyword) Humans / Diabetic Nephropathies / Adiponectin / Sensitivity and Specificity / Sand / Biomarkers / Diabetes Mellitus (Tokushima University Institutional Repository) ● Metadata: 118797 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.464 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37940533 ● Search Scopus @ Elsevier (PMID): 37940533 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.464 (Tokushima University Institutional Repository: 118797, DOI: 10.2152/jmi.70.464, PubMed: 37940533)
24.	Hiroyasu Mori, Yasunobu Tokuda, Eriko Yoshida, Kenji Uchida and Munehide Matsuhisa : Chronic Intake of a Meal Including Alaska Pollack Protein Increases Skeletal Muscle Mass and Strength in Healthy Older Women: A Double-Blind Randomized Controlled Trial, The Journal of Nutrition, Vol.152, No.12, 2761-2770, 2022. (Summary) In animal studies, a meal containing Alaska pollack protein (APP) induces fast-twitch muscle hypertrophy. To our knowledge, no interventional studies have examined the benefits of APP intake on muscle mass and muscle weakness and the prevention of sarcopenia in older individuals. We evaluated the effects of APP intake on skeletal muscle mass, muscle strength, and physical performance among healthy community-dwelling older Japanese women. In this double-blind randomized controlled trial, healthy women 65 y old were allocated to an APP or whey protein control (CON) group. Participants ingested test protein meals (5.0-5.1 g protein/serving) daily for 24 wk. Between-group differences in the change of skeletal muscle mass index (SMI) as the primary outcome and muscle strength as a secondary outcome were tested using multifrequency BIA and a handheld dynamometer, respectively, at baseline, and 4, 12, and 24 wk. The mean changes in the measured primary and secondary outcome variables from baseline to 4, 12, and 24 wk were compared using unpaired t tests. There were no between-group differences in nutritional status, food intake, or total energy and protein intakes at baseline, 12 wk, or 24 wk. The change in SMI was 0.12 kg/m2 (95% CI: 0.01, 0.23 kg/m2) and 0.11 kg/m2 (95% CI: 0.03, 0.19 kg/m2) greater in the APP group than in the CON group at 12 wk and 24 wk (P 0.03) and knee extension strength was 0.07 Nm/kg BW (95% CI: 0.02, 0.12 Nm/kg BW) and 0.05 Nm/kg BW (95% CI: 0.00, 0.09 Nm/kg BW) higher in the APP group than in the CON group at these times (P 0.015), respectively. The groups did not differ at 4 wk. Daily intake of a meal containing APP compared with whey protein increases skeletal muscle mass and lower-extremity muscle strength in healthy older women, suggesting that an APP-containing meal may be useful in the prevention of sarcopenia in this group.This trial was registered at as UMIN000035718. (Keyword) Animals / Female / Sarcopenia / Whey Proteins / Muscle, Skeletal / Alaska / Muscle Strength / Meals / Double-Blind Method / Dietary Supplements / Dietary Proteins (Link to Publication Site) ● Publication site (DOI): 10.1093/jn/nxac219 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36138493 ● Search Scopus @ Elsevier (PMID): 36138493 ● Search Scopus @ Elsevier (DOI): 10.1093/jn/nxac219 (DOI: 10.1093/jn/nxac219, PubMed: 36138493)
25.	Munehide Matsuhisa, Hideaki Miyoshi, Daisuke Yabe, Yoko Takahashi, Yukiko Morimoto and Yasuo Terauchi : Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study., Diabetes Therapy, Vol.14, No.1, 219-236, 2022. (Summary) UMIN-CTR Trials Registry, UMIN000044126; registered 10 May 2021. (Tokushima University Institutional Repository) ● Metadata: 118685 (Link to Publication Site) ● Publication site (DOI): 10.1007/s13300-022-01333-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36422802 ● Search Scopus @ Elsevier (PMID): 36422802 ● Search Scopus @ Elsevier (DOI): 10.1007/s13300-022-01333-w (Tokushima University Institutional Repository: 118685, DOI: 10.1007/s13300-022-01333-w, PubMed: 36422802)
26.	Group Study ISCHIA, Munehide Matsuhisa and Akio Kuroda : Prevention of hypoglycemia by intermittent-scanning continuous glucose monitoring device combined with structured education in patients with type 1 diabetes mellitus: A randomized, crossover trial., Diabetes Research and Clinical Practice, Vol.195, 110147, 2022. (Summary) The use of isCGM combined with structured education significantly reduced the time below range in patients with T1DM. (Keyword) Adult / Humans / Blood Glucose / Diabetes Mellitus, Type 1 / Blood Glucose Self-Monitoring / Cross-Over Studies / Hypoglycemia / Insulin / Hypoglycemic Agents (Tokushima University Institutional Repository) ● Metadata: 118711 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.diabres.2022.110147 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36396114 ● Summary page in Scopus @ Elsevier: 2-s2.0-85147783072 (Tokushima University Institutional Repository: 118711, DOI: 10.1016/j.diabres.2022.110147, PubMed: 36396114, Elsevier: Scopus)
27.	Tomoyo Hara, Ryoko Uemoto, Akiko Sekine, Yukari Mitsui, Shiho Masuda, Hiroki Yamagami, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Yasumasa Ikeda, Itsuro Endo, Soichi Honda, Katsuhiko Yoshimoto, Akira Kondo, Toshiaki Tamaki, Toshio Matsumoto, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Plasma Heparin Cofactor II Activity Is Inversely Associated with Hepatic Fibrosis of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus., Journal of Atherosclerosis and Thrombosis, 2022. (Summary) Plasma HCII activity was inversely associated with clinical hepatic fibrosis indices including FIB-4 index, NFS and APRI and with the prevalence of advanced hepatic fibrosis in patients with T2DM. The results suggest that HCII can serve as a novel biomarker for assessment of hepatic fibrosis of NAFLD in patients with T2DM. (Tokushima University Institutional Repository) ● Metadata: 118258 (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.63752 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36244745 ● Search Scopus @ Elsevier (PMID): 36244745 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.63752 (Tokushima University Institutional Repository: 118258, DOI: 10.5551/jat.63752, PubMed: 36244745)
28.	Takafumi Masuda, Naoto Katakami, Naohiro Taya, Kazuyuki Miyashita, Mitsuyoshi Takahara, Ken Kato, Akio Kuroda, Munehide Matsuhisa and Iichiro Shimomura : Comparison of continuous subcutaneous insulin infusion treatment and multiple daily injection treatment on the progression of diabetic complications in Japanese patients with juvenile-onset type 1 diabetes mellitus., Journal of Diabetes Investigation, 2022. (Summary) To evaluate whether continuous subcutaneous insulin infusion attenuates the progression of diabetic complications, we retrospectively extracted data from 35 individuals who had developed type 1 diabetes mellitus aged ≤20 years and whose treatment had been changed from multiple daily injections to continuous subcutaneous insulin infusion. The annual changes in estimated glomerular filtration rate, urinary albumin excretion rate, carotid intima-media thickness and brachial-ankle pulse wave velocity during each treatment period were calculated. Although mean glycated hemoglobin under the continuous subcutaneous insulin infusion treatment was lower than that under the multiple daily injection treatment, there were no significant differences in annual changes in diabetic nephropathy and atherosclerosis between the two treatment periods. This pilot study showed that, in Japanese patients with juvenile-onset type 1 diabetes mellitus, there was no significant difference in the progression of diabetic nephropathy and atherosclerosis, at least in the early stage, between the two treatments. (Tokushima University Institutional Repository) ● Metadata: 117821 (Link to Publication Site) ● Publication site (DOI): 10.1111/jdi.13819 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35474612 ● Search Scopus @ Elsevier (PMID): 35474612 ● Search Scopus @ Elsevier (DOI): 10.1111/jdi.13819 (Tokushima University Institutional Repository: 117821, DOI: 10.1111/jdi.13819, PubMed: 35474612)
29.	Asami Okada, Misuzu Yamada-Yamashita, Yukari Tominaga, Kyoka Jo, Hiroyasu Mori, Reiko Suzuki, Masashi Ishizu, Motoyuki Tamaki, Yuko Akehi, Yuichi Takashi, Daisuke Koga, Eisuke Shimokita, Fuminori Tanihara, Kiyoe Kurahashi, Sumiko Yoshida, Yukari Mitsui, Shiho Masuda, Itsuro Endo, Ken-ichi Aihara, Shoji Kagami, Masahiro Abe, Kevin Ferreri, Yoshio Fujitani, Munehide Matsuhisa and Akio Kuroda : Novel method utilizing bisulfite conversion with dual amplification-refractory mutation system polymerase chain reaction to detect circulating pancreatic β-cell cfDNA., Journal of Diabetes Investigation, Vol.13, No.7, 1140-1148, 2022. (Summary) We developed a novel method for detecting unmethylated insulin DNA in circulation that can be performed using a conventional real-time PCR system. This method would be useful for analyzing dynamic profiles of β-cells in human disease such as type 1 diabetes. (Tokushima University Institutional Repository) ● Metadata: 117206 (Link to Publication Site) ● Publication site (DOI): 10.1111/jdi.13806 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35396829 ● Search Scopus @ Elsevier (PMID): 35396829 ● Search Scopus @ Elsevier (DOI): 10.1111/jdi.13806 (Tokushima University Institutional Repository: 117206, DOI: 10.1111/jdi.13806, PubMed: 35396829)
30.	Yumi Kuwamura, Sumiko Yoshida, Kiyoe Kurahashi, Masuko Sumikawa, Hiromichi Yumoto, Hirokazu Uemura and Munehide Matsuhisa : Effectiveness of a Diabetes Oral Nursing Program Including a Modified Diabetes Oral Health Assessment Tool for Nurses (M-DiOHAT©): A 12-Month Follow-Up Intervention Study, The Journal of Medical Investigation : JMI, Vol.69, No.1,2, 86-96, 2022. (Summary) This study aimed to evaluate the effectiveness of a diabetes oral nursing intervention program for individuals with diabetes. Fifty-six participants with diabetes underwent a diabetes oral nursing intervention program. The program's effect was evaluated through questionnaires and small interviews. The modified diabetes oral health assessment tool (M-DiOHAT©) was used to assess and educate four factors;oral conditions, behaviors, perceptions and knowledge about diabetes and periodontal disease, and health information-sharing, among participants at baseline, 3, 6, and 12 months later. Primary outcomes included changes in the M-DiOHAT© total scores. Secondary outcomes included scores on the motivation stage of changes in oral health behaviors' scales, dental visits, number of present teeth, hemoglobin A1c (HbA1c), and participants' comments. The M-DiOHAT© total score and the motivation stage score significantly improved with the narrative comment of "being motivated to practice oral health behaviors" between the baseline and 12 months later. Eight participants visited the dentist, whereas no differences were observed in the number of present teeth or HbA1c. This program improved participants' M-DiOHAT© total score, motivation stage score, and dental visits. These results suggest the program improved oral health perceptions and behaviors among individuals with diabetes. J. Med. Invest. 69 : 86-96, February, 2022. (Keyword) diabetes mellitus / nursing intervention / oral health behaviors / perception (Tokushima University Institutional Repository) ● Metadata: 117017 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.86 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35466152 ● Search Scopus @ Elsevier (PMID): 35466152 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.86 (Tokushima University Institutional Repository: 117017, DOI: 10.2152/jmi.69.86, PubMed: 35466152)
31.	Yukari Mitsui, Akio Kuroda, Masashi Ishizu, Hiroyasu Mori, Kiyoe Kurahashi, Takeshi Kondo, Sumiko Yoshida, Yuko Akehi, Ken-ichi Aihara, Itsuro Endo, Masahiro Abe and Munehide Matsuhisa : Basal insulin requirement in patients with type 1 diabetes depends on the age and body mass index., Journal of Diabetes Investigation, Vol.13, No.2, 292-298, 2022. (Summary) T (Tokushima University Institutional Repository) ● Metadata: 116546 (Link to Publication Site) ● Publication site (DOI): 10.1111/jdi.13547 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33740836 ● Search Scopus @ Elsevier (PMID): 33740836 ● Search Scopus @ Elsevier (DOI): 10.1111/jdi.13547 (Tokushima University Institutional Repository: 116546, DOI: 10.1111/jdi.13547, PubMed: 33740836)
32.	Kenya Kusunose, H Yoshida, A Tanaka, H Teragawa, Y Akasaki, Y Fukumoto, K Eguchi, H Kamiya, K Kario, Hirotsugu Yamada, Masataka Sata, K Node and Munehide Matsuhisa : Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study, Hypertension Research, Vol.45, No.1, 106-115, 2022. (Tokushima University Institutional Repository) ● Metadata: 116992 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41440-021-00752-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34657137 ● Search Scopus @ Elsevier (PMID): 34657137 ● Search Scopus @ Elsevier (DOI): 10.1038/s41440-021-00752-9 (Tokushima University Institutional Repository: 116992, DOI: 10.1038/s41440-021-00752-9, PubMed: 34657137)
33.	Kana Beppu, Ayuka Kawakami, Yuna Mishima, Rie Tsutsumi, Masashi Kuroda, Hiroyasu Mori, Akio Kuroda, Munehide Matsuhisa and Hiroshi Sakaue : Taste receptor gene expression is associated with decreased eGFR in patients with diabetes., The Journal of Medical Investigation : JMI, Vol.69, No.1.2, 120-126, 2022. (Summary) Dysgeusia is not only associated with zinc deficiency but also with certain drugs or diseases, including diabetes and renal failure. It often lowers the patient's quality of life and hinders access to proper nutrition. The underlying mechanism is unclear and there is a lack of awareness among patients. Here, we focused on lingual taste receptor gene expression in diabetes and elucidated the relationship between taste receptor gene expression and renal function. Forty-seven patients with diabetes and 10 healthy subjects (control group) were enrolled. Lingual foliate papillae were scraped and the derived cDNA was quantified by real-time polymerase chain reaction. Dysgeusia was assessed using SALSAVE?. All statistical analyses were performed using JMP? software 13. The expression of T1R1 and T1R2 was significantly upregulated in type 2 diabetes patients as compared with that in healthy subjects (P<0.01) but did not change in type 1 diabetes patients. T1R3 expression positively correlated and Scnn1 expression negatively correlated with estimated glomerular filtration rate, suggesting that altered taste receptor gene expression could reflect impaired renal function. Thus, alterations in T1R3 and Scnn1 expression in diabetes correlated with renal function. Taste receptor gene expression dysregulation could indicate dysgeusia associated with impaired renal function in patients with diabetes. J. Med. Invest. 69 : 120-126, February, 2022. (Keyword) Diabetes Mellitus, Type 2 / Dysgeusia / Gene Expression / Humans / Quality of Life / Receptors, G-Protein-Coupled / Taste (Tokushima University Institutional Repository) ● Metadata: 117023 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.120 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35466133 ● CiNii @ National Institute of Informatics (CRID): 1390291932617710464 ● Summary page in Scopus @ Elsevier: 2-s2.0-85128801393 (Tokushima University Institutional Repository: 117023, DOI: 10.2152/jmi.69.120, PubMed: 35466133, CiNii: 1390291932617710464, Elsevier: Scopus)
34.	Asami Okada, Misuzu Yamada, Hiroyasu Mori, 明比祐子, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Akio Kuroda : 循環血中遊離 DNA を用いた膵β細胞傷害の新規検出法の確立, Shikoku Acta Medica, Vol.77, No.5,6, 249-245, 2021. (Summary) In people with type1 diabetes(T1D), biomarkers that can sensitively and quantitatively evaluate injury of pancreatic beta cell are required in order to predict the onset of the disease at an early stage and to provide interventions to prevent the progression of the disease. We developed a new method for quantifying pancreatic beta cell-derived insulin DNA in circulation that combines bisulfite conversion and Amplification Refractory Mutation System(ARMS)PCR, which can be performed using a conventional real-time PCR system. We applied this method to T1D patients and healthy adults, both could be detected in about 30% of cases. The results in healthy adults indicate that this method may have sensitivity to detect the turnover of pancreatic beta cells at physiological conditions. In post-onset T1D patients, there were many negatives because the amount of residual pancreatic beta cells was extremely small. However, in some cases with a short duration of the disease, pancreatic beta cell-derived insulin DNA was detected in negative correlation between the duration of the disease, that suggested the residual pancreatic beta cells continue to be slowly destroyed. It was demonstrated that the time course of pathophysiology in T1D could be understood using this method. (Keyword) Insulin / DNA methylation / RT-PCR / Type1 diabetes / cell-free DNA (Tokushima University Institutional Repository) ● Metadata: 117138 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050292317645976448 (Tokushima University Institutional Repository: 117138, CiNii: 1050292317645976448)
35.	吉川紘平, 金子遥祐, 辻誠士郎, 河田沙紀, 川原綾香, 森建介, 遠藤ふうり, Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Akio Kuroda, 明比祐子, Itsuro Endo, Makoto Funaki, Seiji Fukumoto, Masahiro Abe and Munehide Matsuhisa : TIA様症状を契機に診断されたインスリノーマの1例, Shikoku Acta Medica, Vol.77, No.5-6, 275-280, 2021. (Summary) We report the case of a67-year-old woman who had symptoms suggestive of a transient ischemic attack(TIA), such as lightheadedness and transient visual changes before meals for 4 months. She experienced altered consciousness before lunch and was taken to the emergency room2weeks ago. She had repeated hypoglycemia with a blood glucose level of 31 mg/dL. Insulin secretion was not suppressed, with an immunoreactive insulin level of 14．0 μU/mL and connecting peptide immunoreactivity of 1．83 ng/mL for occasional blood glucose levels of 49 mg/dL. Dynamic CT revealed a 17‐mm mass enhanced during the arterial phase in the pancreatic uncinate process, suggestive of a pancreatic neuroendocrine tumor. A selective arterial secretagogue(calcium)injection test revealed the localization of insulinoma in the head of the pancreas. Therefore, pancreatoduodenectomy was performed. Hyperglycemia occurred after the surgery, and it was judged that the insulinoma was resected. This case showed TIA-like symptoms without signs of sympathetic overdrive associated with hypoglycemia. Thus, the diagnosis was delayed. Insulinoma may present with symptoms of neuroglycopenia but not autonomic activity due to hypoglycemia. Insulinoma should be distinguished in patients with unknown neurological symptoms since neuroglycopenia caused by insulinoma is diverse. (Keyword) Insulinoma / Hypoglycemia / Neuroglycopenia / Transient ischemic attack (Tokushima University Institutional Repository) ● Metadata: 116831 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520292182331094144 (Tokushima University Institutional Repository: 116831, CiNii: 1520292182331094144)
36.	川原綾香, Kiyoe Kurahashi, 工藤千晶, 鎌田基夢, Shinsuke Katoh, Yukiko Tomioka, 辻本賀美, 安井沙耶, 遠藤ふうり, 桝田志保, 三井由加里, Sumiko Yoshida, Ken-ichi Aihara, Itsuro Endo, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 歩行不能だったが，多職種の高度な連携と患者特性に配慮したケアにより自宅生活可能となった高度肥満症の一例, Shikoku Acta Medica, Vol.76, No.5-6, 317-322, 2021. (Summary) A 48-year-old man who weighed 216 kg was significantly overweight with a body mass index (BMI)of 75．6kg/m2, and was unable to walk due to disuse syndrome. Because of the psychological and social problems in the background, a psychological examination was performed and the staff took time to build a trusting relationship with the patient, taking into account his characteristics. With diet and rehabilitation, he was able to lose weight to 124kg and BMI 43．9kg/m2 over 600 days, and was able to walk with assistive devices and defecate by himself. The patient was discharged from our hospital after a series of multidisciplinary meetings with medical, nursing, welfare, and governmental agencies to create an environment for home recuperation. The reasons for the improvement to enable him to be discharged from the hospital were due to the multi-disciplinary meetings among the staff inside and outside the hospital, information sharing and advanced coordination, and smooth communication with the patient by taking into account his characteristics from a psychological standpoint. (Keyword) Sever obesity / disuse syndrome / Patient-specific care / Multidisciplinary team (Tokushima University Institutional Repository) ● Metadata: 115801 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050568937749256704 (Tokushima University Institutional Repository: 115801, CiNii: 1050568937749256704)
37.	Takahiro Fukaishi, Yuko Nakagawa, Ayako Fukunaka, Takashi Sato, Akemi Hara, Keiko Nakao, Michiko Saito, Kenji Kohno, Takeshi Miyatsuka, Motoyuki Tamaki, Munehide Matsuhisa, Taka-Aki Matsuoka, Tetsuya Yamada, Hirotaka Watada and Yoshio Fujitani : Characterisation of Ppy-lineage cells clarifies the functional heterogeneity of pancreatic beta cells in mice., Diabetologia, Vol.64, No.12, 2803-2816, 2021. (Summary) The single-cell RNA sequence (scRNA-seq) analysis datasets generated in this study have been deposited in the Gene Expression Omnibus (GEO) under the accession number GSE166164 ( www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE166164 ). (Keyword) Animals / Glucose / Insulin / Insulin-Secreting Cells / Islets of Langerhans / Mice / Streptozocin (Tokushima University Institutional Repository) ● Metadata: 117216 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00125-021-05560-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34498099 ● Search Scopus @ Elsevier (PMID): 34498099 ● Search Scopus @ Elsevier (DOI): 10.1007/s00125-021-05560-x (Tokushima University Institutional Repository: 117216, DOI: 10.1007/s00125-021-05560-x, PubMed: 34498099)
38.	Munehide Matsuhisa, Hiroyasu Mori, Satoshi Taniguchi, Yuu Tamaki and Akio Kuroda : 情報を活かし地域に沿った腎症重症化予防策「行政・医療機関の情報を活用したヒューマンネットワークによる糖尿病重症化」, 日本糖尿病情報学会誌 18: 43-49, 2021.8.31, Vol.18, 43-49, 2021.
39.	Yuichi Takashi, Shun Sawatsubashi, Itsuro Endo, Yukiyo Ohnishi, Masahiro Abe, Munehide Matsuhisa, Daiji Kawanami, Toshio Matsumoto and Seiji Fukumoto : Skeletal FGFR1 signaling is necessary for regulation of serum phosphate level by FGF23 and normal life span., Biochemistry and Biophysics Reports, Vol.27, 101107, 2021. (Summary) Fibroblast growth factor (FGF) 23 produced by the bone is the principal hormone to regulate serum phosphate level. Serum FGF23 needs to be tightly regulated to maintain serum phosphate in a narrow range. Thus, we hypothesized that the bone has some phosphate-sensing mechanism to regulate the production of FGF23. Previously we showed that extracellular phosphate induces the phosphorylation of FGF receptor 1 (FGFR1) and FGFR1 signaling regulates the expression of , whose product works to increase FGF23 production . In this study, we show the significance of FGFR1 in the regulated FGF23 production and serum phosphate level . We generated late-osteoblast/osteocyte-specific -knockout mice ( ) by crossing the and the floxed mouse lines. We evaluated serum phosphate and FGF23 levels, the expression of in the bone, the body weight and life span. A selective ablation of aborted the increase of serum active full-length FGF23 and the enhanced expression of in the bone by a high phosphate diet. These mice showed more pronounced hyperphosphatemia compared with control mice. In addition, these mice fed with a control diet showed body weight loss after 23 weeks of age and shorter life span. These results reveal a novel significance of FGFR1 signaling in the phosphate metabolism and normal life span. (Tokushima University Institutional Repository) ● Metadata: 116283 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bbrep.2021.101107 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34458594 ● Search Scopus @ Elsevier (PMID): 34458594 ● Search Scopus @ Elsevier (DOI): 10.1016/j.bbrep.2021.101107 (Tokushima University Institutional Repository: 116283, DOI: 10.1016/j.bbrep.2021.101107, PubMed: 34458594)
40.	Sonyun Hata, Hiroyasu Mori, Tetsuyuki Yasuda, Yoko Irie, Tsunehiko Yamamoto, Yutaka Umayahara, Kayoko Ryomoto, Kazutomi Yoshiuchi, Sumiko Yoshida, Iichiro Shimomura, Akio Kuroda and Munehide Matsuhisa : A low serum IGF-1 is correlated with sarcopenia in subjects with type 1 diabetes mellitus: Findings from a post-hoc analysis of the iDIAMOND study., Diabetes Research and Clinical Practice, Vol.179, 2021. (Summary) A low serum IGF-1 level is correlated with sarcopenia and low skeletal muscle mass in subjects with T1DM. (Keyword) Cross-Sectional Studies / Diabetes Mellitus, Type 1 / Hand Strength / Humans / Insulin-Like Growth Factor I / Muscle, Skeletal / Sarcopenia (Link to Publication Site) ● Publication site (DOI): 10.1016/j.diabres.2021.108998 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34390761 ● Search Scopus @ Elsevier (PMID): 34390761 ● Search Scopus @ Elsevier (DOI): 10.1016/j.diabres.2021.108998 (DOI: 10.1016/j.diabres.2021.108998, PubMed: 34390761)
41.	Shota Suzuki, Atsuhito Tone, Takashi Murata, Kunihiro Nishimura, Yoshihiro Miyamoto, Naoki Sakane, Noriko Satoh-Asahara, Masao Toyoda, Yushi Hirota, Munehide Matsuhisa, Akio Kuroda, Ken Kato, Ryuji Kouyama, Junnosuke Miura, Akiko Suganuma, Tsutomu Tomita, Michio Noguchi, Cheol Son, Masato Kasahara, Yukie Ito, Shu Kasama and Kiminori Hosoda : Protocol for a Randomized, Crossover Trial to Decrease Time in Hypoglycemia by Combined Intervention of the Usage of Intermittent-Scanning Continuous Glucose Monitoring Device and the Structured Education Regarding its Usage: Effect of Intermittent-Scanning Continuous Glucose Monitoring to Glycemic Control Including Hypoglycemia and Quality of Life of Patients with Type 1 Diabetes Mellitus Study (ISCHIA Study)., The Tokai Journal of Experimental and Clinical Medicine, Vol.46, No.2, 59-68, 2021. (Summary) The ISCHIA study will contribute to the standardization of patient education regarding the prevention of hypoglycemia by using isCGM. (Tokushima University Institutional Repository) ● Metadata: 118709 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34216477 ● Summary page in Scopus @ Elsevier: 2-s2.0-85110829170 (Tokushima University Institutional Repository: 118709, PubMed: 34216477, Elsevier: Scopus)
42.	Munehide Matsuhisa and Akio Kuroda : 先進糖尿病治療の進歩, Journal of the The Japan Diabetes Society, Vol.13, No.6, 62-68, 2021.
43.	Hiroyasu Mori, Akio Kuroda, Sumiko Yoshida, Tetsuyuki Yasuda, Yutaka Umayahara, Sayoko Shimizu, Kayoko Ryomoto, Kazutomi Yoshiuchi, Tsunehiko Yamamoto, Taka-Aki Matsuoka, Iichiro Shimomura and Munehide Matsuhisa : High prevalence and clinical impact of dynapenia and sarcopenia in Japanese patients with type 1 and type 2 diabetes: Findings from the Impact of Diabetes Mellitus on Dynapenia study., Journal of Diabetes Investigation, Vol.12, No.6, 1050-1059, 2021. (Summary) Sarcopenia and dynapenia were more frequent in patients with type 1 diabetes and type 2 diabetes than in individuals without diabetes, which might contribute to their impaired quality of life and incidental falls. (Tokushima University Institutional Repository) ● Metadata: 116547 (Link to Publication Site) ● Publication site (DOI): 10.1111/jdi.13436 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33063949 ● Search Scopus @ Elsevier (PMID): 33063949 ● Search Scopus @ Elsevier (DOI): 10.1111/jdi.13436 (Tokushima University Institutional Repository: 116547, DOI: 10.1111/jdi.13436, PubMed: 33063949)
44.	Tomoyo Hara, Ryoko Uemoto, Akiko Sekine, Yukari Mitsui, Shiho Masuda, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Yasumasa Ikeda, Itsuro Endo, Soichi Honda, Katsuhiko Yoshimoto, Akira Kondo, Toshiaki Tamaki, Toshio Matsumoto, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Plasma Heparin Cofactor II Activity Is Inversely Associated with Albuminuria and Its Annual Deterioration in Patients with Diabetes., Journal of Diabetes Investigation, 2021. (Summary) The plasma HCII activity was inversely and specifically associated with glomerular injury in patients with diabetes. The results suggest that HCII can serve as a novel predictive factor for early-stage DKD development, as represented by albuminuria. (Tokushima University Institutional Repository) ● Metadata: 116545 (Link to Publication Site) ● Publication site (DOI): 10.1111/jdi.13602 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34043882 ● Search Scopus @ Elsevier (PMID): 34043882 ● Search Scopus @ Elsevier (DOI): 10.1111/jdi.13602 (Tokushima University Institutional Repository: 116545, DOI: 10.1111/jdi.13602, PubMed: 34043882)
45.	Abiru Norio, Shimada Akira, Nishimura Rimei, Munehide Matsuhisa, Ozaki Asuka · and Ikegam Hiroshi : Glycemic control status, diabetes management patterns, and clinical characteristics of adults with type 1 diabetes in Japan: Study of Adults Glycemia in T1DM subanalysis, Diabetology International, Vol.12, No.4, 460-473, 2021. (Link to Publication Site) ● Publication site (DOI): 10.1007/s13340-021-00504-7 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1007/s13340-021-00504-7 (DOI: 10.1007/s13340-021-00504-7)
46.	Munehide Matsuhisa and Akio Kuroda : Progression of the advanced technology and therapy for diabetes mellitus, The Journal of the Japanese Society of Internal Medicine, Vol.110, No.3, 420-426, 2021. (Keyword) 重症低血糖 / 持続血糖モニター(CGM) / 持続皮下インスリン注入療法(CSII) / sensor augmented pump (SAP) (Tokushima University Institutional Repository) ● Metadata: 118692 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050861228447747840 (Tokushima University Institutional Repository: 118692, CiNii: 1050861228447747840)
47.	Masashi Ishizu, Hiroyasu Mori, Mami Ohishi, Akio Kuroda, Y Akehi, Sumiko Yoshida, Ken-ichi Aihara, M Aiba, T Kawano, Seiichi Hashida and Munehide Matsuhisa : Urinary adiponectin excretion is an early predictive marker of the decline of the renal function in patients with diabetes mellitus., Journal of Diabetes and its Complications, Vol.35, No.4, 107848, 2021. (Summary) Since diabetes-associated kidney complication changes from diabetic nephropathy to diabetic kidney disease (DKD), more suitable biomarkers than urinary albumin are required. It has been hypothesized that urinary adiponectin (u-ADPN) is associated with the progression of DKD. We therefore evaluated the effectiveness of u-ADPN in predicting the decline of the renal function in patients with diabetes prior to end-stage renal disease. An ultrasensitive immune complex transfer enzyme immunoassay (ICT-EIA) was used to measure total and high molecular weight (HMW) adiponectin separately. We evaluated the relationships between the creatinine-adjusted urinary total-ADPN and HMW-ADPN, albumin (UACR) and liver-type fatty acid binding protein (L-FABP) at baseline and the 2-year change of the estimated glomerular filtration rate (ΔeGFR). This 2-year prospective observational study included 201 patients with diabetes. These patients were divided into three groups according to their ΔeGFR: ≤-10 mL/min/1.73m, >-10 and ≤0 mL/min/1.73m, and >0 mL/min/1.73m. Jonckheere-Terpstra test showed that lower ΔeGFR was associated with higher u-HMW-ADPN (p = 0.045). In logistic regression analysis, u-HMW-ADPN was associated with ΔeGFR after adjusted age, sex, and basal eGFR. Urinary HMW-ADPN could predict a declining renal function in patients with diabetes. (Tokushima University Institutional Repository) ● Metadata: 115675 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jdiacomp.2021.107848 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33558151 ● Search Scopus @ Elsevier (PMID): 33558151 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jdiacomp.2021.107848 (Tokushima University Institutional Repository: 115675, DOI: 10.1016/j.jdiacomp.2021.107848, PubMed: 33558151)
48.	Munehide Matsuhisa : ICTがもたらす地域医療連携と糖尿病診療の未来, 大阪府内科医会会誌, Vol.29, No.1-2, 20-27, 2020. (Tokushima University Institutional Repository) ● Metadata: 118713 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050298355878921344 (Tokushima University Institutional Repository: 118713, CiNii: 1050298355878921344)
49.	Yuichi Takashi, Shu Wakino, Hitoshi Minakuchi, Masashi Ishizu, Akio Kuroda, Hisato Shima, Manabu Tashiro, Keiko Miya, Kazuyoshi Okada, Jun Minakuchi, Shu Kawashima, Munehide Matsuhisa, Toshio Matsumoto and Seiji Fukumoto : Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients., Journal of Bone and Mineral Metabolism, Vol.38, No.1, 70-77, 2020. (Summary) Fibroblast growth factor (FGF) 23 is a bone-derived hormone regulating serum inorganic phosphate (Pi) concentration. FGF23 is also involved in the development of chronic kidney disease (CKD)-mineral and bone disorder. Serum FGF23 concentration begins to increase early in the progression of CKD and can be remarkably high in hemodialysis patients with end-stage renal disease. It has been reported that high FGF23 concentration is a risk factor for cardiac dysfunction, atherosclerosis, infection or systemic inflammation in CKD patients. FGF23 was also shown to induce cardiac hypertrophy directly acting on cardiomyocytes. However, it is still controversial whether high FGF23 is causing cardiac dysfunction, atherosclerosis, infection or systemic inflammation in CKD patients. In the current study, we investigated whether FGF23 concentration is associated with cardiac dysfunction, atherosclerosis, infection or systemic inflammation in Japanese hemodialysis patients. We recruited 119 hemodialysis patients and examined the association between serum FGF23 concentration and several parameters concerning mineral metabolism, cardiac dysfunction, atherosclerosis, infection, and systemic inflammation. Serum FGF23 concentration was independently associated with serum calcium and Pi concentration (β = 0.276, p < 0.001; β = 0.689, p < 0.001). However, serum FGF23 concentration was not associated with parameters of cardiac dysfunction, atherosclerosis, infection, and systemic inflammation, either. Our results do not support the hypothesis that high FGF23 in dialysis patients is the cause of cardiac dysfunction, atherosclerosis, infection or systemic inflammation. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00774-019-01027-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31420749 ● Search Scopus @ Elsevier (PMID): 31420749 ● Search Scopus @ Elsevier (DOI): 10.1007/s00774-019-01027-7 (DOI: 10.1007/s00774-019-01027-7, PubMed: 31420749)
50.	Takahisa Hirose, Masato Odawara, Munehide Matsuhisa, Ryusuke Koshida, Masayuki Senda, Yasushi Tanaka and Yasuo Terauchi : Risk of hypoglycemia in Japanese people with type 2 diabetes mellitus who initiated or switched to insulin glargine 300 U/mL: A subgroup analysis of 12-month post-marketing surveillance study (X-STAR study)., Diabetes Research and Clinical Practice, Vol.172, 2020. (Summary) Our study found no apparent increase in the hypoglycemia risk in people with older age and renal impairment who were administered Gla-300. These results would provide reassuring information on Gla-300 use. (Keyword) Aged / Diabetes Mellitus, Type 2 / Female / Humans / Hypoglycemia / Hypoglycemic Agents / Insulin Glargine / Japan / Male / Middle Aged / Prospective Studies (Tokushima University Institutional Repository) ● Metadata: 115565 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.diabres.2020.108647 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33359753 ● Search Scopus @ Elsevier (PMID): 33359753 ● Search Scopus @ Elsevier (DOI): 10.1016/j.diabres.2020.108647 (Tokushima University Institutional Repository: 115565, DOI: 10.1016/j.diabres.2020.108647, PubMed: 33359753)
51.	Yumi Kuwamura, Sumiko Yoshida, Kiyoe Kurahashi, 澄川真珠子, Eijiro Sakamoto, Akio Kuroda, Ken-ichi Aihara, Makoto Funaki, Hiromichi Yumoto, Hirokazu Uemura, 岡本美鈴, 大和光, Munehide Matsuhisa, Itsuro Endo and Sachi Kishida : 糖尿病患者の口腔保健行動アセスメントツールを用いた看護支援プログラムの評価, Journal of the The Japan Diabetes Society, Vol.63, No.Supplement, S117, 2020. (Keyword) diabetes mellitus / oral health behaviors / assessment / 看護支援
52.	Toshihiro Watanabe, Yuki Fujimoto, Aya Morimoto, Mai Nishiyama, Akinori Kawai, Seiki Okada, Motohiro Aiba, Tomoharu Kawano, Mina Kawahigashi, Masashi Ishizu, Hiroyasu Mori, Munehide Matsuhisa, Akiko Hata, Makoto Funaki and Seiichi Hashida : Development of fully automated and ultrasensitive assays for urinary adiponectin and their application as novel biomarkers for diabetic kidney disease., Scientific Reports, Vol.10, No.1, 15869, 2020. (Summary) Glomerular filtration rate (GFR) and urinary albumin excretion rate (UAER) are used to diagnose and classify the severity of chronic kidney disease. Total adiponectin (T-AN) and high molecular weight adiponectin (H-AN) assays were developed using the fully automated immunoassay system, HI-1000 and their significance over conventional biomarkers were investigated. The T-AN and H-AN assays had high reproducibility, good linearity, and sufficient sensitivity to detect trace amounts of adiponectin in the urine. Urine samples after gel filtration were analyzed for the presence of different molecular isoforms. Low molecular weight (LMW) forms and monomers were the major components (93%) of adiponectin in the urine from a diabetic patient with normoalbuminuria. Urine from a microalbuminuria patient contained both high molecular weight (HMW) (11%) and middle molecular weight (MMW) (28%) adiponectin, although the LMW level was still high (52%). The amount of HMW (32%) and MMW (42%) were more abundant than that of LMW (24%) in a diabetic patient with macroalbuminuria. T-AN (r = - 0.43) and H-AN (r = - 0.38) levels showed higher correlation with estimated GFR (eGFR) than UAER (r = - 0.23). Urinary levels of both T-AN and H-AN negatively correlated with renal function in diabetic patients and they may serve as new biomarkers for diabetic kidney disease. (Tokushima University Institutional Repository) ● Metadata: 115617 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-020-72494-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32985540 ● Search Scopus @ Elsevier (PMID): 32985540 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-020-72494-6 (Tokushima University Institutional Repository: 115617, DOI: 10.1038/s41598-020-72494-6, PubMed: 32985540)
53.	Munehide Matsuhisa, Masato Odawara, Takahisa Hirose, Ryusuke Koshida, Masayuki Senda, Yasushi Tanaka and Yasuo Terauchi : Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study)., Expert Opinion on Pharmacotherapy, Vol.22, No.2, 249-256, 2020. (Summary) Gla-300 showed no unprecedented safety concerns for insulin-experienced T1DM patients in Japanese clinical settings. Our results provide insights into strategies for blunted Gla-300 up-titration dose, despite insufficient HbA1c control and lifestyle modification. (Keyword) Adult / Aged / Blood Glucose / Diabetes Mellitus, Type 1 / Dose-Response Relationship, Drug / Female / Glycated Hemoglobin A / Humans / Hypoglycemia / Hypoglycemic Agents / Insulin Glargine / Japan / Male / Middle Aged / Product Surveillance, Postmarketing / Prospective Studies (Tokushima University Institutional Repository) ● Metadata: 116523 (Link to Publication Site) ● Publication site (DOI): 10.1080/14656566.2020.1810665 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32840155 ● Search Scopus @ Elsevier (PMID): 32840155 ● Search Scopus @ Elsevier (DOI): 10.1080/14656566.2020.1810665 (Tokushima University Institutional Repository: 116523, DOI: 10.1080/14656566.2020.1810665, PubMed: 32840155)
54.	Takashi Murata, Akio Kuroda, Munehide Matsuhisa, Masao Toyoda, Moritsugu Kimura, Yushi Hirota, Ken Kato, Hideaki Sawaki, Atsuhito Tone, Satoshi Kawashima, Akira Okada, Tomokazu Watanabe, Shinsuke Nirengi, Akiko Suganuma and Naoki Sakane : Predictive Factors of the Adherence to Real-Time Continuous Glucose Monitoring Sensors: A Prospective Observational Study (PARCS STUDY)., Journal of Diabetes Science and Technology, 2020. (Summary) Higher adherence to CGM sensors may be associated with a heavier emotional burden of diabetes and a worse QOL in relation to CSII at baseline. (Link to Publication Site) ● Publication site (DOI): 10.1177/1932296820939204 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32762345 ● Search Scopus @ Elsevier (PMID): 32762345 ● Search Scopus @ Elsevier (DOI): 10.1177/1932296820939204 (DOI: 10.1177/1932296820939204, PubMed: 32762345)
55.	Masato Odawara, Munehide Matsuhisa, Takahisa Hirose, Ryusuke Koshida, Masayuki Senda, Yasushi Tanaka and Yasuo Terauchi : Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study)., Expert Opinion on Pharmacotherapy, 1-10, 2020. (Summary) Gla-300, in clinical practice, provides an effective and safe therapy as HbA1c was reduced/maintained in insulin-naïve/experienced Japanese T2DM patients without new safety signal. This study provides insights into the current Japanese clinical practices where insulin use is delayed and conservative despite relatively low HbA1c achievement. (Tokushima University Institutional Repository) ● Metadata: 115912 (Link to Publication Site) ● Publication site (DOI): 10.1080/14656566.2020.1785430 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32693663 ● Search Scopus @ Elsevier (PMID): 32693663 ● Search Scopus @ Elsevier (DOI): 10.1080/14656566.2020.1785430 (Tokushima University Institutional Repository: 115912, DOI: 10.1080/14656566.2020.1785430, PubMed: 32693663)
56.	Shota Suzuki, Yukie Ito, Shu Kasama, Takashi Murata, Munehide Matsuhisa and Masato Kasahara : Ethics and practical mitigations for ongoing clinical trials during the COVID-19 pandemic., Diabetology International, Vol.11, No.3, 240-241, 2020. (Link to Publication Site) ● Publication site (DOI): 10.1007/s13340-020-00449-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32793405 ● Search Scopus @ Elsevier (PMID): 32793405 ● Search Scopus @ Elsevier (DOI): 10.1007/s13340-020-00449-3 (DOI: 10.1007/s13340-020-00449-3, PubMed: 32793405)
57.	Thomas Danne, Munehide Matsuhisa, Christian Sussebach, Harmonie Goyeau, Felipe Lauand, Elisabeth Niemoeller and B Geremia Bolli : Lower Risk for Severe Hypoglycaemia with Insulin Glargine 300 U/mL vs Glargine 100 U/mL in Participants with Type 1 Diabetes: a Meta-Analysis of 6-Month Phase 3 Clinical Trials., Diabetes, Obesity & Metabolism, 2020. (Summary) Severe hypoglycaemia (SH) remains a challenge to people with type 1 diabetes (T1DM) and new generation basal insulins may improve patient outcomes. This post-hoc meta-analysis explored the risk of SH with insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in a pooled population with T1DM from three randomised, multicentre, 6-month similarly designed phase 3 trials: EDITION 4, EDITION JP 1, and EDITION JUNIOR. Endpoints included incidence and time to first occurrence of SH. Among 629 and 626 participants randomised to Gla-300 and Gla-100, HbA (Tokushima University Institutional Repository) ● Metadata: 115897 (Link to Publication Site) ● Publication site (DOI): 10.1111/dom.14109 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32515543 ● Search Scopus @ Elsevier (PMID): 32515543 ● Search Scopus @ Elsevier (DOI): 10.1111/dom.14109 (Tokushima University Institutional Repository: 115897, DOI: 10.1111/dom.14109, PubMed: 32515543)
58.	Munehide Matsuhisa, Yasushi Takita, Risa Nasu, Yukiko Nagai, Kenji Ohwaki and Hirotaka Nagashima : Nasal glucagon as a viable alternative for treating insulin-induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: A phase 3 randomized crossover study., Diabetes, Obesity & Metabolism, Vol.22, No.7, 1167-1175, 2020. (Summary) Nasal glucagon was non-inferior to IMG for successful treatment of insulin-induced hypoglycaemia in Japanese patients with T1DM/T2DM, supporting use of NG as a rescue treatment for severe hypoglycaemia. (Tokushima University Institutional Repository) ● Metadata: 115085 (Link to Publication Site) ● Publication site (DOI): 10.1111/dom.14019 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32115879 ● Search Scopus @ Elsevier (PMID): 32115879 ● Search Scopus @ Elsevier (DOI): 10.1111/dom.14019 (Tokushima University Institutional Repository: 115085, DOI: 10.1111/dom.14019, PubMed: 32115879)
59.	Yasumitsu Takahi, Kazuyuki Miyashita, Mitsuyoshi Takahara, Naoto Katakami, Akio Kuroda, Taka-Aki Matsuoka, Munehide Matsuhisa, Toshinori Ito and Iichiro Shimomura : Predictive factors of posttransplant glucose intolerance in Japanese patients with type 1 diabetes after pancreas transplantation., Endocrine Journal, Vol.66, No.12, 1101-1112, 2019. (Summary) 120 at the initial examination. In conclusion, insulinogenic index and iAUCR from OGTT performed in the early posttransplantation period were predictive factors of future glucose intolerance. (Tokushima University Institutional Repository) ● Metadata: 118705 (Link to Publication Site) ● Publication site (DOI): 10.1507/endocrj.EJ19-0180 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31495809 ● Search Scopus @ Elsevier (PMID): 31495809 ● Search Scopus @ Elsevier (DOI): 10.1507/endocrj.EJ19-0180 (Tokushima University Institutional Repository: 118705, DOI: 10.1507/endocrj.EJ19-0180, PubMed: 31495809)
60.	鶴尾美穂, 住友正治, 大島康志, 小松まち子, 鈴木麗子, Ken-ichi Aihara, 安藝菜奈子, 坂東智子, 高橋保子, 丸岡重代, 原田和代, 若槻真吾, 桜井えつ, 井野口卓, 白神敦久, 豊崎纏, Munehide Matsuhisa and 宇都宮正登 : The Attempt to Develop the Tokushima City Certified Diabetes Supporter (TCDS) for the Advancement of the Quality of Home Medical Care for the Diabetic Patients, Shikoku Acta Medica, Vol.75, No.3, 97-102, 2019. (Summary) The Tokushima City Medical Association has cultivated the talented persons of nursing care profession by both the education of diabetes and the instruction of medical treatments to secure the quality of home care for increasing diabetic patients. They are certified to be the Tokushima City Certified Diabetes Supporter(TCDS). In Tokushima Prefecture, the rate of aging and the certification rate of care need are ranked high in Japan, and the medical measures should be provided for the aged diabetic patients utilizing team nursing care as well as team medical care, because many of these patients are obliged to receive home medical care owing to the introduction of community-based integrated care systems. Tokushima Prefecture kept the worst of age-adjusted diabetes mortality and also the worst of crude diabetes mortality in recent years. Therefore, the program for the TCDS was arranged by the staffs composed of board certified fellows of the Japan Diabetes Society, certified diabetes physicians of Tokushima, and Tokushima local certified diabetes educators (Tokushima LCDEs). The program includes the lectures of diabetes and medical treatments, the practical training, and the group work by the World Café system collaborated with the medical staffs across many different fields, using the dramatic skit presented by the medical doctors and the LCDE staffs after narrating the scenario for the blood glucose control of diabetic patients to be treated. The persons who have completed the training course are certified as the TCDS by The Tokushima City Medical Association. The workshop is held twice a year and the certification is renewed every three years without examination. In conclusion, it is suggested that the development of TCDS leads to the improvement of the ability of nursing care staffs to support diabetic treatments and the advancement of the quality of home medical care for the aged diabetic patients. (Tokushima University Institutional Repository) ● Metadata: 113809 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050845763745700992 (Tokushima University Institutional Repository: 113809, CiNii: 1050845763745700992)
61.	Yumi Kuwamura, Eijiro Sakamoto, Masuko Sumikawa, Munehide Matsuhisa, Daisuke Hinode, Hirokazu Uemura and Sachi Kishida : Assessing the oral health of in-patients with diabetes using a clinical version of the diabetes oral health assessment tool© and its association with dental examinations, The Journal of Medical Investigation : JMI, Vol.66, No.3,4, 328-336, 2019. (Tokushima University Institutional Repository) ● Metadata: 114163 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.328 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31656299 ● Search Scopus @ Elsevier (PMID): 31656299 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.66.328 (Tokushima University Institutional Repository: 114163, DOI: 10.2152/jmi.66.328, PubMed: 31656299)
62.	Tetsuya Ikemoto, Rui Feng, Shuichi Iwahashi, Shin-ichiro Yamada, Yu Saitou, Yuji Morine, Satoru Imura, Munehide Matsuhisa and Mitsuo Shimada : In vitro and in vivo effects of insulin-producing cells generated by xeno-antigen free 3D culture with RCP piece., Scientific Reports, Vol.9, No.1, 2019. (Summary) To establish widespread cell therapy for type 1 diabetes mellitus, we aimed to develop an effective protocol for generating insulin-producing cells (IPCs) from adipose-derived stem cells (ADSCs). We established a 3D culture using a human recombinant peptide (RCP) petaloid μ-piece with xeno-antigen free reagents. Briefly, we employed our two-step protocol to differentiate ADSCs in 96-well dishes and cultured cells in xeno-antigen free reagents with 0.1 mg/mL RCP μ-piece for 7 days (step 1), followed by addition of histone deacetylase inhibitor for 14 days (step 2). Generated IPCs were strongly stained with dithizone, anti-insulin antibody at day 21, and microstructures resembling insulin secretory granules were detected by electron microscopy. Glucose stimulation index (maximum value, 4.9) and MAFA mRNA expression were significantly higher in 3D cultured cells compared with conventionally cultured cells (P < 0.01 and P < 0.05, respectively). The hyperglycaemic state of streptozotocin-induced diabetic nude mice converted to normoglycaemic state around 14 days after transplantation of 96 IPCs under kidney capsule or intra-mesentery. Histological evaluation revealed that insulin and C-peptide positive structures existed at day 120. Our established xeno-antigen free and RCP petaloid μ-piece 3D culture method for generating IPCs may be suitable for clinical application, due to the proven effectiveness in vitro and in vivo. (Tokushima University Institutional Repository) ● Metadata: 114941 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-019-47257-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31341242 ● Search Scopus @ Elsevier (PMID): 31341242 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-019-47257-7 (Tokushima University Institutional Repository: 114941, DOI: 10.1038/s41598-019-47257-7, PubMed: 31341242)
63.	Hiroyasu Mori, Akio Kuroda and Munehide Matsuhisa : Clinical impact of sarcopenia and dynapenia on diabetes., Diabetology International, Vol.10, No.3, 183-187, 2019. (Summary) Sarcopenia as a progressive and generalized skeletal muscle disorder that is associated with an increased likelihood of adverse outcomes, including falls, fractures, physical disability, and mortality. On the other hand, an age-related decline in muscle strength prior to the reduction of muscle mass, is proposed to be "dynapenia". Sarcopenia and dynapenia have recently been recognized as a diabetic complications in type 2 diabetes. We firstly indicated that sarcopenia was frequently observed in 16.6% of patients with type 1 diabetes aged even over 40 years. Additionally, we recently reported that the prevalence rate of dynapenia was higher than sarcopenia in patients with type 2 diabetes. Chronic hyperglycemia accelerates accumulation of advanced glycation end products (AGEs), which causes diabetic vascular complications through oxidative stress and chronic inflammation. We also demonstrated that skin autofluorescence (AF) as a marker of AGEs, was the independent determinant for skeletal muscle mass and strength in patients with type 2 diabetes and muscle strength in type 1 diabetes. Therefore, the early diagnosis of muscle weakness is essential for patients with diabetes and sustained good glycemic control with exercise and dietary intervention might be beneficial to prevent the progression of muscle weakness in these patients. (Tokushima University Institutional Repository) ● Metadata: 114038 (Link to Publication Site) ● Publication site (DOI): 10.1007/s13340-019-00400-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31275784 ● Summary page in Scopus @ Elsevier: 2-s2.0-85068062045 (Tokushima University Institutional Repository: 114038, DOI: 10.1007/s13340-019-00400-1, PubMed: 31275784, Elsevier: Scopus)
64.	Yuichi Takashi, Hidetaka Kosako, Shun Sawatsubashi, Yuka Kinoshita, Nobuaki Ito, Maria K. Tsoumpra, Masaomi Nangaku, Masahiro Abe, Munehide Matsuhisa, Shigeaki Kato, Toshio Matsumoto and Seiji Fukumoto : Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation, Proceedings of the National Academy of Sciences of the United States of America, Vol.116, No.23, 11418-11427, 2019. (Summary) Fibroblast growth factor (FGF) 23 produced by bone is a hormone that decreases serum phosphate (Pi). Reflecting its central role in Pi control, serum FGF23 is tightly regulated by serum Pi alterations. FGF23 levels are regulated by the transcriptional event and posttranslational cleavage into inactive fragments before its secretion. For the latter, O-glycosylation of FGF23 by gene product prevents the cleavage, leading to an increase in serum FGF23. However, the molecular basis of Pi sensing in the regulation of serum FGF23 remains elusive. In this study, we showed that high Pi diet enhanced the skeletal expression of , but not , with expected increases in serum FGF23 and Pi in mice. induction by high Pi was further observed in osteoblastic UMR 106 cells, and this was mediated by activation of the extracellular signal-regulated kinase (ERK) pathway. Through proteomic searches for the upstream sensor for high Pi, we identified one subtype of the FGF receptor (FGFR1c), which was phosphorylated by high Pi in the absence of FGFs. The mode of unliganded FGFR activation by high Pi appeared different from that of FGFR bound to a canonical FGFR ligand (FGF2) when phosphorylation of the FGFR substrate 2α and ERK was monitored. Finally, we showed that an FGFR inhibitor and conditional deletion of in osteoblasts/osteocytes abrogated high Pi diet-induced increases in serum FGF23 and femoral expression in mice. Thus, these findings uncover an unrecognized facet of unliganded FGFR function and illustrate a Pi-sensing pathway involved in regulation of FGF23 production. (Tokushima University Institutional Repository) ● Metadata: 113621 (Link to Publication Site) ● Publication site (DOI): 10.1073/pnas.1815166116 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31097591 ● Search Scopus @ Elsevier (PMID): 31097591 ● Search Scopus @ Elsevier (DOI): 10.1073/pnas.1815166116 (Tokushima University Institutional Repository: 113621, DOI: 10.1073/pnas.1815166116, PubMed: 31097591)
65.	Yuichi Takashi, Masashi Ishizu, Hiroyasu Mori, Kazuyuki Miyashita, Fumie Sakamoto, Naoto Katakami, Taka-Aki Matsuoka, Tetsuyuki Yasuda, Seiichi Hashida, Munehide Matsuhisa and Akio Kuroda : Circulating osteocalcin as a bone-derived hormone is inversely correlated with body fat in patients with type 1 diabetes., PLoS ONE, Vol.14, No.5, 2019. (Summary) The objective of the present study was to investigate the correlations between serum undercarboxylated osteocalcin (ucOC) or osteocalcin (OC) concentrations and %body fat, serum adiponectin and free-testosterone concentration, muscle strength and dose of exogenous insulin in patients with type 1 diabetes. We recruited 73 Japanese young adult patients with childhood-onset type 1 diabetes. All participants were receiving insulin replacement therapy. The correlations between logarithmic serum ucOC or OC concentrations and each parameter were examined. Serum ucOC and OC concentrations were inversely correlated with %body fat (r = -0.319, P = 0.007; r = -0.321, P = 0.006, respectively). Furthermore, multiple linear regression analyses were performed to determine whether or not serum ucOC or OC concentrations were factors associated with %body fat. Serum ucOC and OC concentrations remained significant factors even after adjusting for gender, HbA1c, body weight-adjusted total daily dose of insulin and duration of diabetes (β = -0.260, P = 0.027; β = -0.254, P = 0.031, respectively). However, serum ucOC and OC concentrations were not correlated with serum adiponectin or free-testosterone concentrations, muscle strength or dose of exogenous insulin. In conclusion, our study demonstrates the inverse correlation between serum ucOC or OC concentrations and body fat in patients with type 1 diabetes. (Tokushima University Institutional Repository) ● Metadata: 114023 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0216416 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31050684 ● Search Scopus @ Elsevier (PMID): 31050684 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0216416 (Tokushima University Institutional Repository: 114023, DOI: 10.1371/journal.pone.0216416, PubMed: 31050684)
66.	Akemi Hara, Yuko Nakagawa, Keiko Nakao, Motoyuki Tamaki, Tetsuya Ikemoto, Mitsuo Shimada, Munehide Matsuhisa, Hiroki Mizukami, Nobuhiro Maruyama, Hirotaka Watada and Yoshio Fujitani : Development of monoclonal mouse antibodies that specifically recognize pancreatic polypeptide., Endocrine Journal, Vol.66, No.5, 459-468, 2019. (Summary) Pancreatic polypeptide (PP) is a 36-amino acid peptide encoded by the Ppy gene, which is produced by a small population of cells located in the periphery of the islets of Langerhans. Owing to the high amino acid sequence similarity among neuropeptide Y family members, antibodies against PP that are currently available are not convincingly specific to PP. Here we report the development of mouse monoclonal antibodies that specifically bind to PP. We generated Ppy knockout (Ppy-KO) mice in which the Ppy-coding region was replaced by Cre recombinase. The Ppy-KO mice were immunized with mouse PP peptide, and stable hybridoma cell lines producing anti-PP antibodies were isolated. Firstly, positive clones were selected in an enzyme-linked immunosorbent assay for reactivity with PP coupled to bovine serum albumin. During the screening, hybridoma clones producing antibodies that cross-react to the peptide YY (PYY) were excluded. In the second screening, hybridoma clones in which their culture media produce no signal in Ppy-KO islets but detect specific cells in the peripheral region of wild-type islets, were selected. Further studies demonstrated that the selected monoclonal antibody (23-2D3) specifically recognizes PP-producing cells, not only in mouse, but also in human and rat islets. The monoclonal antibodies with high binding specificity for PP developed in this study will be fundamental for future studies towards elucidating the expression profiles and the physiological roles of PP. (Tokushima University Institutional Repository) ● Metadata: 118704 (Link to Publication Site) ● Publication site (DOI): 10.1507/endocrj.EJ18-0441 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30842364 ● Summary page in Scopus @ Elsevier: 2-s2.0-85067126364 (Tokushima University Institutional Repository: 118704, DOI: 10.1507/endocrj.EJ18-0441, PubMed: 30842364, Elsevier: Scopus)
67.	Naoki Sakane, Takashi Murata, Atsuhito Tone, Ken Kato, Moritsugu Kimura, Satoshi Kawashima, Hideaki Sawaki, Yushi Hirota, Akira Okada, Akio Kuroda, Munehide Matsuhisa, Tomokazu Watanabe, Akiko Suganuma, Shinsuke Nirengi and Masao Toyoda : Development and Validation of the Continuous Subcutaneous Insulin Infusion-related Quality of Life (CSII-QOL) Scale., Diabetes Technology & Therapeutics, Vol.22, No.3, 216-221, 2019. (Summary) The CSII-QOL is the first CSII-related QOL scale for people with T1D. This short, validated, and reliable instrument might potentially be useful in future clinical studies and routine clinical patient care. Further validation is required to confirm these issues because of the small and potentially biased sample. (UMIN-CTR: UMIN000031595). (Link to Publication Site) ● Publication site (DOI): 10.1089/dia.2019.0216 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31638420 ● Search Scopus @ Elsevier (PMID): 31638420 ● Search Scopus @ Elsevier (DOI): 10.1089/dia.2019.0216 (DOI: 10.1089/dia.2019.0216, PubMed: 31638420)
68.	Hiroyasu Mori, Akio Kuroda, Masashi Ishizu, Mami Ohishi, Yuichi Takashi, Yinhua Otsuka, Satoshi Taniguchi, Motoyuki Tamaki, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Yuko Akehi and Munehide Matsuhisa : Association of accumulated advanced glycation end-products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes., Journal of Diabetes Investigation, 2019. (Summary) Advanced glycation end-products (AGEs), which are a major cause of diabetic vascular complications, accumulate in various tissues under chronic hyperglycemic conditions, as well as with aging in patients with diabetes. The loss of muscle mass and strength, so-called sarcopenia and dynapenia, has recently been recognized as a diabetic complication. However, the influence of accumulated AGEs on muscle mass and strength remains unclear. The present study aimed to evaluate the association of sarcopenia and dynapenia with accumulated AGEs in patients with type 2 diabetes. We recruited 166 patients with type 2 diabetes aged 30 years (mean age 63.2 ± 12.3 years; body mass index 26.3 ± 4.9 kg/m ; glycated hemoglobin 7.1 ± 1.1%). Skin autofluorescence as a marker of AGEs, limb skeletal muscle mass index, grip strength, knee extension strength and gait speed were assessed. Sarcopenia and dynapenia were observed in 7.2 and 13.9% of participants, respectively. Skin autofluorescence was significantly higher in patients with sarcopenia and dynapenia. Skin autofluorescence was the independent determinant for skeletal muscle mass index, grip strength, knee extension strength, sarcopenia and dynapenia. Accumulated AGEs could contribute to reduced muscle mass and strength, leading to sarcopenia and dynapenia in patients with type 2 diabetes. (Tokushima University Institutional Repository) ● Metadata: 114022 (Link to Publication Site) ● Publication site (DOI): 10.1111/jdi.13014 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30677242 ● Search Scopus @ Elsevier (PMID): 30677242 ● Search Scopus @ Elsevier (DOI): 10.1111/jdi.13014 (Tokushima University Institutional Repository: 114022, DOI: 10.1111/jdi.13014, PubMed: 30677242)
69.	Takashi Murata, Shinsuke Nirengi, Naoki Sakane, Akio Kuroda, Yushi Hirota, Munehide Matsuhisa, Mitsuyoshi Namba and Tetsuro Kobayashi : Safety of the batteries and power units used in insulin pumps: A pilot cross-sectional study by the Association for the Study of Innovative Diabetes Treatment in Japan., Journal of Diabetes Investigation, Vol.9, No.4, 903-907, 2018. (Summary) As trouble related to the batteries and power units of insulin pumps was frequent, practical guidance should be provided to respective patients regarding the use of reliable batteries, and to be well prepared for unexpected insulin pump failure. (Tokushima University Institutional Repository) ● Metadata: 115508 (Link to Publication Site) ● Publication site (DOI): 10.1111/jdi.12765 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29055098 ● Search Scopus @ Elsevier (PMID): 29055098 ● Search Scopus @ Elsevier (DOI): 10.1111/jdi.12765 (Tokushima University Institutional Repository: 115508, DOI: 10.1111/jdi.12765, PubMed: 29055098)
70.	Munehide Matsuhisa and Akio Kuroda : New risk factors of severe hypoglycemia., Journal of Diabetes Investigation, Vol.10, No.2, 219-220, 2018. (Tokushima University Institutional Repository) ● Metadata: 115362 (Link to Publication Site) ● Publication site (DOI): 10.1111/jdi.12925 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30175462 ● Search Scopus @ Elsevier (PMID): 30175462 ● Search Scopus @ Elsevier (DOI): 10.1111/jdi.12925 (Tokushima University Institutional Repository: 115362, DOI: 10.1111/jdi.12925, PubMed: 30175462)
71.	Masahiko Miyagi, Hiroshi Uchino, Naoki Kumashiro, Mariko Higa, Koki Shin, Makiko Sasamoto, Hiroji Kitazato, Motoyuki Tamaki, Munehide Matsuhisa and Takahisa Hirose : Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm., Diabetes Therapy, Vol.9, No.5, 1959-1968, 2018. (Summary) Trial Registry (UMIN-CTR) as UMIN000012224. (Tokushima University Institutional Repository) ● Metadata: 118703 (Link to Publication Site) ● Publication site (DOI): 10.1007/s13300-018-0486-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30121725 ● Search Scopus @ Elsevier (PMID): 30121725 ● Search Scopus @ Elsevier (DOI): 10.1007/s13300-018-0486-1 (Tokushima University Institutional Repository: 118703, DOI: 10.1007/s13300-018-0486-1, PubMed: 30121725)
72.	Mitsuyoshi Namba, Toshio Iwakura, Rimei Nishimura, Kohei Akazawa, Munehide Matsuhisa, Yoshihito Atsumi, Jo Satoh and Toshimasa Yamauchi : The current status of treatment-related severe hypoglycemia in Japanese patients with diabetes mellitus: A report from the committee on a survey of severe hypoglycemia in the Japan Diabetes Society., Journal of Diabetes Investigation, 2018. (Summary) ) than among those with type 1 diabetes (73.3 [53.5-91.1] mL/min/1.73 m (Tokushima University Institutional Repository) ● Metadata: 115507 (Link to Publication Site) ● Publication site (DOI): 10.1111/jdi.12790 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29498232 ● Search Scopus @ Elsevier (PMID): 29498232 ● Search Scopus @ Elsevier (DOI): 10.1111/jdi.12790 (Tokushima University Institutional Repository: 115507, DOI: 10.1111/jdi.12790, PubMed: 29498232)
73.	Shusuke Yagi, Ken-ichi Aihara, Takeshi Kondo, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Daiju Fukuda, Yutaka Nakaya, Kin-Ichiro Suwaki, Takashi Takeji, Toshihiro Wada, Masdan Hotimah Salim, Saori Hama, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Takeshi Tobiume, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Munehide Matsuhisa, Michio Shimabukuro, Masashi Akaike and Masataka Sata : Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus., Advances in Therapy, Vol.35, No.1, 124-134, 2017. (Summary) Predictors for the effect of sodium glucose co-transporter 2 (SGLT2) inhibitors at lowering hemoglobin A1c (HbA1c) levels in type 2 diabetes mellitus patients remain unclear. We therefore aimed to elucidate these predictors in type 2 diabetes patients after 3 months of SGLT2 treatment. A total of 302 consecutive type 2 diabetes patients who had been treated with SGLT2 inhibitors as monotherapy or add-on therapy to existing antidiabetic treatments were enrolled retrospectively. After excluding 27 patients whose HbA1c levels could not be evaluated 3 months after treatment, the glucose-lowering effects of SGLT2 inhibitors were assessed in 275 patients by measuring HbA1c levels before and 3 months after treatment. The predictors for changes in HbA1c levels after 3 months of treatment were evaluated. SGLT2 inhibitor treatment for 3 months decreased HbA1c levels from 7.8 ± 1.2% to 7.4 ± 1.0% (p < 0.0001). A multiple regression analysis showed that the independent determinants for SGLT2 inhibitor treatment effect included decreased HbA1c levels after 1 month of treatment, high baseline HbA1c levels, and a high estimated glomerular filtration rate (eGFR). We show that type 2 diabetes patients who received the greatest glucose-lowering effect with SGLT2 inhibitor treatment were those with preserved renal function (high baseline eGFR) and high baseline HbA1c levels. Moreover, SGLT2 inhibitor treatment efficacy could be predicted by the patients' initial response to treatment. (Link to Publication Site) ● Publication site (DOI): 10.1007/s12325-017-0639-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29185199 ● Summary page in Scopus @ Elsevier: 2-s2.0-85035102977 (DOI: 10.1007/s12325-017-0639-z, PubMed: 29185199, Elsevier: Scopus)
74.	Kohjiro Ueki, Takayoshi Sasako, Yukiko Okazaki, Masayuki Kato, Sumie Okahata, Hisayuki Katsuyama, Mikiko Haraguchi, Ai Morita, Ken Ohashi, Kazuo Hara, Atsushi Morise, Kazuo Izumi, Naoki Ishizuka, Yasuo Ohashi, Mitsuhiko Noda, Takashi Kadowaki, Group Study J-DOIT3 and Munehide Matsuhisa : Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial., The Lancet. Diabetes & Endocrinology, Vol.5, No.12, 951-964, 2017. (Summary) Ministry of Health, Labour and Welfare of Japan, Asahi Kasei Pharma, Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Kissei Pharmaceutical, Kowa Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Novo Nordisk, Ono Pharmaceutical, Pfizer, Sanwa Kagaku Kenkyusho, Shionogi, Sumitomo Dainippon Pharma, Taisho Toyama Pharmaceutical, and Takeda. (Link to Publication Site) ● Publication site (DOI): 10.1016/S2213-8587(17)30327-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29079252 ● Search Scopus @ Elsevier (PMID): 29079252 ● Search Scopus @ Elsevier (DOI): 10.1016/S2213-8587(17)30327-3 (DOI: 10.1016/S2213-8587(17)30327-3, PubMed: 29079252)
75.	Akio Kuroda, Satoshi Taniguchi, Yuko Akehi, Hiroyasu Mori, Motoyuki Tamaki, Reiko Suzuki, Yinhua Otsuka and Munehide Matsuhisa : Accuracy and Time Delay of Glucose Measurements of Continuous Glucose Monitoring and Bedside Artificial Pancreas During Hyperglycemic and Euglycemic Hyperinsulinemic Glucose Clamp Study., Journal of Diabetes Science and Technology, Vol.11, No.6, 1096-1100, 2017. (Summary) Both CGM and AP failed to follow plasma glucose values during nonphysiologically rapid glucose rising, but indicated accurate values during physiological glucose change. (Keyword) Adult / Biomarkers / Blood Glucose / Diabetes Mellitus, Type 2 / Female / Glucose Clamp Technique / Humans / Hypoglycemic Agents / Insulin / Insulin Infusion Systems / Male / Middle Aged / Monitoring, Ambulatory / Pancreas, Artificial / Point-of-Care Systems / Predictive Value of Tests / Reproducibility of Results / Retrospective Studies / Time Factors / Treatment Outcome (Tokushima University Institutional Repository) ● Metadata: 114040 (Link to Publication Site) ● Publication site (DOI): 10.1177/1932296817735122 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28992720 ● Search Scopus @ Elsevier (PMID): 28992720 ● Search Scopus @ Elsevier (DOI): 10.1177/1932296817735122 (Tokushima University Institutional Repository: 114040, DOI: 10.1177/1932296817735122, PubMed: 28992720)
76.	Kiyoe Kurahashi, Itsuro Endo, Takeshi Kondo, Kana Morimoto, Sumiko Yoshida, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Kohhei Nakajima, Yoshifumi Mizobuchi, Shinji Nagahiro, Masahiro Abe and Seiji Fukumoto : Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review., Internal Medicine, Vol.56, No.18, 2455-2461, 2017. (Summary) Acromegaly is caused by excessive growth hormone secretion, usually from pituitary adenomas. Somoatostatin analogues are widely used as primary or adjunctive therapy in the management of acromegaly. In this report, we present a case with remarkable shrinkage of a tumor after relatively short-term octreotide long-acting release (LAR) administration. During the 30-month follow-up after starting octreotide LAR, there was no recurrence of acromegaly with remarkable shrinkage of the tumor on pituitary magnetic resonance imaging. A literature review of the predictors for tumor shrinkage after the administration of somatostatin analogues in patients with acromegaly is also discussed in relation to this case. (Tokushima University Institutional Repository) ● Metadata: 114396 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.8223-16 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28824054 ● Summary page in Scopus @ Elsevier: 2-s2.0-85029653591 (Tokushima University Institutional Repository: 114396, DOI: 10.2169/internalmedicine.8223-16, PubMed: 28824054, Elsevier: Scopus)
77.	Hiroyasu Mori, Akio Kuroda, Michiko Araki, Reiko Suzuki, Satoshi Taniguchi, Motoyuki Tamaki, Yuko Akehi and Munehide Matsuhisa : Advanced glycation end products is a risk for muscle weakness in Japanese patients with type 1 diabetes., Journal of Diabetes Investigation, Vol.8, No.3, 377-382, 2017. (Summary) Accumulation of advanced glycation end products (AGEs) is thought to contribute to muscle weakness in a diabetic animal model. Skin autofluorescence (AF) is a proposed marker for accumulation of AGEs in the skin. We aimed to investigate the relationship between AGEs accumulation, sarcopenia, and muscle function of Japanese patients with type 1 diabetes. Thirty-six patients with type 1 diabetes participated in this cross-sectional study. Sarcopenia parameters (skeletal muscle mass index (SMI) and knee extension strength) were compared with subcutaneous AGEs accumulation using skin AF. The prevalence of sarcopenia and impaired knee extension strength was 16.6% (male: 0.0%, female: 22.2%) and 47.2% (male: 22.2%, female: 55.6%), respectively. Knee extension strength was negatively correlated with skin AF (r²= 0.14, p < 0.05), but not with SMI. In conclusion, the AGEs accumulation might be one of the reasons of impaired lower limb muscle function in Japanese patients with type 1 diabetes. This article is protected by copyright. All rights reserved. (Tokushima University Institutional Repository) ● Metadata: 114021 (Link to Publication Site) ● Publication site (DOI): 10.1111/jdi.12582 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27727515 ● Search Scopus @ Elsevier (PMID): 27727515 ● Search Scopus @ Elsevier (DOI): 10.1111/jdi.12582 (Tokushima University Institutional Repository: 114021, DOI: 10.1111/jdi.12582, PubMed: 27727515)
78.	Hirotsugu Yamada, Atsushi Tanaka, Kenya Kusunose, Rie Amano, Munehide Matsuhisa, Hiroyuki Daida, Masaaki Ito, Hiroyuki Tsutsui, Mamoru Nanasato, Haruo Kamiya, K Yasuko Bando, Masato Odawara, Hisako Yoshida, Toyoaki Murohara, Masataka Sata and Koichi Node : Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study., Cardiovascular Diabetology, Vol.16, No.1, 63, 2017. (Summary) Diabetes is associated closely with an increased risk of cardiovascular events, including diastolic dysfunction and heart failure that leads to a shortening of life expectancy. It is therefore extremely valuable to evaluate the impact of antidiabetic agents on cardiac function. However, the influence of dipeptidyl peptidase 4 inhibitors on cardiac function is controversial and a major matter of clinical concern. We therefore evaluated the effect of sitagliptin on echocardiographic parameters of diastolic function in patients with type 2 diabetes as a sub-analysis of the PROLOGUE study. (Tokushima University Institutional Repository) ● Metadata: 114509 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12933-017-0546-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28490337 ● Search Scopus @ Elsevier (PMID): 28490337 ● Search Scopus @ Elsevier (DOI): 10.1186/s12933-017-0546-2 (Tokushima University Institutional Repository: 114509, DOI: 10.1186/s12933-017-0546-2, PubMed: 28490337)
79.	Naoji Mita, Shinji Kawahito, Tomohiro Soga, Kazumi Takaishi, Hiroshi Kitahata, Munehide Matsuhisa, Mitsuo Shimada, Kinoshita Hiroyuki, Yasuo Tsutsumi and Katsuya Tanaka : Strict blood glucose control by an artificial endocrine pancreas during hepatectomy may prevent postoperative acute kidney injury, Journal of Artificial Organs, Vol.20, No.1, 76-83, 2017. (Summary) The aim of the present study was to evaluate the usefulness of a closed-loop system (STG-55; Nikkiso, Tokyo, Japan), a type of artificial endocrine pancreas for the continuous monitoring and control of intraoperative blood glucose, for preventing postoperative acute kidney injury (AKI) in patients undergoing hepatectomy. Thirty-eight patients were enrolled in this study. Glucose concentrations were controlled with either a manual injection of insulin based on a commonly used sliding scale (manual insulin group, n = 19) or the programmed infusion of insulin determined by the control algorithm of the artificial endocrine pancreas (programmed insulin group, n = 19). After the induction of anesthesia, a 20-G intravenous catheter was inserted into the peripheral forearm vein of patients in the programmed insulin group and connected to an artificial endocrine pancreas (STG-55). The target range for glucose concentrations was set to 100-150 mg/dL. The mean serum creatinine concentrations of preoperative, postoperative 24 and 48 h were 0.72, 0.78, and 0.79 mg/dL in the programmed insulin group, and 0.81, 0.95, and 1.03 mg/dL in the manual insulin group, respectively. Elevations in serum creatinine concentrations postoperative 48 h were significantly suppressed in the programmed insulin group. The STG-55 closed-loop system was effective for maintaining strict blood glucose control during hepatectomy with minimal variability in blood glucose concentrations and for suppressing elevations in serum creatinine concentrations. Strict blood glucose control by an artificial endocrine pancreas during hepatectomy may prevent postoperative AKI. (Keyword) Acute Kidney Injury / Aged / Aged, 80 and over / Blood Glucose / Creatinine / Female / Hepatectomy / Humans / Insulin / Insulin Infusion Systems / Japan / Male / Middle Aged / Pancreas, Artificial / Postoperative Complications / Treatment Outcome (Tokushima University Institutional Repository) ● Metadata: 110117 (Link to Publication Site) ● Publication site (DOI): 10.1007/s10047-016-0925-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27557726 ● Search Scopus @ Elsevier (PMID): 27557726 ● Search Scopus @ Elsevier (DOI): 10.1007/s10047-016-0925-6 (Tokushima University Institutional Repository: 110117, DOI: 10.1007/s10047-016-0925-6, PubMed: 27557726)
80.	Akio Kuroda, Tsuruo Miho, Aki Nanako, Takeshi Kondo, Oguro Yukari, Motoyuki Tamaki, Ken-ichi Aihara, Itsuro Endo, Toshio Matsumoto, Masahiro Abe and Munehide Matsuhisa : A Pirot study comparing the CGM-assessed glycemic profiles of patients with type 1 diabetes on insulin degludec and insulin glargine, Diabetology International, Vol.8, No.1, 112-115, 2017. (Link to Publication Site) ● Publication site (DOI): 10.1007/s13340-016-0289-4 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-85013200573 (DOI: 10.1007/s13340-016-0289-4, Elsevier: Scopus)
81.	Mitsuyoshi Namba, Toshio Iwakura, Rimei Nishimura, Kohei Akazawa, Munehide Matsuhisa, Yoshihito Atsumi, Jo Satoh, Toshimasa Yamauchi and Mellitus: A Report from the Committee on a Survey of Severe Hypoglycemia in the Japan Diabetes Society : The Current Status of Treatment-related Severe Hypoglycemia in Japanese Patients with Diabetes Mellitus: A Report from the Committee on a Survey of Severe Hypoglycemia in the Japan Diabetes Society, Journal of the The Japan Diabetes Society, Vol.60, No.12, 826-842, 2017. (Summary) <p>Despite great strides in pharmacotherapy for diabetes, there is increasing concern over the risk of hypoglycemia in diabetes patients receiving pharmacotherapy as they become older. This has prompted the Japan Diabetes Society (JDS) to initiate a survey on the current status of severe hypoglycemia in the clinical setting. In July 2015, after receiving approval from the JDS Scientific Survey/Research Ethics Committee, the JDS extended an invitation to executive educators, who represented a total of 631 healthcare facilities accredited by the JDS for diabetes education, to participate in the proposed survey. Among these educators, those who expressed their willingness to participate in the survey were sent an application form to obtain ethical approval from their hospitals. After receiving approval, they were asked to enter relevant clinical data (on an unlinked, anonymous basis) into a web-based registry. The current survey was fully funded by the JDS Scientific Survey/Research Committee. A case registry (clinical case database) was launched after collecting facility-specific information (healthcare facility database) from all of the participating facilities and after obtaining informed consent from all of the participating patients. The current survey, which defined severe hypoglycemia as "the presence of hypoglycemic symptoms requiring assistance from another person to treat and plasma venous glucose levels at the onset/diagnosis of disease or glucose levels that were clearly less than 60 mg/dL at presentation (capillary whole blood glucose, <50 mg/dL) ", was conducted between April 1, 2014 and March 31, 2015, During the study period, facility-specific information was collected from a total of 193 healthcare facilities with a total of 798 case reports collected from 113 facilities. (View PDF for the rest of the abstract.)</p> (Link to Publication Site) ● Publication site (DOI): 10.11213/tonyobyo.60.826 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001204908851968 ● Summary page in Scopus @ Elsevier: 2-s2.0-85040044085 (DOI: 10.11213/tonyobyo.60.826, CiNii: 1390001204908851968, Elsevier: Scopus)
82.	Tomoyuki Yuasa, Kikuko Amo-Shiinoki, Shuhei Ishikura, Mitsuyoshi Takahara, Takaaki Matsuoka, Hideaki Kaneto, Akio Kuroda, Munehide Matsuhisa and Seiichi Hashida : Sequential cleavage of insulin receptor by calpain 2 and -secretase impairs insulin signalling., Diabetologia, Vol.59, No.12, 2711-2721, 2016. (Summary) Sequential cleavage of IR by calpain 2 and -secretase may contribute to insulin signalling in cells and its inhibition may be partly responsible for the glucose-lowering effects of metformin. Thus, IR cleavage may offer a new mechanism for the aetiology of insulin resistance. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00125-016-4102-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27695899 ● Summary page in Scopus @ Elsevier: 2-s2.0-84989201840 (DOI: 10.1007/s00125-016-4102-5, PubMed: 27695899, Elsevier: Scopus)
83.	Takeshi Kondo, Itsuro Endo, Yukari Ooguro, Kana Morimoto, Kiyoe Kurahashi, Sumiko Yoshida, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Masahiro Abe and Seiji Fukumoto : Suppression of the Hypothalamic-pituitary-adrenal Axis by Maximum Androgen Blockade in a Patient with Prostate Cancer., Internal Medicine, Vol.55, No.24, 3623-3626, 2016. (Summary) A 78-year-old Japanese man showed suppression of the hypothalamic-pituitary-adrenal axis during maximum androgen blockade (MAB) therapy including chlormadinone acetate (CMA) for prostate cancer. After stopping the MAB therapy, both the basal ACTH level and the response to CRH recovered. While no reports have indicated that CMA suppresses the hypothalamic-pituitary-adrenal axis in patients with prostate cancer, CMA has been shown to inhibit this axis in animals. These observations suggest that we must monitor the hypothalamic-pituitary-adrenal axis in patients treated with CMA, especially under stressful conditions. (Keyword) Adrenal Glands / Adrenocorticotropic Hormone / Aged / Androgen Antagonists / Animals / Antineoplastic Agents / Chlormadinone Acetate / Corticotropin-Releasing Hormone / Diabetes Mellitus, Type 2 / Humans / Hypothalamo-Hypophyseal System / Male / Pituitary-Adrenal System / Prostatic Neoplasms / Treatment Outcome (Tokushima University Institutional Repository) ● Metadata: 114392 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.55.7359 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27980263 ● Summary page in Scopus @ Elsevier: 2-s2.0-85007140325 (Tokushima University Institutional Repository: 114392, DOI: 10.2169/internalmedicine.55.7359, PubMed: 27980263, Elsevier: Scopus)
84.	Hirofumi Tomiyama, Takashi Miwa, Kenshi Kan, Munehide Matsuhisa, Haruo Kamiya, Mamoru Nanasato, Tomoki Kitano, Hiroaki Sano, Jun Ohno, Masato Iida, Masataka Sata, Hirotsugu Yamada, Koji Maemura, Atsushi Tanaka, Toyoaki Murohara and Koichi Node : Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study., Cardiovascular Diabetology, Vol.15, No.1, 150, 2016. (Summary) No conclusive evidence has been obtained yet on the significance of the effects of dipeptidyl peptidase-4 (DPP-4 inhibitor) treatment on the arterial stiffness in clinical settings. In addition, the effects of good glycemic control on the arterial stiffness have also not been clarified yet. As a sub-analysis of the PROLOGUE study, we examined the effect of a DPP-4 inhibitor (sitagliptin) on the 2-year progression of the arterial stiffness and also to determine the effect of good glycemic control on the rate of progression of the arterial stiffness. In the PROLOGUE study, the study participants were either allocated to add-on sitagliptin treatment or to continued treatment with conventional anti-diabetic agents. Among the 463 participants of the PROLOGUE study, we succeeded in measuring the brachial-ankle pulse wave velocity (baPWV) at least two times during the 2-year study period in 96 subjects. The changes in the baPWV during the study period were similar between the both groups (i.e., with/without staglipitin), overall. On the other hand, when the study subjects were divided into two groups according to the glycemic control status during the study period {good glycemic control group (GC) = hemoglobin (Hb)A1c <7.0 at both 12 and 24 months after the treatment randomization; poor glycemic control group (PC) = HbA1c ≥7.0 at either 12 months, 24 months, or both}, the 2-year increase of the baPWV was marginally significantly larger in the PC group (144 ± 235 cm/s) as compared to that the GC group (-10 ± 282 cm/s) (p = 0.036). While the present study could not confirm the beneficial effect of sitagliptin per se on the arterial stiffness, the results suggested that good glycemic control appears to be beneficial for delaying the annual progression of the arterial stiffness. Trial registration University Hospital Medical Information Network Clinical Trials Registry UMIN000004490. (Tokushima University Institutional Repository) ● Metadata: 114508 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12933-016-0472-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27809848 ● Summary page in Scopus @ Elsevier: 2-s2.0-84994050554 (Tokushima University Institutional Repository: 114508, DOI: 10.1186/s12933-016-0472-8, PubMed: 27809848, Elsevier: Scopus)
85.	Munehide Matsuhisa, Masayoshi Koyama, Xi Cheng, Mariko Sumi, C Matthew Riddle, B Geremia Bolli and Takahisa Hirose : Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension)., Diabetes Research and Clinical Practice, Vol.122, 133-140, 2016. (Summary) Over 12months' treatment, participants with type 1 diabetes receiving Gla-300 achieved sustained glycaemic control and experienced less nocturnal hypoglycaemia that was confirmed (<3.0mmol/L [<54mg/dL]) or severe compared with Gla-100, supporting the 6-month results. (Keyword) Adult / Blood Glucose / Blood Glucose Self-Monitoring / Diabetes Mellitus, Type 1 / Female / Follow-Up Studies / Hemoglobin A, Glycosylated / Humans / Hypoglycemia / Hypoglycemic Agents / Insulin Glargine / Insulin, Long-Acting / Japan / Male / Middle Aged / Time Factors (Link to Publication Site) ● Publication site (DOI): 10.1016/j.diabres.2016.10.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27835765 ● Search Scopus @ Elsevier (PMID): 27835765 ● Search Scopus @ Elsevier (DOI): 10.1016/j.diabres.2016.10.002 (DOI: 10.1016/j.diabres.2016.10.002, PubMed: 27835765)
86.	Fuminori Tanihara, Tatsuya Takemoto, Eri Kitagawa, Shengbin Rao, Kim Lanh Thi Do, Akira Onishi, Yukiko Yamashita, Chisato Kosugi, Hitomi Suzuki, Shoichiro Sembon, Shunichi Suzuki, Michiko Nakai, Masakazu Hashimoto, Akihiro Yasue, Munehide Matsuhisa, Sumihare Noji, Tatsuya Fujimura, Dai-Ichiro Fuchimoto and Takeshige Otoi : Somatic cell reprogramming-free generation of genetically modified pigs., Science Advances, Vol.2, No.9, 2016. (Summary) Genetically modified pigs for biomedical applications have been mainly generated using the somatic cell nuclear transfer technique; however, this approach requires complex micromanipulation techniques and sometimes increases the risks of both prenatal and postnatal death by faulty epigenetic reprogramming of a donor somatic cell nucleus. As a result, the production of genetically modified pigs has not been widely applied. We provide a simple method for CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 gene editing in pigs that involves the introduction of Cas9 protein and single-guide RNA into in vitro fertilized zygotes by electroporation. The use of gene editing by electroporation of Cas9 protein (GEEP) resulted in highly efficient targeted gene disruption and was validated by the efficient production of Myostatin mutant pigs. Because GEEP does not require the complex methods associated with micromanipulation for somatic reprogramming, it has the potential for facilitating the genetic modification of pigs. (Tokushima University Institutional Repository) ● Metadata: 110154 (Link to Publication Site) ● Publication site (DOI): 10.1126/sciadv.1600803 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27652340 ● Search Scopus @ Elsevier (PMID): 27652340 ● Search Scopus @ Elsevier (DOI): 10.1126/sciadv.1600803 (Tokushima University Institutional Repository: 110154, DOI: 10.1126/sciadv.1600803, PubMed: 27652340)
87.	A Tanaka, T Murohara, I Taguchi, K Eguchi, M Suzuki, M Kitakaze, Y Sato, T Ishizu, Y Higashi, Hirotsugu Yamada, M Nanasato, Michio Shimabukuro, H Teragawa, S Ueda, S Kodera, Munehide Matsuhisa, T Kadokami, K Kario, Y Nishio, T Inoue, K Maemura, J Oyama, M Ohishi, Masataka Sata, H Tomiyama, K Node and Investigators Study PROTECT : Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study., Cardiovascular Diabetology, Vol.15, No.1, 133, 2016. (Summary) BACKGROUND: Type 2 diabetes mellitus is associated strongly with an increased risk of micro- and macro-vascular complications, leading to impaired quality of life and shortened life expectancy. In addition to appropriate glycemic control, multi-factorial intervention for a wide range of risk factors, such as hypertension and dyslipidemia, is crucial for management of diabetes. A recent cardiovascular outcome trial in diabetes patients with higher cardiovascular risk demonstrated that a SGLT2 inhibitor markedly reduced mortality, but not macro-vascular events. However, to date there is no clinical evidence regarding the therapeutic effects of SGLT2 inhibitors on arteriosclerosis. The ongoing PROTECT trial was designed to assess whether the SGLT2 inhibitors, ipragliflozin, prevented progression of carotid intima-media thickness in Japanese patients with type 2 diabetes mellitus.METHODS: A total of 480 participants with type 2 diabetes mellitus with a HbA1c between 6 and 10 % despite receiving diet/exercise therapy and/or standard anti-diabetic agents for at least 3 months, will be randomized systematically (1:1) into either ipragliflozin or control (continuation of conventional therapy) groups. After randomization, ipragliflozin (50-100 mg once daily) will be added on to the background therapy in participants assigned to the ipragliflozin group. The primary endpoint of the study is the change in mean intima-media thickness of the common carotid artery from baseline to 24 months. Images of carotid intima-media thickness will be analyzed at a central core laboratory in a blinded manner. The key secondary endpoints include the change from baseline in other parameters of carotid intima-media thickness, various metabolic parameters, and renal function. Other cardiovascular functional tests are also planned for several sub-studies.DISCUSSION: The PROTECT study is the first to assess the preventive effect of ipragliflozin on progression of carotid atherosclerosis using carotid intima-media thickness as a surrogate marker. The study has potential to clarify the protective effects of ipragliflozin on atherosclerosis. Trial registration Unique Trial Number, UMIN000018440 ( https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021348 ). (Keyword) Adult / Aged / Biomarkers / Carotid Artery Diseases / Carotid Artery, Common / Carotid Intima-Media Thickness / Clinical Protocols / Diabetes Mellitus, Type 2 / Diabetic Angiopathies / Drug Therapy, Combination / Female / Glucosides / Hemoglobin A, Glycosylated / Humans / Hypoglycemic Agents / Japan / Male / Middle Aged / Prospective Studies / Research Design / Sodium-Glucose Transporter 2 / Thiophenes / Time Factors / Treatment Outcome / Young Adult (Tokushima University Institutional Repository) ● Metadata: 114507 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12933-016-0449-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27619983 ● Search Scopus @ Elsevier (PMID): 27619983 ● Search Scopus @ Elsevier (DOI): 10.1186/s12933-016-0449-7 (Tokushima University Institutional Repository: 114507, DOI: 10.1186/s12933-016-0449-7, PubMed: 27619983)
88.	Saeko Osawa, Naoto Katakami, Akio Kuroda, Mitsuyoshi Takahara, Fumie Sakamoto, Dan Kawamori, Takaaki Matsuoka, Munehide Matsuhisa and Iichiro Shimomura : Skin Autofluorescence is Associated with Early-stage Atherosclerosis in Patients with Type 1 Diabetes., Journal of Atherosclerosis and Thrombosis, 2016. (Summary) Skin AF was significantly associated with the presence and/or severity of diabetic complications and was an independent risk factor for carotid atherosclerosis. (Tokushima University Institutional Repository) ● Metadata: 115485 (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.35592 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27592627 ● Search Scopus @ Elsevier (PMID): 27592627 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.35592 (Tokushima University Institutional Repository: 115485, DOI: 10.5551/jat.35592, PubMed: 27592627)
89.	B Allen King, Akio Kuroda, Munehide Matsuhisa and Todd Hobbs : A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes., Current Diabetes Reports, Vol.16, No.9, 2016. (Summary) Dosing guidelines for patients with type 1 diabetes using continuous subcutaneous insulin infusion (CSII), which are historically based on clinical experience and retrospective studies of patients consuming an American diet, recommend that basal insulin should represent approximately 50 % of the total daily dose (TDD). Recent prospective studies in the USA and Japan conclude that the more appropriate proportion is closer to 30-40 % of TDD. In addition, currently used formulas for calculating the carbohydrate-to-insulin ratio (CIR) and correction factor (CF) may lead to underdosing of bolus insulin by as much as 12.8-50 % for a hypothetical patient. The discrepancies between traditional formulas and data from newer studies can be accounted for by the more rigorous design of the newer studies (e.g., prospective design, controlled diets, meal omission, and frequent glucose monitoring). International differences in diet composition may also be important to consider when developing dosing recommendations for CSII. (Tokushima University Institutional Repository) ● Metadata: 115078 (Link to Publication Site) ● Publication site (DOI): 10.1007/s11892-016-0772-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27457238 ● Search Scopus @ Elsevier (PMID): 27457238 ● Search Scopus @ Elsevier (DOI): 10.1007/s11892-016-0772-0 (Tokushima University Institutional Repository: 115078, DOI: 10.1007/s11892-016-0772-0, PubMed: 27457238)
90.	J Oyama, T Murohara, M Kitakaze, T Ishizu, Y Sato, K Kitagawa, H Kamiya, M Ajioka, M Ishiara, K Dai, M Nanasato, Masataka Sata, K Maemura, H Tomiyama, Y Higashi, K Kaku, Hirotsugu Yamada, Munehide Matsuhisa, K Yamashita, YK Bando, N Kashihara, S Ueda, T Inoue, K Node and Investigators Study PROLOGUE : The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial., PLoS Medicine, Vol.13, No.6, e1002051, 2016. (Summary) BACKGROUND: Experimental studies have suggested that dipeptidyl peptidase-4 (DPP-4) inhibitors provide cardiovascular protective effects. We performed a randomized study to evaluate the effects of sitagliptin added on to the conventional therapy compared with conventional therapy alone (diet, exercise, and/or drugs, except for incretin-related agents) on the intima-media thickness (IMT) of the carotid artery, a surrogate marker for the evaluation of atherosclerotic cardiovascular disease, in people with type 2 diabetes mellitus (T2DM).METHODS AND FINDINGS: We used a multicenter PROBE (prospective, randomized, open label, blinded endpoint) design. Individuals aged 30 y with T2DM (6.2% HbA1c < 9.4%) were randomly allocated to receive either sitagliptin (25 to 100 mg/d) or conventional therapy. Carotid ultrasound was performed at participating medical centers, and all parameters were measured in a core laboratory. Of the 463 enrolled participants with T2DM, 442 were included in the primary analysis (sitagliptin group, 222; conventional therapy group, 220). Estimated mean (± standard error) common carotid artery IMT at 24 mo of follow-up in the sitagliptin and conventional therapy groups was 0.827 ± 0.007 mm and 0.837 ± 0.007 mm, respectively, with a mean difference of -0.009 mm (97.2% CI -0.028 to 0.011, p = 0.309). HbA1c level at 24 mo was significantly lower with sitagliptin than with conventional therapy (6.56% ± 0.05% versus 6.72% ± 0.05%, p = 0.008; group mean difference -0.159, 95% CI -0.278 to -0.041). Episodes of serious hypoglycemia were recorded only in the conventional therapy group, and the rate of other adverse events was not different between the two groups. As it was not a placebo-controlled trial and carotid IMT was measured as a surrogate marker of atherosclerosis, there were some limitations of interpretation.CONCLUSIONS: In the PROLOGUE study, there was no evidence that treatment with sitagliptin had an additional effect on the progression of carotid IMT in participants with T2DM beyond that achieved with conventional treatment.TRIAL REGISTRATION: University Hospital Medical Information Network Clinical Trials Registry UMIN000004490. (Tokushima University Institutional Repository) ● Metadata: 114321 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pmed.1002051 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27351380 ● Search Scopus @ Elsevier (PMID): 27351380 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pmed.1002051 (Tokushima University Institutional Repository: 114321, DOI: 10.1371/journal.pmed.1002051, PubMed: 27351380)
91.	Munehide Matsuhisa, M. Koyama, X Cheng, Y Takahashi, M C Riiddle, G B Boli, T Hirose and on behalf of the Edition JP 1 study group : New insulin glargine 300 U/mL versus glargine 100 U/mL in Japanese adults with type 1 diabetes using basal and mealtime insulinglucose control and hypoglycaemia in a randomized controlled trial, Diabetes, Obesity & Metabolism, Vol.18, No.4, 375-383, 2016. (Summary) To compare efficacy and safety of new insulin glargine 300 U/ml (Gla-300) with that of insulin glargine 100 U/ml (Gla-100) in Japanese adults with type 1 diabetes. The EDITION JP 1 study (NCT01689129) was a 6-month, multicentre, open-label, phase III study. Participants (n = 243) were randomized to Gla-300 or Gla-100 while continuing mealtime insulin. Basal insulin was titrated with the aim of achieving a fasting self-monitored plasma glucose target of 4.4-7.2 mmol/l. The primary endpoint was change in glycated haemoglobin (HbA1c) over 6 months. Safety measures included hypoglycaemia and change in body weight. Gla-300 was non-inferior to Gla-100 for the primary endpoint of HbA1c change over the 6-month period {least squares [LS] mean difference 0.13 % [95 % confidence interval (CI) -0.03 to 0.29]}. The annualized rate of confirmed (≤3.9 mmol/l) or severe hypoglycaemic events was 34 % lower with Gla-300 than with Gla-100 at night [rate ratio 0.66 (95 % CI 0.48-0.92)] and 20 % lower at any time of day [24 h; rate ratio 0.80 (95 % CI 0.65-0.98)]; this difference was most pronounced during the first 8 weeks of treatment. Severe hypoglycaemia was infrequent. The basal insulin dose increased in both groups (month 6 dose: Gla-300 0.35 U/kg/day, Gla-100 0.29 U/kg/day). A between-treatment difference in body weight change over 6 months favouring Gla-300 was observed [LS mean difference -0.6 kg (95 % CI -1.1 to -0.0); p = 0.035]. Adverse event rates were comparable between the groups. In Japanese adults with type 1 diabetes using basal plus mealtime insulin, less hypoglycaemia was observed with Gla-300 than with Gla-100, particularly during the night, while glycaemic control did not differ. (Keyword) Adult / Delayed-Action Preparations / Diabetes Mellitus, Type 1 / Dose-Response Relationship, Drug / Drug Administration Schedule / Drug Resistance, Multiple / Drug Therapy, Combination / Female / Follow-Up Studies / Hemoglobin A, Glycosylated / Humans / Hyperglycemia / Hypoglycemia / Hypoglycemic Agents / Insulin Detemir / Insulin Glargine / Japan / Male / Middle Aged / risk (Tokushima University Institutional Repository) ● Metadata: 115086 (Link to Publication Site) ● Publication site (DOI): 10.1111/dom.12619 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26662964 ● Summary page in Scopus @ Elsevier: 2-s2.0-84959866323 (Tokushima University Institutional Repository: 115086, DOI: 10.1111/dom.12619, PubMed: 26662964, Elsevier: Scopus)
92.	Takeshi Kondo, Itsuro Endo, Ken-ichi Aihara, Ohnishi Yukiyo, Dong Bingzi, Oguro Yukari, Kiyoe Kurahashi, Sumiko Yoshida, Yuichi Fujinaka, Akio Kuroda, Munehide Matsuhisa, Seiji Fukumoto, Toshio Matsumoto and Masahiro Abe : Serum carboxy-terminal telopeptide of type I collagen levels are associated with carotid atherosclerosis in patients with cardiovascular risk factors., Endocrine Journal, Vol.63, No.4, 397-404, 2016. (Summary) Carboxy-terminal telopeptide of type I collagen (ICTP) is generated through matrix metalloproteinase (MMP)-dependent type I collagen digestion, and has been widely utilized as a biomarker for bone turnover. The fact that atherosclerotic lesions are rich in both type I collagen and MMP-producing macrophages led to the hypothesis that serum ICTP concentrations may serve as a non-invasive clinical biomarker for atherosclerosis. Therefore, the association of serum ICTP concentrations with the maximum intima-media thickness (IMT) of carotid arteries, a surrogate index of systemic atherosclerosis, or brachial-ankle pulse wave velocity (baPWV) in patients with atherosclerotic risk factors was evaluated. A total of 52 male and 65 female (mean age: 62.8 yrs) patients without renal failure, malignancies or bone diseases known to affect serum ICTP concentrations were recruited. Patients with max IMTs ≥1.1 mm showed significantly higher serum ICTP concentrations compared with patients with max IMTs <1.1 mm (3.33 ± 0.97 vs 2.82 ± 0.65 ng/mL, p<0.05). Serum ICTP concentration was also positively correlated with max IMT (p<0.001) or baPWV values (p<0.05). Multivariate analyses also revealed that serum ICTP concentrations were correlated with max IMT (p<0.001; 95% CI 0.200 to 0.454). These results suggest that serum ICTP concentrations can be used as a non-invasive biomarker for systemic atherosclerosis. (Tokushima University Institutional Repository) ● Metadata: 109666 (Link to Publication Site) ● Publication site (DOI): 10.1507/endocrj.EJ15-0589 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26877258 ● Summary page in Scopus @ Elsevier: 2-s2.0-84964267287 (Tokushima University Institutional Repository: 109666, DOI: 10.1507/endocrj.EJ15-0589, PubMed: 26877258, Elsevier: Scopus)
93.	Akio Kuroda and Munehide Matsuhisa : Carbohydrate Counting and Its Consumption, Journal of the The Japan Diabetes Society, Vol.59, No.1, 24-26, 2016. (Keyword) カーボカウント / 血糖コントロール / 食事療法 / 食品交換表 (Link to Publication Site) ● Publication site (DOI): 10.11213/tonyobyo.59.24 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001204909511040 ● Search Scopus @ Elsevier (DOI): 10.11213/tonyobyo.59.24 (DOI: 10.11213/tonyobyo.59.24, CiNii: 1390001204909511040)
94.	Munehide Matsuhisa : 糖尿病地域医療連携のIT化の試み∼その現状と課題∼, NPO法人日本糖尿病情報学会誌, Vol.14, 2016.
95.	Saeko Osawa, Dan Kawamori, Naoto Katakami, Mitsuyoshi Takahara, Fumie Sakamoto, Takashi Katsura, Tetsuyuki Yasuda, Hideaki Kaneto, Munehide Matsuhisa, Taka-Aki Matsuoka and Iichiro Shimomura : Significant elevation of serum dipeptidyl peptidase-4 activity in young-adult type 1 diabetes., Diabetes Research and Clinical Practice, Vol.113, 135-142, 2016. (Summary) Serum DPP-4 activity is significantly elevated in Japanese type 1 diabetes, suggesting pathophysiological significance of the enzyme in type 1 diabetes. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.diabres.2015.12.022 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26827118 ● Summary page in Scopus @ Elsevier: 2-s2.0-84960077763 (DOI: 10.1016/j.diabres.2015.12.022, PubMed: 26827118, Elsevier: Scopus)
96.	Yumi Kuwamura, Sumikawa Masuko, Tetsuya Tanioka, Toshihiko Nagata, Eijiro Sakamoto, Hiromi Murata, Munehide Matsuhisa, Ken-ichi Aihara, Daisuke Hinode, Hirokazu Uemura, Hirokazu Ito, Yuko Yasuhara and Rozzano De Castro Locsin : Development of the Diabetes Oral Health Assessment Tool © for Nurses, Health, Vol.7, No.12, 1710-1720, 2015. (Keyword) diabetes mellitus / oral health behaviors / Oral Status / Nursing Assessment / Diabetes Nurse Specialist (Link to Publication Site) ● Publication site (DOI): 10.4236/health.2015.712186 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.4236/health.2015.712186 (DOI: 10.4236/health.2015.712186)
97.	Jin Temma, Munehide Matsuhisa, Toru Horie, Akio Kuroda, Hiroyasu Mori, Motoyuki Tamaki, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe and Toshio Matsumoto : Non-invasive Measurement of Skin Autofluorescence as a Beneficial Surrogate Marker for Atherosclerosis in Patients with Type 2 Diabetes, The Journal of Medical Investigation : JMI, Vol.62, No.3-4, 126-129, 2015. (Summary) Advanced glycation end-products (AGEs) are thought to play a major role in the pathogenesis of diabetic vascular complications. Skin autofluorescence (AF) was recently reported to represent tissue AGEs accumulation with a non-invasive method. The aim of the present study was to evaluate association between AF value and diabetic vascular complications, such as retinopathy, nephropathy and cervical atherosclerosis using the carotid intima-media thickness (IMT), an established marker of cardiovascular disease in patients with type 2 diabetes. A total of 68 patients with type 2 diabetes were enrolled in a cross-sectional manner. AGEs accumulation was measured with AF reader. Clinical parameters were collected at the time of AF and IMT measurement. Max-IMT was correlated with age and AF (r=0.407, p=0.001), but not with HbA1c, GA, and pentosidine. Also, AF was not correlated with HbA1c, GA and pentosidine, but was correlated with age (r=0.560, p<0.001), duration of diabetes (r=0.256, p<0.05). Multivariate regression analysis revealed that AF, but not age, was an independent determinant of max-IMT. In conclusion, AF might be a beneficial surrogate marker for evaluating carotid atherosclerosis in patients with type 2 diabetes non-invasively. J. Med. Invest. 62: 126-129, August, 2015. (Tokushima University Institutional Repository) ● Metadata: 111266 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.62.126 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26399335 ● Summary page in Scopus @ Elsevier: 2-s2.0-84942054596 (Tokushima University Institutional Repository: 111266, DOI: 10.2152/jmi.62.126, PubMed: 26399335, Elsevier: Scopus)
98.	Kenichi Deguchi, Tetsuya Enishi, Nori Sato, Hajime Miura, Yuichi Fujinaka, Munehide Matsuhisa and Shinsuke Katoh : Acute effect of fast walking on postprandial blood glucose control in type 2 diabetes, Diabetology International, 2015. (Link to Publication Site) ● Publication site (DOI): 10.1007/s13340-015-0217-z (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1007/s13340-015-0217-z (DOI: 10.1007/s13340-015-0217-z)
99.	寺内康夫, 池田勧夫, 弘世貴久, Munehide Matsuhisa and 小田原雅人 : インスリン治療による低血糖と日常生活への影響に関するアンケート調査, Japanese Journal of Medicine and Pharmaceutical Science, Vol.72, No.6, 1059-1074, 2015.
100.	Noriko Kambe, Shinji Kawahito, Naoji Mita, Kazumi Takaishi, Tosiko Katayama, Yoko Sakai, Tomohiro Soga, Hiroaki Kawano, Munehide Matsuhisa, Mitsuo Shimada, Tetsuya Kitagawa and Hiroshi Kitahata : Impact of newly developed, next-generation artificial endocrine pancreas, The Journal of Medical Investigation : JMI, Vol.62, No.1-2, 41-44, 2015. (Summary) Recent studies have shown that strict perioperative blood glucose management may reduce mortality and morbidity in critically ill adult patients. The purpose of this study was to assess the accuracy and efficacy of the intraoperative application of a newly developed, next-generation artificial endocrine pancreas (STG-55, Nikkiso Co., Ltd., Tokyo, Japan). Twenty patients scheduled to undergo surgery were enrolled in this study. The STG-55 is designed to be more user-friendly than its conventional counterpart (STG-22) while maintaining the latter's fundamental functions, such as a closed-loop system using algorithms for insulin and glucose infusion. After anesthetic induction, a 20G intravenous catheter was inserted into a peripheral forearm vein and connected to a continuous blood glucose monitor. The resultant 105 scores for paired blood glucose values were compared by Bland-Altman analysis. Stable blood glucose values were maintained automatically, and there were no complications related to use of the STG-55. A close correlation (r=0.96) was observed between continuous glucose measurements using the STG-55 and conventional intermittent glucose measurements. The difficulty of manipulation using this system was decreased by improved preparation procedures. The glycemic control system using the STG-55 could provide an alternative way to achieve effective and safe perioperative glycemic control. (Keyword) artificial endocrine pancreas (Tokushima University Institutional Repository) ● Metadata: 111244 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.62.41 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25817282 ● Summary page in Scopus @ Elsevier: 2-s2.0-84925857956 (Tokushima University Institutional Repository: 111244, DOI: 10.2152/jmi.62.41, PubMed: 25817282, Elsevier: Scopus)
101.	Masato Tagi, Yuu Tamaki, Tomiaki Morikawa, Munehide Matsuhisa and Hiroki Moriguchi : The Behavior Modification to the Lifestyle by Healthy Condition Visualization which Utilized NFC Communication Pedometer, Japan Journal of Medical Informatics, Vol.34, No.6, 281-291, 2015. (Summary) To record individual body weight and physical activity has been shown to be beneficial for maintaining personal health. We, therefore, established a system which connects a personal computer and health appliances to record body weight, daily step, and blood pressure. We applied this system to 226 employees in 3 companies during the period of October, 2011-March, 2013 and evaluated whether this system could improve individual behavioral modification. One hundred sixty seven persons (73.9%) had continuously recorded the measurement of the pedometer for at least one year. We compared the average of the first three months with the average of the next three months. As a result, the number of steps tended to increase to 7,515±4,629 steps from 7,299±3,731steps (p=0.075). As for blood pressure, the systolic phase significantly decreased from 129.2±13.2 mmHg to 127.1±13.5 mmHg (p=0.028), and diastolic phase decreased from 78.6±9.8 mmHg to 76.0±9.9 mmHg (p=0.00016). BMI also significantly decreased from 23.3±2.9 kg/m2 to 23.2±2.8 kg/m2(p=0.029). In conclusion, to record daily step, body weight and blood pressure by using newly established system improved individual behavior towards a healthy condition. (Keyword) NFC communication pedometer / Healthcare administration / Visualization / Behavioral modification / Lifestyle improvement (Link to Publication Site) ● Publication site (DOI): 10.14948/jami.34.281 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205751456384 ● Search Scopus @ Elsevier (DOI): 10.14948/jami.34.281 (DOI: 10.14948/jami.34.281, CiNii: 1390001205751456384)
102.	Munehide Matsuhisa, Akio Kuroda and Yuu Tamaki : Establishment of the Local Medical Care System for Diabetes Using by ICT Network in Tokushima, 日本糖尿病情報学会誌 = Journal of the Japan Association of Diabetes Informatics, No.12, 12-20, 2014. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1521699231080411776 (CiNii: 1521699231080411776)
103.	Keiko Fujisawa, Tetsuyuki Yasuda, Hideaki Kaneto, Naoto Katakami, Mayumi Tsuji, Fumiyo Kubo, Shugo Sasaki, Kazuyuki Miyashita, Toyoko Naka, Ryuuichi Kasami, Akio Kuroda, Munehide Matsuhisa and Iichiro Shimomura : Short- and long-term effect of sitagliptin after near normalization of glycemic control with insulin in poorly controlled Japanese type 2 diabetic patients., Journal of Diabetes Investigation, Vol.5, No.5, 548-553, 2014. (Summary) These findings suggest that near normalization of glycemic control with insulin improves the clinical response to sitagliptin in poorly controlled type 2 diabetic patients. (Link to Publication Site) ● Publication site (DOI): 10.1111/jdi.12176 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25411623 ● Search Scopus @ Elsevier (PMID): 25411623 ● Search Scopus @ Elsevier (DOI): 10.1111/jdi.12176 (DOI: 10.1111/jdi.12176, PubMed: 25411623)
104.	Naoki Shimo, Tetsuyuki Yasuda, Hideaki Kaneto, Naoto Katakami, Akio Kuroda, Fumie Sakamoto, Mitsuyoshi Takahara, Yoko Irie, Keiko Horikawa, Kazuyuki Miyashita, Takeshi Miyatsuka, Kazutomi Yoshiuchi, Dan Kawamori, Ken'ya Sakamoto, Taka-aki Matsuoka, Keisuke Kosugi, Iichiro Shimomura and Munehide Matsuhisa : Vitamin D deficiency is significantly associated with retinopathy in young Japanese type 1 diabetic patients., Diabetes Research and Clinical Practice, Vol.106, No.2, e41-3, 2014. (Summary) The aim of this study was to examine the possible association of vitamin D deficiency with diabetic retinopathy in 75 young Japanese type 1 diabetic patients. A multivariate regression analysis, duration of diabetes and vitamin D deficiency were independent determinants of diabetic retinopathy. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.diabres.2014.08.005 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25287616 ● Search Scopus @ Elsevier (PMID): 25287616 ● Search Scopus @ Elsevier (DOI): 10.1016/j.diabres.2014.08.005 (DOI: 10.1016/j.diabres.2014.08.005, PubMed: 25287616)
105.	Kayo Hirose, Shinji Kawahito, Naoji Mita, Kazumi Takaishi, Tomiya Kawahara, Tomohiro Soga, Toshiko Katayama, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Mitsuo Shimada, Munehide Matsuhisa and Hiroshi Kitahata : Usefulness of artificial endocrine pancreas during resection of insulinoma., The Journal of Medical Investigation : JMI, Vol.61, No.3-4, 421-425, 2014. (Summary) A 71-year-old woman had an episode of syncope due to hypoglycemia of 27 mg/dl. She was diagnosed with insulinoma and scheduled for laparoscopic enucleation along with the use of an artificial endocrine pancreas (STG-22, Nikkiso Co., Ltd., Tokyo, Japan). Anesthesia was maintained with sevoflurane and remifentanil. Her blood glucose level was controlled using the artificial endocrine pancreas, which enabled continuous blood glucose monitoring and computer-operated glucose and insulin infusion to maintain the blood glucose level at a steady state. The target concentration of blood glucose was set at 80-120 mg/dl during surgery. Until removal of the tumor, the blood glucose level was kept at around 80-100 mg/dl. After removal of the tumor, the blood glucose level gradually increased, but it was kept in the normal range by the artificial endocrine pancreas. The artificial endocrine pancreas was useful to monitor and maintain blood glucose levels during and after the removal of insulinoma, without any hyper- or hypoglycemia. J. Med. Invest. 61: 421-425, August, 2014. (Tokushima University Institutional Repository) ● Metadata: 109597 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.61.421 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25264066 ● Summary page in Scopus @ Elsevier: 2-s2.0-84907483198 (Tokushima University Institutional Repository: 109597, DOI: 10.2152/jmi.61.421, PubMed: 25264066, Elsevier: Scopus)
106.	Ken-ichiro Kato, Toshinari Takamura, Yumie Takeshita, Yasuji Ryu, Hirofumi Misu, Tsuguhito Ota, Kumpei Tokuyama, Shoichiro Nagasaka, Munehide Matsuhisa, Osamu Matsui and Shuichi Kaneko : Ectopic fat accumulation and distant organ-specific insulin resistance in Japanese people with nonalcoholic fatty liver disease., PLoS ONE, Vol.9, No.3, e92170, 2014. (Summary) Unexpectedly, fat accumulation in the skeletal muscle and adipose tissue was not associated with organ-specific IR. Instead, liver fat was associated not only with hepatic IR but also with skeletal muscle IR, suggesting a central role of fatty liver in systemic IR and that a network exists between liver and skeletal muscle. (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0092170 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24651470 ● CiNii @ National Institute of Informatics (CRID): 1050845760881138176 ● Summary page in Scopus @ Elsevier: 2-s2.0-84898645515 (DOI: 10.1371/journal.pone.0092170, PubMed: 24651470, CiNii: 1050845760881138176, Elsevier: Scopus)
107.	Hidenori Yoshii, Tomio Onuma, Tsutomu Yamazaki, Hirotaka Watada, Munehide Matsuhisa, Masayasu Matsumoto, Kazuo Kitagawa, Masafumi Kitakaze, Yoshimitsu Yamasaki and Ryuzo Kawamori : Effects of Pioglitazone on Macrovascular Events in Patients with Type 2 Diabetes Mellitus at High Risk of Stroke: The PROFIT-J Study., Journal of Atherosclerosis and Thrombosis, Vol.21, No.6, 563-573, 2014. (Summary) Aim: The present study evaluated the effects of pioglitazone treatment on the incidence of primary cardiovascular events in Japanese subjects with type 2 diabetes mellitus at high risk of stroke. Methods: A prospective, multicenter, randomized, open label, comparative study was conducted among diabetic patients recruited from 50 medical institutions nationwide. A total of 522 patients with hypertension and/or dyslipidemia who had one or more silent cerebral infarcts, advanced carotid atherosclerosis or microalbuminuria at baseline were randomly treated with (n=254) or without pioglitazone (n=268) and observed for a medium of 672 days. The hypertension and dyslipidemia were concurrently treated according to the respective treatment guidelines. The primary outcome was the time to the first occurrence of a composite of all-cause death, nonfatal cerebral infarction and nonfatal myocardial infarction. Results: Treatment with pioglitazone resulted in significant reductions in the levels of HbA1c, diastolic blood pressure and LDL-cholesterol and a significant increase in the levels of HDL-cholesterol. The pioglitazone non-users exhibited a significant reduction in the LDL-cholesterol levels alone. Primary events were registered during the study period in nine patients in the pioglitazone group and 10 patients in the non-pioglitazone group. The difference in the cumulative incidence of the primary outcome was not significant between the two groups(1.8% per year). Conclusions: Pioglitazone therapy produces immediate and effective improvements in glycemic control, diastolic blood pressure and lipid profiles. While this study was too underpowered to determine the effects of pioglitazone on the incidence of cardiovascular events, the results indicated that two years of pioglitazone treatment did not produce any statistically significant reductions in the rate of primary cardiovascular events. (Keyword) Pioglitazone / Primary prevention / Mortality-macrovascular events / Diabetes mellitus (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.21626 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24477028 ● CiNii @ National Institute of Informatics (CRID): 1390001204430867840 ● Summary page in Scopus @ Elsevier: 2-s2.0-84903184764 (DOI: 10.5551/jat.21626, PubMed: 24477028, CiNii: 1390001204430867840, Elsevier: Scopus)
108.	Mizuho Kinouchi, Ken-ichi Aihara, Yuichi Fujinaka, Sumiko Yoshida, Yukari Ooguro, Kiyoe Kurahashi, Takeshi Kondo, Nanako Aki, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Toshio Matsumoto : Diabetic conditions differentially affect the endothelial function, arterial stiffness and carotid atherosclerosis., Journal of Atherosclerosis and Thrombosis, Vol.21, No.5, 486-500, 2014. (Summary) Aim: The levels of fasting and postprandial plasma glucose, HbA1c and other risk factors for atherosclerosis have distinct effects in patients with and those without diabetes mellitus. The aim of this study was to determine the impact of diabetic surrogate markers on the endothelial function, arterial stiffness and carotid atherosclerosis in individuals with and without diabetes. Methods: A total of 320 Japanese subjects(mean age: 61.2±12.1 years) were recruited in this study. Demographic, clinical and laboratory parameters, including 75 g OGTT(155 subjects) results, were examined. The endothelial function was evaluated according to the flow-mediated vasodilation of the brachial artery(%FMD). In addition, arterial stiffness was evaluated according to the brachial-ankle pulse wave velocity(baPWV), and carotid atherosclerotic changes were estimated according to the maximum intima-media thickness(max-IMT) and resistive index of the common carotid artery(CCA-RI). A multiple regression analysis was performed to identify independent determinants of these vascular surrogate markers. Results: None of the glucose-related parameters were associated with the %FMD. In contrast, the presence of T2DM, the HbA1c level and an increased plasma glucose level at 60 minutes during 75 g OGTT were associated with an increased baPWV. The HbA1c level was also correlated with an increased max-IMT. The fasting plasma glucose(FPG) level and the presence of T2DM correlated with an increased CCA-RI. In the subjects with T2DM, the protective effects of high-density lipoprotein cholesterol(HDL-C) on the %FMD and baPWV were abolished. Conclusions: Various glucose metabolism parameters have different effects the degree of arterial stiffness and presence of carotid atherosclerosis, but not the endothelial function, suggesting that pharmacological intervention has the potential to preserve the endothelial function in diabetic individuals. In addition, the presence of T2DM blunts the vascular protective effects of HDL-C on the endothelial function and progression of arterial stiffness. (Keyword) Type 2 diabetes / Endothelial function / Arterial stiffness / Carotid atherosclerosis (Tokushima University Institutional Repository) ● Metadata: 106061 (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.20834 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24401746 ● CiNii @ National Institute of Informatics (CRID): 1390001204430842112 ● Summary page in Scopus @ Elsevier: 2-s2.0-84901494272 (Tokushima University Institutional Repository: 106061, DOI: 10.5551/jat.20834, PubMed: 24401746, CiNii: 1390001204430842112, Elsevier: Scopus)
109.	Akio Kuroda, 丸山千寿子 and Munehide Matsuhisa : Carbohydrate Content in Dishes Other than Staple Foods Based on the Food Exchange Lists (7th edition) Allowing for a 50-60 % Energy Intake from Carbohydrates, Journal of the The Japan Diabetes Society, Vol.57, No.12, 921-922, 2014. (Keyword) 食品交換表 / カーボカウント (Link to Publication Site) ● Publication site (DOI): 10.11213/tonyobyo.57.921 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001204906835712 ● Summary page in Scopus @ Elsevier: 2-s2.0-84937120633 (DOI: 10.11213/tonyobyo.57.921, CiNii: 1390001204906835712, Elsevier: Scopus)
110.	Takeshi Kondo, Akio Kuroda, 曽我部公子, 大黒由加里, 倉橋清衛, Motoyuki Tamaki, Mizuho Kinouchi, Sumiko Yoshida, 安芸菜奈子, Itsuro Endo, Ken-ichi Aihara, Yuichi Fujinaka, Munehide Matsuhisa and Toshio Matsumoto : Comparison of Continuous Glucose Monitoring (CGM) Values before and after Adrenalectomy in a Case of Adrenaline-producing Pheochromocytoma, Journal of the The Japan Diabetes Society, Vol.57, No.9, 729-735, 2014. (Summary) A 77-year-old woman was incidentally found to have a left adrenal mass measuring 2.5 cm in January 2012. The urine metanephrine concentration was 3.0 mg/day (normal range, 0.04-0.19 mg/day), and an iodine-131 metaiodobenzylguanidine (MIBG) scan showed uptake in the area of the left adrenal gland, leading to a diagnosis of pheochromocytoma. In addition, the patient had a history of diabetes mellitus for nine years, with gradually worsening blood glucose control since 2010. The patient was subsequently admitted to our hospital for perioperative care. On admission, her fasting blood glucose level was 121 mg/dl and her HbA1c level was 8.5 %. She was treated with basal-bolus insulin therapy during hospitalization and underwent adrenalectomy at the urology department after her glycemic control had improved. The total daily insulin dose was immediately decreased from 50 to 14 units after the adrenalectomy procedure. In addition, the mean glucose level on preoperative continuous glucose monitoring (CGM) had been 141 mg/dl with a standard deviation (SD) of 54. However, after the operation, the mean glucose level increased to 153 mg/dl while the SD decreased to 24; thus, the range of glycemic fluctuation markedly decreased after surgery. Therefore, excess endogenous adrenalin primarily contributed to the glycemic fluctuations observed in this patient with pheochromocytoma. (Keyword) 褐色細胞腫 / アドレナリン / 糖尿病 / CGM(持続血糖モニター) (Link to Publication Site) ● Publication site (DOI): 10.11213/tonyobyo.57.729 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001204908593792 ● Summary page in Scopus @ Elsevier: 2-s2.0-84908507898 (DOI: 10.11213/tonyobyo.57.729, CiNii: 1390001204908593792, Elsevier: Scopus)
111.	小林哲郎, 難波光義, Akio Kuroda, Munehide Matsuhisa, 山田研太郎, 今村洋一, 金重勝博, 浜口朋也, 川村智行, 佐藤譲, 高橋和眞, 丸山太郎, 西村理明, 勝野朋幸, 楠宜樹, 清水一紀, 柳澤克之, 粟田卓也 and 雨宮伸 : Consensus Statement on Continuous Subcutaneous Insulin Infusion and Continuous Glucose Monitoring, Journal of the The Japan Diabetes Society, Vol.57, No.6, 403-415, 2014. (Summary) The use of continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) in clinical practice is increasing in Japan. Against this background, the Association for the Study of Innovative Diabetes Treatment in Japan (ASINDTJ) arranged a Consensus Statement of opinions for the optimal and safe routine use of CSII and CGM. The Consensus Statement on the routine use of CSII and CGM includes patient selection and indications for clinical outcomes as well as risk management for routine use. The development of patient educational programs conducted by diabetologists in association with certified diabetes educators (CDEs) regarding the use of pumps and/or CGM is a prerequisite for clinical use. In addition, items associated with CSII and CGM, such as insulin dose adjustment, application methods for use in daily life, diet and exercise, risk management of pump difficulties, " sick day" occasions and skin problems, are included in the Consensus Statement. Our consensus opinion and suggestions also emphasize the usefulness of CSII and CGM in adult diabetic patients as well as children with type 1 and type 2 diabetes and pregnant diabetic patients. According to the Consensus Statement, the development of detailed educational guidelines for the use of CSII and CGM is needed. (Keyword) Continuous subcutaneous insulin infusion(CSII)(C-14) (Link to Publication Site) ● Publication site (DOI): 10.11213/tonyobyo.57.403 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001204907971072 ● Summary page in Scopus @ Elsevier: 2-s2.0-84903996238 (DOI: 10.11213/tonyobyo.57.403, CiNii: 1390001204907971072, Elsevier: Scopus)
112.	弘世貴久, 渡邉隆宏, 綿田裕孝, 安孫子亜津子, 羽田勝計, 武部典子, 佐藤譲, 山口賢, 石原寿光, 前田朝美, 江藤一弘, 太田明雄, 田中逸, 武田貞二, 駒津光久, 卯木智, 前川聡, 伊藤裕進, 能宗伸輔, 廣峰義久, 川畑由美子, 池上博司, 寺前純吾, 花房俊昭, 富永貴元, 井上康, 谷澤幸生, Toshio Matsumoto, Akio Kuroda, Munehide Matsuhisa, 野見山崇, 柳瀬敏彦, 小林邦久, 近藤龍也, 荒木栄一, 石井則夫, 井形元雄, 久木留大介, 本島寛之 and 河盛隆造 : Effectiveness of miglitol combined with various types of insulin therapy for reducing the daily glycemic fluctuation on Japanese type 2 diabetic patients: Evaluation with self-monitoring blood glucose (SMBG), Therapeutic Research, Vol.34, No.12, 1503-1511, 2013. (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-84893163294 (Elsevier: Scopus)
113.	Kenya Sakamoto, Fumiyo Kubo, Kazutomi Yoshiuchi, Akemi Ono, Toshiyuki Sato, Koji Tomita, Kazuhiko Sakaguchi, Munehide Matsuhisa, Hideaki Kaneto, Hiroshi Maegawa, Hiromu Nakajima, Atsunori Kashiwagi and Keisuke Kosugi : Usefulness of a novel system for measuring glucose area under the curve while screening for glucose intolerance in outpatients., Journal of Diabetes Investigation, Vol.4, No.6, 552-559, 2013. (Summary) The findings suggest that our glucose AUC measurement system using MIET would be useful for screening of glucose intolerance. In the future, this system may prove to be a useful aid as a screen for glucose intolerance before performing an OGTT for diagnosis. (Link to Publication Site) ● Publication site (DOI): 10.1111/jdi.12096 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24843709 ● Search Scopus @ Elsevier (PMID): 24843709 ● Search Scopus @ Elsevier (DOI): 10.1111/jdi.12096 (DOI: 10.1111/jdi.12096, PubMed: 24843709)
114.	Kazuhiko Sakaguchi, Yushi Hirota, Naoko Hashimoto, Wataru Ogawa, Tomoya Hamaguchi, Toshihiro Matsuo, Jun-ichiro Miyagawa, Mitsuyoshi Namba, Toshiyuki Sato, Seiki Okada, Koji Tomita, Munehide Matsuhisa, Hideaki Kaneto, Keisuke Kosugi, Hiroshi Maegawa, Hiromu Nakajima and Atsunori Kashiwagi : Evaluation of a minimally invasive system for measuring glucose area under the curve during oral glucose tolerance tests: usefulness of sweat monitoring for precise measurement., Journal of Diabetes Science and Technology, Vol.7, No.3, 678-688, 2013. (Summary) We confirmed the effectiveness of a sweat monitoring patch for precise AUC measurement using MIET. This novel, easy-to-use system has potential for glucose excursion evaluation in daily clinical practice. (Keyword) Area Under Curve / Diabetes Mellitus / Extracellular Fluid / Female / Glucose / Glucose Tolerance Test / Humans / Hydrogels / Male / Middle Aged / Monitoring, Physiologic / Self Care / Sweat (Link to Publication Site) ● Publication site (DOI): 10.1177/193229681300700313 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23759401 ● Summary page in Scopus @ Elsevier: 2-s2.0-84892428268 (DOI: 10.1177/193229681300700313, PubMed: 23759401, Elsevier: Scopus)
115.	Kazuyuki Miyashita, Tetsuyuki Yasuda, Hideaki Kaneto, Akio Kuroda, Tetsuhiro Kitamura, Michio Otsuki, Yasuyuki Okamoto, Noboru Hamada, Munehide Matsuhisa and Iichiro Shimomura : A Case of Hypocalcemia with Severe Vitamin D Deficiency following Treatment for Graves' Disease with Methimazole., Case Reports in Endocrinology, Vol.2013, 2013. (Summary) We herein report the case of a 41-year-old Japanese female office worker who developed symptomatic hypocalcemia with severe vitamin D deficiency following treatment for Graves' disease with methimazole. The patient's hypocalcemia was mainly caused by vitamin D deficiency due to unbalanced diets and inadequate exposure to sunlight in addition to the resolution of hyperthyroidism. Vitamin D deficiency is increasing worldwide, and it has been more recently shown to relate to the pathogenesis of Graves' disease. However, vitamin D deficiency as a cause of hypocalcemia has received little attention. Taken together, this case suggests that we should take more care in calcium kinetics and vitamin D status during treatment for Graves' disease with antithyroid drugs. (Link to Publication Site) ● Publication site (DOI): 10.1155/2013/512671 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23710380 ● Search Scopus @ Elsevier (PMID): 23710380 ● Search Scopus @ Elsevier (DOI): 10.1155/2013/512671 (DOI: 10.1155/2013/512671, PubMed: 23710380)
116.	Sumiko Yoshida, Akio Kuroda, 新居沙央里, 松本友里, 近藤絵里, 安藝菜奈子, Itsuro Endo, Ken-ichi Aihara, 鈴木麗子, Toshio Matsumoto and Munehide Matsuhisa : The New Paradigm 722 Insulin Pump Can Achieve Good Glycemic Control with Carbohydrate Counting Alone : A Case Report of Type 1 Diabetes Mellitus, Journal of the The Japan Diabetes Society, Vol.56, No.4, 240-245, 2013. (Summary) インスリンポンプParadigm712は，インスリン作用時間(AIT)が8時間の設定のため，十分な食後血糖補正インスリン投与を提案しないが，新しいParadigm 722はAITを2~8時間に設定できる．そこで，Paradigm 722の食後血糖補正インスリン量の妥当性を検証した．症例は1型糖尿病の50歳代女性．入院の上インスリンリスプロでParadigm 722を導入，食事スキップで基礎インスリンを設定し，糖質/インスリン比を各食前(11，15，13)g/Uとしたカーボカウントのもと，AITを3時間，インスリン効果値を60mg/dl/Uと設定した．退院前1週間の食後2時間血糖補正の際，150mg/dlを目標にインスリン効果値を用いた補正による自己算出インスリン量とポンプでの自動算出インスリン量とを比較した．食後高血糖に対する補正インスリンは，14回中7回で自己算出量よりも自動算出量が適切であった．Paradigm 722による食後補正インスリン自動算出法は，自己算出法と同等で，これを用いることで良好な血糖管理が簡便になった．(著者抄録) (Keyword) インスリン作用 / 持続皮下インスリン注入療法 / カーボカウント / 1型糖尿病 (Link to Publication Site) ● Publication site (DOI): 10.11213/tonyobyo.56.240 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001204909103744 ● Summary page in Scopus @ Elsevier: 2-s2.0-84878045431 (DOI: 10.11213/tonyobyo.56.240, CiNii: 1390001204909103744, Elsevier: Scopus)
117.	K Shima, H Ishimoto, N Hari, Y Shintani, Y Fukushima, Y Noma, Munehide Matsuhisa, A Otsuka, M Saito, I Imoto, T Okabe, Y Nakagawa, H Fujiwara, Y Fujinaka, M Sei, A Shirakami, M Komatsu, M Tsuruo, K Matsumoto, T Tanaka, M Miyamoto, H Ogawa and Y Furuta : Outcomes of 6 years of activities by the Tokushima Medical Associations Steering Committee for Diabetes prevention to prevent type 2 diabetes in the general population of Tokushima Prefecture., Diabetology International, Vol.4, No.1, 23-33, 2013. (Link to Publication Site) ● Publication site (DOI): 10.1007/s13340-012-0089-4 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-84875305688 (DOI: 10.1007/s13340-012-0089-4, Elsevier: Scopus)
118.	Naoto Katakami, Hideaki Kaneto, Fumie Sakamoto, Mitsuyoshi Takahara, Yoko Irie, Keiko Fujisawa, Kazuyuki Miyashita, Tetsuyuki Yasuda, Taka-Aki Matsuoka, Kazutomi Yoshiuchi, Ken'ya Sakamoto, Akio Kuroda, Munehide Matsuhisa, Keisuke Kosugi and Iichiro Shimomura : Plasma pentraxin 3 levels are associated with carotid IMT in type 1 diabetic patients., Diabetes Research and Clinical Practice, Vol.99, No.2, 185-91, 2013. (Summary) AIMS: Pentraxin3 (PTX3), a recently discovered inflammatory mediator, is produced abundantly in various cells in atherosclerotic lesions, and therefore, its plasma level could reflect local inflammation at the site of atherosclerotic lesion. The present study evaluated whether plasma PTX3 levels are associated with subclinical atherosclerosis in young subjects with type 1 diabetes. METHODS: Plasma PTX3 levels, urinary albumin excretion, diabetic retinopathy, and carotid intima-media thickness (IMT) were examined in 78 Japanese type 1 diabetic patients (30 men and 48 women, aged 28.5±5.3 years (±SD), duration of diabetes 19.7±6.5 years). RESULTS: There was statistically significant association between plasma PTX3 levels and Max-IMT (r=0.363, p=0.001). A stepwise multivariate regression analysis including conventional coronary risk factors as independent variables revealed that plasma PTX3 levels (=0.389, p<0.001), duration of diabetes (=0.256, p=0.035), and serum triglyceride levels (=0.371, p<0.001) were independent determinants of Max-IMT. In addition, plasma PTX3 levels was an independent determinant of urinary albumin excretion, an indicator of diabetic nephropathy (=0.258, p=0.018). However, there was no significant association between plasma PTX3 levels and diabetic retinopathy. CONCLUSIONS: Increased levels of plasma PTX3 are associated with accelerated atherosclerotic change and increased albuminuria in young patients with type 1 diabetes. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.diabres.2012.11.020 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23245734 ● Search Scopus @ Elsevier (PMID): 23245734 ● Search Scopus @ Elsevier (DOI): 10.1016/j.diabres.2012.11.020 (DOI: 10.1016/j.diabres.2012.11.020, PubMed: 23245734)
119.	Akio Kuroda, Hideaki Kaneto, Satoshi Kawashima, Kenya Sakamoto, Mitsuyoshi Takahara, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Naoto Katakami, Taka-Aki Matsuoka, Iichiro Shimomura and Munehide Matsuhisa : Regular insulin, rather than rapid-acting insulin, is a suitable choice for premeal bolus insulin in lean patients with type 2 diabetes mellitus., Journal of Diabetes Investigation, Vol.4, No.1, 78-81, 2013. (Summary) The aim of the present study was to compare the usefulness of premeal rapid-acting and regular insulin in type 2 diabetes patients. A total of 56 type 2 diabetic patients were investigated during hospitalization. Premeal rapid-acting insulin was applied instead of other medications. Premeal insulin was titrated to adjust premeal and bedtime blood glucose levels to 81-120 mg/dL. Premeal rapid-acting insulin was changed to regular insulin just before a meal at the same dosage if the postmeal blood glucose level was lower than the premeal blood glucose level. A total of 15 patients changed to regular insulin, and 41 patients continued rapid-acting insulin. The blood glucose level was comparable between these two groups. Body mass index was significantly lower in the patients using regular insulin. According to the multivariate logistic regression analysis, low body mass index was an independent variable accounting for the usefulness of regular insulin. Regular insulin, rather than rapid-acting insulin, is a suitable choice for premeal insulin in lean type 2 diabetic patients. (Link to Publication Site) ● Publication site (DOI): 10.1111/j.2040-1124.2012.00231.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24843634 ● Summary page in Scopus @ Elsevier: 2-s2.0-84873175220 (DOI: 10.1111/j.2040-1124.2012.00231.x, PubMed: 24843634, Elsevier: Scopus)
120.	Fumie Sakamoto, Naoto Katakami, Hideaki Kaneto, Tetsuyuki Yasuda, Mitsuyoshi Takahara, Kazuyuki Miyashita, Akio Kuroda, Munehide Matsuhisa, Keisuke Kosugi and Iichiro Shimomura : Association of serum YKL-40 levels with urinary albumin excretion rate in young Japanese patients with type 1 diabetes mellitus., Endocrine Journal, Vol.60, No.1, 73-79, 2013. (Summary) YKL-40 is a marker of inflammation and endothelial dysfunction, both of which play important roles in the progression of diabetic complications. However, little information has been obtained about serum YKL-40 levels in type 1 diabetic patients. We evaluated YKL-40 levels and its association with diabetic micro- and macroandgiopathy in 131 young Japanese type 1 diabetic patients without advanced diabetic complications (aged 24.7±5.9 years) and 97 age- and gender-matched healthy controls. YKL-40 levels were significantly elevated in type 1 diabetic patients than in healthy controls (median (range) 46.4 (20.3-136.7) and 52.3 (21.4-274.1) ng/ml, respectively, p = 0.006). There was a significant positive association between YKL-40 levels and urinary albumin creatinine ratio (UACR) (r = 0.226, p = 0.013). Furthermore, a multivariate regression analysis demonstrated that YKL-40 levels were a determinant of UACR independently of conventional risk factors. In addition, YKL-40 levels were significantly higher in participants with diabetic retinopathy compared to those without it (median (range) 55.5 (23.3-274.1) and 50.3 (21.4-237.4) ng/ml, respectively, p = 0.039). Serum YKL-40 levels were elevated in type 1 diabetic patients and associated with increasing level of albuminuria. YKL-40 could be a predictor to assess the risk of diabetic microangiopathy in the early stage in type 1 diabetic patients. (Link to Publication Site) ● Publication site (DOI): 10.1507/endocrj.EJ12-0238 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22986489 ● Search Scopus @ Elsevier (PMID): 22986489 ● Search Scopus @ Elsevier (DOI): 10.1507/endocrj.EJ12-0238 (DOI: 10.1507/endocrj.EJ12-0238, PubMed: 22986489)
121.	Shugo Sasaki, Tetsuyuki Yasuda, Hideaki Kaneto, Akio Kuroda, Yukari Fujita, Keiko Fujisawa, Yukiko Tabuchi, Ryuichi Kasami, Taka-Aki Matsuoka, Munehide Matsuhisa and Iichiro Shimomura : Basal insulin requirements after progesterone treatment in a type 1 diabetic pregnant woman., Internal Medicine, Vol.52, No.2, 259-262, 2013. (Summary) We herein report the case of a 37-year-old type 1 diabetic pregnant woman treated with an insulin pump. Although the patient's glycemic control deteriorated following progesterone treatment for the prevention of preterm delivery and miscarriage, it was improved by adjusting the basal insulin rate on the days of progesterone treatment. Excess progesterone is known to impair both insulin sensitivity and secretion. The present case is the first report to evaluate deterioration of glycemic control induced by progesterone treatment and to determine the dose of insulin required in a type 1 diabetic pregnant woman whose insulin secretion was completely depleted. (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.52.8675 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23318859 ● Summary page in Scopus @ Elsevier: 2-s2.0-84872424073 (DOI: 10.2169/internalmedicine.52.8675, PubMed: 23318859, Elsevier: Scopus)
122.	Tsuyoshi Okada, Shinji Kawahito, Naoji Mita, Munehide Matsuhisa, Hiroshi Kitahata, Mitsuo Shimada and Shuzo Oshita : Usefulness of continuous blood glucose monitoring and control for patients undergoing liver transplantation., The Journal of Medical Investigation : JMI, Vol.60, No.3-4, 205-212, 2013. (Summary) The STG-22 closed-loop system is effective for maintaining strict blood glucose control during liver transplantation with minimal variability in blood glucose concentration. (Tokushima University Institutional Repository) ● Metadata: 106358 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.60.205 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24190037 ● Summary page in Scopus @ Elsevier: 2-s2.0-84887004443 (Tokushima University Institutional Repository: 106358, DOI: 10.2152/jmi.60.205, PubMed: 24190037, Elsevier: Scopus)
123.	Miwa Yamaguchi, Akio Kuroda, Yumiko Kotani, Akiko Matsumura, Sakurako Kamano, Hirokazu Uemura, Ichiro Yokota, Shoji Kagami, Kokichi Arisawa and Munehide Matsuhisa : Evaluation of the Sugar Content in the Side Dishes Served in Elementary School Lunches, Journal of the The Japan Diabetes Society, Vol.55, No.12, 952-956, 2012. (Summary) Kuroda et al. proposed a simple method for calculating the carbohydrate content based on a food exchange list (Shokuhin Koukanhyou), with a sugar content of dietary staples of 40 % for rice, 50 % for bread, and 20 % for boiled noodles and a side dish containing 20 g sugar. This study focused on the sugar content in in school lunches, which have a nutrient composition that is different from diabetic meals. The total energy content of school lunches and the sugar content in their side dishes were investigated in 42 school lunches served in elementary school. The average energy intake in the total lunch increased depending on the school grade (670±44 to 752±50 kcal; means±standard deviation). On the other hand, the sugar content of side dishes increased from 29.7±7.5 g in the 1<sup>st</sup>-2<sup>nd</sup> grade to 31.2±8.1 g in the 5<sup>th</sup>-6<sup>th</sup> grade, thus it could be estimated to be 30 g regardless of the energy intake. Two hundred milliliters of milk containing approximately 10 g of carbohydrate was served in every school lunch, which accounted for the 10 g increase in comparison to hospital lunches. These results indicate that the sugar content in the side dishes of elementary school lunches can be estimated to be 30 g regardless of the energy intake.<br> (Keyword) 食事療法 / カーボカウント / 糖質 (Link to Publication Site) ● Publication site (DOI): 10.11213/tonyobyo.55.952 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001204908494592 ● Summary page in Scopus @ Elsevier: 2-s2.0-84873382013 (DOI: 10.11213/tonyobyo.55.952, CiNii: 1390001204908494592, Elsevier: Scopus)
124.	Toyoko Naka, Hideaki Kaneto, Naoto Katakami, Taka-Aki Matsuoka, Ayako Harada, Yoshimitsu Yamasaki, Munehide Matsuhisa and Iichiro Shimomura : Association of serum copper levels and glycemic control in patients with type 2 diabetes., Endocrine Journal, Vol.60, No.3, 393-396, 2012. (Summary) It has been suggested that copper ion is involved in the pathogenesis of various diseases. The aim of this study is to examine the association of serum copper levels and glycemic control in patients with type 2 diabetes. We recruited a total of 132 patients with type 2 diabetes, and measured their serum copper levels by atomic absorption spectrometry. Serum copper levels were positively correlated with HbA1c levels (r=0.176, p=0 .044). In addition, after 3-month glycemic control, we evaluated whether the improvement of glycemic control influenced serum copper levels. As hemoglobin A1c (HbA1c) levels were decreased (from 8.7% to 6.8%, p<0.001), copper levels tended to be decreased (from 105.7 g/dL to 101.8 g/dL, p=0.069). In conclusion, it is likely that serum copper levels are associated with glycemic control in patients with type 2 diabetes. (Link to Publication Site) ● Publication site (DOI): 10.1507/endocrj.EJ12-0342 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23197044 ● Search Scopus @ Elsevier (PMID): 23197044 ● Search Scopus @ Elsevier (DOI): 10.1507/endocrj.EJ12-0342 (DOI: 10.1507/endocrj.EJ12-0342, PubMed: 23197044)
125.	Akio Kuroda, Tetsuyuki Yasuda, Mitsuyoshi Takahara, Fumie Sakamoto, Ryuichi Kasami, Kazuyuki Miyashita, Sumiko Yoshida, Eri Kondo, Ken-ichi Aihara, Itsuro Endo, Taka-Aki Matsuoka, Hideaki Kaneto, Toshio Matsumoto, Iichiro Shimomura and Munehide Matsuhisa : Carbohydrate-to-Insulin Ratio Is Estimated from 300-400 Divided by Total Daily Insulin Dose in Type 1 Diabetes Patients Who Use the Insulin Pump., Diabetes Technology & Therapeutics, Vol.14, No.11, 1077-1080, 2012. (Summary) Abstract Background: To optimize insulin dose using insulin pump, basal and bolus insulin doses are widely calculated from total daily insulin dose (TDD). It is recommended that total daily basal insulin dose (TBD) is 50% of TDD and that the carbohydrate-to-insulin ratio (CIR) equals 500 divided by TDD. We recently reported that basal insulin requirement is approximately 30% of TDD. We therefore investigated CIR after adjustment of the proper basal insulin rate. Subjects and Methods: Forty-five Japanese patients with type 1 diabetes were investigated during several weeks of hospitalization. The patients were served standard diabetes meals (25-30 kcal/kg of ideal body weight). Each meal omission was done to confirm basal insulin rate. Target blood glucose level was set at 100 and 150 mg/dL before and 2 h after each meal, respectively. After the basal insulin rate was fixed and target blood glucose levels were achieved, TBD, CIR, TDD, and their products were determined. Results: Mean (±SD) blood glucose levels before and 2 h after meals were 121±47 and 150±61 mg/dL, respectively. TDD was 31.5±9.0 U, and TBD was 27.0±6.5% of TDD. CIR×TDD of breakfast was significantly lower than those of lunch and supper (288±73 vs. 408±92 and 387±83, respectively; P<0.01). Conclusions: CIR has diurnal variance and is estimated from the formula CIR=300/TDD at breakfast or CIR=400/TDD at lunch and supper in type 1 diabetes patients. These results indicate that the insulin dose has been underestimated by using previously established calculations. (Link to Publication Site) ● Publication site (DOI): 10.1089/dia.2012.0109 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23101953 ● Search Scopus @ Elsevier (PMID): 23101953 ● Search Scopus @ Elsevier (DOI): 10.1089/dia.2012.0109 (DOI: 10.1089/dia.2012.0109, PubMed: 23101953)
126.	Mitsuyoshi Takahara, Hideaki Kaneto, Naoto Katakami, Munehide Matsuhisa and Iichiro Shimomura : Effect of metformin on hepatic glucose production in Japanese patients with type 2 diabetes mellitus., Endocrine Journal, Vol.59, No.9, 845-847, 2012. (Summary) We investigated the effect of metformin on hepatic glucose production and peripheral glucose uptake in Asian patients with type 2 diabetes mellitus. We recruited ten Japanese patients whose fasting glucose levels remained poorly controlled under meal-time injection of short-acting insulin. Metformin was added to their insulin therapy, and both hepatic glucose production and peripheral glucose uptake were assessed before and one week after metformin treatment, with the use of stable isotope [6,6-²H₂] glucose. Metformin was titrated to a maximum dose of 500 mg. As a result, fasting glucose levels and hepatic glucose production were significantly improved after the metformin treatment (p < 0.01 and 0.02), whereas their peripheral glucose uptake was not significantly changed (p = 0.63). Furthermore, the change of fasting glucose levels was significantly correlated with that of hepatic glucose production, whose coefficient ρ was 0.76 (p = 0.01). On the other hand, there was no significant correlation between the change of fasting glucose levels and that of peripheral glucose uptake (p = 0.43). In conclusion, low dose of metformin significantly reduced hepatic glucose production in Japanese patients with type 2 diabetes mellitus. The efficacy of metformin on correcting fasting hyperglycemia was strongly associated with reduced hepatic glucose production, rather than ameliorated peripheral glucose uptake. (Keyword) Blood Glucose / Deuterium / Diabetes Mellitus, Type 2 / Drug Monitoring / multi-drug resistance / Drug Therapy, Combination / Female / Gluconeogenesis / glucose / Humans / Hyperglycemia / Hypoglycemic Agents / Infusions, Intravenous / Insulin, Short-Acting / modern Japan / drug delivery system / Male / Metformin / Middle Aged (Link to Publication Site) ● Publication site (DOI): 10.1507/endocrj.EJ12-0068 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22673502 ● Search Scopus @ Elsevier (PMID): 22673502 ● Search Scopus @ Elsevier (DOI): 10.1507/endocrj.EJ12-0068 (DOI: 10.1507/endocrj.EJ12-0068, PubMed: 22673502)
127.	Akio Kuroda and Munehide Matsuhisa : 血糖正常化 : カーボカウントを用いたアプローチ (特集血糖値の把握と正常化を目指して), Journal of the The Japan Diabetes Society, Vol.4, No.1, 78-84, 2012. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520291856194701184 (CiNii: 1520291856194701184)
128.	Naoto Katakami, Hideaki Kaneto, Taka-aki Matsuoka, Mitsuyoshi Takahara, Norikazu Maeda, Ikki Shimizu, Keizo Ohno, Takeshi Osonoi, Koichi Kawai, Fukashi Ishibashi, Kenichi Imamura, Atsunori Kashiwagi, Ryuzo Kawamori, Munehide Matsuhisa, Tohru Funahashi, Yoshimitsu Yamasaki and Iichiro Shimomura : Adiponectin G276T gene polymorphism is associated with cardiovascular disease in Japanese patients with type 2 diabetes., Atherosclerosis, Vol.220, No.2, 437-442, 2011. (Summary) It is likely that the G allele of the ADIPOQ G276T polymorphism is a susceptibility allele for CVD in Japanese type 2 diabetic patients, especially when they accompany obesity. (Keyword) Adiponectin / analysis of variance / Asian Continental Ancestry Group / Cerebral Infarction / Chi-Square Distribution / Cross-Sectional Studies / Diabetes Complications / Diabetes Mellitus, Type 2 / Female / Gene Frequency / Genetic Predisposition to Disease / Humans / modern Japan / Logistic Models / Male / Middle Aged / Myocardial Infarction / obesity / Odds Ratio / Phenotype / Polymorphism, Genetic / Prevalence / Risk Assessment / Risk Factors (Link to Publication Site) ● Publication site (DOI): 10.1016/j.atherosclerosis.2011.11.010 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22138143 ● Search Scopus @ Elsevier (PMID): 22138143 ● Search Scopus @ Elsevier (DOI): 10.1016/j.atherosclerosis.2011.11.010 (DOI: 10.1016/j.atherosclerosis.2011.11.010, PubMed: 22138143)
129.	Munehide Matsuhisa, 河盛隆造 and VISION研究会 : DPP-4阻害薬ビルダグリプチンの臨床評価, ㈱医薬情報研究所, Vol.60, 2011.
130.	坂本扶美枝, Akio Kuroda, 川嶋聡, 加藤研, 植田江梨子, 高原充佳, 宮下和幸, 嵩龍一, 安田哲行, 松岡孝昭, 種村匡弘, 伊藤壽記, 高原史郎, 山崎義光, Munehide Matsuhisa, 金藤秀明 and 下村伊一郎 : Pancreas after Kidney Transplant from Donor with Elevated Agonal HbA1c : A Case Report, Journal of the The Japan Diabetes Society, Vol.54, No.6, 417-424, 2011. (Keyword) 膵臓移植 / 腎移植[術] / 1型糖尿病 / インスリン分泌 (Link to Publication Site) ● Publication site (DOI): 10.11213/tonyobyo.54.417 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001204906605952 ● Summary page in Scopus @ Elsevier: 2-s2.0-79960918086 (DOI: 10.11213/tonyobyo.54.417, CiNii: 1390001204906605952, Elsevier: Scopus)
131.	M Seike, T Saito, Y Kochi, T Ohara, Munehide Matsuhisa, K Sakaguchi, K Tomita, K kosugi, A kashiwagi, M Kasuga, M Tomita, Y Naito and H Nakajima : Computational assessment of insulin secretion and insulin sensitivity from 2 horal glucose torerance tests for clinical use for type 2 diabetes, The Journal of Physiological Sciences, Vol.61, No.4, 321-330, 2011. (Summary) In type 2 diabetes mellitus, glucose homeostasis is tightly maintained through insulin secretion and insulin sensitivity. Therefore, finding an accurate method to assess insulin secretion and sensitivity using clinically available data would enhance the quality of diabetic medical care. In an effort to find such a method, we developed a computational approach to derive indices of these factors using a 2-h oral glucose tolerance test (OGTT). To evaluate our method, clinical data from subjects who received an OGTT and a glucose clamp test were examined. Our insulin secretion index was significantly correlated with an analogous index obtained from a hyperglycemic clamp test (r = 0.90, n = 46, p < 0.001). Our insulin sensitivity index sensitivity was also significantly correlated with an analogous index obtained from a hyperinsulinemic-euglycemic clamp test (r = 0.56, n = 79, p < 0.001). These results suggest that our method can potentially provide an accurate and convenient tool toward improving the management of diabetes in clinical practice by assessing insulin secretion and insulin sensitivity. (Keyword) Adult / Aged / Algorithms / Automatic Data Processing / Blood Glucose / Diabetes Mellitus, Type 2 / Female / Glucose Tolerance Test / Humans / Insulin / Insulin Resistance / Male / Middle Aged / Models, Biological (Link to Publication Site) ● Publication site (DOI): 10.1007/s12576-011-0153-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21594678 ● Search Scopus @ Elsevier (PMID): 21594678 ● Search Scopus @ Elsevier (DOI): 10.1007/s12576-011-0153-z (DOI: 10.1007/s12576-011-0153-z, PubMed: 21594678)
132.	Y Fujiwara, K Kishida, M Terao, M Takahara, Munehide Matsuhisa, T Funahashi, I Shimomura and Y Shimizu : Beneficial effects of foot care nursing for people with daibetes mellitus:an uncontrolled before and after intervention study, Journal of Advanced Nursing, Vol.67, No.9, 1952-1962, 2011. (Summary) The aim of this study was to assess the effectiveness of a preventative foot care nursing programme for diabetic patients. Foot complications are common in diabetic patients and prevention of such complications requires foot care. However, there is little information on the effectiveness of foot care nursing on the incidence and recurrence of diabetic foot. We developed a diabetic foot care programme based on the International Working Group on the Diabetic Foot. We studied 88 patients who attended our foot care programme for 2 years, and collected data from April 2005 to March 2009. Patients were divided into four groups according to the risk classification, and received foot care. We evaluated the incidence of foot ulceration or recurrence and non-ulcerated foot condition. Characteristics of the patients were analysed using the paired t-test and McNemar's test, and changes in severity of tinea pedis and grade of callus were analysed using Wilcoxon's signed rank sum test. The programme reduced the severity score of tinea pedis (P < 0·001) and improved callus grade (P < 0·001). All these were evaluated by Wilcoxon's signed rank sum test. None of the patients of risk-group-3 (history of foot ulceration) showed recurrence of callus-related foot ulcers. Six high-risk patients developed foot ulceration during the programme because of minor injury, but the ulcers healed without development of gangrene. A nurse-based foot care programme is effective in preventing diabetic foot in diabetic patients. (Keyword) Aged / Callosities / Diabetes Mellitus / Diabetic Foot / Female / Hallux Valgus / Humans / Male / Middle Aged / Onychomycosis / Patient Education as Topic / Preventive Medicine / Program Evaluation / Recurrence / Referral and Consultation / Risk Factors / Severity of Illness Index / Statistics, Nonparametric / Tinea Pedis / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1365-2648.2011.05640.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21480962 ● Search Scopus @ Elsevier (PMID): 21480962 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1365-2648.2011.05640.x (DOI: 10.1111/j.1365-2648.2011.05640.x, PubMed: 21480962)
133.	Mitsuyoshi Takahara, Hideaki Kaneto, Naoto Katakami, Taka-Aki Matsuoka, Munehide Matsuhisa and Iichiro Shimomura : Impaired suppression of endogenous glucose production in lean Japanese patients with type 2 diabetes mellitus., Diabetes Research and Clinical Practice, Vol.93, No.1, 1-2, 2011. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.diabres.2011.03.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21440320 ● Search Scopus @ Elsevier (PMID): 21440320 ● Search Scopus @ Elsevier (DOI): 10.1016/j.diabres.2011.03.002 (DOI: 10.1016/j.diabres.2011.03.002, PubMed: 21440320)
134.	Akio Kuroda, Hideaki Kaneto, Tetsuyuki Yasuda, Munehide Matsuhisa, Kazuyuki Miyashita, Noritaka Fujiki, Keiko Fujisawa, Tsunehiko Yamamoto, Mitsuyoshi Takahara, Fumie Sakamoto, Taka-Aki Matsuoka and Iichiro Shimomura : Basal Insulin Requirement Is ~30% of the Total Daily Insulin Dose in Type 1 Diabetic Patients, Who Use the Insulin Pump., Diabetes Care, Vol.34, No.5, 1089-1090, 2011. (Summary) OBJECTIVE To investigate the basal insulin requirement in total daily insulin dose in Japanese type 1 diabetic patients, who use the insulin pump. RESEARCH DESIGN AND METHODS The basal insulin requirement in 35 type 1 diabetic patients without detectable C-peptide using the insulin pump (Paradigm 712) was investigated during 2-3 weeks of hospitalization. The patients were served diabetic diets of 25-30 kcal/kg ideal body weight. Each meal omission was done to confirm stable blood glucose levels within 30 mg/dL variance until the next meal. Target blood glucose level was set at 100 mg/dL before each meal and 150 mg/dL at 2 h after each meal. RESULTS Total daily insulin dose was 31.6 ± 8.5 units, and total basal insulin requirement was 8.7 ± 2.9 units, which was 27.7 ± 6.9% of the total daily dose. CONCLUSIONS Basal insulin requirement is ∼30% of the total daily dose in Japanese type 1 diabetic patients, who use the insulin pump. (Link to Publication Site) ● Publication site (DOI): 10.2337/dc10-2149 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21430086 ● Search Scopus @ Elsevier (PMID): 21430086 ● Search Scopus @ Elsevier (DOI): 10.2337/dc10-2149 (DOI: 10.2337/dc10-2149, PubMed: 21430086)
135.	N Katakami, H Kaneto, M Takahara, T Matsuoka, K Imamura, F Ishibashi, T Kanda, K Kawai, T Osonoi, Munehide Matsuhisa, A Kashiwagi, R Kawamori, I Shimomura and Y Yamasaki : Aldose reductase C-106T gene polymorphisnm is associated with diabetic retinopathy in Japanese patients with type 2 diabetes, Diabetes Research and Clinical Practice, Vol.92, No.3, e57-60, 2011. (Summary) It is likely that the C allele of the polymorphism at position -106 in the promoter of aldose reductase gene, which codes a rate-limiting enzyme of the polyol pathway, is a susceptibility allele for diabetic retinopathy in Japanese type 2 diabetic patients. (Keyword) Aged / Aldehyde Reductase / Alleles / Asian Continental Ancestry Group / Diabetes Mellitus, Type 2 / Diabetic Retinopathy / Female / Genetic Predisposition to Disease / Humans / Male / Middle Aged / Polymorphism, Genetic (Link to Publication Site) ● Publication site (DOI): 10.1016/j.diabres.2011.02.017 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21420193 ● Search Scopus @ Elsevier (PMID): 21420193 ● Search Scopus @ Elsevier (DOI): 10.1016/j.diabres.2011.02.017 (DOI: 10.1016/j.diabres.2011.02.017, PubMed: 21420193)
136.	Tetsuyuki Yasuda, Hideaki Kaneto, Naoto Katakami, Akio Kuroda, Taka-Aki Matsuoka, Yoshimitsu Yamasaki, Munehide Matsuhisa and Iichiro Shimomura : YKL-40, a new biomarker of endothelial dysfunction, is independently associated with albuminuria in type 2 diabetic patients., Diabetes Research and Clinical Practice, Vol.91, No.2, e50-2, 2011. (Summary) The aim of this study was to examine the possible association between YKL-40, a new biomarker of endothelial dysfunction, and albuminuria in 180 type 2 diabetic patients. Multivariate logistic regression analyses demonstrated that serum YKL-40 level was a determinant of albuminuria independently of conventional risk factors. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.diabres.2010.11.015 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21159401 ● Search Scopus @ Elsevier (PMID): 21159401 ● Search Scopus @ Elsevier (DOI): 10.1016/j.diabres.2010.11.015 (DOI: 10.1016/j.diabres.2010.11.015, PubMed: 21159401)
137.	Ryuuichi Kasami, Hideaki Kaneto, Naoto Katakami, Satoru Sumitsuji, Keita Yamasaki, Tadashi Kuroda, Kouichi Tachibana, Tetsuyuki Yasuda, Akio Kuroda, Taka-Aki Matsuoka, Munehide Matsuhisa and Iichiro Shimomura : Relationship between carotid intima-media thickness and the presence and extent of coronary stenosis in type 2 diabetic patients with carotid atherosclerosis but without history of coronary artery disease., Diabetes Care, Vol.34, No.2, 468-470, 2011. (Summary) Our data suggest that max-IMT might be closely associated with the extent of coronary stenosis in type 2 diabetic patients without history of CAD but with carotid atherosclerosis. (Link to Publication Site) ● Publication site (DOI): 10.2337/dc10-1222 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21270201 ● Search Scopus @ Elsevier (PMID): 21270201 ● Search Scopus @ Elsevier (DOI): 10.2337/dc10-1222 (DOI: 10.2337/dc10-1222, PubMed: 21270201)
138.	Naoto Katakami, Hideaki Kaneto, Munehide Matsuhisa, Iichiro Shimomura and Yoshimitsu Yamasaki : Effects of glimepiride and glibenclamide on carotid atherosclerosis in type 2 diabetic patients., Diabetes Research and Clinical Practice, Vol.92, No.1, 20-22, 2011. (Summary) We performed a 3-year observation study of type 2 diabetic patients treated with glibenclamide or glimepiride and found that the annual progression of the maximum carotid intima-media thickness was significantly attenuated in the subjects treated with glimepiride (n=20) as compared with those treated with glibenclamide (n=20) (-0.044±0.171mm/year vs. 0.077±0.203mm/year, p=0.0474). (Link to Publication Site) ● Publication site (DOI): 10.1016/j.diabres.2010.12.023 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21257219 ● Search Scopus @ Elsevier (PMID): 21257219 ● Search Scopus @ Elsevier (DOI): 10.1016/j.diabres.2010.12.023 (DOI: 10.1016/j.diabres.2010.12.023, PubMed: 21257219)
139.	Satoshi Kawashima, Taka-aki Matsuoka, Hideaki Kaneto, Yoshihiro Tochino, Kenji Katoh, Kaoru Yamamoto, Tsunehiko Yamamoto, Munehide Matsuhisa and Iichiro Shimomura : Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice., Biochemical and Biophysical Research Communications, Vol.404, No.1, 534-540, 2010. (Summary) Male db/db mice were treated with a chow including pio, alo, or both of them from 8 to 16 weeks of age. Insulin glargine (gla) was daily injected subcutaneously during the same period. (Keyword) Animals / Blood Glucose / Body Weight / Deoxyguanosine / Dipeptidyl-Peptidase IV Inhibitors / Hemoglobin A, Glycosylated / Hypoglycemic Agents / Insulin / Insulin Resistance / Insulin-Secreting Cells / Maf Transcription Factors, Large / Mice / Mice, Inbred C57BL / Piperidines / Receptors, Glucagon / Thiazolidinediones / Triglycerides / Uracil (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bbrc.2010.12.021 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21144823 ● Search Scopus @ Elsevier (PMID): 21144823 ● Search Scopus @ Elsevier (DOI): 10.1016/j.bbrc.2010.12.021 (DOI: 10.1016/j.bbrc.2010.12.021, PubMed: 21144823)
140.	Naoto Katakami, Hideaki Kaneto, Takeshi Osonoi, Miyoko Saitou, Mitsuyoshi Takahara, Fumie Sakamoto, Kaoru Yamamoto, Tetsuyuki Yasuda, Taka-Aki Matsuoka, Munehide Matsuhisa, Yoshimitsu Yamasaki and Iichiro Shimomura : Usefulness of lipoprotein ratios in assessing carotid atherosclerosis in Japanese type 2 diabetic patients., Atherosclerosis, Vol.214, No.2, 442-447, 2010. (Summary) TC/HDL-C and LDL-C/HDL-C ratios are useful as a tool to assess the risk of early stage atherosclerosis in Japanese type 2 diabetic patients. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.atherosclerosis.2010.10.035 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21146820 ● Search Scopus @ Elsevier (PMID): 21146820 ● Search Scopus @ Elsevier (DOI): 10.1016/j.atherosclerosis.2010.10.035 (DOI: 10.1016/j.atherosclerosis.2010.10.035, PubMed: 21146820)
141.	Toshihiko Shiraiwa, Mitsuyoshi Takahara, Hideaki Kaneto, Takeshi Miyatsuka, Kaoru Yamamoto, Kazutomi Yoshiuchi, Ken'ya Sakamoto, Taka-Aki Matsuoka, Munehide Matsuhisa, Yoshimitsu Yamasaki and Iichiro Shimomura : Efficacy of occasional self-monitoring of postprandial blood glucose levels in type 2 diabetic patients without insulin therapy., Diabetes Research and Clinical Practice, Vol.90, No.3, e91-2, 2010. (Keyword) Blood Glucose / Blood Glucose Self-Monitoring / Diabetes Mellitus, Type 2 / Hemoglobin A, Glycosylated / Humans / Postprandial Period (Link to Publication Site) ● Publication site (DOI): 10.1016/j.diabres.2010.09.022 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21030103 ● Search Scopus @ Elsevier (PMID): 21030103 ● Search Scopus @ Elsevier (DOI): 10.1016/j.diabres.2010.09.022 (DOI: 10.1016/j.diabres.2010.09.022, PubMed: 21030103)

Academic Paper (Unrefereed Paper):

1.	Hajime Yamakage, Takaaki Jo, Masashi Tanaka, Sayaka Kato, Koji Hasegawa, Izuru Masuda, Munehide Matsuhisa, Kazuhiko Kotani, Mitsuhiko Noda and Noriko Satoh-Asahara : Five percent weight loss is a significant 1-year predictor and an optimal 5-year cut-off for reducing the number of obesity-related cardiovascular disease risk components: the Japan Obesity and Metabolic Syndrome Study., Frontiers in Endocrinology, Vol.15, 1343153, 2024. (Summary) This study aimed to identify the amount of weight loss needed in patients with obesity to improve metabolic syndrome (MetS), a risk factor for cardiovascular disease (CVD), over a long period of time. A total of 576 patients with obesity were enrolled in this study. Effects of continuous physician-supervised weight loss on the cumulative MetS components excluding abdominal circumference (defined as obesity-related CVD risk score) were investigated during a 5-year follow-up period. The extent of weight loss required to reduce the obesity-related CVD risk components was assessed using receiver operating characteristic (ROC) curve analyses. Of the 576 participants, 266 completed 5-year follow-up, with 39.1% and 24.1% of them achieving ≥5.0% and ≥7.5% weight loss at the 5-year follow-up, respectively. The area under the ROC curve for reducing the obesity-related CVD risk components was 0.719 [0.662-0.777] at 1 year and 0.694 [0.613-0.775] at 5 years. The optimal cut-off value for weight loss was 5.0% (0.66 sensitivity and 0.69 specificity) and the value with 0.80 specificity was 7.5% (0.45 sensitivity) at 5 years. Greater reductions in weight were associated with greater improvements in the obesity-related CVD risk score at all follow-up periods (-trend <0.001). Obesity-related CVD risk score was significantly improved by 5.0-7.5% and ≥7.5% weight loss at 1 year ( = 0.029 and < 0.001, respectively) and ≥7.5% weight loss at 5 years ( = 0.034). A weight loss of ≥5.0% at 1 year and ≥7.5% at 5 years could reduce the number of obesity-related CVD risk components in patients with obesity. (Keyword) Humans / Metabolic Syndrome / Cardiovascular Diseases / Japan / Obesity / Risk Factors (Tokushima University Institutional Repository) ● Metadata: 119490 (Link to Publication Site) ● Publication site (DOI): 10.3389/fendo.2024.1343153 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38601201 ● Search Scopus @ Elsevier (PMID): 38601201 ● Search Scopus @ Elsevier (DOI): 10.3389/fendo.2024.1343153 (Tokushima University Institutional Repository: 119490, DOI: 10.3389/fendo.2024.1343153, PubMed: 38601201)
2.	Hideya Kashihara, Kouzou Yoshikawa, Mitsuo Shimada, Munehide Matsuhisa and Sumiko Yoshida : クリニカルカンファレンスから(第23回) 徳島大学病院の症例高度肥満による続発性無月経に対し腹腔鏡下スリーブ状胃切除術を施行し妊娠・出産に至った一例, 肥満症治療学展望, Vol.9, No.3, 34-35, 2022. (Keyword) Dydrogesterone(治療的利用) 術後期経口投与腹腔鏡法無月経(病因,診断,薬物療法) 胃形成術出産 *肥満症(合併症,診断,外科的療法) ヒト妊娠成人(19∼44) 女
3.	Tomoharu Kawano, Munehide Matsuhisa, Seiichi Hashida, Satoshi Numata, Kazuyuki Fujimoto, Akio Kuroda, Tetsuyuki Yasuda, Kazuyuki Miyashita, Fumie Sakamoto, Naoto Katakami and Taka-aki Matsuoka : Development of highly sensitive enzyme immunoassay (ICT-EIA) for IA-2 autoantibody and application for detection of three islet-specific autoantibodies ( GADA, IA-2A and IAA) in type I diabetes mellitus, Research bulletin of Tokushima Bunri University, Vol.96, 35-44, 2018. (Summary) <p>Development of highly sensitive enzyme immunoassay (ICT-EIA) for IA-2 autoantibody and application for detection of three islet-specific autoantibodies ( GADA, IA-2A and IAA) in type I diabetes mellitus Tomoharu Kawano, Satoshi Numata, Yuki Fujimoto, Akio Kuroda, Tetsuyuki Yasuda,Kazuyuki Miyashita, Fumie Sakamoto, Naoto Katakami, Taka-aki Matsuoka, Munehide Matsuhisa and Seiichi Hashida Summary Detection of pancreatic islet-related autoantibodies( insulin antibody [IAA]; glutamic acid decarboxylase antibody [GADA]; and islet antigen-2 antibody [IA-2A], is essential for the diagnosis and prediction of the onset of type I diabetes mellitus. Depending on the disease duration, the detection rate of each autoantibody is different, and using only one kind of autoantibody detection risks overlooking a positive result. The detection precision of type I diabetes mellitus would thus be improved by measuring all three kinds of autoantibodies. We developed a highly sensitive enzyme immunoassay( ICT-EIA) for IA-2 autoantibody. ICT-EIAs for IAA and GADA have already been developed. Using three ICT-EIAs, we attempted to measure autoantibodies in sera from patients with type I diabetes mellitus. Patients comprised 25 males and 51 females( mean age, 33.3±5.7 years; disease duration, 23.9±6.7 years) with type I diabetes mellitus who had been undergoing treatment with insulin for between 11 and 40 years. Among these patients, urinary C-peptide-positive results were seen in three patients. IAA, GADA and IA-2A in sera were measured by ICT-EIA. The newly developed ICT-EIA for IA-2 antibodies was approximately 100-times more sensitive than the conventional ELISA. The positive ratio was 77.6%, representing a high rate of detection. In addition, even in patients with a disease duration >30 years, the positive rate was 64.3%. ICT-EIA was thus suggested to be useful in combination assays for pancreatic islet-related autoantibodies (IAA, GADA and IA-2A).</p><p> </p><p></p> (Link to Publication Site) ● Publication site (DOI): 10.24596/tokusimabunriu.96.0_35 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001288124302336 ● Search Scopus @ Elsevier (DOI): 10.24596/tokusimabunriu.96.0_35 (DOI: 10.24596/tokusimabunriu.96.0_35, CiNii: 1390001288124302336)

Review, Commentary:

1.	Munehide Matsuhisa : 糖尿病診療におけるデジタル医療:いまとこれから, Journal of the The Japan Diabetes Society, Vol.67, No.6, 238-241, 2024.
2.	Munehide Matsuhisa : ICT医療連携システムの糖尿病診療への活用, 糖尿病合併症, Vol.38, No.1, 65-70, 2024.
3.	Munehide Matsuhisa : 個に届くと糖尿病の地域対策∼カードシステムも含め∼, 西宮市医師会医学雑誌, Vol.9, No.44, 2024.
4.	Munehide Matsuhisa : 高齢者糖尿病の病態特徴をその治療, The Journal of the Japanese Society of Internal Medicine, Vol.113, No.3, 522-526, 2024.
5.	Munehide Matsuhisa : 低血糖の重症化とその対策, 日本糖尿病協会, Vol.64, No.3, 5-10, 2024.
6.	Munehide Matsuhisa : 高齢者へのCGM導入, Calm 糖尿病におけるShared Decision Marking(SDM), Vol.11, No.1, 8-13, Oct. 2023.
7.	Akio Kuroda and Munehide Matsuhisa : 1型糖尿病における強化インスリン療法の実際, 糖尿病・内分泌代謝内科特集成人1型糖尿病の成員, 診断, 治療アップデート, Vol.57, No.4, 433-438, Oct. 2023.
8.	Munehide Matsuhisa, 清水健一郎, 泉史隆 and 西村理明 : 間歇スキャン式持続血糖測定器(intermittently scanned CGM)の非補助的使用についての歴史的背景と展望, Diabetology, Endocrinology & Metabolology, Vol.56, No.3, 350-364, Mar. 2023. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520295757710762624 (CiNii: 1520295757710762624)
9.	Munehide Matsuhisa : 低血糖の病態と対処法, 別冊医学のあゆみ 1型糖尿病―診療と研究の最前線, 70-74, Mar. 2023.
10.	Akio Kuroda and Munehide Matsuhisa : カーボカウント最前線, 別冊医学のあゆみ 1型糖尿病―診療と研究の最前線, 20-33, Mar. 2023.
11.	Akio Kuroda and Munehide Matsuhisa : 糖尿病合併症妊娠に対する食事療法とインスリン療法, 月刊糖尿病#149, Vol.59, No.2, 36-41, Feb. 2023.
12.	Munehide Matsuhisa : 糖尿病治療の関連する低血糖症の疫学―重症低血糖を中心にー, 糖尿病・内分泌代謝内科 54(4) 390-395 2022, Vol.54, No.4, 390-395, 2022.
13.	Munehide Matsuhisa : 持続血糖モニタリングがもたらした新しい血糖マネジメント指標, 日本糖尿病眼学会誌 27 2022(別冊), 2022.
14.	Munehide Matsuhisa : 低血糖, 週刊日本医事新報 2022, No.5146, 44-45, Dec. 2022.
15.	Munehide Matsuhisa : Q5 2型糖尿病の電話・オンラインでの栄養指導は?, NutritionCare, Vol.15, No.9, 31-33, Sep. 2022.
16.	Akio Kuroda, 鈴木麗子, 冨永ゆかり, Hiroyasu Mori, 岡本美鈴 and Munehide Matsuhisa : 1 か月で 23 回インスリンポンプ注入が 3 時間以上中断しており，ケトアシドーシス症状を繰り返していた 1 型糖尿病の一例, 第22回日本糖尿病インフォマティクス学会年次学術集会, Aug. 2022.
17.	Munehide Matsuhisa : 新しい時代のヒューマンデータ活用による慢性疾患の克服, 糖尿病プラクティス, Vol.39, No.3, 361-362, May 2022.
18.	Munehide Matsuhisa : ⑩ 糖尿病とウェルエイジング, いのち輝く, Vol.100, 28-30, May 2022.
19.	Akio Kuroda and Munehide Matsuhisa : カーボカウント最前線, Journal of Clinical and Experimental Medicine, Vol.281, No.6, 606-611, May 2022. (Keyword) カーボカウント / 糖質 / 経験則 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520292182357377024 (CiNii: 1520292182357377024)
20.	Munehide Matsuhisa : 低血糖の病態と対処法, Journal of Clinical and Experimental Medicine, Vol.281, No.6, 648-652, May 2022. (Keyword) 重症低血糖 / 無自覚性低血糖 / 低血糖関連自律神経応答不全 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520573657333651712 (CiNii: 1520573657333651712)
21.	Akio Kuroda and Munehide Matsuhisa : Continuous Glucose Monitoring(CGM), 日本医師会雑誌内分泌疾患・糖尿病・代謝疾患-診療のエッセンス- 150特別号, No.2, S262-S264, 2021.
22.	Munehide Matsuhisa : 徳島大学先端酵素学研究所糖尿病対策事業地域連携の取組 2020地域連携事業成果報告書, 35, 2021.
23.	Munehide Matsuhisa : ⑧インスリン発見100年の今，コロナ禍で考える健康習慣と糖尿病, いのち輝く, No.96, 28-31, Sep. 2021.
24.	杉山隆 and Munehide Matsuhisa : 特集にあたって女性ライフステージと糖尿病―今知りたいベストプラクティスとはー, 糖尿病プラクティス, Vol.38, No.5, 525, Sep. 2021.
25.	Munehide Matsuhisa : 高齢糖尿病者の病態と治療, 板野郡医師会報, No.25, 71, Jul. 2021.
26.	Akio Kuroda and Munehide Matsuhisa : 1型糖尿病のインスリン療法, 2型と何が違う?, レジデント#132, Vol.14, No.2, 61-67, Jul. 2021.
27.	Munehide Matsuhisa and Hiroyasu Mori : Introduction of Artificial Intelligence in Diabetes Care, Diabetology, Endocrinology & Metabolology, Vol.52, No.6, 588-593, Jun. 2021. (Keyword) artificial intelligence (AI) / electronic health record (EHR) / personal health record / deep learning (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520010381271148544 (CiNii: 1520010381271148544)
28.	Munehide Matsuhisa : 重症低血糖の救急処置の新しい一手―グルカゴン点鼻薬―, 内科総合誌 M.P.(Medical Practice), Vol.38, No.10, 1602-1604, Jun. 2021.
29.	Munehide Matsuhisa : グルカゴンの点鼻粉末剤は注射製剤に取って代わるか?, カレントテラピー, Vol.39, No.5, 41-45, May 2021.
30.	Munehide Matsuhisa : 点鼻グルカゴン製剤∼有効性, 安全性を中心に∼, 月刊糖尿病特集グルカゴン(膵β細胞)はどこまでわかったか, Vol.13, No.3, 86-92, Mar. 2021. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1521980706152208896 (CiNii: 1521980706152208896)
31.	Munehide Matsuhisa : 糖尿病治療に関連する重症低血糖の実態と対策, 月刊糖尿病DIABETES, Vol.13, No.1, 6-12, Jan. 2021. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1524232505966083584 (CiNii: 1524232505966083584)
32.	Akio Kuroda and Munehide Matsuhisa : 1型糖尿病の移行期医療, Journal of Clinical and Experimental Medicine, Vol.276, No.5, 550-552, Jan. 2021. (Keyword) 1型糖尿病 / 移行期医療 / 小児慢性特定疾病 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520010381311915520 (CiNii: 1520010381311915520)
33.	Munehide Matsuhisa : 徳島大学先端酵素学研究所糖尿病対策事業地域連携の取組 2019地域連携事業成果報告書, 38, 2020.
34.	Munehide Matsuhisa : 高齢糖尿病と重症低血糖―治療目標の設定と治療法の選択, Medical View Point, Vol.11, 4-5, Nov. 2020.
35.	Munehide Matsuhisa : 糖尿病薬が使いやすく, 日経メディカル, 54-58, Aug. 2020. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520009408026251904 (CiNii: 1520009408026251904)
36.	Akio Kuroda and Munehide Matsuhisa : 将来のCGMはどうなりますか?, Modern Physician 新興医学出版社, Vol.40, No.2, 166-168, Jul. 2020. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1523669554572096768 (CiNii: 1523669554572096768)
37.	Akio Kuroda and Munehide Matsuhisa : 解説&症例でわかるCSII, 月刊糖尿病ケア株式会社メディカ出版, Vol.17, No.8, 37-40, Jul. 2020.
38.	Munehide Matsuhisa : 新しくなった糖尿病性腎症重症化予防プログラム, 徳島市医師会報ぞめき一般社団法人徳島市医師会, No.41, 31, Feb. 2020.
39.	Akio Kuroda and Munehide Matsuhisa : 実践カーボカウント, 月刊糖尿病ライフ日本糖尿病協会, Vol.59, No.10, 34-38, 2019.
40.	Munehide Matsuhisa : 糖尿病を克服するー全国一の死亡率の理由と対応を知るー, 企業と大学(第11回授業)ライフ・シフト大学, Vol.13, 53, Nov. 2019.
41.	Munehide Matsuhisa : 「糖尿病死亡ワーストワン」がもたらす地域医療の革新, 糖尿病療養指導のためのDM Ensemble 特集血糖変動をどうみるか∼CGM,FGMの活用方法を探る∼, Vol.8, No.3, 36-41, Nov. 2019. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520573331185916672 (CiNii: 1520573331185916672)
42.	Munehide Matsuhisa : 放置しない糖尿病合併症-アンメットニーズに応えるために-, 阿南医報15, Jul. 2019.
43.	Munehide Matsuhisa : 糖尿病における骨格筋の量と質，サルコペニアとダイナぺニア, DITN, No.484, 1, Jul. 2019.
44.	Hiroyasu Mori and Munehide Matsuhisa : テレビカンファレンスシステムを活用した遠隔栄養指導の有用性と展望, The Japanese Journal of Clinical Nutrition, Vol.135, No.1, Jul. 2019.
45.	Munehide Matsuhisa : 糖尿病医療における精密医療とデータ連携, Precision Medicine, No.5, 22-25, Apr. 2019.
46.	Munehide Matsuhisa and Akio Kuroda : 携帯型人工膵臓 Closed-loop insulin delivery systemの現状, Diabetes Journal, Vol.47, No.1, 29-33, Mar. 2019.
47.	Munehide Matsuhisa : Integrated use of glucose data from individual to society, Journal of Clinical and Experimental Medicine, Vol.268, No.7, 572-575, Feb. 2019. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1521136279742850048 (CiNii: 1521136279742850048)
48.	Munehide Matsuhisa : 序, 糖尿病療養指導ガイドブック2018, 2018.
49.	Munehide Matsuhisa : 臨床現場でのデジタルヘルス活用概論(第3回)ICTが拓く糖尿病診療の未来, ミクス = Medical information express : 医薬情報&マーケティング, Vol.46, No.9, 56-58, Aug. 2018. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1524232505629856384 (CiNii: 1524232505629856384)
50.	Munehide Matsuhisa : 「働き盛り」の糖尿病はこう治療する, 診断と治療, Vol.106, No.3, 268-274, Mar. 2018. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1524232504718682880 (CiNii: 1524232504718682880)
51.	Munehide Matsuhisa : 治療実地医家はどのように肥満症を治療すべきか薬物療法, 内科総合誌Medical Practice, Vol.35, No.2, 299-303, Feb. 2018.
52.	Munehide Matsuhisa : 治療 4．インスリン製剤にかかわる最近のエビデンス, The Medical Frontline, Vol.73, No.1, 78-84, Jan. 2018.
53.	Munehide Matsuhisa : 11代謝疾患 2型糖尿病, 今日の治療方針, 703-708, Jan. 2018.
54.	谷口諭 and Munehide Matsuhisa : 徳島県における地域医療連携Development of electric health records(EHR) in Tokushima, Journal of Clinical and Experimental Medicine, Vol.262, No.13, 1195-1200, Dec. 2017. (Keyword) EHR / PHR / 地域医療連携 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1523106603326830592 (CiNii: 1523106603326830592)
55.	Munehide Matsuhisa : 徳島県での糖尿病性腎症重症化予防対策, Journal of Clinical and Experimental Medicine, Vol.263, No.7, 591-595, Nov. 2017. (Keyword) 徳島県医師会糖尿病対策班 / 徳島県栄養士会栄養ケアステーション / 減塩指導 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520291854754509952 (CiNii: 1520291854754509952)
56.	Munehide Matsuhisa : 高齢者のシックディ対策, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.75, No.11, 1739-1744, Oct. 2017.
57.	Munehide Matsuhisa : 特集考える糖尿病適切な運動と食べる楽しみ, いのち輝く秋, No.86, 6-9, Sep. 2017.
58.	Munehide Matsuhisa : SAP(Sensor Augmented Pump:CGMとCSⅡが一体化したシステム)やFGM(Flash Glucose Monitoring)の進歩, Medical Practice, Vol.34, No.9, 493-495, Sep. 2017.
59.	Munehide Matsuhisa : 低血糖のメカニズムと高齢者糖尿病の治療, 糖尿病の最新治療Current Diabetology, Vol.8, No.4, 152-157, Aug. 2017.
60.	Akio Kuroda and Munehide Matsuhisa : 低血糖の対策を今一度考える, DIABETES UPDATE, Vol.6, No.3, Jul. 2017.
61.	Munehide Matsuhisa : 序, 糖尿病療養指導ガイドブック2017, May 2017.
62.	出口憲市, Hajime Miura, Munehide Matsuhisa and Shinsuke Katoh : 糖尿病の運動療法, 糖尿病ケア2017, 178-182, Mar. 2017.
63.	Munehide Matsuhisa : 境界型糖尿病に対する運動療法単独介入と食事療法併用運動介入による糖代謝恒常性への改善効果, DIABETES UPDATE, Vol.6, No.1, 24-26, Feb. 2017.
64.	Munehide Matsuhisa and Yuu Tamaki : 糖尿病地域医療連携におけるICTへの期待, 月刊糖尿病, Vol.9, No.1, 36-46, Jan. 2017.
65.	Munehide Matsuhisa : 食後過血糖を防ぐ肝臓の役割:その重要性, PROGRESS IN MEDICINE, Vol.37, No.3, 49(351)-53(355), Jan. 2017.
66.	Munehide Matsuhisa : インスリン治療の落とし穴, Medical Practice, Vol.34, No.1, 161, Jan. 2017.
67.	Munehide Matsuhisa : 糖尿病とシックデイの対処法, 糖尿病ガイドシリーズ:糖尿病とシックデイの対処法をよく知ろう, 2-12, Dec. 2016.
68.	Munehide Matsuhisa : 肥満症の診断基準に必須な合併症と治療法, 内分泌・糖尿病・代謝内科, Vol.43, No.4, 275-281, Oct. 2016.
69.	Munehide Matsuhisa : 低血糖の病態生理, 月刊糖尿病, Vol.8, No.9, 15-21, Sep. 2016.
70.	Akio Kuroda and Munehide Matsuhisa : 低血糖を防ぐ∼これからの治療∼, 月刊糖尿病, Vol.8, No.9, 89-93, Sep. 2016.
71.	Akio Kuroda and Munehide Matsuhisa : 低血糖への恐怖(fear of hypoglycemia)をのりこえるために, 糖尿病診療マスター, Vol.14, No.8, 616-621, Aug. 2016.
72.	Munehide Matsuhisa : 1型糖尿病でのインスリン治療, 特集知っておきたい救急薬の使い方, Vol.36, No.6, 595, Jun. 2016.
73.	Hiroyasu Mori, 鈴木麗子, Akio Kuroda, Motoyuki Tamaki, 明比祐子, Munehide Matsuhisa, Michiko Araki and Hiroshi Sakaue : 1型糖尿病患者における皮下蓄積AGEsとサルコペニアとの関連の検討, The Journal of Adult Diseases, Vol.46, No.5, 608-609, May 2016.
74.	Munehide Matsuhisa : 低血糖対策, 新時代の臨床糖尿病学下, 643-647, Apr. 2016.
75.	出口憲市, Hajime Miura, Munehide Matsuhisa and Shinsuke Katoh : すこし運動したくなってきた人向け短時間でも効果的な運動の3つの提案, 糖尿病ケア, No.2, Feb. 2016.
76.	Munehide Matsuhisa : リアルタイムCGMと持続皮下インスリン注入療法, 内科臨床誌メディチーナ, Vol.53, No.1, 109-111, Jan. 2016.
77.	Akio Kuroda and Munehide Matsuhisa : 血糖変動を安定させることについて, 糖尿病ケア, Vol.12, No.11, 23-27, Nov. 2015.
78.	Munehide Matsuhisa : エンパグリフロジンが心血管リスクを抑制-欧州糖尿病学会の報告から-, MMJ, Vol.11, No.5, 251-254, Oct. 2015.
79.	Munehide Matsuhisa : 肥満と肥満症の違い, The Japanese Journal of Clinical Nutrition, Vol.127, No.4, 370-374, Sep. 2015.
80.	Munehide Matsuhisa : シックデイでの低血糖対策, 糖尿病療養指導のためのDM Ensemble, Vol.4, No.2, 12-14, Aug. 2015.
81.	Munehide Matsuhisa : CGMは糖尿病の血糖管理に有用か, Vol.5, No.3, 5-18, Aug. 2015.
82.	Akio Kuroda and Munehide Matsuhisa : カーボカウントの基本と臨床での適応例, 最新インスリン療法:改訂第2版, 240-247, May 2015.
83.	Akio Kuroda and Munehide Matsuhisa : 1食に含まれる糖質量をおおまかに計算する方法はあるの?, Nutrition Care, Vol.8, No.5, 49-51, May 2015. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520854806141714176 (CiNii: 1520854806141714176)
84.	Akio Kuroda and Munehide Matsuhisa : インスリンが効きやすい日と効きにくい日があるの?, Nutrition Care, Vol.8, No.5, 46-48, May 2015. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1523951030884715392 (CiNii: 1523951030884715392)
85.	Akio Kuroda and Munehide Matsuhisa : 運動するときのカーボカウントはどうするの?, Nutrition Care, Vol.8, No.5, 44-45, May 2015.
86.	Munehide Matsuhisa : 糖尿病, とくしま病院ガイドすこから2015, 3-5, Mar. 2015.
87.	Akio Kuroda and Munehide Matsuhisa : 持続皮下イインスリン注入療法(CSⅡ)の実際, 糖尿病治療のニューパラダイム, Vol.3, 79-85, Mar. 2015.
88.	Munehide Matsuhisa : インスリン療法の適応と薬物療法におけるポジショニング, 糖尿病治療のニューパラダイム;第3巻, Mar. 2015.
89.	Munehide Matsuhisa and Akio Kuroda : CSⅡ(持続皮下注入療法)の進歩最新の糖尿病の実地日常診療, Medical Practice, Vol.32, No.1, 114-116, Jan. 2015.
90.	Munehide Matsuhisa : 糖尿病死亡ワーストワンからの飛躍, 日本糖尿病情報学会誌, Vol.13, 2015.
91.	Munehide Matsuhisa : 1型糖尿病における最適なインスリン治療, Diabetes Contemporary, Vol.2, No.1, 52-53, 2015.
92.	Munehide Matsuhisa : 肥満症治療としての糖質制限食は有効ですか?, Modern Physician, Vol.35, No.2, 150-154, 2015.
93.	Munehide Matsuhisa : 2型糖尿病患者におけるSGLT2阻害薬への代謝応答, Diabetes Strategy, Vol.4, No.4, 32-33, Nov. 2014.
94.	Munehide Matsuhisa : NAFLD合併糖尿病糖尿病内科の立場から, 月刊糖尿病, Vol.6, No.10, 55-61, Nov. 2014. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1521699231076093056 (CiNii: 1521699231076093056)
95.	Munehide Matsuhisa : Regional medical cooperation for diabetes care using by Information and Communication Technology, Endocrinology, Diabetology & Metabolism, Vol.38, No.6, 504-513, Jun. 2014. (Keyword) Information and Communication Technology (ICT) / disease management / electronic health records (EHR) / personal health records (PHR) (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520010380057100800 (CiNii: 1520010380057100800)
96.	Akio Kuroda and Munehide Matsuhisa : カーボカウント, 中山書店, Mar. 2014.
97.	Akio Kuroda and Munehide Matsuhisa : カーボカウント, Nutrition Care, 64-70, Jan. 2014.
98.	Munehide Matsuhisa : 糖尿病・前糖尿病患者の運動療法の理論と実践, Internal Medicine, Vol.113, No.1, 101-105, Jan. 2014.
99.	Akio Kuroda and Munehide Matsuhisa : 低血糖リスクを減じる糖尿病治療の実際, Practice, Vol.31, No.1, 83-88, Jan. 2014.
100.	Munehide Matsuhisa : 低血糖の病態生理UPDATEー低血糖をより理解するためにー, Practice, Vol.31, No.1, 69-74, Jan. 2014.
101.	鈴木麗子, 大和光, Kazuyoshi Kawazoe, Ken-ichi Aihara, Itsuro Endo, 安芸菜奈子, 倉橋清衛, Toshio Matsumoto, Akio Kuroda and Munehide Matsuhisa : インスリン注射により生じた皮下硬血を有する患者の実態調査とその介入の有用性の検討, Practice, Vol.31, No.6, 815-821, 2014.
102.	Munehide Matsuhisa : えーっ!インスリン製剤が効かない!?コラム5 こんな症例もありました, 糖尿病ケア, Vol.11, No.10, 52-53, 2014.
103.	Akio Kuroda and Munehide Matsuhisa : 糖尿病薬物治療における低血糖回避の試みー最近の進歩④CSⅡの新時代, Diabetes Frontier, Vol.25, No.4, 465-471, 2014.
104.	Munehide Matsuhisa : Q&A 糖尿病なんでも相談室, べんちのーと, Vol.25, No.2, 23, 2014.
105.	Akio Kuroda and Munehide Matsuhisa : カーボカウントの考え方と実践, 糖尿病治療のニューパラダイム, Vol.1, 158-162, 2014.
106.	Munehide Matsuhisa : 1型糖尿病診療のツボを押さえたテキストブック登場, Practice, Vol.30, No.4, 471, 2013.
107.	Akio Kuroda and Munehide Matsuhisa : 食事療法を見直す実践カーボカウントはこうして行う, Diabetes Frontier, Vol.24, No.1, 82-86, 2013.
108.	Akio Kuroda and Munehide Matsuhisa : 総解1型糖尿病いまさら聞けない2型糖尿病との違い食事療法における違い, 糖尿病ケア, Vol.10, No.2, 131-134, 2013. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520854806131708416 (CiNii: 1520854806131708416)
109.	Akio Kuroda and Munehide Matsuhisa : SMBG記録と食事記録の方法:はじめてのカーボカウント教室ポイントを知って明日からチャレンジ, 糖尿病ケア, Vol.10, No.1, 38-41, 2013. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520854806135995520 (CiNii: 1520854806135995520)
110.	Munehide Matsuhisa : ITを活用した糖尿病地域連携`オール徳島'で糖尿病克服を目指す, パス最前線, 34-37, Nov. 2013.
111.	Munehide Matsuhisa : 健康生活をバトンタッチ!糖尿病は要注意, いのち輝く, No.74, 8-13, Sep. 2013.
112.	Akio Kuroda and Munehide Matsuhisa : 膵臓移植の説明, 週刊日本医事新報特集号, No.4666, 120-123, Sep. 2013.
113.	Akio Kuroda and Munehide Matsuhisa : 食品交換表とカーボカウント, 糖尿病ケア, 162-168, Sep. 2013.
114.	Munehide Matsuhisa : 血糖を下げる唯一のホルモン「インスリン」，糖尿病ではインスリン分泌量が減少する，糖尿病ではインスリンが効かなくなる, 糖尿病ケア, Vol.10, No.8, 20-28, Aug. 2013.
115.	Munehide Matsuhisa : 糖尿病診療最前線, Diabetes Horizons-Practice and Progress, Vol.2, No.3, 20-24, Jul. 2013.
116.	Munehide Matsuhisa : 糖尿病大血管症における体質と遺伝素因, 日本体質医学会雑誌, Vol.75, No.2, 27-32, Jun. 2013. (Keyword) 糖尿病大血管症 / 疾患感受性遺伝子 / SNP / 酸化ストレス / 血液凝固 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1522543654837472384 (CiNii: 1522543654837472384)
117.	Akio Kuroda and Munehide Matsuhisa : 糖質制限食をめぐって:カーボカウントの理論と実際ならびにその新たな展開, 糖尿病別冊, Vol.3, 72-76, May 2013. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1521417756103407488 (CiNii: 1521417756103407488)
118.	Munehide Matsuhisa : 総解1型糖尿病いまさら聞けない2型糖尿病との違い運動療法における違い, 糖尿病ケア, Vol.10, No.2, 135-137, Feb. 2013. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1523106605944023424 (CiNii: 1523106605944023424)
119.	Munehide Matsuhisa : 糖尿病の重症化予防へ, 機関誌JAHMC, Vol.24, No.11, 2-6, 2013.
120.	Munehide Matsuhisa : この一冊でカーボカウント・インスリンポンプ・CGMがわかる!糖尿病3Cワークブック, Practice, Vol.30, No.4, 471, 2013.
121.	Akio Kuroda and Munehide Matsuhisa : カーボカウントの理論と実際医師の立場からのカーボカウントの実際について, 糖尿病の療養指導2012, 97-101, 2012.
122.	Munehide Matsuhisa and Akio Kuroda : 追加インスリンで始める患者の臨床像と注意点:2型糖尿病のインスリン療法, 月刊糖尿病, Vol.4, No.10, 35-42, 2012. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520854806149458816 (CiNii: 1520854806149458816)
123.	Akio Kuroda and Munehide Matsuhisa : 糖尿病合併妊娠における血糖管理の最適化, 糖尿病と妊娠, Vol.12, No.1, 35-39, 2012.
124.	Akio Kuroda and Munehide Matsuhisa : 特殊な状況での糖尿病管理についての疑問ーインスリンの上手な使い方・膵全摘術時，ステロイド使用時，妊婦さん，シックデイ，1型糖尿病のとき, 増刊レジデントノート, Vol.14, No.8, 92-97, 2012.
125.	Akio Kuroda and Munehide Matsuhisa : インスリンポンプ療法の現状と将来, Diabetes Journal, Vol.40, No.2, 102-107, 2012.
126.	Munehide Matsuhisa : 糖尿病治療薬, Vol.16, No.12, 294-299, Nov. 2012.
127.	Akio Kuroda and Munehide Matsuhisa : 糖尿病における膵島破壊と再生機転, 再生医療叢書, 2-8, Oct. 2012.
128.	Munehide Matsuhisa : 行政と県医師会が全面バックアップする糖尿病対策班の独創的事業, 病院新時代61, 35-38, Sep. 2012.
129.	Munehide Matsuhisa : 糖尿病と妊娠ー新たなパラダイムに立つ, Practice, Vol.29, No.4, 377-378, Jul. 2012.
130.	Munehide Matsuhisa and Akio Kuroda : Pharmacokinetic characteristics and clinical indication of insulin analogues, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.70, No.3, 658-663, May 2012. (Keyword) 超速効型インスリン / 時効型インスリン / 超時効型インスリン / 頻回インスリン療法 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22768594 ● CiNii @ National Institute of Informatics (CRID): 1522262180490112896 ● Summary page in Scopus @ Elsevier: 2-s2.0-84868659724 (PubMed: 22768594, CiNii: 1522262180490112896, Elsevier: Scopus)
131.	Akio Kuroda and Munehide Matsuhisa : Medical nutrition therapy using food exchange list and carbohydrate counting, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.70, No.3, 754-758, May 2012. (Keyword) 食事療法 / カーボカウント / 食品交換表 / 食後血糖値 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22768611 ● CiNii @ National Institute of Informatics (CRID): 1522825130113812992 ● Summary page in Scopus @ Elsevier: 2-s2.0-84868641272 (PubMed: 22768611, CiNii: 1522825130113812992, Elsevier: Scopus)
132.	Akio Kuroda and Munehide Matsuhisa : カーボカウントの有効な活用法, 別冊プラクティス, 64-70, Mar. 2012.
133.	Akio Kuroda and Munehide Matsuhisa : 食事療法, The Japanese journal of clinical and experimental medicine, Vol.89, No.1, 39-42, Jan. 2012.
134.	Munehide Matsuhisa : Novel medical network for diabetes care in Tokushima, Shikoku Acta Medica, Vol.67, No.5,6, 187-192, Dec. 2011. (Summary) The annual incidence of diabetes-related death in Tokushima Prefecture has kept the highestin Japan since1992, except2007. Such high incidence of death in diabetic patients might be relatedto renal failure and myocardial infarction. Therefore, we should make more effort to prevent diabeticmicro-and macro-angiopathy. Since the number of diabetologist was not enough to cover TokushimaPrefecture, most of diabetic patients were treated by family doctors. It is, therefore, important tocreate a bidirectional network for diabetes care between family doctors and diabetologists. We justhave been established a novel medical network for diabetic patients, so called"Tokushima MedicalNet", in which family doctors and diabetologists easily communicate medical records in each otherusing by the cloud computing system. We believe that expansion of this network over TokushimaPrefecture could contribute to improve disease management and decrease advanced complicationsin diabetic patients. (Keyword) cloud computing system / disease management / medical network / diabetic macroangiopathy / diabetic microangiopathy (Tokushima University Institutional Repository) ● Metadata: 85108 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050564287417281280 (Tokushima University Institutional Repository: 85108, CiNii: 1050564287417281280)
135.	Akio Kuroda and Munehide Matsuhisa : 重症低血糖に対する対処法と注意点, Diabetes Frontier, Vol.6, No.22, 624-628, Dec. 2011.
136.	Munehide Matsuhisa and Akio Kuroda : コントロール指標2:GA vs HbA1c, 月刊糖尿病:1型糖尿病の臨床に基づいた診断と治療, Vol.3, No.12, 55-66, Oct. 2011.
137.	Akio Kuroda and Munehide Matsuhisa : 食品交換表とカーボカウントの融合ーカーボカウントの実践, 糖尿病の療養指導2011, 66-70, Sep. 2011.
138.	Akio Kuroda and Munehide Matsuhisa : 糖尿病食事療法-個別化・多様化するニーズへの対応「カーボカウントティング法の実践応用」, Practice, Vol.28, No.5, 493-499, Sep. 2011.
139.	Akio Kuroda and Munehide Matsuhisa : カーボカウンティング法の実践応用, Practice, Vol.28, No.5, 493-499, Sep. 2011.
140.	Akio Kuroda and Munehide Matsuhisa : 糖尿病腎症見える化シート, 糖尿病ケア2011年秋季増刊, 156-159, Sep. 2011.
141.	Munehide Matsuhisa and Akio Kuroda : 透析になったら何がどうなる?∼生活・症状∼, 糖尿病ケア2011秋季増刊, 160-163, Sep. 2011.
142.	Akio Kuroda and Munehide Matsuhisa : 妊娠時のカーボカウントを用いた血糖管理, 糖尿病と妊娠, Vol.11, No.1, 41-46, Aug. 2011.
143.	Munehide Matsuhisa : 徳島県の新しい糖尿病医療連携を目指す試み:職場における健康づくりの事例(ITを利用した職場との連携), Shikoku Acta Medica, Vol.65, No.5,6, Jul. 2011.
144.	Akio Kuroda and Munehide Matsuhisa : 1型糖尿病へのインスリンポンプ導入の実際と治療効果, Endocrinology, Diabetology & Metabolism, Vol.32, No.6, 581-587, Jun. 2011. (Keyword) insulin pump therapy / basal insulin / bolus insulin / temporary basal rate / carbohydrate counting (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1522262179766794368 (CiNii: 1522262179766794368)
145.	Akio Kuroda and Munehide Matsuhisa : -, 最新インスリン療法, 216-221, Jun. 2011.
146.	Munehide Matsuhisa : 県と大学病院が推進する徳島の検診ツアー糖尿病の心血管病リスク精査に特化, MD, Vol.502, No.5, 19-21, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1523388080929528704 (CiNii: 1523388080929528704)
147.	Munehide Matsuhisa : 食後高血糖とIMT, 月刊糖尿病, Vol.3, No.5, 47-54, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1521417756101519744 (CiNii: 1521417756101519744)
148.	Munehide Matsuhisa : 徳島県における糖尿病の地域連携, Diabetes Frontier, Vol.22, No.2, 145-148, Apr. 2011.
149.	Munehide Matsuhisa, 野出孝一, 寺内康夫 and 石原正治 : 糖尿病と循環器疾患, Cardiovascular frontier, Vol.2, No.2, 81-86, Apr. 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1522825130991368960 (CiNii: 1522825130991368960)
150.	Munehide Matsuhisa : 糖尿病とシックディの対処法をよく知ろう, 糖尿病ガイドシリーズ, Feb. 2011.
151.	Munehide Matsuhisa : 膵移植後の膵機能, 膵臓, Vol.26, No.2, 161-168, 2011.
152.	Munehide Matsuhisa : Kidney transplantation for diabetic nephropathy, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.68, No.9, 519-524, Nov. 2010. (Keyword) 献腎移植 / 生体腎移植 / ステロイド薬 / カルシニューリン阻害薬 / 移植後新規発症糖尿病 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1523669554814288640 (CiNii: 1523669554814288640)
153.	Munehide Matsuhisa : Kidney transplantation for diabetic nephropathy, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.68, No.Suppl 9, 519-524, Nov. 2010. (Keyword) Diabetic Nephropathies / Humans / Kidney Transplantation / Postoperative Complications (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21667507 ● Search Scopus @ Elsevier (PMID): 21667507 (PubMed: 21667507)
154.	Munehide Matsuhisa : 先端技術で人を呼ぶ病院と工場に眠る宝, 日経BP社, 95-96, Oct. 2010.
155.	Munehide Matsuhisa : 高血糖とIMT, 月刊糖尿病, Vol.2, No.9, 38-45, Aug. 2010.
156.	Munehide Matsuhisa : 食後高血糖,食後高脂血症の診断マーカーをみる, Vascular Medicine, Vol.6, No.3, 38-42, Jul. 2010.
157.	Munehide Matsuhisa : 2型糖尿病におけるインスリン治療のあり方, 阿南医報, Vol.162, No.6, 15-16, Jun. 2010.
158.	Munehide Matsuhisa : 経済効果だけでなく医療面のスキルアップにも有効受け入れ態勢のシステムアップが課題, シニアビジネスマーケット, No.74, 48-49, 2010.
159.	Munehide Matsuhisa : 先進的な研究成果で徳島の存在感を世界へ, 県政だよりアワーとくしま, Vol.309, No.8, 2010.
160.	Munehide Matsuhisa : インスリン療法の適応と薬物療法におけるポジショニング, Biomedicine & Therapeutics, Vol.44, No.1, 66-71, 2010.

Proceeding of International Conference:

1.	Hiroki Yamagami, Tomoyo Hara, Yukari Mitsui, Shiho Masuda, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Analysis of clinical factors involved in AGE accumulation in people with type 2 diabetes, IDF-WPR Congress 2023/15th Scientific Meeting of AASD, Jul. 2023.
2.	Yosuke Kaneko, Saya Yasui, Minae Hosoi, Akihiro Tani, Hiroki Yamagami, Hiroyasu Mori, Tomoyo Hara, Yukari Mitsui, Kiyoe Kurahashi, Sumiko Yoshida, Shingen Nakamura, Akio Kuroda, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo, Takeshi Soeki, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Dehydroepiandrosterone sulfate and skeletal muscle disorders in patients with type 2 diabetes, IDF-WPR Congress 2023/15th Scientific Meeting of AASD, Tokyo, Jul. 2023.
3.	Yumi Kuwamura, Kiyoe Kurahashi, Sumiko Yoshida, Hiromichi Yumoto, Maki Hosoki, Yukihiro Momota, Ken-ichi Aihara, Masuko Sumikawa, Hirokazu Uemura, Munehide Matsuhisa and Itsuro Endo : Evaluation of Nursing Educational Material on Oral Health Behavior of Persons with Diabetes: Part 3 -- Physicians' Survey, International Diabetes Federation Western Pacific Congress 2023 /15th Scientific Meeting of Asian Association for the study of Diabetes, Kyoto, Japan, Jul. 2023.
4.	Tomoyo Hara, Hiroki Yamagami, Yukari Mitsui, Shiho Masuda, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Clinical factors and glycemic control in Japanese people with type 2 diabetes treated with weekly Dulaglutide at a dose of 0.75 mg, IDF-WPR Congress 2023/15th Scientific Meeting of AASD, Jul. 2023.
5.	Akio Kuroda and Munehide Matsuhisa : isCGM scan frequency and exploring correlated factors: Post hoc Analysis of the ISCHIA Study, 2nd Annual Advances Hypoglycaemia Scientific Conference Virtual meeting 2022, Dec. 2022.
6.	Shiho Masuda, Tomoyo Hara, Hiroki Yamagami, Mitsui Yukari, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Shingen Nakamura, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Evaluation of Vascular Function for Prediction of Renal Prognosis in Japanese Patients with Lifestyle-Related Diseases, The 29th Scientific Meeting of the International Society of Hypertension, Oct. 2022.
7.	Gimenez Marga, Khunti Kamlesh, Syring Kristen, Baker Levenia, Chenji Suresh, Threlkeld Rebecca, Yan Yu and Munehide Matsuhisa : Indirect Treatment Comparison (ITC) of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycaemia, 58th EASD Annual Meeting, Stockholm, Sweden, Sep. 2022.
8.	Gimenez Marga, Khunti Kamlesh, Syring Kristen, Baker Levenia, Chenji Suresh, Threlkeld Rebecca, Yan Yu and Munehide Matsuhisa : Indirect Treatment Comparison (ITC) of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycaemia, American Diabetes Association 83th Scientific Session, New Orleans, LA, Jun. 2022.
9.	Tomoyo Hara, Mitsui Yukari, Masuda Shiho, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Plasma heparin cofactor activity is inversely associated with the development NAFLD in patients with diabetes, American Diabetes Association 82nd Scientific Sessions, Jun. 2022.
10.	Tomoyo Hara, Mitsui Yukari, Masuda Shiho, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Heparin cofactor II prevents the development of albuminuria in patients with diabetes, EASD 2021 57th Annual Meeting, Sep. 2021.
11.	Akio Kuroda, Misuzu Yamada, Asami Okada, Yukari Tominaga, Kyoka Joh, Natsuki Ohrei, Hiroyasu Mori and Munehide Matsuhisa : Circulating cell free DNA and its clinical application, The 15th Symposium of the Institute Network for Biomedical Sciences, Nov. 2020.
12.	Tomoyo Hara, H Yamagami, Y Mitsui, S Masuda, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Plasma heparin cofactor activity is inversely associated with the development NAFLD in patients with diabetes, American Diabetes Association 80th Scientific Session, Chicago, Jun. 2020.
13.	Seaquist Elizabeth, Khunti Kamlesh, Zhang Xiaotian, Wang Qianqian, Takita Yasushi, Child J Christopher, Nagai Yukiko, Yan Yu and Munehide Matsuhisa : Nasal Glucagon Reversed Insulin-Induced Hypoglycemia in Adults with Diabetes: A Pooled Analysis., American Diabetes Association 80th Scientific Session, Jun. 2020. (Link to Publication Site) ● Publication site (DOI): 10.2337/db20-1074-P (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.2337/db20-1074-P (DOI: 10.2337/db20-1074-P)
14.	T Danne, Munehide Matsuhisa, C Sussebach, H Goyeau, F Lauand, E Niemöller and B Bolli : Lower risk for severe hypoglycemia with gla-300 vs. Gla-100 in patients with type 1 diabetes (t1d): a meta-analysis of 6-month phase 3 clinical trials., The 13th International Conference on Advanced Technologies & Treatments for Diabetes, Feb. 2020.
15.	Murata Tskashi, Suzuki Shota, Sakane Naoki, Nishimura Kunihiro, Toyoda Masao, Hirota Yushi, Munehide Matsuhisa, Akio Kuroda, Kato Ken, Kouyama Ryuji, Miura Junnosuke, Tone Atsuhito, Suganuma Akiko, Tomita Tsutomu, Noguchi Michio, Son Cheol, Ito Yukie, Kasama Shu, Satoh-asahara Noriko, Miyamoto Yoshihiro and Hosoda Kiminori : Effect of Intermittent-scanning CGM to glycemic control including hypoglycemia and quality of life of patients with type 1 diabetes mellitus (ischia study): study design., The 13th International Conference on Advanced Technologies & Treatments for Diabetes, Feb. 2020.
16.	Wadwa Paul R., Munehide Matsuhisa, N Zhang, Thieu T. Vivian, Q Wang, K Ohwaki, Child J Christopher, Threlkeld Jaye Rebecca and P Choudhary : Nasal glucagon successfully reversed insulin-induced hypoglycaemia in adults with diabetes with nadlr blood glucose <3.0 Mmol/L (54 MG/DL): A pooled analysis., The 13th International Conference on Advanced Technologies & Treatments for Diabetes, Feb. 2020.
17.	Y Nagai, Munehide Matsuhisa, R Nasu, Y Takita, Q Wang and K Ohwaki : Nasal Glucagon Reversed Insulin-Induced Hypoglycemia in Japanese Adults with Diabetes with Nadir Plasma Glucose <54 mg/dL, International Diabetes Federation Congress, Dec. 2019.
18.	T Danne, Munehide Matsuhisa, C Sussebach, H Goyeau, F Lauand, E Niemoeller and G.B Bolli : Lower risk for severe hypoglycemia with Gla-300 vs. Gla-100 in patients with type 1 diabetes: a meta-analysis of 6-month phase 3 clinical trials, ISPAD 2019 45th Annual Conferrence, Oct. 2019.
19.	Choudhary Pratik, Munehide Matsuhisa, Zhang Nan, Thieu T. Vivian, Wang Qianqian, Ohwaki Kenji, Child J Christopher, Threlkeld Jaye Rebecca and Wadwa Paul R. : Nasal Glucagon Successfully Reversed Insulin-Induced Hypoglycaemia in Diabetic Adults with Nadir Blood Glucose 3.0 mmol/L (<54 mg/dL), A Pooled Analysis.55th EASD Annual Meeting, Sep. 2019.
20.	Wadwa Paul R., Munehide Matsuhisa, Zhang Nan, Thieu T. Vivian, Wang Qianqian, Ohwaki Kenji, Child J Christopher, Threlkeld Jaye Rebecca and Choudhary Pratik : Nasal Glucagon Successfully Reversed Insulin-Induced Hypoglycaemia in Diabetic Adults with Nadir Blood Glucose <3.0 mmol/L (54 mg/dL): A Pooled Analysis, 55th EASD Annual Meeting, Sep. 2019.
21.	Misuzu Yamada, Akio Kuroda, Yukari Tominaga and Munehide Matsuhisa : Verification of Pancreatic β Cell Injury Detection Method Using Serum cfDNA, 55th EASD Annual Meeting, Sep. 2019.
22.	Masao Toyoda, Atsuhito Tone, Ken Kato, Moritsugu Kimura, Satoshi Kawashima, Hideaki Sawaki, Yushi Hirota, Akira Okada, Akio Kuroda, Munehide Matsuhisa, Tomokazu Watanabe, Akiko Suganuma, Takashi Murata and Naoki Sakane : Development and Validation of the Continuous Subcutaneous Insulin Infusion-Related Quality of Life (CSIL-QOL) Scale, American Diabetes Association 79th Scientific Sessions, Jun. 2019.
23.	Munehide Matsuhisa, Y Takita, R Nasu, K Ohwaki and H Nagashima : Nasal glucagon: A viable alternative to treat insulin-induced hypoglycemia in Japanease patients with type 1 and 2 diabetes., American Diabetes Association 79th Scientific Sessions, Jun. 2019. (Link to Publication Site) ● Publication site (DOI): 10.2337/db19-22-OR (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.2337/db19-22-OR (DOI: 10.2337/db19-22-OR)
24.	Akio Kuroda, Misuzu Yamada, Yuichi Takashi, Mami Ohishi, Hiroyasu Mori, Masashi Ishizu, Reiko Suzuki, Yinhua Otsuka, Yukari Tominaga and Munehide Matsuhisa : Detection of Vascular Endothelial Cell DNA in the Circulation Using Dual Amplification Refractory Mutation System PCR., American Diabetes Association 79th Scientific Sessions, San Francisco, Jun. 2019.
25.	Yumi Kuwamura, Sumiko Yoshida, Kiyoe Kurahashi, Masuko Sumikawa, Eijiro Sakamoto, Akio Kuroda, Hikari Yamato, Misuzu Okamoto, Hirokazu Uemura, Daisuke Hinode, Hiromichi Yumoto, Ken-ichi Aihara, Makoto Funaki, Munehide Matsuhisa, Itsuro Endo and Sachi Kishida : Oral health behaviors of outpatients with diabetes based on the Revised Diabetes Oral Health Assessment Tool for nurses, Journal of Diabetes Investigation, Vol.10, No.Supplement1, 26, Sendai-City, Miyagi Prefecture, May 2019. (Keyword) oral health behaviors / diabetes nursing / assessment
26.	Yuichi Takashi, Yuka Kinoshita, Nobuaki Ito, Shun Sawatsubashi, Hidetaka Kosako, Masahiro Abe, Munehide Matsuhisa, Toshio Matsumoto and Seiji Fukumoto : FGF receptor 1c works as a phosphate-sensor to regulate FGF23 production, ASBMR 2018 Annual Meeting Registration Confirmation, Sep. 2018.
27.	Yumi Kuwamura, Sumiko Yoshida, Kiyoe Kurahashi, Masuko Sumikawa, Eijiro Sakamoto, Ken-ichi Aihara, Hiromichi Yumoto, Munehide Matsuhisa, Itsuro Endo, Toshiyuki Yasui and Sachi Kishida : The Relationship Between the Modified Diabetes Oral Health Assessment Tool© for Nurses, Self-Efficacy Scale, and Outcome Expectancy Scale for Self-Care of Patients with Periodontal Disease, 2nd Technological Competency as Caring in the Health Sciences 2018, 63, Aug. 2018. (Keyword) nurse / diabetes mellitus / oral health / self-efficacy / outcome expectancy
28.	Akio Kuroda, Misuzu Yamada, Yukari Tominaga, Reiko Suzuki, Motoyuki Tamaki, Yuko Akehi, Yuichi Takashi, Daisuke Otsuka, Eisuke Shimokita, Fuminori Tanihara, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe, Kevin Ferreri and Munehide Matsuhisa : Detection of pancreatic beta cell DNA in the circulation using the amplification refractory mustation system PCR, American Diabetes Association 78th Scientific Sessions, Orlando, Jun. 2018.
29.	Munehide Matsuhisa, Hiroyasu Mori, Mami Ohishi, Masashi Ishizu, Reiko Suzuki, Ineko Takikawa, Satoshi Taniguchi, Motoyuki Tamaki, Yuko Akehi, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki and Akio Kuroda : The risk factors for rapid decline of renal function in Japanese patients with diabetes mellitus, American Diabetes Association 78th Scientific Sessions, Orlando, Jun. 2018.
30.	Sumiko Yoshida, Kiyoe Kurahashi, Akio Kuroda, Itsuro Endo, Ken-ichi Aihara, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : Changes of oxidative stress markers in patient of diabetes educational hospitalization., The Endocrine Society's Annual Meeting 2018, Chicago, Mar. 2018.
31.	Kana Morimoto, Masuda Shiho, Kiyoe Kurahashi, Motoyuki Tamaki, Takeshi Kondo, Sumiko Yoshida, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Akehi Yuko, Makoto Funaki, Seiji Fukumoto, Munehide Matsuhisa and Ken-ichi Aihara : Identification of clinical determinants for coefficient of variation of - intervals in patients with type 2 diabetes., International Conference on Diabetes and Its Complications 2017, Baltimore, Nov. 2017. (Keyword) therapy / 合併症
32.	Yumi Kuwamura, Masuko Sumikawa, Eijiro Sakamoto, Ineko Takikawa, Hikari Yamako, Hirokazu Uemura, Sachi Kishida, Toshihiko Nagata and Munehide Matsuhisa : Nurses' Implementation and Opinion of Assessment of Oral Health Behavior in Patients with Diabetes, Journal of Diabetes Investigation, Vol.8, No.Supplement S1 May, 50, Nagoya, May 2017. (Keyword) Nurse / oral health behaviors / diabetes
33.	Kana Morimoto, Kiyoe Kurahashi, Takeshi Kondo, Sumiko Yoshida, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Analysis of sodium restriction-induced blood pressure reduction in hospitalized patients with type 2 diabetes mellitus, The 10th Congress of the Asian-Pacific Society of Atherosclerosis and Vascular Diseases, Tokyo, Jul. 2016.
34.	Akio Kuroda, J Temma, T Horie, Hiroyasu Mori, Motoyuki Tamaki, Ken-ichi Aihara and Munehide Matsuhisa : Noninvasive measurement of skin autofluorescence as a beneficial surrogate marker for atherosclerosis in patients with type 2 diabetes, American Diabetes Association 75th Scientific Sessions, 2015.
35.	Munehide Matsuhisa, M Koyama, X Cheng, M Sumi, T Hirose and group behalf of the EDITION JP 1 study on : Sustained glycemic control and less nocturnal hypoglycemia with new insulin glargine 300 U/ml compared with glargine 100 U/ml over 12 months in Japanese people with type 1 diabetes, American Diabetes Association 75th Scientific Sessions, Jun. 2015.
36.	Munehide Matsuhisa, M Koyama, X Cheng, S Shimizu, T Hirose and group behalf of the EDITION JP 1 study on : New Insulin Glargine 300 U/mL: Glycemic Control and Hypoglycemia in Japanese People with T1DM (EDITION JP 1), European Association for study of Diabetes, Sep. 2014.
37.	Munehide Matsuhisa, M Koyama, X Cheng, S Shimizu, T Hirose and group behalf of the EDITION JP 1 study on : New Insulin Glargine 300 U/mL: Glycemic Control and Hypoglycemia in Japanese People with T1DM (EDITION JP 1), American Diabetes Association 74th Scientific Sessions, Jun. 2014.
38.	A King, Akio Kuroda and Munehide Matsuhisa : Combined Japanese and American prospective studies of dosing factor interrelationships support changing the current dosing recommendation for pump-treated T1DM, American Diabetes Association 74th Scientific Sessions, Jun. 2014.
39.	Akio Kuroda, 鶴尾美穂, Takeshi Kondo, 安芸奈菜子, 大黒由加里, Itsuro Endo, Ken-ichi Aihara, Motoyuki Tamaki, Toshio Matsumoto and Munehide Matsuhisa : Comparison of insulin Glargine with Insulin Degludec in Type 1 Diabetes Patients., 第74回アメリカ糖尿病学会, Jun. 2014.
40.	Akio Kuroda and Munehide Matsuhisa : Estimated glomerular filtration rate is the determinant of extended bolus insulin duration time of insulin pump., 7th International Conference on advanced technologies & Treatments for Diabetes., Feb. 2014.
41.	Akio Kuroda, Takeshi Kondo, Ken-ichi Aihara, Itsuro Endo, T Yasuda, H Kaneto, T Matsuoka, Toshio Matsumoto and Munehide Matsuhisa : The characteristics of type 1 diabetes patients who use insulin pump with square-wave bolus insulin., 73th America Diabetes Association (poster), Jun. 2013.
42.	Ken-ichi Aihara, Sumiko Yoshida, Mizuho Kinouchi, Takeshi Kondo, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Toshio Matsumoto : Diabetes Spoils the Favorable Effect of HDL-Cholesterol on Endothelial Function in the Elderly with Cardiovascular Risk Factors, American Heart Association Scientific Sessions 2012, ロサンゼルス, Nov. 2012.
43.	Akio Kuroda and Munehide Matsuhisa : Basal insulin requirement is approximately 30% of the total daily insulin dose in type 1 diabetic patients who use the insulin pump, 1st Annual World Congress of Diabetes 2012 Symposium, Jun. 2012.
44.	Akio Kuroda, YASUDA TETSUYUKI, TAKAHARA MITSUYOSHI, SAKAMOTO FUMIE, KASAMI RYUUICHI, MIYASHITA KAZUYUKI, MATSUOKA TAKA-AKI, Sumiko Yoshida, KONDO ERI, Itsuro Endo, Ken-ichi Aihara, KANETO HIDEAKI, Toshio Matsumoto, SHIMOMURA IICHIRO and Munehide Matsuhisa : Carbohydrate-to-Insulin Ratio is Calculated to be 300-400 Divided by Total Daily Insulin Dose in Type 1 Diabetic Patients Who Are on Insulin Pump Therapy, American Diabetes Association 72nd Scieentific Sessions, Philadelphia, Jun. 2012.
45.	Akio Kuroda, Munehide Matsuhisa, M. Takahara, T. Yasuda, R. Kataoka, R. Kasami, F. Sakamoto, T.-A. Matsuoka, H. Kaneto and I. Shimomura : Acetaminophen and eGFR are useful clinical markers for determining bolus insulin duration time in type 1 diabetic patients using insulin pump, Advanced Technologies & Treatments for Diabetes, Feb. 2012.
46.	K Fujisawa, T Yasuda, H Kaneto, Munehide Matsuhisa, Akio Kuroda, R Kasami, M Tsuji, I Shimomura, T Sato, S Okada, K Hagino, Y Kikkawa, J Kojima, T Watanabe and H Nakajima : Measurement of Glucose Area under the Curve Using Minimally Invasive Interstitial Fluid Extraction: Use in Evaluation of Drug Efficacy, The 16th Japan-Korea Symposium on Diabetes Mellitus, Oct. 2011.
47.	M Seike, Munehide Matsuhisa, Y Tashima, jianyin Lu, Y Kouchi, Y Naito, K Sakaguchi, K Tomita, K Kosugi, H Nakajima and A Kashiwagi : Demonstration of a Mathematical Model Predicting Splanchnic Glucose Output:Evaluation by Glucose Clamp, 70th Scientific Sessions, Jun. 2010.
48.	S Kawashima, TA Matsuoka, K Kato, Y Tochino, T Yamamoto, K Yamamoto, I Shimomura, Munehide Matsuhisa and H Kaneto : Combination Therapy with Pioglitazone and DPP4 Inhibitor Preserves Pancreatic B-Cell Function Comparably with Insulin in Diabetic Mice, 70th Scientific Sessions, Jun. 2010.
49.	K Yamamoto, TA Matsuoka, S Kawashima, R Kasami, K Yoshiuchi, I Shimomura, Munehide Matsuhisa and H Kaneto : Foxa2 and HNF6 DOwn-Regulate MafA Gene Expression through Conserved Foxa2 Binding Cis-Element, 70th Scientific Sessions, Jun. 2010.
50.	S Kawashima, TA Matsuoka, K Kato, Y Tochino, T Yamamoto, K Yamamoto, I Shimomura, Munehide Matsuhisa and H Kaneto : Combination Therapy with Pioglitazone and DPP4 Inhibitor Preserves Pancreatic B-Cell Function Comparably with Insulin in Diabetic Mice, 70th Scientific Sessions, Jun. 2010.
51.	K Yamamoto, TA Matsuoka, S Kawashima, R Kasami, K Yoshiuchi, I Shimomura, Munehide Matsuhisa and H Kaneto : Foxa2 and HNF6 Down-Regulate MafA Gene Expression through Conserved Foxa2 Binding Cis-Element, 70th Scientific Sessions, Jun. 2010.

Proceeding of Domestic Conference:

1.	Masashi Ishizu, Akio Kuroda, 鈴木麗子 and Munehide Matsuhisa : 心電図異常における糖尿病の意義の検討 -令和3年度徳島県市町村国保特定健診・後期高齢者医療健診データの解析結果-, 第24回日本糖尿病インフォマティクス学会年次学術集会, Aug. 2024.
2.	Munehide Matsuhisa : CDEに求める経口2型糖尿病治療薬の低血糖対策, 第11回JADEC年次学術集会, Jul. 2024.
3.	Munehide Matsuhisa : 糖尿病に関連したダイナペニアへの運動療法のエビデンスの創出高齢者糖尿病臨床研究助成報告, 第11回JADEC年次学術集会, Jul. 2024.
4.	Tomoyo Hara, 横田海友, 清水一磨, 浅井孝仁, Hiroki Yamagami, 三井由加里, 桝田志保, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 心血管疾患リスクを有する患者における可溶型DPP-4/CD26と動脈硬化指標との連関解析, 第56回日本動脈硬化学会総会, Jul. 2024.
5.	Yoshihiko Ueno, Taka-aki Yano, Takeo Minamikawa, Yosuke Seki, Masanobu Haraguchi, Koji Yasutomo, Munehide Matsuhisa, Takuya Sasaki, 木村賢二 and Takeshi Yasui : 地方国立大学の定員増における新教育組織の設置および入口戦略としての入試制度設計と実施――徳島大学 MPEプログラムを例として――, 令和6年度全国大学入学者選抜研究連絡協議会大会(第19回), May 2024.
6.	杉山雄大, 山岡巧弥, 今井健二郎, 井花庸子, 大杉満, 池上博司, 梶尾裕, 中島直樹, 南昌江, 安田和基, Munehide Matsuhisa, 山内敏正, 植木浩二郎, 山田尚子 and 島田朗 : 匿名医療保険等関連情報データベース (NDB) を用いた本邦における1型糖尿病患者数と属性分布の検討, 第67日本糖尿病学会学術集会, May 2024.
7.	大杉満, 杉山雄大, Munehide Matsuhisa, 浦上達彦, 川村智之, 西村理明, 廣田勇士, 山内敏正, 植木浩二郎, 田嶼尚子 and 島田朗 : 診療録直結型全国糖尿病データベース (J-DREAMS)による1型糖尿病症例の合併症実態調査・第一報, 第67日本糖尿病学会学術集会, May 2024.
8.	山本あかね, 廣田勇士, 坂根直樹, 上田真莉子, 齋藤修一郎, 目黒周, 細田公則, 伊藤新, 加藤研, 小谷紀子, Akio Kuroda, Munehide Matsuhisa, 三浦順之助, 島田朗, 利根淳仁, 豊田雅夫 and 村田敬 : 1型糖尿病におけるisCGMによる低血糖を含む血糖管理に及ぼす効果に関する性差の検討 : ISCHIA研究post-ho解析, 第67日本糖尿病学会学術集会, May 2024.
9.	宮下和幸, 片上直人, Akio Kuroda, Munehide Matsuhisa and 下村伊一郎 : 膵腎同時移植後の体重内臓脂肪量の推移と動脈硬化に及ぼす影響, 第67日本糖尿病学会学術集会, May 2024.
10.	Munehide Matsuhisa and Akio Kuroda : 先進糖尿病医療は低血糖を予防・改善できるか, 第67日本糖尿病学会学術集会シンポジウム, May 2024.
11.	Tomoyo Hara, 横田海友, 清水一磨, 浅井孝仁, Hiroki Yamagami, 三井由加里, 桝田志保, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 糖尿病患者における可溶型DPP-4/CD26と動脈硬化指標との関連, 第67日本糖尿病学会学術集会, May 2024.
12.	Munehide Matsuhisa : インスリン治療の現在，そして近未来, 第51回日本膵・膵島移植学会学術集会, Feb. 2024.
13.	Munehide Matsuhisa : 糖尿病をもつ高齢者の病態と対策, 第58回糖尿病学の進歩, Feb. 2024.
14.	Munehide Matsuhisa, Akio Kuroda and 宮下和幸 : 膵臓移植の現状と展望, 第58回糖尿病学の進歩特別企画, Feb. 2024.
15.	Akio Kuroda and Munehide Matsuhisa : 重症低血糖・潜在的低血糖とその対策, 第58回糖尿病学の進歩, Feb. 2024.
16.	Masashi Ishizu and Munehide Matsuhisa : 心電図異常に関わる背景因子の検討-令和2年度徳島県市町村国保特定健診・後期高齢者医療健診データの解析, 第8回日本糖尿病・生活習慣病ヒューマンデータ学会, Dec. 2023.
17.	Munehide Matsuhisa : 進むデジタル糖尿病診療の今, 第8回日本糖尿病・生活習慣病ヒューマンデータ学会, Dec. 2023.
18.	Xiao Shan, Masato Tagi, 小西健史, Hiroyasu Mori, Munehide Matsuhisa and Jun Hirose : AIを用いた糖尿病患者に対する食事提案システムの開発, 医療情報学連合大会論文集 43回, 995-997, Nov. 2023.
19.	Munehide Matsuhisa and Akio Kuroda : CGM の進歩と残された課題, 第22回日本先進糖尿病治療・1型糖尿病研究会, Nov. 2023.
20.	Munehide Matsuhisa : 糖尿病治療に伴う低血糖, 第33回臨床内分泌代謝Update, Nov. 2023.
21.	浅井孝仁, Tomoyo Hara, 清水一磨, 吉田麻衣子, 山上絋規, 三井由加里, Kiyoe Kurahashi, Akio Kuroda, Munehide Matsuhisa and Itsuro Endo : ランレオチドを投与した14症例の糖代謝への影響に関する検討, 第33回臨床内分泌代謝Update, Nov. 2023.
22.	Tomoyo Hara, 清水一磨, 浅井孝仁, 吉田麻衣子, Hiroki Yamagami, 三井由加里, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 2型糖尿病患者の非アルコール性脂肪性肝疾患における尿中可溶性ウロキナーゼ型プラスミノーゲン活性化受容体の臨床的意義, 第38回日本糖尿病合併症学会, Oct. 2023.
23.	益田貴史, 片上直人, 田矢直大, 渡邉裕尭, 宮下和幸, 高原充佳, 加藤研, Akio Kuroda, Munehide Matsuhisa and 下村伊一郎 : 若年発症1型糖尿病患者における血糖コントロールと糖尿病合併症の経時的変化および糖尿病合併症の進展に関連する因子, 第38回日本糖尿病合併症学会, Oct. 2023.
24.	Akio Kuroda, Asami Okada, Hiroyasu Mori, 冨永ゆかり, Masashi Ishizu and Munehide Matsuhisa : 循環血中遊離 DNA を標的とした血管内皮細胞傷害の検出, 第38回日本糖尿病合併症学会, Oct. 2023.
25.	Munehide Matsuhisa : ICT 医療連携システムの糖尿病診療への活用, 第38回日本糖尿病合併症学会シンポジウム, Oct. 2023.
26.	MIMA Shunsuke, Hiroyuki Yamasaki, BANDO Mayu, Shinji Nagasaka, Yutaro Yamashita, Kazuhide Mineda, Yoshiro Abe, Sumiko Yoshida, Itsuro Endo, Munehide Matsuhisa, Masahiro Takaiwa and Ichiro Hashimoto : 糖尿病患者の歩行時における足底圧・せん断応力と足底部皮下組織量の研究, 第32回日本形成外科学会基礎学術集会, Oct. 2023.
27.	清水一磨, Hiroki Yamagami, Tomoyo Hara, 答島悠貴, 浅井孝仁, 三井由加里, Kiyoe Kurahashi, Munehide Matsuhisa and Itsuro Endo : 診断に7年間を要したTSH産生下垂体micro adenomaの一例, 第33回臨床内分泌代謝Update, Oct. 2023.
28.	Munehide Matsuhisa : 糖尿病や肥満のある高齢者の病態的特徴と治療, 第25回日本褥瘡学会学術集会教育講演, Sep. 2023.
29.	Hiroyasu Mori, Satoshi TANIGUCHI, Yuu Tamaki, 野村友美, 鈴木麗子, Akio Kuroda, 明比祐子, 長嶋伸光, 比木武 and Munehide Matsuhisa : 2型糖尿病患者の臨床用PHRを用いた自動支援メッセージがセルフモニタリングや体重管理に与える効果:無作為化比較試験, 第23回日本糖尿病インフォマティクス学会年次学術集会 YIA優秀演題賞受賞, Aug. 2023.
30.	Munehide Matsuhisa : 糖尿病医療を支えるIot・Ict技術のこれから, 第10回日本糖尿病協会学術集会会長企画, Jul. 2023.
31.	Munehide Matsuhisa : 高齢者糖尿病の秒遺体的特徴とその治療, 2023年度日本内科学会生涯教育講演会教育講演, Jul. 2023.
32.	Sumiko Yoshida, Akio Kuroda, Munehide Matsuhisa and Itsuro Endo : 糖尿病血糖管理入院における尿Titin N-terminal Fragmentの変化の検討, 第66回日本内分泌学会学術総会, Jun. 2023.
33.	Hiroki Yamagami, Tomoyo Hara, Yuki Tohjima, Takahito Asai, 三井由加里, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : 2型糖尿病患者のSkin autofluorscenceを規定する因子の検討, 第96回日本内分泌学会学術総会, Jun. 2023.
34.	答島悠貴, Tomoyo Hara, 浅井孝仁, Hiroki Yamagami, 三井由加里, 倉橋衛清, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 当院におけるインスリングラルギン/リキシセナチド(iGlarLixi)導入症例の臨床背景および効果の検討, 第66回日本糖尿病学会年次学術集会, May 2023.
35.	Munehide Matsuhisa : 無自覚性低血糖の病態と対策, 第66回日本糖尿病学会年次学術集会教育講演, May 2023.
36.	Hiroki Yamagami, Tomoyo Hara, Yuki Tohjima, Takahito Asai, 三井由加里, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : 2型糖尿病患者のAGEs蓄積に関わる臨床的因子の解析, 第66回日本糖尿病学会年次学術集会, May 2023.
37.	Yuki Tohjima, Tomoyo Hara, Takahito Asai, Hiroki Yamagami, 三井由加里, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 当院におけるインスリングラルギン/リキシセナチド (iGlarLixi)導入症例の臨床背景および効果の検討, 第66回日本糖尿病学会年次学術集会, May 2023.
38.	Munehide Matsuhisa : より上質な血糖マネジメントえおめざしたisCGMの活用, 第66回日本糖尿病学会年次学術集会, May 2023.
39.	村田敬, 坂根直樹, 廣田勇士, 豊田雅夫, Munehide Matsuhisa, Akio Kuroda, 伊藤新, 目黒周, 三浦順之助, 的場ゆか, 加藤研 and 鈴木渉太 : 1 型糖尿病患者における FreeStyle リブレ(第 3 世代アルゴリズム)の計測特性分析, 第66回日本糖尿病学会年次学術集会, May 2023.
40.	Tomoyo Hara, Yuki Tohjima, Takahito Asai, Hiroki Yamagami, 三井由加里, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 糖尿病患者における腎糸球体および尿細管障害特異的なリスク因子の臨床的検討, 第66回日本糖尿病学会年次学術集会, May 2023.
41.	白木ゆり, 三好秀明, Munehide Matsuhisa, 矢部大介, 髙橋容子 and 寺内康夫 : iGlarLixi の胃腸障害発現に対する潜在的因子の評価-SPARTA Japan post-hoc Analysis, 第66回日本糖尿病学会年次学術集会, May 2023.
42.	益田貴史, 片上直人, 今田侑, 藤川慧, 細江重郎, 田矢直大, 渡邉裕尭, 大森一生, 佐々木周伍, 高原充佳, 宮下和幸, 加藤研, 河盛段, Akio Kuroda, 安田哲行, Munehide Matsuhisa and 下村伊一郎 : 若年発症 1 型糖尿病患者における糖尿病性腎症，動脈硬化に関連する因子, 第66回日本糖尿病学会年次学術集会, May 2023.
43.	Munehide Matsuhisa : 糖尿病診療DX 現況と近未来, 第66回日本糖尿病学会年次学術集会ランチョンセミナー, May 2023.
44.	Akio Kuroda and Munehide Matsuhisa : 2 型糖尿病における潜在的低血糖とその対策, 第66回日本糖尿病学会年次学術集会シンポジウム, May 2023.
45.	佐々木宏和, 三好秀明, Munehide Matsuhisa, 矢部大介, 髙橋容子 and 寺内康夫 : インスリン治療下の 2 型糖尿病における iGlarLixi の用量調節と治療目標値達成との関連性の評価―SPARTA Japan post-hoc 解析, 第66回日本糖尿病学会年次学術集会, May 2023.
46.	三好秀明, Munehide Matsuhisa, 矢部大介, 髙橋容子 and 寺内康夫 : インスリン未治療 2 型糖尿病における iGlarLixi の用量調節と治療目標値達成との関連性の評価―SPARTA Japan post-hoc 解析, 第66回日本糖尿病学会年次学術集会, May 2023.
47.	MIMA Shunsuke, Hiroyuki Yamasaki, BANDO Mayu, Yoshiro Abe, Kazuhide Mineda, Yutaro Yamashita, Munehide Matsuhisa and Ichiro Hashimoto : 糖尿病性神経障害が足底部皮下組織に与える影響, 第66回日本形成外科学会総会・学術集会, Apr. 2023.
48.	Munehide Matsuhisa : 低血糖のエビデンス, 重症低血糖を防ぐために, 第 57 回糖尿病学の進歩シンポジウム, Feb. 2023.
49.	Yuki Tohjima, Tomoyo Hara, 浅井孝仁, Hiroki Yamagami, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Akio Kuroda, Munehide Matsuhisa, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 首下がりを契機に診断に至ったCushing病の一例, 内科学会第127回四国地方会, Dec. 2022.
50.	Munehide Matsuhisa : 糖尿病診療のデジタル化第 42 回医療情報学連合大会, 第 23 回医療情報学会学術大会, Nov. 2022.
51.	Yuki Tohjima, 三井由加里, 浅井孝仁, Tomoyo Hara, Hiroki Yamagami, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Akio Kuroda, Masahiro Abe and Munehide Matsuhisa : レパグリニドとクロピドグレルの併用による遷延性低血糖を認めた一例, 日本糖尿病学会中国四国地方会第60回総会, Nov. 2022.
52.	Tomoyo Hara, Kiyoe Kurahashi, Hirofumi Hamano, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : デュラグルチド使用中患者の HbA1c管理に影響を与える因子の検討, 日本糖尿病学会中国四国地方会第60回総会, Nov. 2022.
53.	Munehide Matsuhisa : 進歩する1型糖尿病内科治療に対し膵・膵島移植の適応とは, 第58回日本移植学会総会シンポジウム, Oct. 2022.
54.	西村理明, 島田朗, 阿比留教生, Munehide Matsuhisa, 髙橋容子 and 池上博司 : 成人1型糖尿病の年齢層別にみる心理社会面・生活の質とHbA1c管理目標値達成との関連:SAGE studyサブ解析, 第21回日本先進糖尿病治療・1型糖尿病研究会, Oct. 2022.
55.	豊田雅夫, 村田敬, 坂根直樹, 齋藤仁通, 加藤研, 廣田勇士, Akio Kuroda, Munehide Matsuhisa, 島田朗 and 細田公則 : 間歇スキャンCGMの精度に対する接触性皮膚炎の影響(ISCHIA研究post-hoc解析), 第21回日本先進糖尿病治療・1型糖尿病研究会, Oct. 2022.
56.	Munehide Matsuhisa : 先進糖尿病治療と重症低血糖, 第21回日本先進糖尿病治療・1型糖尿病研究会ランチョンセミナ, Oct. 2022.
57.	益田貴史, 片上直人, 田矢直大, 宮下和幸, 髙原充佳, Akio Kuroda, Munehide Matsuhisa and 下村伊一郎 : 日本人若年発症1型糖尿病の合併症進展にインスリンポンプ療法が及ぼす影響の検討, 第21回日本先進糖尿病治療・1型糖尿病研究会, Oct. 2022.
58.	Munehide Matsuhisa : CGMが変えたインスリン治療, 第22回日本内分泌学会九州支部学術集会, Sep. 2022.
59.	鶴尾美穂, Akio Kuroda and Munehide Matsuhisa : FreeStyleリブレ Link 使用によりHbA1c が改善した 1 型糖尿病の 1 例, 第22回日本糖尿病インフォマティクス学会年次学術集会, Aug. 2022.
60.	三井由加里, Akio Kuroda, Tomoyo Hara, Hiroki Yamagami, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Masahiro Abe and Munehide Matsuhisa : 持続皮下インスリン注入療法下 1 型糖尿病合併妊娠における分娩直後のインスリン投与設定変更の提案, 第22回日本糖尿病インフォマティクス学会年次学術集会, Aug. 2022.
61.	鶴尾美穂, Akio Kuroda and Munehide Matsuhisa : ハイブリッド型クローズドループインスリンポンプが有効であった高齢1型糖尿病の 1 例, 第22回日本糖尿病インフォマティクス学会年次学術集会, Aug. 2022.
62.	Munehide Matsuhisa : ICTが拓く糖尿病診療の未来, 第22回日本糖尿病インフォマティクス学会年次学術集会イブニングセミナー, Aug. 2022.
63.	Shiho Masuda, Tomoyo Hara, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 生活習慣病患者のeGFR年間変化量予測における血管内皮機能の意義, 第54回日本動脈硬化学会総会・学術集会, Jul. 2022.
64.	Munehide Matsuhisa : 糖尿病をもつ高齢者の病態と治療を考える, 第9回日本糖尿病協会年次学術集会, Jul. 2022.
65.	Tomoyo Hara, 山上紘規, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 糖尿病患者における血漿Heparin Cofactor II活性とNAFLD病態指標の連関解析, 第8回肝臓と糖尿病・代謝研究会, Jun. 2022.
66.	Munehide Matsuhisa : 最適なインスリン治療のための知と技, 第 65 回日本糖尿病学会年次学術集会, May 2022.
67.	益田貴史, 片上直人, 今田侑, 藤川慧, 細江重郎, 田矢直大, 渡邉裕尭, 大森一生, 佐々木周伍, 下直樹, 髙原充佳, 宮下和幸, 加藤研, 河盛段, Akio Kuroda, 安田哲行, Munehide Matsuhisa and 下村伊一郎 : 日本人若年発症 1 型糖尿病患者の合併症進展にインスリンポンプ療法が及ぼす影響の検討, 第 65 回日本糖尿病学会年次学術集会, May 2022.
68.	宮下和幸, 片上直人, Akio Kuroda, Munehide Matsuhisa and 下村伊一郎 : 膵臓移植後 10 年にわたる移植膵機能の推移, 第 65 回日本糖尿病学会年次学術集会, May 2022.
69.	Toshiki Otoda, Tomoyuki Yuasa, 関根明子, 上元良子, Hiroyasu Mori, Tomoyo Hara, Motoyuki Tamaki, Toshiaki Tamaki, Munehide Matsuhisa and Ken-ichi Aihara : SGLT2 阻害薬投与による蛋白尿減少および炎症抑制効果の検討, 第 65 回日本糖尿病学会年次学術集会, May 2022.
70.	森博康, Akio Kuroda, 明比祐子 and Munehide Matsuhisa : 2 型糖尿病患におけるダイナペニアとサルコペニアの総エネルギー・栄養素摂取量等の影響:横断的検証, 第 65 回日本糖尿病学会年次学術集会, May 2022.
71.	Toshiki Otoda, Tomoyuki Yuasa, 関根明子, 上元良子, Hiroyasu Mori, Tomoyo Hara, Motoyuki Tamaki, Toshiaki Tamaki, Munehide Matsuhisa and Ken-ichi Aihara : SGLT2阻害薬投与による蛋白尿減少および炎症抑制効果の検討, 第65回日本糖尿病学会年次学術集会, May 2022.
72.	Munehide Matsuhisa : 糖尿病診療のデジタル化の最新情報, 第 65 回日本糖尿病学会年次学術集会, May 2022.
73.	Munehide Matsuhisa : 高齢者糖尿病患者における低血糖の課題, 第 65 回日本糖尿病学会年次学術集会シンポジウム, May 2022.
74.	寺内康夫, 三好秀明, Munehide Matsuhisa, 矢部大介 and 高橋容子 : 実臨床下の日本人成人2型糖尿病におけるiGlarLixiの有用性と安全性:後ろ向き研究 SPARTA Japan, 第 65 回日本糖尿病学会年次学術集会, May 2022.
75.	三好秀明, Munehide Matsuhisa, 矢部大介, 高橋容子 and 寺内康夫 : 実臨床下の，経口血糖降下薬で効果不十分な日本人成人 2 型糖尿病における iGlarLixi の有用性と安全性:後ろ向き研究 SPARTA Japan, 第 65 回日本糖尿病学会年次学術集会, May 2022.
76.	奥谷早也香, 三好秀明, Munehide Matsuhisa, 矢部大介, 高橋容子 and 寺内康夫 : 実臨床下のBIとGLP-1RAの併用から切替えた成人2型糖尿病におけるiGlarLixiの有用性と安全性:後ろ向き研究SPARTA Japan, 第 65 回日本糖尿病学会年次学術集会, May 2022.
77.	Sumiko Yoshida, 辻誠一郎, Kiyoe Kurahashi, 宮恵子, 島久登, 田代学, 井上朋子, 水口潤, 中村信元, Akio Kuroda, Itsuro Endo, Masahiro Abe and Munehide Matsuhisa : 透析患者における新型コロナワクチン抗体と糖尿病の関連の検討, 第 65 回日本糖尿病学会年次学術集会, May 2022.
78.	阿部勧, 三好秀明, Munehide Matsuhisa, 矢部大介, 髙橋容子 and 寺内康夫 : 実臨床下の日本人成人 2 型糖尿病における年齢および罹病期間別の iGlarLixi の有用性と安全性:後ろ向き研究 SPARTA Japan, 第 65 回日本糖尿病学会年次学術集会, May 2022.
79.	Munehide Matsuhisa, 三好秀明, 矢部大介, 髙橋容子 and 寺内康夫 : 実臨床下の，BOT にて効果不十分な日本人成人 2 型糖尿病における iGlarLixi の有用性と安全性:後ろ向き研究 SPARTA Japan, 第 65 回日本糖尿病学会年次学術集会, May 2022.
80.	Sumiko Yoshida, 辻誠士郎, Kiyoe Kurahashi, 宮恵子, 島久登, 田代学, 井上朋子, 水口潤, Shingen Nakamura, Akio Kuroda, Itsuro Endo, Masahiro Abe and Munehide Matsuhisa : 透析患者における新型コロナワクチン抗体と糖尿病の関連の検討, Journal of the The Japan Diabetes Society, Vol.65, No.Suppl.1, S-165, Apr. 2022. (Keyword) 血液透析ウイルス抗体腎不全-慢性(治療) 糖尿病性腎症(治療) 予防接種 COVID-19ワクチン(治療的利用) *Tozinameran(治療的利用) ヒト男女
81.	Sumiko Yoshida, 辻誠士郎, 金子遥祐, 森建介, 河田沙紀, 川原綾香, 遠藤ふうり, Tomoyo Hara, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Masahiro Abe and Munehide Matsuhisa : 精神疾患とうつ尺度が減量入院効果に及ぼす影響, 第41回日本肥満学会・第38回日本肥満症治療学会, Mar. 2022.
82.	辻誠士郎, Sumiko Yoshida, 金子遥祐, 森建介, 河田沙紀, 川原綾香, 遠藤ふうり, Tomoyo Hara, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Masahiro Abe and Munehide Matsuhisa : 行動療法を重視した2週間の減量入院後の減量効果の検討, 第41回日本肥満学会・第38回日本肥満症治療学会, Mar. 2022.
83.	辻誠士郎, Sumiko Yoshida, 金子遥祐, 森建介, 河田沙紀, 川原綾香, 遠藤ふうり, Tomoyo Hara, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Masahiro Abe and Munehide Matsuhisa : 行動療法を重視した2週間の減量入院後の減量効果の検討, 第42回日本肥満学会第39回日本肥満症治療学会学術集会, Mar. 2022.
84.	Sumiko Yoshida, 辻誠士郎, 金子遥祐, 森建介, 河田沙紀, 川原綾香, 遠藤ふうり, Tomoyo Hara, Kiyoe Kurahashi, 明比祐子, Itsuro Endo, Masahiro Abe and Munehide Matsuhisa : 精神疾患とうつ尺度が減量入院効果に及ぼす影響, 第42回日本肥満学会第39回日本肥満症治療学会学術集会, Mar. 2022.
85.	Munehide Matsuhisa : 新しい時代の1型糖尿病治療, 第49回日本膵・膵島移植研究会, Mar. 2022.
86.	宮下和幸, 富丸慶人, 片上直人, 小林省吾, Akio Kuroda, Munehide Matsuhisa, 江口英利 and 下村伊一郎 : 膵臓移植後10年にわたる移植膵機能の推移, 第49回日本膵・膵島移植研究会, Mar. 2022.
87.	Hiroyasu Mori, 徳田泰伸, 吉田恵里子, 内田健志 and Munehide Matsuhisa : スケソウダラ速筋タンパクの摂取が要介護高齢者の骨格筋量と筋力，身体機能に与える効果:単群前後比較試験, 第33回日本老年医学会四国地方会, Jan. 2022.
88.	山崎裕行, Yutaro Yamashita, Kazuhide Mineda, 石田創士, 安倍吉郎, Akio Kuroda, Munehide Matsuhisa, 高岩昌弘 and 橋本一郎 : 糖尿病末梢神経障害による歩容変化と重心動揺性 ―3次元歩行解析による検討―, 第2回日本フットケア・足病医学会年次学術集会, Dec. 2021.
89.	山崎裕行, Yutaro Yamashita, Kazuhide Mineda, Soushi Ishida, Yoshiro Abe, Akio Kuroda, Munehide Matsuhisa, Masahiro Takaiwa and Ichiro Hashimoto : 糖尿病性末梢神経障害による歩容変化と重心動揺性ー 3次元歩行解析による検討ー, 第2回日本フットケア・足病医学会年次学術集会, Dec. 2021.
90.	青山理央, 川原綾香, Kiyoe Kurahashi, Tomoyo Hara, Sumiko Yoshida, Akio Kuroda, Munehide Matsuhisa, Munehide Matsuhisa, Seiji Fukumoto, Itsuro Endo and Masahiro Abe : 1型糖尿病とバセドウ病を同時に診断した1例, 日本内科学会第125回四国地方会, Dec. 2021.
91.	Toshiki Otoda, Tomoyuki Yuasa, 関根明子, 上元良子, Hiroyasu Mori, Motoyuki Tamaki, Toshiaki Tamaki, Munehide Matsuhisa and Ken-ichi Aihara : SGLT2阻害薬の投与が蛋白尿減少効果をもたらす要因の検討, 第6回日本糖尿病・生活習慣病ヒューマンデータ学会, Dec. 2021.
92.	Shiho Masuda, Tomoyo Hara, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 生活習慣病患者におけるeGFR年間変化量と血管内皮機能の連関解析, 第6回日本糖尿病・生活習慣病ヒューマンデータ学会, Dec. 2021.
93.	Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 糖尿病患者における血漿Heparin Cofactor II活性とNAFLD病態指標の連関, 第6回日本糖尿病・生活習慣病ヒューマンデータ学会, Dec. 2021. (Keyword) ヘパリンコファクターII / NAFLD / diabetes
94.	Munehide Matsuhisa : 間歇スキャン式CGMがもたらした臨床効果と展望, 第20回日本先進糖尿病治療研究会・第18回1型糖尿病研究会合同シンポジウム, Nov. 2021.
95.	Hiroyasu Mori, 秦誠倫, 安田哲行, 山本恒彦, 馬屋原豊, 良本佳代子, 吉内和富, Sumiko Yoshida, Akio Kuroda and Munehide Matsuhisa : 1型糖尿病における低IGF-1血症が骨格筋量の低下やサルコペニア合併に及ぼす影響の検討:横断的研究, 第20回日本先進糖尿病治療研究会・第18回1型糖尿病研究会, Nov. 2021.
96.	Akio Kuroda and Munehide Matsuhisa : 食後血糖管理を目的とする食事の際の追加インスリンの選び方, 第20回日本先進糖尿病治療研究会・第18回1型糖尿病研究会, Nov. 2021.
97.	ISCHIAグループ and Munehide Matsuhisa : 系統的教育を伴う間歇スキャンCGM使用による低血糖時間の減少:クロスオーバー他施設ランダム化比較研究, 第20回日本先進糖尿病治療研究会・第18回1型糖尿病研究会, Nov. 2021.
98.	川原綾香, Kiyoe Kurahashi, 河田沙紀, 金子遥祐, 遠藤ふうり, Tomoyo Hara, 辻誠士郎, Sumiko Yoshida, Akio Kuroda, Itsuro Endo and Munehide Matsuhisa : 肝膿瘍とサイトメガロウイルス胃炎を合併した2型糖尿病の一例, 日本糖尿病学会中国四国地方会第59回総会, Oct. 2021.
99.	金子遥祐, Tomoyo Hara, 河田沙紀, 川原綾香, 遠藤ふうり, 辻誠士郎, Kiyoe Kurahashi, Sumiko Yoshida, Akio Kuroda, Itsuro Endo and Munehide Matsuhisa : PD-1抗体が1型糖尿病発症に関与したと考えられる非典型的な3例(29文字), 日本糖尿病学会中国四国地方会第59回総会, Oct. 2021.
100.	河田沙紀, Kiyoe Kurahashi, 川原綾香, 金子遥祐, 遠藤ふうり, Tomoyo Hara, 辻誠士郎, Sumiko Yoshida, Akio Kuroda, Itsuro Endo and Munehide Matsuhisa : 糖尿病ケトアシドーシスが改善後にケトーシスが再燃した2型糖尿病の1例, 日本糖尿病学会中国四国地方会第59回総会, Oct. 2021.
101.	Asami Okada, Misuzu Yamada, Hiroyasu Mori, 明比祐子, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Akio Kuroda : 1型糖尿病患者における膵β細胞傷害の定量化の試み, 日本糖尿病学会中国四国地方会第59回総会, Oct. 2021.
102.	Munehide Matsuhisa and Akio Kuroda : 血糖変動を可視化する新しい血糖管理目標Time in range(TIR), 第36回日本糖尿病合併症学会・第27回糖尿病眼学会総会シンポジウム, Oct. 2021.
103.	Akio Kuroda, Masashi Ishizu, 鶴尾美穂, Hiroyasu Mori, 明比祐子, 岡本美鈴, 鈴木麗子, 寺澤敏秀 and Munehide Matsuhisa : 持続グルコースモニタリングの推定HbA1c値と実測HbA1c値との解離に関する検討, 第21回日本糖尿病インフォマティクス学会年次学術集会, Aug. 2021.
104.	Asami Okada, Misuzu Yamada, Hiroyasu Mori, 明比祐子, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Akio Kuroda : 循環血中遊離DNAを用いた膵β細胞障害の新規検出法の確立, 第263回徳島医学会学術集会, Aug. 2021.
105.	吉川紘平, 金子遥祐, 辻誠士郎, 河田沙紀, 川原綾香, 森健介, 遠藤ふうり, 原倫世, Kiyoe Kurahashi, Sumiko Yoshida, Akio Kuroda, 明比祐子, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Seiji Fukumoto : TIA様発作を契機に診断されたインスリノーマの一例, 第263回徳島医学会, Aug. 2021.
106.	Munehide Matsuhisa : 高齢糖尿病患者における運動療法の障壁∼サルコペニアとダイナペニア∼, 第64回日本糖尿病学会年次学術集会シンポジウム, May 2021.
107.	Hiroyasu Mori, Akio Kuroda, Sumiko Yoshida, 安田哲行, 馬屋原豊, 清水彩洋子, 良本佳代子, 吉内和富, 山本恒彦 and Munehide Matsuhisa : 2型糖尿病患者のサルコペニア合併に血清グリコアルブミン/HbA1cが関連する, 第64回日本糖尿病学会年次学術集会, May 2021.
108.	Munehide Matsuhisa, Hiroyasu Mori and Akio Kuroda : 高齢 1 型糖尿病の病態と診療上の課題, 第64回日本糖尿病学会年次学術集会, May 2021.
109.	辻誠士郎, Sumiko Yoshida, 平岡栞名, Kohsuke Miyataka, Minae Hosoki, Tomoyo Hara, 三井由加里, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Makoto Funaki, Seiji Fukumoto, Masahiro Abe and Munehide Matsuhisa : 行動療法を中心とした2週間の減量入院プログラムの退院後の減量効果, 第64回日本糖尿病学会年次学術集会, May 2021.
110.	遠藤理子, Kiyoe Kurahashi, 平岡栞名, 細木美苗, 宮高紘輔, 辻誠士郎, Sumiko Yoshida, Itsuro Endo, Munehide Matsuhisa and Masahiro Abe : 慢性膵炎の急性増悪を繰り返し，仮性脾動脈瘤の急速な増大を認めた一例, 第124回日本内科学会四国地方会(WEB開催), May 2021.
111.	Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo and Munehide Matsuhisa : 血漿 Heparin Cofactor \|\| 活性とNAFLD病態指標の連関解析, 第94回日本内分泌学会学術総会, Apr. 2021.
112.	Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 血漿Heparin Cofactor II活性とNAFLD病態指標の連関解析, 第94回日本内分泌学会学術総会, Apr. 2021.
113.	山崎裕行, Yutaro Yamashita, Kazuhide Mineda, Yoshiro Abe, Akio Kuroda, Munehide Matsuhisa, Masahiro Takaiwa and Ichiro Hashimoto : シンポジウム: 歩容分析から糖尿病性足病変の予防を検討する ∼特徴的な歩容変化と重心動揺性について∼, 第64回日本形成外科学会総会・学術集会, Apr. 2021.
114.	益田貴史, 宮下和幸, 富丸慶人, 小林省吾, 片山直人, Akio Kuroda, 伊藤壽記, 土岐祐一郎, 江口栄利, Munehide Matsuhisa and 下村伊一郎 : 膵臓移植後に動脈硬化性疾患を発症した6症例の検討, 第48回日本膵・膵島移植研究会, Mar. 2021.
115.	Munehide Matsuhisa, Akio Kuroda and 宮下和幸 : 膵臓移植におけるチーム医療と糖尿病専門医の役割, 第48回日本膵・膵島移植研究会ワークショップ, Mar. 2021.
116.	Munehide Matsuhisa and Akio Kuroda : 糖尿病地域医療連携のICT化への試み, 第35回日本糖尿病合併症学会第26回日本糖尿病眼学会総会合同シンポジウム, Dec. 2020.
117.	Munehide Matsuhisa : 先進糖尿病治療の進歩, 日本内科学会学術集会第48回内科学の展望, Nov. 2020.
118.	Hiroyasu Mori, Akio Kuroda, Sumiko Yoshida, 安田哲行, 馬屋原豊, 清水彩洋子, 良本佳代子, 吉内和富, 山本恒彦, 下村伊一郎 and Munehide Matsuhisa : 2型糖尿病患者におけるダイナぺニアとサルコペニアの臨床的特徴, 日本糖尿病学会中国四国地方会第58総会, Oct. 2020.
119.	Akio Kuroda, Masashi Ishizu, 鶴尾美穂, Hiroyasu Mori, 明比祐子, 岡本美鈴, 鈴木麗子, 寺澤敏秀 and Munehide Matsuhisa : 持続グルコースモニタリングの推定HbA1c値と実測HbA1c値との解離に関する検討, 日本糖尿病学会中国四国地方会第58総会, Oct. 2020.
120.	Masashi Ishizu, Hiroyasu Mori, 明比祐子, Akio Kuroda, Motoyuki Tamaki, Sumiko Yoshida, Ken-ichi Aihara, 藍場元弘, 河野友晴, Seiichi Hashida and Munehide Matsuhisa : 糖尿病性腎症における尿アディポネクチンの意義(第2報), 日本糖尿病学会中国四国地方会第58総会, Oct. 2020.
121.	平岡栞名, 三井由加里, 細木美苗, 宮高紘輔, 辻誠士朗, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Akio Kuroda, Masahiro Abe and Munehide Matsuhisa : 原田病，重症筋無力症を合併した1型糖尿病の1例, 日本糖尿病学会中国四国地方会第58総会, Oct. 2020.
122.	辻誠士朗, Kiyoe Kurahashi, 平岡栞名, 細木美苗, 宮高紘輔, 三井由加里, Sumiko Yoshida, Akio Kuroda, Itsuro Endo, Masahiro Abe and Munehide Matsuhisa : びまん性膵腫大を契機に膵癌再発と診断したGAD抗体陽性の糖尿病の一例, 日本糖尿病学会中国四国地方会第58総会, Oct. 2020.
123.	山崎裕行, Yutaro Yamashita, Kazuhide Mineda, Soushi Ishida, Yoshiro Abe, Akio Kuroda, Munehide Matsuhisa, 高岩昌弘 and Ichiro Hashimoto : 糖尿病患者の歩行に関する3D解析調査∼糖尿病足病変患者の歩行支援に向けて∼, 第29回日本形成外科学会基礎学術集会, Oct. 2020.
124.	山崎裕行, Yutaro Yamashita, Kazuhide Mineda, Soushi Ishida, Yoshiro Abe, Akio Kuroda, Munehide Matsuhisa, 高岩昌弘 and Ichiro Hashimoto : 糖尿病患者の歩行に関する3D解析調査∼糖尿病足病変患者の歩行支援に向けて∼, 第29回日本形成外科学会基礎学術集会, Oct. 2020.
125.	山崎裕行, Yutaro Yamashita, Kazuhide Mineda, Soushi Ishida, Yoshiro Abe, Akio Kuroda, Munehide Matsuhisa, 高岩昌弘 and Ichiro Hashimoto : 糖尿病患者の歩行に関する3D解析調査∼糖尿病足病変患者の歩行支援に向けて∼, 第29回日本形成外科学会基礎学術集会, Oct. 2020.
126.	山崎裕行, Yutaro Yamashita, Kazuhide Mineda, Soushi Ishida, Yoshiro Abe, Akio Kuroda, Munehide Matsuhisa, 高岩昌弘 and Ichiro Hashimoto : 糖尿病患者の歩行に関する3D解析調査∼糖尿病足病変患者の歩行支援に向けて∼, 第29回日本形成外科学会基礎学術集会, Oct. 2020.
127.	山崎裕行, Yutaro Yamashita, Kazuhide Mineda, Soushi Ishida, Yoshiro Abe, Akio Kuroda, Munehide Matsuhisa, 高岩昌弘 and Ichiro Hashimoto : 糖尿病患者の歩行に関する3D解析調査∼糖尿病足病変患者の歩行支援に向けて∼, 第29回日本形成外科学会基礎学術集会, Oct. 2020.
128.	山崎裕行, Yutaro Yamashita, Kazuhide Mineda, Soushi Ishida, Yoshiro Abe, Akio Kuroda, Munehide Matsuhisa, 高岩昌弘 and Ichiro Hashimoto : 糖尿病患者の歩行に関する3D解析調査∼糖尿病足病変患者の歩行支援に向けて∼, 第29回日本形成外科学会基礎学術集会, Oct. 2020.
129.	山崎裕行, Yutaro Yamashita, Kazuhide Mineda, Soushi Ishida, Yoshiro Abe, Akio Kuroda, Munehide Matsuhisa, 高岩昌弘 and Ichiro Hashimoto : 糖尿病患者の歩行に関する3D解析調査∼糖尿病足病変患者の歩行支援に向けて∼, 第29回日本形成外科学会基礎学術集会, Oct. 2020.
130.	清水彩洋子, 馬屋原豊, 清水成, 畑雅久, 藤田洋平, 桂央士, 良本佳代子, 安田哲行, 山本恒彦, 吉内和富, Sumiko Yoshida, 良本佳代子, Akio Kuroda, Hiroyasu Mori, 下村伊一郎 and Munehide Matsuhisa : 2型糖尿病の肝線維化が血清IGF 1と筋肉量・筋力低下に与える影響, 第63回日本糖尿病学会年次学術集会, Oct. 2020.
131.	秦誠倫, Hiroyasu Mori, 竹本有里, 藤井浩平, 永田慎平, 山本裕一, 狭間洋至, Sumiko Yoshida, 吉内和富, 山本恒彦, 馬屋原豊, 良本佳代子, Akio Kuroda, 安田哲行, 下村伊一郎 and Munehide Matsuhisa : 1型糖尿病患者のサルコペニアには血清IGF-1低値が関連する, 第63回日本糖尿病学会年次学術集会, Oct. 2020.
132.	Hiroyasu Mori, Akio Kuroda, Sumiko Yoshida, 安田哲行, 馬屋原豊, 清水彩洋子, 良本佳代子, 吉内和富, 山本恒彦, 下村伊一郎 and Munehide Matsuhisa : 1型および2型糖尿病患におけるダイナぺニアとサルコペニアの臨床的特徴 iDIAMOND Studyからの報告, 第63回日本糖尿病学会年次学術集会, Oct. 2020.
133.	Munehide Matsuhisa : 重症低血糖へ点鼻グルカゴン製剤が果たす役割, 第63回日本糖尿病学会年次学術集会シンポジウム, Oct. 2020.
134.	Munehide Matsuhisa : 高齢糖尿病患者における血糖管理 ①高齢糖尿病患者と低血糖, 第63回日本糖尿病学会年次学術集会シンポジウム, Oct. 2020.
135.	Sumiko Yoshida, 工藤千晶, 辻本賀美, 安井沙耶, 遠藤ふうり, 桝田志保, 三井由加里, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Seiji Fukumoto, Masahiro Abe and Munehide Matsuhisa : 血糖管理入院でのテストステロン値の変化の検討, 第63回日本糖尿病学会年次学術集会, Oct. 2020.
136.	Akio Kuroda, Masashi Ishizu, 鶴尾美穂, Hiroyasu Mori, 明比祐子, 岡本美鈴, 鈴木麗子, 寺澤敏秀 and Munehide Matsuhisa : 持続グルコースモニタリングの推定HbA1c値と実測HbA1c値との解離に関する検討, 第20回日本糖尿病情報学会年次学術集会, Sep. 2020.
137.	徳里望, Hiroshi Sakaue, Rie Tsutsumi, Masashi Kuroda, Saeko Masumoto, 森万理恵, 別府香名, Rie Tsutsumi, Hiroyasu Mori, Munehide Matsuhisa, Hiroshi Sakaue, 神田彩恵, Rie Tsutsumi, 三島優奈, 上嶋奈々子, 松本裕華, 原加奈子, Masashi Kuroda and Hiroshi Sakaue : ロイシンの抗動脈硬化作用の検討, Journal of the The Japan Diabetes Society, Vol.63, No.9, 657, Sep. 2020. (Keyword) Catechin 肥満(実験的) Biflavonoids Proanthocyanidins 認知機能低下(実験的) 消化管微生物叢 Procyanidin マウス動物 / 血液透析糸球体濾過量腎不全-慢性(治療,合併症) 糖尿病(合併症) 味覚障害(病因) 味蕾 Leptin(血液) G-Protein-Coupled Receptors T1R Receptor ヒト / Cholesterol(血液) Leucine(治療的利用) LDL Cholesterol(血液) 動脈硬化症(薬物療法,実験的) マウス動物メス
138.	Munehide Matsuhisa : 糖尿病患者の高齢化による諸問題, 第54回糖尿病学の進歩, Sep. 2020.
139.	川原綾香, Kiyoe Kurahashi, 工藤千晶, 鎌田基夢, Shinsuke Katoh, Yukiko Tomioka, 辻本賀美, 安井沙耶, 遠藤ふうり, 桝田志保, 三井由加里, Sumiko Yoshida, Ken-ichi Aihara, Itsuro Endo, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 歩行不能だったが，多職種の高度な連携と患者特性に配慮したケアにより自宅生活可能となった高度肥満症の一例, 第261回徳島医学会学術集会, Aug. 2020.
140.	平岡栞名, 三井由加里, Hirokazu Miki, Seidai Satou, Momoyo Azuma, 遠藤ふうり, 宮髙紘輔, 辻誠士郎, 桝田志保, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 発熱・全身リンパ節腫脹で発症し，リンパ節生検で診断しえた結核性リンパ節炎の一例, 第261回徳島医学会学術集会, Aug. 2020.
141.	Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : NAFLD病態指標血漿Heparin Cofactor IIの連関, 第52回日本動脈硬化学会総会・学術集会, Aug. 2020.
142.	Sumiko Yoshida, 工藤千晶, 辻本賀美, 安井沙耶, 遠藤ふうり, 桝田志保, 三井由香里, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa, Masahiro Abe and Seiji Fukumoto : 糖尿病教育入院でのテストステロン値の変化の検討, 第93回日本内分泌学会学術総会, Vol.96, No.1, 287, Jul. 2020.
143.	Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : NAFLD病態指標Fib4-indexと血漿Heparin Cofactor Ⅱの連関, 第52回日本動脈硬化学会総会・学術集会, Jul. 2020. (Keyword) NAFLD / Heparin Cofactor Ⅱ
144.	川原綾香, Kiyoe Kurahashi, 工藤千晶, 鎌田基夢, 加藤真介, 富岡有紀子, 辻本賀美, Saya Yasui, Furi Endo, Shiho Masuda, 三井由加里, Sumiko Yoshida, Ken-ichi Aihara, Itsuro Endo, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 歩行不能だったが，多職種の密な連携と患者特性に配慮したケアにより自宅生活可能となった高度肥満症の一例, 第260回徳島医学会学術集会大塚講堂, Feb. 2020.
145.	Munehide Matsuhisa : 情報連携の高度化が栄養指導へもたらすもの, 第23回日本病態栄養学会年次学術集会シンポジウム, Jan. 2020.
146.	Hiroyasu Mori, Akio Kuroda, 安田哲行, 馬屋原豊, 清水彩洋子, 良本佳代子, 吉内和富, 山本恒彦, Sumiko Yoshida and Munehide Matsuhisa : 2型糖尿病のダイナぺニアの臨床的特徴の検討, 第54回日本成人病(生活習慣病)学会, Jan. 2020.
147.	Tomoyuki Yuasa, 鶴尾美穂, 岸潤, Akio Kuroda, 寺澤敏秀 and Munehide Matsuhisa : ANCA関連血管炎にステロイドを投与し血糖コントロールが改善した1型糖尿病の1例, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
148.	三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, 白神敦久 and Munehide Matsuhisa : SGLT2阻害薬による正常血糖糖尿病ケトアシドーシスの1例, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
149.	森万理江, Kana Beppu, Rie Tsutsumi, Hiroyasu Mori, Munehide Matsuhisa and Hiroshi Sakaue : 糖尿病および透析患者における味覚障害と舌味覚受容体発言の関連について, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
150.	毛利咲恵, 鶴尾美穂, 坂東佐知子, 添木武, 松本直也, Tomoyuki Yuasa, Akio Kuroda, Masataka Sata, Masahiro Abe, 寺澤敏秀 and Munehide Matsuhisa : 発熱，高血糖，低K血症を契機に一時的にBrugada型心電図を呈した糖尿病の1例, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
151.	奥村慈子, 鶴尾美穂, Tomoyuki Yuasa, 瀬尾浩二, 木内美瑞穂, 金川泰彦, Akio Kuroda, 松本俊夫, Masahiro Abe, 寺澤敏秀 and Munehide Matsuhisa : 急激にせん妄状態が悪化した高齢2型糖尿病の1例, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
152.	上野裕子, 鶴尾美穂, Tomoyuki Yuasa, Akio Kuroda, 木内美瑞穂, 西正晴, Saya Yasui, Masahiro Abe, 寺澤敏秀 and Munehide Matsuhisa : 高齢者糖尿病患者に対するLCDEと徳島市糖尿病サポーター(TCDS)の連携した取り組み, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
153.	Kiyoe Kurahashi, 工藤千晶, 鎌田基夢, Shinsuke Katoh, Yoshiko Suzuki, 秋月佐代, Yukiko Tomioka, Sumiko Yoshida, 明比祐子, Itsuro Endo and Munehide Matsuhisa : 療養環境整備に苦慮した，歩行不能の高度肥満症の一例, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
154.	三井由加里, Akio Kuroda, Masashi Ishizu, 桝田志保, Kiyoe Kurahashi, Sumiko Yoshida, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe and Munehide Matsuhisa : 頻回インスリン注射療法下の1型糖尿病患者における基礎インスリン比率の検討, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
155.	桝田志保, Sumiko Yoshida, 安井沙耶, 辻本賀美, 工藤千晶, Furi Endo, 三井由加里, Kiyoe Kurahashi, Akio Kuroda, Itsuro Endo and Munehide Matsuhisa : 肥満外科手術後早期に基礎インスリン必要量が減少した高度肥満1型用尿病の1例, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
156.	Misuzu Yamada, Akio Kuroda, 冨永ゆかり and Munehide Matsuhisa : 1型糖尿病患者血中循環遊離DNAと関連する因子の解析, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
157.	Furi Endo, Sumiko Yoshida, 工藤千晶, 辻本賀美, 安井沙耶, 桝田志保, 三井由加里, Kiyoe Kurahashi, Akio Kuroda, Itsuro Endo and Munehide Matsuhisa : 免疫チェックポイント阻害薬関連1型糖尿病の5例, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
158.	鶴尾美穂, Akio Kuroda, Tomoyuki Yuasa, 木内美瑞穂, 安井沙耶, Toshio Matsumoto, Masahiro Abe, 寺澤敏秀 and Munehide Matsuhisa : TIR(Time-In-Range)とHbA1cとの関連∼HbA1cと組み合わせる血糖管理方法∼, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
159.	森岡隆子, Akio Kuroda, 鶴尾美穂, 堀筋冨士子, 秋田賢子, 松本幸恵, Tomoyuki Yuasa, Toshio Matsumoto, Masahiro Abe, 寺澤敏秀 and Munehide Matsuhisa : 予測低血糖自動注入停止型インスリンポンプが有効だった高齢1型糖尿病例, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
160.	安井沙耶, 桝田志保, 辻本賀美, 工藤千晶, Furi Endo, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Akio Kuroda, Itsuro Endo and Munehide Matsuhisa : 基礎インスリン適正化とスクエアボーラス導入で血糖管理が改善した1型糖尿病の1例, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
161.	斎村玉緒, Akio Kuroda, 鶴尾美穂, 福井健壮, 掘貫理恵, 藤原敏孝, Tomoyuki Yuasa, Toshio Matsumoto, Masahiro Abe, 寺澤敏秀 and Munehide Matsuhisa : 脳悪性リンパ腫を発症した2がた糖尿病の1例, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
162.	大島康志, 安藝菜奈子, 鶴尾美穂, 住友正治, 小松まち子, 髙橋保子, 鈴木麗子, Ken-ichi Aihara, 宇都宮正登 and Munehide Matsuhisa : 介護に携わる医療従事者を対象にした徳島市糖尿病サポーター研修受講者の意識調査, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
163.	鶴尾美穂, 住友正治, 小松まち子, 大島康志, 坂東智子, Hiroyasu Mori, Masashi Ishizu, 髙橋保子, Ken-ichi Aihara, Munehide Matsuhisa and 宇都宮正登 : 徳島市医師会糖尿病腎症重症化予防パイロット事業後アンケート結果, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
164.	Munehide Matsuhisa, 鶴尾美穂 and 野間喜彦 : 透析導入ワーストワン県での糖尿病腎症重症化予防対策, 第31回日本糖尿病性腎症研究会特別企画, Nov. 2019.
165.	Hiroyasu Mori, Akio Kuroda and Munehide Matsuhisa : 高齢糖尿病患者の肥満と筋障害との関連, 第40回日本肥満学会・第37回日本肥満症治療学会, Nov. 2019.
166.	Munehide Matsuhisa : 特定健診が地域に与えたもの，これから為すべきこと, 第40回日本肥満学会・第37回日本肥満症治療学会, Nov. 2019.
167.	Akio Kuroda, 鶴尾美穂, Masashi Ishizu and Munehide Matsuhisa : Time-In-RangeとHbA1cとの関連∼HbA1cと組み合わせる血糖管理方法∼, 第19回日本先進糖尿病治療研究会・第17回1型糖尿病研究会, Nov. 2019.
168.	村田敬, 利根淳仁, 加藤研, 豊田雅夫, 澤木秀明, Akio Kuroda, 廣田勇士, 川嶋聡, Munehide Matsuhisa and 坂根直樹 : リアルタイム持続血糖測定器(CGM)センサーのアドヒアランスとインスリンポンプ療法におけるQOLの関連(PARCS研究第2報), 第19回日本先進糖尿病治療研究会・第17回1型糖尿病研究会, Nov. 2019.
169.	三井由加里, Akio Kuroda, Masashi Ishizu, Kiyoe Kurahashi, Sumiko Yoshida, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe and Munehide Matsuhisa : 頻回インスリン注射療法下の1型糖尿病患者における基礎インスリン比率の検討, 第19回日本先進糖尿病治療研究会・第17回1型糖尿病研究会, Nov. 2019.
170.	Munehide Matsuhisa : 先進糖尿病治療の重症低血糖への効果, 第19回日本先進糖尿病治療研究会・第17回1型糖尿病研究会, Nov. 2019.
171.	Masashi Ishizu, Hiroyasu Mori, Mami Ohishi, 鈴木麗子, 岡本美鈴, 明比祐子, Akio Kuroda, Motoyuki Tamaki, Yuichi Takashi, Sumiko Yoshida, Ken-ichi Aihara, 藍場元弘, 河野友晴, Seiichi Hashida and Munehide Matsuhisa : 糖尿病性腎臓病における尿中アディポネクチン排泄の臨床的意義, 第40回日本肥満学会・第37回日本肥満症治療学会, Nov. 2019.
172.	Munehide Matsuhisa : 低血糖の重症化機序とその対策, 第57回日本糖尿病学会東北地方会, Nov. 2019.
173.	Yuichi Takashi, Shun Sawatsubashi, Itsuro Endo, Masahiro Abe, Munehide Matsuhisa, Toshio Matsumoto and Seiji Fukumoto : FGFR1は血中FGF23濃度を制御するリン感知受容体である, 第38回日本骨代謝学会学術集会, Oct. 2019.
174.	Munehide Matsuhisa : インスリン感受性の評価法とその意義, 第34回糖尿病合併症学会ワークショップ, Sep. 2019.
175.	Munehide Matsuhisa : 低血糖の病態生理とその対策, 第19回日本内分泌学会四国支部学術集会, Sep. 2019.
176.	Kenya Kusunose, Hirotsugu Yamada and Munehide Matsuhisa : 診断に活かす局所心筋ストレイン解析(会長特別企画【原点を学び未来を創る】8 日常臨床に活かす心筋ストレイン解析), 第67回日本心臓病学会学術集会, Sep. 2019.
177.	Yuichi Takashi, Hidetaka Kosako, Shun Sawatsubashi, Y Kinoshita, N Ito, Munehide Matsuhisa, M Matsumoto and Seiji Fukumoto : FGF recepotor I works as a phosphate-sensor to regulate FGF23 production, 15th Bone Biology Forum, Aug. 2019.
178.	Masashi Ishizu, 鶴尾美穂, 豊崎纏, Ken-ichi Aihara, 坂東智子, 住友正治, 古川浩, 宮本泰文, 小松まち子, 大島康志, 桜井えつ, 若槻真吾, 岡川和人, 林正, 松村光博, 小川紘一, 安岡正治, 細井恵美子, 丸岡重代, 西岡恵子, 髙橋保子, Hiroyasu Mori, Munehide Matsuhisa and 宇都宮正登 : 徳島市医師会糖尿病腎症重症化予防パイロット事業の報告, 第19回日本糖尿病情報学会年次学術集会, Aug. 2019.
179.	安井沙耶, 桝田志保, Sumiko Yoshida, 辻本賀美, 工藤千晶, 遠藤ふうり, 三井由加里, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Munehide Matsuhisa, Masahiro Abe and Seiji Fukumoto : 成長ホルモン分泌不全症と甲状腺機能低下症を呈した小児がん経験者の一例, 第259回徳島医学会学術集会(令和元年度夏期), Aug. 2019.
180.	Munehide Matsuhisa : 療養指導の遠隔化に向けた試み, 第19回日本糖尿病情報学会年次学術集会, Aug. 2019.
181.	鈴木麗子, Hiroyasu Mori, Masashi Ishizu, Yuu Tamaki, Satoshi Taniguchi, Akio Kuroda and Munehide Matsuhisa : スマートスピーカーを活用した個別化糖尿病自己管理支援システムの開発糖尿病患者の行動変容を目指して, 第19回日本糖尿病情報学会年次学術集会, Aug. 2019.
182.	Akio Kuroda and Munehide Matsuhisa : インスリンポンプ療法，CGM の進歩, 第25回日本小児・思春期糖尿病学会年次学術集会シンポジウム, Jul. 2019.
183.	弘世貴久, Munehide Matsuhisa, 小田原雅人, 宇野希世子, 仙田雅之, 田中逸 and 寺内康夫 : 高齢2型糖尿病患者におけるインスリングラルギン300U/ mL投与12か月の有効性と安全性:X-STAR studyサブ解析, 第62回日本糖尿病学会年次学術集会, May 2019.
184.	小田原雅人, Munehide Matsuhisa, 弘世貴久, 宇野希世子, 仙田雅之, 田中逸 and 寺内康夫 : インスリン未治療2型糖尿病患者のインスリングラルギン 300U/mL投与12か月の有効性と安全性:X-STAR studyサブ解析, 第62回日本糖尿病学会年次学術集会, May 2019.
185.	Misuzu Yamada, Akio Kuroda, Rie Tsutsumi, 冨永ゆかり, Hiroshi Sakaue and Munehide Matsuhisa : 循環血中遊離DNAを標的とした血管内皮細胞傷害の検出, 第62回日本糖尿病学会年次学術集会, May 2019.
186.	Munehide Matsuhisa, 小田原雅人, 弘世貴久, 宇野希世子, 仙田雅之, 田中逸 and 寺内康夫 : 1型糖尿病患者のインスリングラルギン300U/mLへの切替え12か月後の有効性と安全性X-STAR studyサブ解析, 第62回日本糖尿病学会年次学術集会, May 2019.
187.	鶴尾美穂, 豊﨑纏, 小松まち子, 住友正治, 大島康志, Ken-ichi Aihara, Hiroyasu Mori, Masashi Ishizu, 岡川和人, 小川絋一, 古川浩, 桜井えつ, 林正, 坂東智子, 細井恵美子, 松村光輝, 宮本泰文, 保岡正治, 高橋保子, 丸岡重代, 西岡恵子, 宇都宮正登 and Munehide Matsuhisa : 徳島市医師会糖尿病腎症重症化予防パイロット事業の取組, 第62回日本糖尿病学会年次学術集会, May 2019.
188.	田矢直大, 片上直人, 宮下和幸, 高原充佳, 加藤研, 安田哲行, 河盛段, Akio Kuroda, Munehide Matsuhisa, 松岡孝昭 and 下村伊一郎 : 日本人1型糖尿病患者における腎症の発症・進展に関わる因子, 第62回日本糖尿病学会年次学術集会, May 2019.
189.	Munehide Matsuhisa : 低血糖を防ぐために知っておきたいこと, 第62回日本糖尿病学会年次学術集会ランチョンセミナー, May 2019.
190.	田中逸, Munehide Matsuhisa, 小田原雅人, 宇野希世子, 仙田雅之, 弘世貴久 and 寺内康夫 : インスリン未治療2型糖尿病患者におけるインスリングラルギン300U/mL入院導入の有効性と安全性の検討:XSTAR studyサブ解析, 第62回日本糖尿病学会年次学術集会, May 2019.
191.	宇野希世子, Munehide Matsuhisa, 小田原雅人, 弘世貴久, 仙田雅之, 田中逸 and 寺内康夫 : 基礎インスリンをインスリングラルギン300U/mLに切替えた2型糖尿病患者の12か月後の安全性と有効性:XSTAR studyサブ解析, 第62回日本糖尿病学会年次学術集会, May 2019.
192.	豊田雅夫, 利根淳仁, 加藤研, 木村守次, 川嶋聡, 澤木秀明, 廣田勇士, 岡田朗, Akio Kuroda, Munehide Matsuhisa, 渡邉知一, 村田敬, 菅沼彰子 and 坂根直樹 : 新規インスリンポンプ使用中患者用QOL尺度(CSIIQOL)の開発および妥当性と信頼性の検証, 第62回日本糖尿病学会年次学術集会, May 2019.
193.	安田純, 池田雅彦, Akio Kuroda, Munehide Matsuhisa and 久保田稔 : 1型糖尿病スカイプミーティング(いちスカ)の総括と展望―インターネット開催の強みを活かした運営の特徴と成果―, 第62回日本糖尿病学会年次学術集会, May 2019.
194.	Masashi Ishizu, Hiroyasu Mori, Mami Ohishi, 鈴木麗子, 岡本美鈴, 明比祐子, Akio Kuroda, Motoyuki Tamaki, Yuichi Takashi, Sumiko Yoshida, Ken-ichi Aihara, 藍場元弘, 河野友晴, Seiichi Hashida and Munehide Matsuhisa : 糖尿病性腎臓病における尿中アディポネクチン排泄率の臨床的意義の検討, 第62回日本糖尿病学会年次学術集会, May 2019.
195.	村田敬, 坂根直樹, 加藤研, 三浦順之助, 豊田雅夫, 利根淳仁, 廣田勇士, 神山隆治, Akio Kuroda, Munehide Matsuhisa, 菅沼彰子, 菅沼彰子, 野口倫生, 宮本恵宏, 西村邦宏 and 細田公則 : 1型糖尿病における間歇スキャンCGMが低血糖も含む血糖コントロールに及ぼす効果の研究(ISCHIA 研究):研究デザイン, 第62回日本糖尿病学会年次学術集会, May 2019.
196.	宮高絋輔, Sumiko Yoshida, Furi Endo, 枡田志保, 三井由加里, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Seiji Fukumoto, Makoto Funaki, Yoshihiro Matsudate, Hiroshi Nokihara, Yasuhiko Nishioka, Masahiro Abe and Munehide Matsuhisa : 免疫チェックポイント阻害薬投与後に1型糖尿病を発症した2例, 第62回日本糖尿病学会年次学術集会, May 2019.
197.	Hiroyasu Mori, Yuu Tamaki, Satoshi Taniguchi, 野村友美, 大塚銀花, 岡本美鈴, 鈴木麗子, Akio Kuroda and Munehide Matsuhisa : テレビカンファレンスシステム活用遠隔栄養指導が2型糖尿病患者の病態や食行動に及ぼす影響:無作為化比較試験, 第62回日本糖尿病学会年次学術集会, May 2019.
198.	Munehide Matsuhisa, Hiroyasu Mori, Satoshi Taniguchi, Yuu Tamaki and Akio Kuroda : EHRと連携するPHR「電子糖尿病ダイアリー」, 第62回日本糖尿病学会年次学術集会シンポジウム, May 2019.
199.	Munehide Matsuhisa : 成人1型糖尿病患者のライフステージと最適化医療, 第92回日本内分泌学会学術総会シンポジウム, May 2019.
200.	Yuichi Takashi, Hidetaka Kosako, Shun Sawatsubashi, Yuka Kinoshita, 伊東伸朗, Masahiro Abe, Munehide Matsuhisa, Shigeaki Kato, Toshio Matsumoto and Seiji Fukumoto : FGFR1はFGF23濃度調節を媒介するリン感知受容体である, 第92回日本内分泌学会学術総会, Vol.95, No.1, 333, May 2019.
201.	Munehide Matsuhisa : 低血糖重症化の病態と対策, 第53回糖尿病学の進歩指定講演, Mar. 2019.
202.	Munehide Matsuhisa : 低血糖リスクを考慮したインスリン治療の実践, 第53回糖尿病学の進歩, Mar. 2019.
203.	鶴尾美穂, 住友正治, 大島康志, 小松まち子, 鈴木麗子, Ken-ichi Aihara, 安藝菜奈子, 坂東智子, Yasuko Takahashi, 丸岡重代, 原田和代, 若槻真吾, 桜井えつ, 井野口卓, 白神敦久, 豊崎纏, Munehide Matsuhisa and 宇都宮正登 : 糖尿病患者の在宅ケア向上をめざした徳島市糖尿病サポーター(TCDS)育成の試み, 第258回徳島医学会学術集会ポスターセッション, Feb. 2019.
204.	Kohsuke Miyataka, Furi Endo, 三井由加里, 枡田志保, Kiyoe Kurahashi, Sumiko Yoshida, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Seiji Fukumoto, Hiroshi Nokihara, Yasuhiko Nishioka, Masahiro Abe and Munehide Matsuhisa : 抗PD-1抗体投与後に1型糖尿病を発症した1例, 第258回徳島医学会学術集会ポスターセッション, Feb. 2019.
205.	Kana Beppu, Rie Tsutsumi, Hiroyasu Mori, 平野春美, 土田健司, Munehide Matsuhisa, Noriaki Takeda and Hiroshi Sakaue : 透析患者における味覚障害と味覚受容体T1R3遺伝子の発現の関連, 第258回徳島医学会学術集会ポスターセッション, Feb. 2019.
206.	Munehide Matsuhisa : 徳島県全域を網羅するICT医療連携システム「阿波あいネット」∼その概要と糖尿病診療への展開∼, 第4回ヘルスケアIT2019 招待講演, Jan. 2019.
207.	Munehide Matsuhisa : ICT医療の進歩と遠隔栄養指導, 第22回日本病態栄養学会, Jan. 2019.
208.	Munehide Matsuhisa, Hiroyasu Mori, Satoshi Taniguchi, Masashi Ishizu, 明比祐子, Yuu Tamaki and Akio Kuroda : 徳島県での地域医療連携基盤の構築とデータ利活用への試み, 第3回日本糖尿病・生活習慣病ヒューマンデータ学会シンポジウム3, Dec. 2018.
209.	Misuzu Yamada, Akio Kuroda, 冨永ゆかり and Munehide Matsuhisa : 組織特異的なエピジェネティック修飾を用いた内皮細胞障害の検出, 第30回分子糖尿病学シンポジウム, Dec. 2018.
210.	秋田賢子, 鶴尾美穂, 森岡隆子, 堀筋冨士子, 上野裕子, 斎村玉緒, 藤島周子, 奥村慈子, 松本幸恵, 福井健壮, 堀貫理恵, 森久志, 細川智也, 野上貴盛, 森上雄三, 橋本章聖, Tomoyuki Yuasa, Akio Kuroda, 寺澤敏秀 and Munehide Matsuhisa : 糖尿病教育入院時の療養指導カードの使用についてのスタッフの評価, 日本糖尿病学会中国四国地方会第56回総会, Oct. 2018.
211.	Misuzu Yamada, Akio Kuroda, 冨永ゆかり and Munehide Matsuhisa : 特異的遺伝子メチル化パターンを用いた膵β細胞障害の検出, 日本糖尿病学会中国四国地方会第56回総会, Oct. 2018.
212.	Masashi Ishizu, Hiroyasu Mori, Mami Ohishi, 鈴木麗子, 明比祐子, Akio Kuroda, Motoyuki Tamaki, Yuichi Takashi, Sumiko Yoshida, Ken-ichi Aihara, 藍場元弘, 河野友晴, Seiichi Hashida and Munehide Matsuhisa : 糖尿病性腎臓病における尿アディポネクチンの意義, 日本糖尿病学会中国四国地方会第56回総会, Oct. 2018.
213.	鶴尾美穂, Akio Kuroda, Tomoyuki Yuasa, Mizuho Kinouchi, Kimiko Sogabe, 加部一行, 瀬尾浩二, Masaharu Nishi, Naoya Matsumoto, Yasuhiko Kanagawa, Masahiro Abe, Toshio Matsumoto, 寺澤敏秀 and Munehide Matsuhisa : リブレ使用糖尿病患者の検討, 日本糖尿病学会中国四国地方会第56回総会, Oct. 2018.
214.	Munehide Matsuhisa : 腎症重症化予防へのチーム総力戦, 日本糖尿病学会中国四国地方会第56回総会, Oct. 2018.
215.	Munehide Matsuhisa : センサーネットワークを活用したPHRとEHRの統合による個別化糖尿病疾病プログラムの開発, ICTイノベーションフォーラム, Oct. 2018.
216.	Hiroyasu Mori, Akio Kuroda, Masashi Ishizu, Yuichi Takashi, Satoshi Taniguchi, Motoyuki Tamaki, 明比祐子 and Munehide Matsuhisa : 2型糖尿病患者における肥満と筋傷害との関連の検証, 第39回日本肥満学会, Oct. 2018.
217.	Toshiki Otoda, Motoyuki Tamaki, Yuichi Takashi, Kana Morimoto, Tomoyuki Yuasa, Munehide Matsuhisa, Hiroyuki Azuma and Ken-ichi Aihara : 肥満合併2型糖尿病患者におけるSGLT2阻害薬の短期的臨床効果に関する検討, 第39回日本肥満学会, Oct. 2018.
218.	明比祐子, Munehide Matsuhisa and 柳瀬敏彦 : 内分泌臨床からみた肥満症との関わり, 第39回日本肥満学会, Oct. 2018.
219.	Misuzu Yamada, Akio Kuroda, 冨永ゆかり and Munehide Matsuhisa : 血清細胞外小胞中DNAを用いた膵β細胞傷害検出のマウスによる検証, 第18回日本先進糖尿病治療研究会, Sep. 2018.
220.	村田敬, 利根淳仁, 加藤研, 豊田雅夫, 澤木秀明, Akio Kuroda, 廣田勇士, 川嶋聡, Munehide Matsuhisa and 坂根直樹 : リアルタイム持続血糖測定器(CGM)センサーのアドヒアランス予測因子に関する前向き観察研究(PARCS研究), 第18回日本先進糖尿病治療研究会, Sep. 2018.
221.	Munehide Matsuhisa : 足を診る糖尿病診療チームの役割, 第3回日本下肢救済・足病学会中国四国地方会学術集会, Sep. 2018.
222.	Kiyoe Kurahashi, Furi Endo, 桝田志保, Sumiko Yoshida, Akio Kuroda, Ken-ichi Aihara, Seiji Fukumoto, Itsuro Endo and Munehide Matsuhisa : 足趾上腕血圧比定値を契機に末梢動脈疾患を診断しえた，重症下肢軟部組織感染症を繰り返す2型糖尿病の一例, 第3回日本下肢救済・足病学会中国四国地方会学術集会, Sep. 2018.
223.	Yuichi Takashi, Masashi Ishizu, Shu Wakino, 水口斉, 島久登, 田代学, 宮恵子, 水口潤, Akio Kuroda, Toshio Matsumoto, Munehide Matsuhisa and Seiji Fukumoto : 血液透析患者における心不全・動脈硬化・感染のリスク因子としてのFGF23, 第18回日本内分泌学会四国支部学術集会, Sep. 2018.
224.	Ken-ichi Aihara, Sumiko Yoshida, Furi Endo, 筒井康継, Tomoyo Hara, 桝田志保, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo, Kana Morimoto, Akio Kuroda, 明比祐子, Makoto Funaki, Munehide Matsuhisa, Seiji Fukumoto and Masahiro Abe : 原発性アルドステロン症におけるミネラルコルチコイド受容体拮抗薬の血管機能への影響, 第18回日本内分泌学会四国支部学術集会, Sep. 2018.
225.	Hiroyasu Mori, Michiko Araki, Akio Kuroda, Masashi Ishizu, Yuichi Takashi, Satoshi Taniguchi, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Motoyuki Tamaki, 明比祐子 and Munehide Matsuhisa : 1型糖尿病患者の血清IGF-1とサルコペニア合併に関する横断的検証, 第18回日本内分泌学会四国支部学術集会, Sep. 2018.
226.	Hiroyasu Mori, Yuu Tamaki, Satoshi Taniguchi, 野村友美, 鈴木麗子, 瀧川稲子, Akio Kuroda and Munehide Matsuhisa : テレビカンファレンスシステムを用いた遠隔栄養指導の介入が2型糖尿病患者の代謝状態や食行動に与える影響, 第18回日本糖尿病情報学会, Aug. 2018.
227.	Satoshi Taniguchi, Yuu Tamaki, Hiroyasu Mori, 鈴木麗子, Motoyuki Tamaki, 白神敦久, 明比祐子, Akio Kuroda and Munehide Matsuhisa : 電子糖尿病ダイアリーの糖尿病患者の自己管理への効果と課題の検証, 第18回日本糖尿病情報学会, Aug. 2018.
228.	Munehide Matsuhisa : 行政・医療機関の情報を活用したヒューマンネットワークによる糖尿病重症化予防, 第18回日本糖尿病情報学会, Aug. 2018.
229.	Munehide Matsuhisa : ICTによる糖尿病診療の課題を克服する試み, 第18回日本糖尿病情報学会, Aug. 2018.
230.	Munehide Matsuhisa : センサーネットワークを活用したPHRとEHRの統合による個別化糖尿病疾病管理プログラムの開発, 第21回ICT技術セミナー, Jul. 2018.
231.	Sumiko Yoshida, 原倫世, 桝田志保, Kiyoe Kurahashi, Akio Kuroda, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe and Munehide Matsuhisa : 高齢者における糖尿病教育入院中の体組成の変化, 第60回日本老年医学会学術集会, Jun. 2018.
232.	Yuichi Takashi, Masashi Ishizu, Hiroyasu Mori, Akio Kuroda and Munehide Matsuhisa : 骨産生ホルモンであるオステオカルシンは1型糖尿病患者の体脂肪を制御する, 第118回日本内科学会四国地方会, Jun. 2018.
233.	Munehide Matsuhisa : 多様な高齢糖尿病，どう診てどう治療するか, 第58回四国支部生涯教育講演会, Jun. 2018.
234.	小田原雅人, 寺内康夫, 田村昌博, 田村昌博, 仙田雅之, Munehide Matsuhisa and 田中逸 : インスリン未治療2型患者のインスリングラルギン300U/mL投与3か月の安全性と有用性:X-STAR studyサブ解析, 第61回日本糖尿病学会年次学術集会, May 2018.
235.	高比康充, 宮下和幸, 宮下和幸, 宮下和幸, Akio Kuroda, 松岡孝昭, Munehide Matsuhisa, 伊藤壽記 and 下村伊一郎 : 日本人1型糖尿病膵移植患者におけるインスリン分泌指標の意義の検討, 第61回日本糖尿病学会年次学術集会, May 2018.
236.	宮下和幸, 高比康充, 田矢直大, 高原充佳, 片上直人, 松岡孝昭, 伊藤壽記, Akio Kuroda, Munehide Matsuhisa, 今川彰久 and 下村伊一郎 : 移植膵機能廃絶にかかわる因子の検討, 第61回日本糖尿病学会年次学術集会, May 2018.
237.	Akio Kuroda, Misuzu Yamada, 冨永ゆかり, 鈴木麗子, Motoyuki Tamaki, 明比祐子, Yuichi Takashi, Masashi Ishizu, 古賀大輔, Issei Imoto, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe, Kevin Ferreri and Munehide Matsuhisa : 膵β細胞特異的PCRによる膵β細胞死の検出, 第61回日本糖尿病学会年次学術集会, May 2018.
238.	中川祐子, 原朱美, 中尾啓子, Motoyuki Tamaki, Munehide Matsuhisa, 水上浩哉, 綿田裕孝 and 藤谷与士夫 : PP特異的抗PPモノクロ-ナル抗体の作製, 第61回日本糖尿病学会年次学術集会, May 2018.
239.	Sumiko Yoshida, 原倫世, 細井美希, 山上紘規, 山口佑樹, 桝田志保, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Seiji Fukumoto, Masahiro Abe and Munehide Matsuhisa : 糖尿病教育入院における筋肉量の変化, 第61回日本糖尿病学会年次学術集会, May 2018.
240.	Toshiki Otoda, Motoyuki Tamaki, Yuichi Takashi, Kana Morimoto, Tomoyuki Yuasa, Munehide Matsuhisa, Hiroyuki Azuma and Ken-ichi Aihara : SGLT2阻害薬の糖代謝および各種代謝指標への短期的効果に関する検討, 第61回日本糖尿病学会年次学術集会, May 2018.
241.	Yuichi Takashi, Masashi Ishizu, Hiroyasu Mori, 宮下和幸, 坂本扶美枝, 片上直人, 松岡孝昭, 安田哲行, Seiichi Hashida, Akio Kuroda and Munehide Matsuhisa : 骨産生ホルモンucOCは1型糖尿病患者の体脂肪率と関係する, 第61回日本糖尿病学会年次学術集会, May 2018.
242.	Munehide Matsuhisa : ICT技術が拓く糖尿病診療の未来, 第61回日本糖尿病学会年次学術集会, May 2018.
243.	Misuzu Yamada, Akio Kuroda, 冨永ゆかり and Munehide Matsuhisa : 血清中エクソソームを用いた膵β細胞障害検出のマウスによる検証, 第61回日本糖尿病学会年次学術集会, May 2018.
244.	山上紘規, Sumiko Yoshida, 原倫世, 細井美希, 山口佑樹, 桝田志保, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Seiji Fukumoto, Masahiro Abe, Yoshihiro Matsudate and Munehide Matsuhisa : 免疫チェックポイント阻害薬投与後に甲状腺機能異常と劇症1型糖尿病を発症した1例, 第61回日本糖尿病学会年次学術集会, May 2018.
245.	山根志真, 亀田博之, 仙田雅之, 田村昌博, 内藤祐介, Munehide Matsuhisa and 寺内康夫 : ランタスXR注ソロスターの使用成績調査(X-STAR study)-投与12か月後の集計報告-, 第61回日本糖尿病学会年次学術集会, May 2018.
246.	河野友晴, 沼田聡, 藤本侑季, Akio Kuroda, 安田哲行, 宮下和幸, 坂本扶美枝, 片上直人, 松岡孝明, Munehide Matsuhisa and Seiichi Hashida : 超感度測定法(ICT-EIA法)による若年性1型糖尿病患者における3種の膵島関連自己抗体, 第61回日本糖尿病学会年次学術集会, May 2018.
247.	Munehide Matsuhisa, 寺内康夫, 田村昌博, 内藤祐介, 仙田雅之, 田中逸 and 小田原雅人 : 基礎インスリンをインスリングラルギン300U/mL に切り替えた1型糖尿病患者での3カ月後の安全性・有用性の検討, 第61回日本糖尿病学会年次学術集会, May 2018.
248.	Masashi Ishizu, Yuichi Takashi, 脇野修, 水口斉, 田代学, 宮恵子, Yoshihiko Noma, 小松まち子, 水口潤, Akio Kuroda, Seiji Fukumoto and Munehide Matsuhisa : 血液透析患者における糖尿病をはじめとする動脈硬化リスク因子の検討, 第61回日本糖尿病学会年次学術集会, May 2018.
249.	Hiroyasu Mori, 鈴木麗子, 瀧川稲子, Masashi Ishizu, Mami Ohishi, Satoshi Taniguchi, 明比祐子, Akio Kuroda and Munehide Matsuhisa : 糖尿病腎症の急速進行に関連するリスク因子の検証:前向き観察研究, 第61回日本糖尿病学会年次学術集会, May 2018.
250.	Motoyuki Tamaki, Yuichi Takashi, Toshiki Otoda, Seiji Fukumoto, Akio Kuroda, 明比祐子, Hiroyasu Mori, Satoshi Taniguchi, 鈴木麗子, Misuzu Yamada, Masashi Ishizu, Mami Ohishi, 白神敦久, Ken-ichi Aihara, Makoto Funaki and Munehide Matsuhisa : かかりつけ患者に対するSGLT2阻害薬の投与開始タイミングの特徴と投与開始後の体重・eGFR・ALT・脂質代謝の変化, 第61回日本糖尿病学会年次学術集会, May 2018.
251.	Ken-ichi Aihara, 上元良子, 石川カズ江, Kana Morimoto, 桝田志保, Hiroki Yamagami, Yuki Yamaguchi, Tomoyo Hara, 細井美希, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, 明比祐子, Itsuro Endo, Makoto Funaki, Seiji Fukumoto, Munehide Matsuhisa, Hiroyuki Azuma and Masahiro Abe : 生活習慣病患者の尿中酸化ストレス指標における糖尿病および薬物療法の影響, 第61回日本糖尿病学会年次学術集会, May 2018.
252.	Sumiko Yoshida, 原倫世, 細井美希, 山上紘規, 山口佑樹, 桝田志保, Kiyoe Kurahashi, Akio Kuroda, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Seiji Fukumoto, Daisuke Hamada, Munehide Matsuhisa and Masahiro Abe : 待機的高リスク整形外科手術における血糖管理の効果, 第91回日本内分泌学会学術総会, Apr. 2018.
253.	Munehide Matsuhisa : インスリン療法での重症低血糖リスクの回避をめざしできること, 第52回糖尿病学の進歩抄録集, Mar. 2018.
254.	Tomoyo Hara, 桝田志保, Sumiko Yoshida, 細井美希, 山上紘規, 山口佑樹, Kiyoe Kurahashi, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Masahiro Abe : 急性合併症を来した高齢1型糖尿病の2症例, 第29回日本老年医学会四国地方会, Feb. 2018.
255.	Yuki Fujimoto, Toshihiro Watanabe, Aya Morimoto, Hana Kumamoto, Kouzou Sudou, Tomokazu Yoshida, Hiroyasu Mori, Munehide Matsuhisa, Akiko Hata, Makoto Funaki, Mayumi Yamamoto and Seiichi Hashida : 腎障害予測指標としての尿中アディポネクチンに関する検討, 第21回日本病態栄養学会年次学術集会, Jan. 2018.
256.	Tomoyo Hara, Kiyoe Kurahashi, Kana Morimoto, 細井美希, Hiroki Yamagami, 山口佑樹, 桝田志保, Sumiko Yoshida, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa, Yoshimi Bando and Seiji Fukumoto : オクトレオチドが有効であったGH-TSH同時産生下垂体腺腫の一例, 第27回臨床内分泌代謝Update, Nov. 2017.
257.	桝田志保, 明比祐子, Sumiko Yoshida, Hiroki Yamagami, Yuki Yamaguchi, 細井美希, Tomoyo Hara, Kiyoe Kurahashi, Itsuro Endo, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Makoto Funaki and 福本誠ニ : 123I-MIBGシンチグラフィ陽性の副腎皮質腺腫の一例, 第27回臨床内分泌代謝Update抄録集, Nov. 2017.
258.	細井美希, Kana Morimoto, Takeshi Kondo, Hiroki Yamagami, Yuki Yamaguchi, Tomoyo Hara, 桝田志保, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, 明比祐子, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa and 福本誠ニ : 多発性骨髄腫治療を契機にプランマー病と判明した一例, 第27回臨床内分泌代謝Update抄録集, Nov. 2017.
259.	Munehide Matsuhisa : EHRを活用した糖尿病の患者支援PHRから診療支援重症化予防プログラムの開発, 第37回医療情報学連合大会抄録集, Nov. 2017.
260.	斎村玉緒, 鶴尾美穂, Akio Kuroda, Tomoyuki Yuasa, 加部一行, Mizuho Kinouchi, Sumiko Yoshida, Hiroki Yamagami, Takeshi Kondo, 西正晴, 松本直也, Toshio Matsumoto, Masahiro Abe, 寺澤敏秀 and Munehide Matsuhisa : フラッシュグルコースモニタリングシステムにより施設入所可能となった高齢1型糖尿病の一例, 日本糖尿病学会中国四国地方会第55回総会抄録集, Nov. 2017.
261.	Yuki Yamaguchi, Sumiko Yoshida, Tomoyo Hara, 細井美希, Hiroki Yamagami, 桝田志保, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, 福本誠ニ, Masahiro Abe, Hideya Kashihara, Kouzou Yoshikawa and Munehide Matsuhisa : 高度肥満症に対するスリーブ状胃切除術の長期の耐糖能異常改善効果の検討, 日本糖尿病学会中国四国地方会第55回総会抄録集, Nov. 2017.
262.	Naoto Kunikata, Sumiko Yoshida, Tomoyo Hara, 細井美希, Hiroki Yamagami, Yuki Yamaguchi, 桝田志保, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, 福本誠ニ, Masahiro Abe, Daisuke Hamada and Munehide Matsuhisa : 待機的整形外科手術の術後経過における糖尿病の影響, 日本糖尿病学会中国四国地方会第55回総会抄録集, Nov. 2017.
263.	Mami Ohishi, Hiroyasu Mori, 鈴木麗子, 明比祐子, Akio Kuroda, Motoyuki Tamaki, Satoshi Taniguchi, Masashi Ishizu, Hiroshi Sakaue and Munehide Matsuhisa : 急速進行性糖尿病腎症に関連するリスク因子の検討, 日本糖尿病学会中国四国地方会第55回総会抄録集, Nov. 2017.
264.	細井美希, Kiyoe Kurahashi, Tomoyo Hara, Yuki Yamaguchi, Hiroki Yamagami, 桝田志保, Sumiko Yoshida, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, 福本誠ニ and Munehide Matsuhisa : 低血糖脳症をきたしたACTH単独欠損症合併1型糖尿病の一例, 日本糖尿病学会中国四国地方会第55回総会抄録集, Nov. 2017.
265.	鶴尾美穂, Toshio Matsumoto, Akio Kuroda, Tomoyuki Yuasa, 加部一行, Takeshi Kondo, Mizuho Kinouchi, 井野口卓, Hiroki Yamagami, 松本直也, 西正晴, 寺澤敏秀, Masahiro Abe and Munehide Matsuhisa : SLADHを発症した高齢1型糖尿病の一例, 日本糖尿病学会中国四国地方会第55回総会抄録集, Nov. 2017.
266.	Hiroyasu Mori, Mami Ohishi, 鈴木麗子, Akio Kuroda, Satoshi Taniguchi, Motoyuki Tamaki, 明比祐子, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki and Munehide Matsuhisa : 2型糖尿病患者における末梢神経障害の合併が骨格筋力の質的低下に及ぼす影響, 第32回日本糖尿病合併症学会, Oct. 2017.
267.	Munehide Matsuhisa : 見えてきた低血糖の実態:これからのインスリン治療はどうあるべきか, 第32回日本糖尿病合併症学会抄録集, Oct. 2017.
268.	Munehide Matsuhisa : 高い安全性をもつインクレチン関連薬の糖尿病血管合併症への有用性, 第32回日本糖尿病合併症学会抄録集, Oct. 2017.
269.	原倫世, Sumiko Yoshida, 山上紘規, 山口佑樹, 細井美希, 桝田志保, Kiyoe Kurahashi, Itsuro Endo, 明比祐子, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Makoto Funaki and Seiji Fukumoto : Frequent syncope and marked blood pressure fluctuation due to antiparkinson drugs: A case report, 2017年10月20日-22日ひめぎんホール, Oct. 2017.
270.	Tomoyo Hara, Sumiko Yoshida, 山上紘規, 山口佑樹, 細井美希, 桝田志保, Kiyoe Kurahashi, Itsuro Endo, 明比祐子, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Makoto Funaki and Seiji Fukumoto : 抗パーキンソン病薬により頻回な失神と著明な血圧変動をきたした一例, 第40回日本高血圧学会総会, Oct. 2017.
271.	Munehide Matsuhisa : 肥満症へのチーム医療:検診，外来診療から外科治療まで, 第38回日本肥満学会抄録集, Oct. 2017.
272.	山上紘規, Kiyoe Kurahashi, 山口佑樹, 細井美希, 原倫世, 桝田志保, Sumiko Yoshida, Itsuro Endo, 明比祐子, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Makoto Funaki and Seiji Fukumoto : バセドウ病とTSH産生下垂体腺腫の合併の一例, 第60回日本甲状腺学会学術集会, Oct. 2017.
273.	細井美希, Sumiko Yoshida, 山上紘規, 山口佑樹, 原倫世, 桝田志保, Kiyoe Kurahashi, Itsuro Endo, 明比祐子, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Makoto Funaki and Seiji Fukumoto : 無セルロプラスミン血症に合併した甲状腺乳頭癌の一例, 第60回日本甲状腺学会学術集会, Oct. 2017.
274.	Munehide Matsuhisa : ICT医療連携に基づく糖尿病治療の未来, 第17回日本糖尿病情報学会年次学術集会抄録集, Sep. 2017.
275.	桝田志保, Kiyoe Kurahashi, Takeshi Kondo, 細井美希, Yuki Yamaguchi, Tomoyo Hara, Hiroki Yamagami, Sumiko Yoshida, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa, Makoto Funaki and 福本誠ニ : デノスマブ投与により術後の血清Ca/P値を容易に管理しえた巨大異所性副甲状腺腺腫の一例, 第17回日本内分泌学会四国支部学術集会抄録集, Sep. 2017.
276.	Tomoyo Hara, Sumiko Yoshida, Yuki Yamaguchi, 細井美希, Hiroki Yamagami, 桝田志保, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa, Makoto Funaki, 福本誠ニ and Masahiro Abe : 当院での免疫チェックポイント阻害薬による下垂体機能低下症の5例, 第17回日本内分泌学会四国支部学術集会抄録集, Sep. 2017.
277.	山口佑樹, Sumiko Yoshida, 細井美希, 山上紘規, 原倫世, 桝田志保, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa, Makoto Funaki, Seiji Fukumoto and Hiromitsu Takizawa : 当院での免疫チェックポインント阻害薬による内分泌異常の発生と有害事象対策, 第255回徳島医学会学術集会(平成29年度夏期), Aug. 2017.
278.	Kana Morimoto, 桝田志保, Kiyoe Kurahashi, Motoyuki Tamaki, Takeshi Kondo, Sumiko Yoshida, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Seiji Fukumoto, Munehide Matsuhisa, Masahiro Abe, Hiroyuki Azuma and Ken-ichi Aihara : 生活習慣病患者における血管内皮機能制御に関わる臨床指標の検討, 第49回日本動脈硬化学会総会・学術集会, Jul. 2017.
279.	Munehide Matsuhisa : 糖尿病治療薬の新たな展望, 第60回日本糖尿病学会年次学術集会抄録集, May 2017.
280.	仙田雅之, 亀田博之, 内藤祐介, 田村昌博, Munehide Matsuhisa and 寺内康夫 : ランタスXR注ソロスターに関する使用成績調査(X-STAR)-投与3か月集計報告-, 第60回日本糖尿病学会年次学術集会抄録集, May 2017.
281.	内藤祐介, 小山政義, 高橋良典, 田村昌博, Munehide Matsuhisa and 弘世貴久 : 基礎インスリン1日1回または2回投与からグラルギン300U/mL1回投与への切り替えにおける有用性と安全性の検討, 第60回日本糖尿病学会年次学術集会抄録集, May 2017.
282.	宮城匡彦, 能代尚記, 芳野弘, 池原佳世子, 北里博仁, 比嘉眞理子, 笹本牧子, 辛浩基, Motoyuki Tamaki, Munehide Matsuhisa, 内野泰 and 弘世貴久 : DPP-4阻害薬含み経口糖尿病薬無効例へ追加する単回注射療法の選択, 第60回日本糖尿病学会年次学術集会抄録集, May 2017.
283.	Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Takeshi Kondo, Kana Morimoto, Motoyuki Tamaki, Tomoyuki Yuasa, Akio Kuroda, 明比祐子, Itsuro Endo, Makoto Funaki, 福本誠ニ and Munehide Matsuhisa : 糖尿病教育入院での酸化ストレスマーカーの変化の検討, 第60回日本糖尿病学会年次学術集会抄録集, May 2017.
284.	Motoyuki Tamaki, Akio Kuroda, Kiyoe Kurahashi, Ken-ichi Aihara, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, 山口普史, 白神敦久 and Munehide Matsuhisa : 課程用電気筋刺激装置(EMS)の10週間継続使用は運動障害を有する2型糖尿病患者の血糖コントロールを改善する, 第60回日本糖尿病学会年次学術集会抄録集, May 2017.
285.	平井愛山 and Munehide Matsuhisa : レセプト情報，特定健診等情報データベース(NDB)の分析からみた糖尿病性腎症重症化予防の実態, 第60回日本糖尿病学科う年次学術集会抄録集, May 2017.
286.	Munehide Matsuhisa : 低血糖, 第60回日本糖尿病学会年次学術集会抄録集, May 2017.
287.	Kana Morimoto, 桝田志保, Kiyoe Kurahashi, Motoyuki Tamaki, Takeshi Kondo, Sumiko Yoshida, Tomoyuki Yuasa, Akio Kuroda, 明比祐子, Itsuro Endo, Makoto Funaki, 福本誠ニ, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : 糖尿病患者における自律神経機能をアルブミン尿の相互関連および各病態に影響を及ぼす因子解析, 第60回日本糖尿病学会年次学術集会, May 2017.
288.	Michiko Araki, Hiroyasu Mori, Akio Kuroda, 鈴木麗子, Mami Ohishi, Satoshi Taniguchi, Motoyuki Tamaki, 明比祐子, Hiroshi Sakaue, Kiyoe Kurahashi, Takeshi Kondo, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki and Munehide Matsuhisa : 1型糖尿病患者における血清IGF-1とサルコペニア罹患との関連, 第60回日本糖尿病学会年次学術集会, May 2017.
289.	秦誠倫, 入江暢子, 竹本有里, 永田慎平, 藤井浩平, 白木梓, 片岡隆太郎, 大楠崇弘, 坂本扶美枝, 河盛段, 片上直人, Akio Kuroda, 松岡孝昭, Munehide Matsuhisa, 下村伊一郎 and 安田哲行 : 1型糖尿病患者の骨格筋量に影響を及ぼす因子，および骨格筋量と糖尿病合併症の関連についての検討, 第60回日本糖尿病学会年次学術集会抄録集, May 2017.
290.	Hiroyasu Mori, Akio Kuroda, Michiko Araki, 鈴木麗子, Mami Ohishi, Satoshi Taniguchi, Motoyuki Tamaki, 明比祐子, Kiyoe Kurahashi, Takeshi Kondo, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki and Munehide Matsuhisa : 2型糖尿病患者における皮下AGE蓄積が筋機能低下に及ぼす影響, 第60回日本糖尿病学会年次学術集会抄録集, May 2017.
291.	Satoshi Taniguchi, 天満仁, Akio Kuroda, 堀江徹, Hiroyasu Mori, 鈴木麗子, 浅野弥生, Michiko Araki, Yuu Tamaki and Munehide Matsuhisa : EHR自己測定機器と連係したPHRの開発と有用性の検証, 第60回日本糖尿病学会年次学術講演会抄録集, May 2017.
292.	Sumiko Yoshida, Akio Kuroda, Minoru Irahara, Kiyoe Kurahashi, Takeshi Kondo, Itsuro Endo, Ken-ichi Aihara and Munehide Matsuhisa : 加重型妊娠高血圧腎症を来し集学的治療で分娩に至った糖尿病腎症の2症例, 第6回臨床高血圧フォーラム, May 2017.
293.	Yuki Fujimoto, Toshihiro Watanabe, Aya Morimoto, Hana Kumamoto, Kouzou Sudo, Tomokazu Yoshida, Hiroyasu Mori, Munehide Matsuhisa, Akiko Hata, Makoto Funaki, Mayumi Yamamoto and Seiichi Hashida : 尿中アディポネクチンの腎障害予測マーカーに関する研究, Journal of the The Japan Diabetes Society, Vol.60, No.Suppl.1, May 2017.
294.	Kana Morimoto, Yuka Takahashi, Saori Yamashita, 上元良子, 石川カズ江, Kiyoe Kurahashi, Takeshi Kondo, Sumiko Yoshida, Akio Kuroda, Itsuro Endo, Tomoyuki Yuasa, Munehide Matsuhisa, 東博之, Masahiro Abe and Ken-ichi Aihara : 生活習慣病患者の血管内皮機能に関わる因子の臨床的検討, 第90回日本内分泌学会学術集会抄録集, Apr. 2017.
295.	Munehide Matsuhisa : 糖尿病地域医療連携の現状と展望, 第51回糖尿病学の進歩, Feb. 2017.
296.	Munehide Matsuhisa : 1型糖尿病における運動療法, 第51回糖尿病学の進歩, Feb. 2017.
297.	Munehide Matsuhisa : ヤング糖尿病患者への運動療法指導の実践, 第51回糖尿病学の進歩, Feb. 2017.
298.	Munehide Matsuhisa : 糖尿病患者と医療者をつなぐPHRの可能性, メディカルジャパン, Feb. 2017.
299.	Michiko Araki, Hiroyasu Mori, Akio Kuroda, 鈴木麗子, Mami Ohishi, Satoshi Taniguchi, Motoyuki Tamaki, 明比祐子, Hiroshi Sakaue and Munehide Matsuhisa : 1型糖尿病患者の血清IGF-1がサルコペニア羅患に及ぼす影響, 第20回日本病態栄養学会年次学術集会, Jan. 2017.
300.	Hiroyasu Mori, Akio Kuroda, Michiko Araki, 鈴木麗子, Mami Ohishi, Satoshi Taniguchi, Motoyuki Tamaki, 明比祐子, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki and Munehide Matsuhisa : 2型糖尿病患者におけるサルコペニアのリスク因子解析, 第51回日本成人病学会学術集会, Jan. 2017.
301.	桝田志保, Sumiko Yoshida, Kiyoe Kurahashi, Takeshi Kondo, Itsuro Endo, Masahiro Abe, Akio Kuroda, Munehide Matsuhisa, Ken-ichi Aihara and Seiji Fukumoto : メーグルコシダーゼ阻害薬による腸管気腫症の一例, 第115回日本内科学会四国地方会, Nov. 2016.
302.	Tomoyo Hara, Kiyoe Kurahashi, Takeshi Kondo, Sumiko Yoshida, Itsuro Endo, Akio Kuroda, Munehide Matsuhisa, Ken-ichi Aihara and Seiji Fukumoto : イピリムマブ投与後に続発性副腎不全を発症した一例, 第115回日本内科学会四国地方会, Nov. 2016.
303.	上田浩之, Itsuro Endo, Takeshi Kondo, Kiyoe Kurahashi, Sumiko Yoshida, Masahiro Abe, Akio Kuroda, Munehide Matsuhisa, Ken-ichi Aihara and Seiji Fukumoto : デノスマブによる耐糖能改善, 第115回日本内科学会四国地方会, Nov. 2016.
304.	Takeshi Kondo, Itsuro Endo, 明比祐子, Kiyoe Kurahashi, Motoyuki Tamaki, Sumiko Yoshida, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Masahiro Abe and Seiji Fukumoto : 免疫チェックポイント阻害剤で中枢性副腎不全を来した2例, 第26回臨床内分泌代謝Update, Nov. 2016.
305.	岡本恵暢, Sumiko Yoshida, Kiyoe Kurahashi, Takeshi Kondo, Kana Morimoto, Motoyuki Tamaki, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Munehide Matsuhisa and Seiji Fukumoto : IGF-2産生神経内分泌癌による重症低血糖の一例, 第26回臨床内分泌代謝Update, Nov. 2016.
306.	Sumiko Yoshida, Kiyoe Kurahashi, Takeshi Kondo, Kana Morimoto, Motoyuki Tamaki, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Munehide Matsuhisa and Seiji Fukumoto : 当院のニボルマブおよびイピリムマブ投与21例の内分泌異常の検討, 第26回臨床内分泌代謝Update, Nov. 2016.
307.	Mami Ohishi, Satoshi Taniguchi, 明比祐子, Hiroyasu Mori, Yuu Tamaki, Akio Kuroda, Motoyuki Tamaki, Michiko Araki, Hiroshi Sakaue and Munehide Matsuhisa : eGFR変化量を用いた透析導入高リスク群抽出アルゴリズムの妥当性の検討, 日本糖尿病学会中国四国地方会第54回総会, Nov. 2016.
308.	Satoshi Taniguchi, 天満仁, Akio Kuroda, 堀江徹, Hiroyasu Mori, 鈴木麗子, 浅野弥生, Michiko Araki, Yuu Tamaki and Munehide Matsuhisa : EHRと連係したPHRの開発と有用性の検証, 日本糖尿病学会中国四国地方会第54回総会, Nov. 2016.
309.	山下沙織, Sumiko Yoshida, 高橋優花, Ken-ichi Aihara, Kiyoe Kurahashi, Takeshi Kondo, Kana Morimoto, Motoyuki Tamaki, Tomoyuki Yuasa, Akio Kuroda, 明比祐子, Itsuro Endo, Makoto Funaki, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 糖尿病教育入院における酸化ストレス減少に影響を及ぼす因子の検討, 日本糖尿病学会中国四国地方会第54回総会, Nov. 2016.
310.	鶴尾美穂, Akio Kuroda, Tomoyuki Yuasa, Takeshi Kondo, Mizuho Kinouchi, Naoko Matsui, 細井恵美子, Masahiro Abe, Toshio Matsumoto, Munehide Matsuhisa and 寺澤敏秀 : γグロブリン療養後に一過性のGAD抗体価上昇がみられた糖尿病の一例, 日本糖尿病学会中国四国地方会第54回総会, Nov. 2016.
311.	Michiko Araki, Hiroyasu Mori, Akio Kuroda, 鈴木麗子, Mami Ohishi, Satoshi Taniguchi, Motoyuki Tamaki, 明比祐子, Hiroshi Sakaue, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki and Munehide Matsuhisa : 1型糖尿病患者の血清IGF-1がサルコペニア罹患に及ぼす影響, 日本糖尿病学会中国四国地方会第54回総会, Nov. 2016.
312.	Hiroyasu Mori, Akio Kuroda, Michiko Araki, 鈴木麗子, Mami Ohishi, Satoshi Taniguchi, Motoyuki Tamaki, 明比祐子, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki and Munehide Matsuhisa : 2型糖尿病患者におけるAGE蓄積とサルコペニアとの関連の検討, 日本糖尿病学会中国四国地方会第54回総会, Nov. 2016.
313.	斎村玉緒, 鶴尾美穂, Akio Kuroda, Takeshi Kondo, Tomoyuki Yuasa, Mizuho Kinouchi, Masahiro Abe, Toshio Matsumoto, 寺澤敏秀 and Munehide Matsuhisa : インスリンポンプの院内検定の試み, 日本糖尿病学会中国四国地方会第54回総会, Nov. 2016.
314.	荒瀬美晴, Takeshi Kondo, Akio Kuroda, Kiyoe Kurahashi, Motoyuki Tamaki, Sumiko Yoshida, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Seiji Fukumoto, Masahiro Abe and Munehide Matsuhisa : 術前後で持続血糖モニター(CGM)を比較したアドレナリン優位褐色細胞腫の二例, 日本糖尿病学会中国四国地方会第54回総会, Nov. 2016.
315.	上田浩之, Takeshi Kondo, Akio Kuroda, Kiyoe Kurahashi, Motoyuki Tamaki, Sumiko Yoshida, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Seiji Fukumoto, Masahiro Abe and Munehide Matsuhisa : 基礎インスリンが不要であった膵性糖尿病の一例, 日本糖尿病学会中国四国地方会第54回総会, Nov. 2016.
316.	Kana Morimoto, 桝田志保, Kiyoe Kurahashi, Motoyuki Tamaki, Takeshi Kondo, Sumiko Yoshida, Tomoyuki Yuasa, Akio Kuroda, 明比祐子, Itsuro Endo, Makoto Funaki, Seiji Fukumoto, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : 糖尿病患者における心電図R-R間隔変動係数に影響を及ぼす因子の検討, 日本糖尿病学会中国四国地方会第54回総会, Nov. 2016.
317.	Michiko Araki, Hiroyasu Mori, Akio Kuroda, 鈴木麗子, Mami Ohishi, Satoshi Taniguchi, Motoyuki Tamaki, 明比祐子, Hiroshi Sakaue, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki and Munehide Matsuhisa : 1型糖尿病患者の血清IGF-1がサルコペニア罹患に及ぼす影響, 第14回1型糖尿病研究会, Nov. 2016.
318.	大澤彩恵子, 片上直人, 高原充佳, 坂本扶美枝, 河盛段, 松岡孝昭, Akio Kuroda, Munehide Matsuhisa and 下村伊一郎 : 1型糖尿病患者における皮下AGEs蓄積量と糖尿病血管合併症との関連の検討, 第14回1型糖尿病研究会, Nov. 2016.
319.	Munehide Matsuhisa : 医療情報活用時代の実現に向けて, 第16回日本糖尿病情報学会年次学術集会シンポジウム, Sep. 2016.
320.	高橋優花, 山下沙織, Sumiko Yoshida, 桝田志保, Kana Morimoto, Kiyoe Kurahashi, Motoyuki Tamaki, Takeshi Kondo, Akio Kuroda, Tomoyuki Yuasa, Itsuro Endo, Munehide Matsuhisa, Seiji Fukumoto, Hiroyuki Azuma, Masahiro Abe and Ken-ichi Aihara : 生活習慣病患者における血管内皮機能正常群および低下群の臨床指標に関する検討, 第16回日本内分泌学会四国支部学術集会, Sep. 2016.
321.	山上紘規, Kiyoe Kurahashi, Kana Morimoto, Takeshi Kondo, Itsuro Endo, 明比祐子, Sumiko Yoshida, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Seiji Fukumoto and Masahiro Abe : バセドウ病を合併したTSH産生下垂体腺腫の一例, 第16回日本内分泌学会四国支部学術集会, Sep. 2016.
322.	Satoshi Taniguchi, 天満仁, Akio Kuroda, 堀江徹, Hiroyasu Mori, 鈴木麗子, 浅野弥生, Michiko Araki, Yuu Tamaki and Munehide Matsuhisa : EHRとPHRの開発と従来の紙媒体記録との比較検証, 第16回日本糖尿病情報学会年次学術集会, Sep. 2016.
323.	遠藤ふうり, Kiyoe Kurahashi, Kana Morimoto, Takeshi Kondo, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Akio Kuroda, 明比祐子, Makoto Funaki, Munehide Matsuhisa, Seiji Fukumoto and Masahiro Abe : 日和見感染を合併したACTH依存性Cushing症候群の1例, 第253回徳島医学会学術集会(平成28年度夏期), Jul. 2016.
324.	Michiko Araki, Hiroyasu Mori, 鈴木麗子, Satoshi Taniguchi, Motoyuki Tamaki, 明比祐子, Akio Kuroda, Hiroshi Sakaue and Munehide Matsuhisa : 1型糖尿病患者における血清IGF-1の低下とサルコペニア羅漢との関連, 第253回徳島医学会学術集会, Jul. 2016.
325.	Munehide Matsuhisa : 院内厳格血糖管理装置-人工膵臓の軌跡と展望-, 第71回日本消化器外科学会ランチョンセミナー, Jul. 2016.
326.	Satoshi Taniguchi, Munehide Matsuhisa, Hiroyasu Mori, Akio Kuroda and Yuu Tamaki : The Effects of using PHR on Self-management Activities in Patients with Diabetes, The 10th Anniversary Meeting of the Japana Association of Applied IT Healthcare, May 2016. (Keyword) PHR / self-management / diabetes mellitus
327.	布村俊幸, Sumiko Yoshida, Kana Morimoto, Kiyoe Kurahashi, Takeshi Kondo, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa, Toshio Matsumoto and Masahiro Abe : 副腎に接する神経線維腫を合併したレックリングハウゼン病の1例, 第114回日本内科学会四国地方会, May 2016.
328.	橋本晶慶, 鶴尾美穂, 秋田賢子, 森岡隆子, Akio Kuroda, Tomoyuki Yuasa, Takeshi Kondo, Mizuho Kinouchi, Toshio Matsumoto, Masahiro Abe, Munehide Matsuhisa and 寺澤敏秀 : 糖尿病教室のスタッフ間の相互評価による改善効果, 第59回日本糖尿病学会年次学術集会, May 2016.
329.	Sumiko Yoshida, Ken-ichi Aihara, Kana Morimoto, Kiyoe Kurahashi, Takeshi Kondo, Motoyuki Tamaki, Akio Kuroda, Itsuro Endo, 明比祐子, Makoto Funaki, Seiji Fukumoto and Munehide Matsuhisa : 当院検診受診者における筋肉量がメタボリックパラメーターに及ぼす影響の検討, 第59回日本糖尿病学会年次学術集会, May 2016.
330.	Munehide Matsuhisa : EHRがintegrateする次世代のPHR, 第59回日本糖尿病学会年次学術集会シンポジウム, May 2016.
331.	宮下和幸, 高原充佳, 坂本扶美枝, 片上直人, 松岡孝昭, Akio Kuroda, Munehide Matsuhisa, 山崎義光, 伊藤壽記, 今川彰久 and 下村伊一郎 : 膵移植後グラフト機能評価としてのアルギニン負荷試験の有用性, 第59回日本糖尿病学会年次学術集会, May 2016.
332.	大澤彩恵子, 片上直人, 高原充佳, 坂本扶美枝, 河盛段, 松岡孝昭, Akio Kuroda, Munehide Matsuhisa and 下村伊一郎 : 1型糖尿病患者における皮下AGEsの蓄積量と糖尿病血管合併症との関連の検討, 第59回日本糖尿病学会年次学術集会, May 2016.
333.	Hiroyasu Mori, Michiko Araki, 鈴木麗子, Akio Kuroda, Motoyuki Tamaki, 明比祐子 and Munehide Matsuhisa : 1型糖尿病患者における皮下AGEsの蓄積が筋機能低下に及ぼす影響, 第59回日本糖尿病学会年次学術集会, May 2016.
334.	Kana Morimoto, Ken-ichi Aihara, Sumiko Yoshida, Kiyoe Kurahashi, Takeshi Kondo, Motoyuki Tamaki, Akio Kuroda, Itsuro Endo, Makoto Funaki, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 減塩による2型糖尿病入院症例の降圧予測指標, 第59回日本糖尿病学会年次学術集会, May 2016.
335.	Sumiko Yoshida, Ken-ichi Aihara, Kana Morimoto, Kiyoe Kurahashi, Takeshi Kondo, Motoyuki Tamaki, Akio Kuroda, Itsuro Endo, 明比祐子, Makoto Funaki, Seiji Fukumoto and Munehide Matsuhisa : 当院検診受診者における筋肉量が高血圧に及ぼす影響の検討, 第5回臨床高血圧フォーラム, May 2016.
336.	Kana Morimoto, Ken-ichi Aihara, Sumiko Yoshida, Kiyoe Kurahashi, Motoyuki Tamaki, Takeshi Kondo, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Masahiro Abe : 血糖管理入院症例における減塩降圧効果と関連する因子および降圧薬に関する検討, 第5回臨床高血圧フォーラム, May 2016.
337.	Kana Morimoto, Ken-ichi Aihara, Sumiko Yoshida, Kiyoe Kurahashi, Takeshi Kondo, Motoyuki Tamaki, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Masahiro Abe : 2型糖尿病患者の塩分制限による降圧効果を規定する因子の検討, 第89回日本内分泌学会学術総会, Apr. 2016.
338.	Ken-ichi Aihara, Sumiko Yoshida, Kana Morimoto, Kiyoe Kurahashi, Takeshi Kondo, Motoyuki Tamaki, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Masahiro Abe : 心筋リモデリングおよび頸動脈硬化症におけるアンジオテンシンII受容体拮抗薬の効果検証, 第89回日本内分泌学会学術総会, Apr. 2016.
339.	宮下和幸, 高原充佳, 坂本扶美枝, Akio Kuroda, 浅岡忠史, 片上直人, 種村匡弘, 江口英利, 今川彰久, Munehide Matsuhisa, 山崎義光, 伊藤壽記 and 下村伊一郎 : 当院における膵移植後患者の移植膵機能の推移, 第43回日本膵・膵島移植研究会ホテルグランビア広島, Mar. 2016.
340.	山上紘規, Kiyoe Kurahashi, 森本佳奈, Takeshi Kondo, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Akio Kuroda, 明比祐子, Makoto Funaki, Munehide Matsuhisa, Seiji Fukumoto and Masahiro Abe : インターフェロンβ治療中に糖尿病ケトアシドーシスを契機とし，急性発症1A型糖尿病と診断された一例, 第252回徳島医学会学術集会長井記念ホール, Feb. 2016.
341.	森本佳奈, Ken-ichi Aihara, Sumiko Yoshida, Kiyoe Kurahashi, Motoyuki Tamaki, Takeshi Kondo, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Masahiro Abe : 2型糖尿病患者における血糖指標と減塩がもたらす血圧低下との連関, 第252回徳島医学会学術集会長井記念ホール, Feb. 2016.
342.	森本佳奈, Takeshi Kondo, Itsuro Endo, 倉橋清衛, Motoyuki Tamaki, Sumiko Yoshida, Akio Kuroda, Munehide Matsuhisa, Seiji Fukumoto, Ken-ichi Aihara and Masahiro Abe : 著明な低カルシウム血症を来した胃癌の骨転移の一例, 第25回臨床内分泌Update, Nov. 2015.
343.	小山広士, Takeshi Kondo, 森本佳奈, Itsuro Endo, 倉橋清衛, Motoyuki Tamaki, Sumiko Yoshida, Akio Kuroda, Munehide Matsuhisa, Seiji Fukumoto, Ken-ichi Aihara and Masahiro Abe : ACTH，コルチゾール基礎値正常のACTH単独欠損症の一例, 第25回臨床内分泌Update, Nov. 2015.
344.	Takeshi Kondo, Itsuro Endo, 森本佳奈, 倉橋清衛, Motoyuki Tamaki, Sumiko Yoshida, Akio Kuroda, Munehide Matsuhisa, Seiji Fukumoto, Ken-ichi Aihara and Masahiro Abe : テタニーで来院し，Gitelman症候群を疑った一例, 第25回臨床内分泌Update, Nov. 2015.
345.	Ken-ichi Aihara, Sumiko Yoshida, Kana Morimoto, Kiyoe Kurahashi, Takeshi Kondo, Motoyuki Tamaki, Akio Kuroda, 明比祐子, Itsuro Endo, Makoto Funaki, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 2型糖尿病患者の左室形態および機能における強化インスリン療法の効果, 日本糖尿病学会第53回中国四国地方会, Oct. 2015.
346.	鶴尾美穂, Akio Kuroda, Takeshi Kondo, Tomoyuki Yuasa, Mizuho Kinouchi, Masahiro Abe, Toshio Matsumoto, Munehide Matsuhisa and 寺澤敏秀 : Sensor Angmented Pump(SAP)療法が有効であった高齢1型糖尿病の1例, 第53回日本糖尿病学会中国四国地方会, Oct. 2015.
347.	森岡隆子, 鶴尾美穂, Akio Kuroda, Tomoyuki Yuasa, Takeshi Kondo, Mizuho Kinouchi, Toshio Matsumoto, Munehide Matsuhisa and 寺澤敏秀 : SGLT2阻害薬が著効したprader, 第53回日本糖尿病学会中国四国地方会米子コンベンションセンター, Oct. 2015.
348.	岡田祐輝, Takeshi Kondo, 森本佳奈, Kiyoe Kurahashi, Motoyuki Tamaki, Sumiko Yoshida, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Seiji Fukumoto, Ken-ichi Aihara and Masahiro Abe : 高CPR血症からグリメピリド誤内服を診断し得た遷延性低血糖の一例, 第53回日本糖尿病学会中国四国地方会米子コンベンションセンター, Oct. 2015.
349.	Ken-ichi Aihara, Sumiko Yoshida, 森本佳奈, Kiyoe Kurahashi, Takeshi Kondo, Motoyuki Tamaki, Akio Kuroda, 明比祐子, Itsuro Endo, Makoto Funaki, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 2型糖尿病患者の左室形態および機能における強化インスリン療法の効果, 第53回日本糖尿病学会中国・四国地方会米子コンベンションセンター, Oct. 2015.
350.	Hiroyasu Mori, Munehide Matsuhisa, Akio Kuroda, Motoyuki Tamaki, Satoshi Taniguchi, Yuu Tamaki, 大塚明廣, Yoshihiko Noma and 徳島県医師会糖尿病対策班 : 徳島県の糖尿病診療の現状と課題∼平成22年と26年の比較∼, 第53回日本糖尿病学会中国・四国地方会米子コンベンションセンター, Oct. 2015.
351.	林亜紀, Sumiko Yoshida, Akio Kuroda, 七篠あつ子, Minoru Irahara, 鶴尾美穂, 森本佳奈, 倉橋清衛, Takeshi Kondo, Motoyuki Tamaki, 明比祐子, Itsuro Endo, Makoto Funaki, Munehide Matsuhisa, Seiji Fukumoto, Ken-ichi Aihara and Masahiro Abe : 分娩前に10g/日以上の蛋白尿を合併し，出産に至った糖尿病腎症の1例, 日本糖尿病学会中国四国地方会第53回総会, Oct. 2015.
352.	荒木迪子, Hiroyasu Mori, Hisami Okumura, 多々納浩, Motoyuki Tamaki, Akio Kuroda, Hiroshi Sakaue and Munehide Matsuhisa : 食事エネルギー密度は日本人2型糖尿病患者の肥満と関連する, 第53回日本糖尿病学会中国四国地方会米子コンベンションセンター, Oct. 2015.
353.	Satoshi Taniguchi, Akio Kuroda, Motoyuki Tamaki, Hwa In, 森本佳奈, Kiyoe Kurahashi, Takeshi Kondo, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe and Munehide Matsuhisa : CGM iPRO2と人工膵臓STG-55との測定グルコース濃度の比較, 第53回日本糖尿病学会中国・四国地方会米子コンベンションセンター, Oct. 2015.
354.	Hisami Okumura, 和田宵湖, 新井田裕樹, Hideya Kashihara, Masaaki Nishi, Kouzou Yoshikawa, 森本佳奈, 倉橋清衛, Takeshi Kondo, Sumiko Yoshida, Motoyuki Tamaki, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Mitsuo Shimada and Munehide Matsuhisa : 本院の腹腔鏡下袖状胃切除術後1年で異なった経過を示した2症例の報告, 第53回糖尿病学会中四国大会, Oct. 2015.
355.	森本佳奈, Ken-ichi Aihara, Sumiko Yoshida, 倉橋清衛, Motoyuki Tamaki, Takeshi Kondo, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Masahiro Abe : Significance of glycemic markers for sodium restriction-induced blood pressure reduction in hospitalized patients with type 2 diabetes, 第38日本高血圧学会総会, Oct. 2015.
356.	Ken-ichi Aihara, Sumiko Yoshida, 森本佳奈, 倉橋清衛, Motoyuki Tamaki, Takeshi Kondo, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Masahiro Abe : Evaluation for long-term efficacy of angiotensin II receptor blocker-based antihypertensive therapy on cardiac remodeling and carotid atherosclerosis, 第38日本高血圧学会総会, Oct. 2015.
357.	森本佳奈, Takeshi Kondo, Itsuro Endo, Kiyoe Kurahashi, Motoyuki Tamaki, Sumiko Yoshida, Akio Kuroda, Munehide Matsuhisa, Seiji Fukumoto, Ken-ichi Aihara and Masahiro Abe : 診断まで長時間を要したACTH分泌低下症の一例, 第15回日本内分泌学会四国支部学術集会高知大学, Sep. 2015.
358.	加藤正樹, 森本佳奈, Ken-ichi Aihara, Sumiko Yoshida, 倉橋清衛, Motoyuki Tamaki, Takeshi Kondo, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Seiji Fukumoto and Masahiro Abe : 2型糖尿病患者の減塩療法による血圧低下に関連する因子の解析, 第15回日本内分泌学会四国支部学術集会, Sep. 2015.
359.	Munehide Matsuhisa : 糖尿病地域医療連携のICT化∼その現状と課題∼, 第15回日本糖尿病情報学会年次学術集会海運クラブ, Aug. 2015.
360.	Satoshi Taniguchi, Yuu Tamaki, Motoyuki Tamaki, Akio Kuroda, 田蒔正治, 林秀樹 and Munehide Matsuhisa : 多職種による在宅糖尿病患者ケアにおける医療介護情報連携システム活用の有用性検証, 第15回日本糖尿病情報学会年次学術集会, Aug. 2015.
361.	Hiroyasu Mori, Munehide Matsuhisa, Akio Kuroda, Motoyuki Tamaki, Satoshi Taniguchi, Yuu Tamaki, Yoshihiko Noma and 大塚明廣 : 徳島県における糖尿病の治療中断と地域医療連携の推進に関連する医療側の課題の検討, 第15回日本糖尿病情報学会年次学術集会, Aug. 2015.
362.	荒木迪子, Hiroyasu Mori, Hisami Okumura, 鞍田三貴, 福尾惠介, Motoyuki Tamaki, Akio Kuroda, Hiroshi Sakaue and Munehide Matsuhisa : 低エネルギー密度食が2型糖尿病患者の食行動や代謝改善に与える効果の検討, 第251回徳島医学会学術集会ポスター, Aug. 2015.
363.	森本佳奈, Ken-ichi Aihara, Sumiko Yoshida, 倉橋清衛, Motoyuki Tamaki, Takeshi Kondo, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Masahiro Abe : 2型糖尿病における血糖指標と減塩がもたらす血圧低下との連関, 第251回徳島医学会学術集会ポスター, Aug. 2015.
364.	Munehide Matsuhisa : 地域の課題として糖尿病に取り組むアカデミズムのチャレンジ, 第13回日本予防医学会学術総会, Jun. 2015.
365.	Yuu Tamaki, Munehide Matsuhisa, Akio Kuroda, Motoyuki Tamaki, Satoshi Taniguchi and Hiroyasu Mori : Construction of Electronic Health Record using IHE profiles, 第19回日本医療情報学会春季学術大会, Jun. 2015.
366.	出口憲市, Tetsuya Enishi, Nori Sato, 後藤強, Toshifumi Ohsawa, 柳澤幸夫, Munehide Matsuhisa and Shinsuke Katoh : 歩幅の異なるWalking様式の3次元動作解析およびエネルギー代謝へ及ぼす影響, 第58回日本糖尿病学会年次学術集会口演, May 2015.
367.	後藤廣平, 鶴尾美穂, Akio Kuroda, 伊澤真弓, Mizuho Kinouchi, Takeshi Kondo, Tomoyuki Yuasa, Toshio Matsumoto, Munehide Matsuhisa and 寺澤敏秀 : SGLT2阻害薬の強化インスリン療法への併用効果の検討, 第58回日本糖尿病学会年次学術集会口演, May 2015.
368.	宮下和幸, 高原充佳, 坂本扶美枝, Akio Kuroda, 安田哲行, 片上直人, 松岡孝昭, 山﨑義光, 伊藤壽記, Munehide Matsuhisa, 今川彰久 and 下村伊一郎 : 膵移植患者における移植膵機能の推移の検討口演, 第58回日本糖尿病学会年次学術集会, May 2015.
369.	Munehide Matsuhisa : 1型糖尿病治療における運動療法のリスク, 第58回日本糖尿病学会年次学術集会海峡メッセ下関, May 2015.
370.	Munehide Matsuhisa : 経口血糖降下薬と基礎インスリンで治療中の2型糖尿病患者に対するインスリングラルギン300U/mLの有効性と安全性, 第58回日本糖尿病学会年次学術集会海峡メッセ下関, May 2015.
371.	池田雅彦, Akio Kuroda, Motoyuki Tamaki, 賀川義光, 能勢洋介, 寺方孝守, 木村那智 and Munehide Matsuhisa : 全国ヤングDMカンファの現状と展望, 第58回日本糖尿病学会年次学術集会ポスター, May 2015.
372.	天満仁, 堀江徹, Hiroyasu Mori, Akio Kuroda and Munehide Matsuhisa : 2型糖尿病患者における皮下AGEと糖尿病血管合併症との関連の検討, 第58回日本糖尿病学会年次学術集会口演, May 2015.
373.	Ken-ichi Aihara, Sumiko Yoshida, 大黒由加里, Motoyuki Tamaki, Takeshi Kondo, 倉橋清衛, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Toshio Matsumoto : ARB基盤高血圧治療の長期心腎保護効果における糖尿病の影響, 第58回総会日本糖尿病学会年次学術集会, May 2015.
374.	Yumi Kuwamura, 澄川真珠子, Hiromi Murata, 瀧川稲子, 大和光, 石田伸子, 菊井聡子, Yasuhiro Hamada, Hirokazu Ito, Yuko Yasuhara, Daisuke Hinode, Hirokazu Uemura, Ken-ichi Aihara, Munehide Matsuhisa, Tetsuya Tanioka and Toshihiko Nagata : 多職種協働での糖尿病患者の口腔保健行動支援:口腔保健行動を査定するための査定シート案についての糖尿病看護の専門家の評価と実施状況, Journal of the The Japan Diabetes Society, Vol.58, No.supplement 1, S290, May 2015. (Keyword) diabetes / oral health behaviors / nursing
375.	白神敦久, 鶴尾美穂, 天満仁, Masako Sei, Yuichi Fujinaka, 新谷保実, 福島泰江, 柴原恵美, 鎌村好孝, 松本正子, 中川洋一, 岡本好史, 田中俊夫, 宮本道代, 吉田結花, 吉積美代, Munehide Matsuhisa, Yoshihiko Noma, Issei Imoto, 宮永俊彦 and 大塚明廣 : 地域糖尿病療養指導士におけるインスリン治療に対する心理的障害の検討, 第58回日本糖尿病学会年次学術集会ポスター, May 2015.
376.	Ken-ichi Aihara, Sumiko Yoshida, 大黒由加里, 倉橋清衛, Takeshi Kondo, Motoyuki Tamaki, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Toshio Matsumoto : 本態性高血圧患者におけるアンジオテンシンII受容体拮抗薬単独およびカルシウム拮抗薬併用による長期心筋保護効果の検証, 第88回日本内分泌学会学術総会, Apr. 2015.
377.	Motoyuki Tamaki, 藤谷与士夫, 原朱美, 福中彩子, 荻原健, 宮塚健, Akio Kuroda, Toshio Matsumoto, 河盛隆造, Munehide Matsuhisa and 綿田裕孝 : 糖尿病発症・進展に関わる新規メカニズムの解明, 第88回日本内分泌学会学術総会シンポジウム, Apr. 2015.
378.	K Node, J Oyama, T Ishizu, M Nanasato, K Kodama, Y Bandoh, H Kamiya, K Kitagawa, S Ueda, H Tomiyama, Masataka Sata, K Maemura, Munehide Matsuhisa, T Inoue, Y Higashi, Hirotsugu Yamada, M Ishihara, A Yamashina, N Kashihara, Y Sato and T Murohara : The Study to Evaluate the Effects of DPP-4 Inhibitor on Atherosclerosis in Patients with Diabetes Mellitus: PROLOGUE Study., 第79回日本循環器学会学術集会, Apr. 2015.
379.	Takeshi Kondo, Itsuro Endo, 大黒由加里, 倉橋清衛, Motoyuki Tamaki, Sumiko Yoshida, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto : 遠位尿細管性アシドーシスの確定診断としてアミノレバンRは有用である．, 第112回日本内科学会総会・講演会, Apr. 2015.
380.	Munehide Matsuhisa : 低血糖症の鑑別診断と治療, 第49回糖尿病学の進歩 (グランヴィア岡山), Feb. 2015.
381.	Munehide Matsuhisa : 徳島県の糖尿病課題に挑むシーズの創出, JST「わが国の未来を拓く地域の実現に関する調査研究」事業招待講演, Feb. 2015.
382.	大黒由加里, Akio Kuroda, Motoyuki Tamaki, 倉橋清衛, Takeshi Kondo, 安芸菜奈子, Itsuro Endo, Ken-ichi Aihara, Toshio Matsumoto and Munehide Matsuhisa : 皮下注射による強化インスリン療養中の1型糖尿病患者における基礎インスリン比率の検討, 第250回徳島医学会学術集会(大塚講堂), Feb. 2015.
383.	Munehide Matsuhisa : 糖尿病の病態理解の深化と治療の進化, 第18回日本病態栄養学会年次学術集会 (国立京都国際会館)ランチョンセミナー, Jan. 2015.
384.	Akio Kuroda, Takeshi Kondo, 安田哲行, 高原充佳, Ken-ichi Aihara, Itsuro Endo, 金藤秀明, 下村伊一郎, Toshio Matsumoto and Munehide Matsuhisa : インスリンポンプ療法での追加インスリン注入時間を規定する因子の検討, 第14回日本先進糖尿病治療研究会(あわぎんホール), Dec. 2014.
385.	大黒由加里, Akio Kuroda, Motoyuki Tamaki, 倉橋清衛, Takeshi Kondo, 安芸菜奈子, Itsuro Endo, Ken-ichi Aihara, Toshio Matsumoto and Munehide Matsuhisa : 皮下注射による強化インスリン療法1型糖尿病患者における基礎インスリン比率の検討, 第12回1型糖尿病研究会(イーグレ姫路), Nov. 2014.
386.	Masato Tagi, Yuu Tamaki, Munehide Matsuhisa and Hiroki Moriguchi : FeliCa通信歩数計を活用した健康データ見える化による行動変容, 医療情報学連合大会論文集, Vol.34, 506-507, Nov. 2014.
387.	Yoshihiko Noma, 小松まち子, 宮恵子, 鶴尾美穂, 天満仁, Munehide Matsuhisa and 島健二 : CGMによる糖尿病患者のフルマラソンでの血糖変動の検討, 日本糖尿病学会中国四国地方会第52回総会, Oct. 2014.
388.	浅井廣平, 鶴尾美穂, Akio Kuroda, Tomoyuki Yuasa, 伊澤真弓, Takeshi Kondo, Mizuho Kinouchi, Toshio Matsumoto, Munehide Matsuhisa and 寺澤敏秀 : SGLT阻害薬の臨床効果の検討, 日本糖尿病学会中国四国地方会第52回総会, Oct. 2014.
389.	鶴尾美穂, Akio Kuroda, Tomoyuki Yuasa, 松本直也, Takeshi Kondo, Mizuho Kinouchi, Toshio Matsumoto, Munehide Matsuhisa and 寺澤敏秀 : SGLT2阻害薬が著効したPrader Willi syndrome 合併糖尿病の1例, 日本糖尿病学会中国四国地方会第52回総会, Oct. 2014.
390.	荒木迪子, Motoyuki Tamaki, Akio Kuroda, 大黒由加里, 倉橋清衛, Takeshi Kondo, Ken-ichi Aihara, Itsuro Endo, 安芸菜奈子, Toshio Matsumoto and Munehide Matsuhisa : 2型糖尿病患者におけるeGFRの妥当性について, 日本糖尿病学会中国四国地方会第52回総会, Oct. 2014.
391.	Motoyuki Tamaki, 荒木迪子, 野崎綾音, 大黒由加里, 倉橋清衛, Takeshi Kondo, Ken-ichi Aihara, Itsuro Endo, 安芸菜奈子, Toshio Matsumoto, Munehide Matsuhisa and Akio Kuroda : 肥満2型糖尿病患者のeGFRは24hrCCrと比較して過小評価されている, 第29回日本糖尿病合併症学会, Oct. 2014.
392.	森本佳奈, Ken-ichi Aihara, 大黒由加里, 倉橋清衛, Takeshi Kondo, Motoyuki Tamaki, 安藝菜奈子, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Toshio Matsumoto : 多剤併用降圧療法と臓器障害モニタリングにより長期にわたり心腎大血管障害の改善が得られた加速型高血圧-悪性高血圧の1例, 第14回日本内分泌学会四国支部学術集会, Sep. 2014.
393.	Munehide Matsuhisa : 糖尿病地域医療連携のIT化の試み∼その現状と課題∼, 第14回日本糖尿病情報学会年次学術集会モーニングセミナー岐阜市文化産業交流センター, Aug. 2014.
394.	Masato Tagi, Yuu Tamaki, Akio Kuroda, Munehide Matsuhisa and Hiroki Moriguchi : 報酬手段を利用した生活習慣改善の試み∼歩数量に応じたポイント付与∼, 日本糖尿病情報学会年次学術集会, Vol.14, Aug. 2014.
395.	Ken-ichi Aihara, 大黒由加里, 倉橋清衛, Takeshi Kondo, Mizuho Kinouchi, Itsuro Endo, Toshio Matsumoto, Motoyuki Tamaki, Akio Kuroda and Munehide Matsuhisa : エゼチミブとコレスチミドの併用で脂質プロフィルが改善した多発性筋炎合併家族性高コレステロール血症へテロ接合体の一例, 第110回日本内科学会四国地方会, Jun. 2014.
396.	森本佳奈, Ken-ichi Aihara, 大黒由加里, 倉橋清衛, Mizuho Kinouchi, Motoyuki Tamaki, 安藝菜奈子, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Toshio Matsumoto : 多剤併用降圧療法により長期的な心・腎・大血管障害の改善が得られた高レニン性高血圧症の1例, 第3回臨床高血圧フォーラム, May 2014.
397.	宮城匡考, 臼井州樹, 能代尚記, 吉原彩, 北里博仁, 比嘉眞理子, 笹本牧子, 辛浩基, Motoyuki Tamaki, Munehide Matsuhisa, 内野康 and 弘世貴久 : DPP-4阻害薬と経口薬併用中の2型糖尿病に対する1日1回のグラルギン追加分リラグリチド切り替えの比較検討, 第57回日本糖尿病学会年次学術集会口演, May 2014.
398.	大黒由加里, Akio Kuroda, Motoyuki Tamaki, 倉橋清衛, Takeshi Kondo, Mizuho Kinouchi, 近藤絵里, Sumiko Yoshida, 安芸菜奈子, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto : 皮下注射による強化インスリン療法1型糖尿病患者における基礎インスリン比率の検討, 第57回日本糖尿病学会年次学術集会口演, May 2014.
399.	Munehide Matsuhisa : 病院における糖尿病診療の情報化の現状と課題, 第57回日本糖尿病学会年次学術集会シンポジウム, May 2014.
400.	Munehide Matsuhisa : 糖尿病診療の情報化ー適正な定着と普及へ向けてー, 第57回日本糖尿病学会年次学術集会シンポジウム, May 2014.
401.	Munehide Matsuhisa : 病院における糖尿病診療の情報化の現状と課題, 第57回日本糖尿病学会年次学術集会シンポジウム(大阪), May 2014.
402.	松本幸恵, 鶴尾美穂, Akio Kuroda, Tomoyuki Yuasa, 秋田賢子, Mizuho Kinouchi, Takeshi Kondo, Munehide Matsuhisa, Toshio Matsumoto and 寺澤敏秀 : 糖尿病患者の考える指示エネルギー量，指示主食量の調査とその介入, 第57回日本糖尿病学会年次学術集会口演, May 2014.
403.	出口憲市, Yuichi Fujinaka, Munehide Matsuhisa, Tetsuya Enishi, Nori Sato and Shinsuke Katoh : 一過性のインターバル形式の運動が急性血糖降下に及ぼす影響, 第57回日本糖尿病学会年次学術集会, May 2014.
404.	今井博久, 中尾裕之, 佐田文宏, 山崎義光, 片上直人, 金藤秀明, 下村伊一郎, 安井洋子 and Munehide Matsuhisa : 岩手県における生活習慣改善の介入研究, 第57回日本糖尿病学会年次学術集会ポスター, May 2014.
405.	松本幸恵, 鶴尾美穂, Akio Kuroda, Tomoyuki Yuasa, 秋田賢子, Mizuho Kinouchi, Takeshi Kondo, Munehide Matsuhisa, Toshio Matsumoto and 寺澤敏秀 : 糖尿病患者の考える指示エネルギー量，指示主食量の調査とその介入, 第57回日本糖尿病学会年次学術集会, May 2014.
406.	鶴尾美穂, 白神敦久, Munehide Matsuhisa, 福島泰江, 新谷保実, 小松まち子, 藤中雄一, 天満仁, Akio Kuroda, 安芸菜奈子, 大島康志, 金崎淑子, Tomoyuki Yuasa, 近藤絵里, 阿部多賀子, 加藤修司, 伊藤祐司, 倉橋清衛, 三浦眞司, 野間喜彦, 島健二 and 川島周 : -, 第57回日本糖尿病学会年次学術集会, May 2014.
407.	Akio Kuroda and Munehide Matsuhisa : 1型糖尿病患者の低血糖回避に向けて(リーガロイヤルホテル大阪), 第57回日本糖尿病学会年次学術集会, May 2014.
408.	Motoyuki Tamaki, 藤谷与士夫, 原朱美, Munehide Matsuhisa and 綿田裕孝 : 肥満2型糖尿病モデルマウスの膵β細胞は，糖脂肪属性による膵β細胞特異的転写因子の発現低下を介して，PP細胞へ分化転換する, 第57回日本糖尿病学会年次学術集会 YIA審査口演, May 2014.
409.	山崎義光, 片上直人, 松岡孝昭, 金藤秀明, 下村伊一郎, Munehide Matsuhisa, 遅野井健, 斎藤三代子, 川井紘一, 今村憲一, 清水一紀, 大野敬三 and 石橋不可止 : 遺伝子多型を用いたオーダーメイド糖尿病薬剤選択法の開発, 第57回日本糖尿病学会年次学術集会ポスター, May 2014.
410.	Motoyuki Tamaki, 藤谷与士夫, 原朱美, Munehide Matsuhisa and 綿田裕孝 : 肥満2型糖尿病モデルマウスの膵β細胞は，糖脂肪毒性による膵β細胞特異的転写因子の発現低下を介して，PP細胞へ分化転換する, 第87回日本内分泌学会学術総会, Apr. 2014.
411.	Ken-ichi Aihara, Mizuho Kinouchi, 大黒由加里, 倉橋清衛, Takeshi Kondo, 安藝菜奈子, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Toshio Matsumoto : 生活習慣病治療薬が血管内皮機能に及ぼす影響の検証, 第111回日本内科学会講演会, Apr. 2014.
412.	Munehide Matsuhisa : 低血糖の科学的側面と社会的側面, 第48回糖尿病学の進歩, Mar. 2014.
413.	Munehide Matsuhisa : 変貌する糖尿病治療と糖尿病対策, 第82回大阪透析研究会, Mar. 2014.
414.	Munehide Matsuhisa : 個別化をめざす糖尿病治療∼高齢糖尿病患者の特徴からみた治療のあり方∼, 第25回日本老年医学会四国地方会教育講演, Feb. 2014.
415.	森本佳奈, Ken-ichi Aihara, 大黒由加里, 倉橋清衛, Takeshi Kondo, Mizuho Kinouchi, Motoyuki Tamaki, 安芸菜奈子, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Toshio Matsumoto : 6年間にわたる多剤併用降圧療法が心・腎・大血管障害の改善に寄与した高レニン性高血圧症の1例, 第248回徳島医学会学術集会, Feb. 2014.
416.	大黒由加里, Takeshi Kondo, 倉橋清衛, 安芸菜奈子, Akio Kuroda, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto : 下垂体の経時的な変化を捉えたシーハン症候群の一例, 第23回臨床内分泌代謝Update, Jan. 2014.
417.	Hwa In, Akio Kuroda, Yuu Tamaki, Masato Tagi, Hiroki Moriguchi, Toshio Matsumoto, Yuichi Fujinaka, 安藝宏信, Tomiaki Morikawa and Munehide Matsuhisa : ITを活用した徳島県糖尿病医療連携システム構築のこころみ, 日本先進糖尿病治療研究会雑誌, Vol.9, 47, Jan. 2014.
418.	Akio Kuroda, Takeshi Kondo, 安田哲行, 高原充佳, Ken-ichi Aihara, Itsuro Endo, 金藤秀明, 下村伊一郎, Toshio Matsumoto and Munehide Matsuhisa : インスリンポンプ療法での追加インスリン注入時間を規定する因子の検討, 第13回日本先進糖尿病治療研究会, Nov. 2013.
419.	大和光, 瀧川稲子, Akiko Matsumura, 山田静恵, 谷佳子, Ken-ichi Aihara, Toshio Matsumoto, Hwa In, Akio Kuroda and Munehide Matsuhisa : 徳島大学病院における糖尿病透析予防指導の有用性の検討, 日本糖尿病学会中国四国地方会第51回総会, Nov. 2013.
420.	大黒由加里, Takeshi Kondo, Akio Kuroda, 倉橋清衛, Mizuho Kinouchi, 安芸菜奈子, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto : 過剰基礎インスリン量が不適切な間食摂取に関連したインスリンポンプ使用1型糖尿病の2例, 日本糖尿病学会中国四国地方会第51回総会, Nov. 2013.
421.	Munehide Matsuhisa : 糖尿病の治療の今，そしてこれから, 日本糖尿病学会中国四国地方会第51回総会, Nov. 2013.
422.	松本幸恵, Akio Kuroda, 秋田賢子, 鶴尾美穂, Mizuho Kinouchi, Takeshi Kondo, Tomoyuki Yuasa, Munehide Matsuhisa, Toshio Matsumoto and 寺澤敏秀 : 主食の摂取状況調査, 日本糖尿病学会中国四国地方会第51回総会, Nov. 2013.
423.	Takeshi Kondo, 大黒由加里, Akio Kuroda, 倉橋清衛, Mizuho Kinouchi, 安芸菜奈子, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto : テストステロン補充で速やかにインスリン抵抗性が改善した汎下垂体機能低下症合併糖尿病例, 日本糖尿病学会中国四国地方会第51回総会, Nov. 2013.
424.	Ken-ichi Aihara, Mizuho Kinouchi, 大黒由加里, Takeshi Kondo, 倉橋清衛, 安藝菜奈子, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Toshio Matsumoto : メタボリックシンドロームおよび糖尿病の有無が血管内皮機能に及ぼす影響, 日本糖尿病学会中国四国地方会第51回総会, Nov. 2013.
425.	Takeshi Kondo, 大黒由加里, Akio Kuroda, 倉橋清衛, Mizuho Kinouchi, 安芸菜奈子, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto : テストステロン補充で速やかにインスリン抵抗性が改善した汎下垂体機能低下症合併糖尿病例, 日本糖尿病学会中国四国地方会第51回総会, Nov. 2013.
426.	Ken-ichi Aihara, Mizuho Kinouchi, Sumiko Yoshida, 大黒由加里, 倉橋清衛, Takeshi Kondo, 安藝菜奈子, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Toshio Matsumoto : 糖代謝異常の血管機能評価に及ぼす効果, 第36回日本高血圧学会総会, Oct. 2013.
427.	Yuu Tamaki, Masato Tagi, Ken-ichiro Shimai, Munehide Matsuhisa and Hiroki Moriguchi : 1-A-8 徳島県における病病・病診連携システムの構築(企業事例交流会(2)), 日本オペレーションズ・リサーチ学会秋季研究発表会アブストラクト集, Sep. 2013.
428.	大黒由加里, Takeshi Kondo, Shiroh Fujii, Shingen Nakamura, 倉橋清衛, Akio Kuroda, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto : 著名な汎血球減少と肝筋逸脱酵素高値を呈した神経性食欲不振症の一例, 第13回日本内分泌学会四国支部学術集会, Sep. 2013.
429.	Takeshi Kondo, 岩佐昌美, 大黒由加里, 倉橋清衛, Akio Kuroda, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto : 不動が惹起した高カルシウム血症で頻回の意識障害を来たした一例, 第13回日本内分泌学会四国支部学術集会, Sep. 2013.
430.	鈴木麗子, 大和光, 瀧川稲子, Ken-ichi Aihara, Itsuro Endo, 安芸菜奈子, 倉橋清衛, Toshio Matsumoto, Akio Kuroda and Munehide Matsuhisa : フットケア外来におけるインスリン皮下硬結の実態調査と皮下硬血患者への介入の結果報告, 第13回日本糖尿病情報学会年次学術集会, Aug. 2013.
431.	Mizuho Kinouchi, Ken-ichi Aihara, Sumiko Yoshida, 大黒由加里, 倉橋清衛, Takeshi Kondo, 安藝菜奈子, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Toshio Matsumoto : 臨床血管機能における糖代謝異常の影響の解析, 第247回徳島医学会学術集会, Aug. 2013.
432.	Ken-ichi Aihara, Mizuho Kinouchi, Sumiko Yoshida, 岩佐昌美, 倉橋清衛, Takeshi Kondo, 安藝菜奈子, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Toshio Matsumoto : Evaluation for influence of diabetes on clinical vascular function, 第45回日本動脈硬化学会総会・学術集会, Jul. 2013.
433.	Ken-ichi Aihara, Toshio Matsumoto, Munehide Matsuhisa and 大和光 : 血管年齢を正確に知ってアンチエイジング!, 第13回日本抗加齢医学会総会, Jun. 2013.
434.	鈴木麗子, 瀧川稲子, 大和光, 菊恵木田, Ken-ichi Aihara, Itsuro Endo, 安芸菜奈子, 倉橋清衛, Toshio Matsumoto, Akio Kuroda and Munehide Matsuhisa : フットケア外来におけるインスリン皮下硬結の実態調査と皮下硬結患者への介入の有用性検討, 第56回日本糖尿病学会年次学術集会, May 2013.
435.	藤島周子, 森岡隆子, 高田妙子, 岩谷沙紀, 斎村玉緒, 秋田賢子, 松本幸恵, Takeshi Kondo, Sumiko Yoshida, Tomoyuki Yuasa, 鶴尾美穂, Akio Kuroda, Munehide Matsuhisa, Toshio Matsumoto and 寺澤敏秀 : 当院の参加型糖尿病教室の取り組み, 第56回日本糖尿病学会年次学術集会, May 2013.
436.	伊澤真弓, Akio Kuroda, 上野裕子, 堀筋富士子, 鶴尾美穂, Sumiko Yoshida, Takeshi Kondo, Tomoyuki Yuasa, Munehide Matsuhisa, Toshio Matsumoto and 寺澤敏秀 : インスリン注入器に関する患者の意識調査, 第56回日本糖尿病学会年次学術集会, May 2013.
437.	河盛隆造, Munehide Matsuhisa, 綿田裕孝, 栗林伸一 and VISION研究会 : DPP-4 阻害薬ビルダグリプチン長期投与による有効性と安全性:VISION研究, 第56回日本糖尿病学会年次学術集会, May 2013.
438.	鶴尾美穂, Akio Kuroda, Sumiko Yoshida, Takeshi Kondo, Tomoyuki Yuasa, Toshio Matsumoto, Munehide Matsuhisa and 寺澤敏秀 : インスリン治療患者に対するチーム医療で行う段階的糖尿病療養指導の試み, 第56回日本糖尿病学会年次学術集会, May 2013.
439.	Akio Kuroda, 鶴尾美穂, Ken-ichi Aihara, Itsuro Endo, 安芸菜奈子, Sumiko Yoshida, Takeshi Kondo, Toshio Matsumoto and Munehide Matsuhisa : 1型糖尿病患者におけるインスリングラルギンからインスリンデグルデッグへの同量での切り替え:CGMSを用いた検討, 第56回日本糖尿病学会年次学術集会, May 2013.
440.	Tomoyuki Yuasa, Munehide Matsuhisa, 橋田誠一 and Yousuke Ebina : 可溶性インスリン受容体が担うインスリン抵抗性の可能性, 第56回日本糖尿病学会年次学術集会特別シンポジウム3, May 2013.
441.	下直樹, 安田哲行, 片上直人, Akio Kuroda, 坂本賢哉, 坂本扶美枝, 山本裕一, 大澤彩恵子, 辻真由美, 嵩龍一, 高原佳充, 宮下和幸, 宮塚健, 河盛段, 吉内和富, 松岡孝昭, 金藤秀明, 小杉圭右, 下村伊一郎 and Munehide Matsuhisa : 若年発症1型糖尿病患者における血清25(OH)D3濃度と血管合併症との関連, 第56回日本糖尿病学会年次学術集会, May 2013.
442.	Takeshi Kondo, Akio Kuroda, Sumiko Yoshida, 安芸菜奈子, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto : 頻回インスリン療法による厳格な血糖管理下におけるシダグリプチン併用のインスリン所要量現象効果の検討, 第56回日本糖尿病学会年次学術集会ポスター, May 2013.
443.	奥村滋子, Akio Kuroda, 片田英子, 澤井敏子, 鶴尾美穂, Sumiko Yoshida, Takeshi Kondo, Tomoyuki Yuasa, Munehide Matsuhisa, Toshio Matsumoto and 寺澤敏秀 : 運転中の低血糖についての意識調査, 第56回日本糖尿病学会年次学術集会, May 2013.
444.	Yumi Kuwamura, 松田宣子, Ayako Tamura, Takako Ichihara, Takako Minagawa, hikari yamato, Akiyo Kanazawa, Ken-ichi Aihara, kiyoe kurahashi, Sumiko Yoshida, Masami Yoshioka, Daisuke Hinode, Munehide Matsuhisa and Akio Kuroda : 糖尿病患者の口腔保健行動に及ぼす影響要因の検討―第1報口腔保健行動に対する認識との関係から―, 第56回日本糖尿病学会年次学術集会, Vol.56, No.Supplement 1, S-167, May 2013.
445.	Takeshi Kondo, Akio Kuroda, 曽我部公子, Sumiko Yoshida, 安藝菜奈子, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto : 術前後で持続血糖測定(CGM)を比較しえたアドレナリン優位褐色細胞腫の1例, 第56回日本糖尿病学会年次学術集会, May 2013.
446.	下直樹, 安田哲行, 片上直人, Akio Kuroda, 坂本賢哉, 坂本扶美枝, 山本裕一, 大澤彩恵子, 辻真由美, 嵩龍一, 高原佳充, 宮下和幸, 宮塚健, 河盛段, 吉内和富, 松岡孝昭, 金藤秀明, 小杉圭右, Munehide Matsuhisa and 下村伊一郎 : 若年発症1型糖尿病患者における血清25(OH)D3濃度と血管合併症との関連, 第86回日本内分泌学会学術総会, Apr. 2013.
447.	松本和久, Sumiko Yoshida, Ken-ichi Aihara, 岩佐昌美, Takeshi Kondo, 倉橋清衛, Mizuho Kinouchi, Itsuro Endo, 安芸菜奈子, Akio Kuroda, Munehide Matsuhisa and Toshio Matsumoto : 膵臓の鉄過剰沈着とインスリン分泌不全を呈した無セルロプラスミン血症合併糖尿病の1例, 第86回日本内分泌学会学術総会, Apr. 2013.
448.	安田哲行, 片上直人, Akio Kuroda, 坂本賢哉, 坂本扶美枝, 下直樹, 山本裕一, 大澤彩恵子, 辻真由美, 嵩龍一, 高原佳充, 宮下和幸, 宮塚健, 河盛段, 吉内和富, 松岡孝昭, 金藤秀明, 小杉圭右, Munehide Matsuhisa and 下村伊一郎 : 自己免疫性甲状腺疾患を合併した1型糖尿病患者における血清ビタミンD濃度の検討, 第86回日本内分泌学会学術総会, Apr. 2013.
449.	松本和久, Ken-ichi Aihara, Sumiko Yoshida, Mizuho Kinouchi, Takeshi Kondo, 倉橋清衛, 安藝菜奈子, Itsuro Endo, Akio Kuroda, Munehide Matsuhisa and Toshio Matsumoto : 膵臓の鉄過剰沈着とインスリン分泌不全を呈した無セルロプラスミン血症合併糖尿病の1例, 第86回日本内分泌学会学術総会, Apr. 2013.
450.	佐藤千穂, 冨岡麗子, 山上真樹子, 宮本登志子, Munehide Matsuhisa, Hiroshi Kitahata, Eiji Takeda, Hiro-omi Kanayama, Hiroaki Yanagawa, 木下成三 and 川島周 : 徳島県内の医療機関における倫理審査体制に関する状況調査, 第246回徳島医学会学術集会, Feb. 2013.
451.	曽我部公子, Takeshi Kondo, Akio Kuroda, Sumiko Yoshida, Nanako Kataoka, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto : 術前後で持続血糖測定(CGM)を比較しえた褐色細胞腫の一例, 第22回臨床内分泌代謝Update, Jan. 2013.
452.	牟田口惇, Takeshi Kondo, Itsuro Endo, Sumiko Yoshida, Nanako Kataoka, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto : 尿細管性アシドーシスの診断にアミノレバンが有用であった一例, 第22回臨床内分泌代謝Update, Jan. 2013.
453.	幸田舞子, Takeshi Kondo, Itsuro Endo, Sumiko Yoshida, Nanako Kataoka, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto : 悪性症候群様の症状から診断されたACTH分泌低下症の一例, 第22回臨床内分泌代謝Update, Jan. 2013.
454.	松崎苑美, Ken-ichi Aihara, Sumiko Yoshida, 倉橋清衛, Takeshi Kondo, Itsuro Endo, Toshio Matsumoto, Nanako Kataoka, Akio Kuroda and Munehide Matsuhisa : 血栓性微小血管障害症様の病態を示したメタボリックシンドロームの1例, 第107回日本内科学会四国地方会, Dec. 2012.
455.	佐埜弘樹, Ken-ichi Aihara, Sumiko Yoshida, Takeshi Kondo, 倉橋清衛, Itsuro Endo, Toshio Matsumoto, Akio Kuroda, Munehide Matsuhisa and Nanako Kataoka : 正常MRI所見を示し，ADH放出障害が主因と考えられた中枢性尿崩症の1例, 日本内科学会第107回四国地方会, Dec. 2012.
456.	Akio Kuroda, 新居沙央里, Sumiko Yoshida, 近藤絵里, Itsuro Endo, Ken-ichi Aihara, 松本友里, Nanako Kataoka, Toshio Matsumoto and Munehide Matsuhisa : 新たなインスリンポンプParadigm722によってカーボカウントのみで血糖管理が可能となった1症例, 第12回日本先進糖尿病治療学会研究会, Dec. 2012.
457.	Akio Kuroda, 高原充佳, 安田哲行, 松岡孝昭, Takeshi Kondo, Itsuro Endo, Ken-ichi Aihara, Sumiko Yoshida, Toshio Matsumoto, 下村伊一郎, 金藤秀明 and Munehide Matsuhisa : 日本人1型糖尿病患者における「500ルールとは?」, 第12回日本先進糖尿病治療研究会, Dec. 2012.
458.	Rumi Katashima, 佐藤千穂, 冨岡麗子, 山上真樹子, 宮本登志子, 木下成三, 川島周, Munehide Matsuhisa, Hiroshi Kitahata, Eiji Takeda, Hiro-omi Kanayama and Hiroaki Yanagawa : 徳島県内の医療機関における倫理審査体制に関する状況調査, 第33回日本臨床薬理学会年会, Nov. 2012.
459.	幸田舞子, Takeshi Kondo, Akio Kuroda, Sumiko Yoshida, 安芸菜奈子, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto : シタグリプチン投与によりインスリン所要量の減少効果が得られた高齢2型糖尿病の一例, 日本糖尿病学会中国四国地方会第50回総会, Nov. 2012.
460.	Takeshi Kondo, Akio Kuroda, 曽我部公子, Sumiko Yoshida, 安芸菜奈子, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto : 術前後で持続血糖測定(CGM)を比較しえたアドレナリン優位褐色細胞腫の一例, 日本糖尿病学会中国四国地方会第50回総会, Nov. 2012.
461.	Takeshi Kondo, Akio Kuroda, 曽我部公子, Sumiko Yoshida, 安芸菜奈子, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto : アドレナリン優位の褐色細胞腫の術前後で持続血糖測定(CGM)により血糖変動を比較した一例, 日本糖尿病学会中国四国地方会第50回総会, Nov. 2012.
462.	伊澤真弓, Akio Kuroda, 上野裕子, 鶴尾美穂, Sumiko Yoshida, Takeshi Kondo, Tomoyuki Yuasa, Munehide Matsuhisa, Toshio Matsumoto and 寺澤敏秀 : インスリン注入器に関する患者の意識調査, 日本糖尿病学会中国四国地方会第50回総会, Nov. 2012.
463.	幸田舞子, Takeshi Kondo, Akio Kuroda, Sumiko Yoshida, Nanako Kataoka, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto : シタグリプチン投与によりインスリン所要量の減少効果が得られた高齢2型糖尿病の一例, 日本糖尿病学会中国四国地方会第50回総会, Nov. 2012.
464.	岩佐昌美, Akio Kuroda, Sumiko Yoshida, Takeshi Kondo, Nanako Kataoka, Itsuro Endo, Ken-ichi Aihara, 福島泰江, Munehide Matsuhisa and Toshio Matsumoto : 血糖管理基準を満たすために分割食を必要としなかった2型糖尿病合併妊娠の1例, 日本糖尿病学会中国四国地方会第50回総会, Nov. 2012.
465.	奥村滋子, Akio Kuroda, 片田英子, 鶴尾美穂, Sumiko Yoshida, Takeshi Kondo, Tomoyuki Yuasa, 松本直也, 笠松哲司, Munehide Matsuhisa, Toshio Matsumoto and 寺澤敏秀 : 運転中の低血糖についての意識調査, 日本糖尿病学会中国四国地方会第50回総会, Nov. 2012.
466.	Masato Tagi, Yuu Tamaki, Munehide Matsuhisa, Ken-ichiro Shimai and Hiroki Moriguchi : ICTを活用した健康データの見える化による行動変容に関する研究, 医療情報学連合大会論文集, Vol.32, 518-519, Nov. 2012.
467.	Munehide Matsuhisa : 糖尿病大血管症における体質と遺伝素因, 第62回日本体質医学会総会モーニングセミナー, Nov. 2012.
468.	Munehide Matsuhisa : 変貌する糖尿病医療の現場, Sep. 2012.
469.	白河綾, Ken-ichi Aihara, Sumiko Yoshida, 倉橋清衛, Takeshi Kondo, Itsuro Endo, 安藝菜奈子, Akio Kuroda, Munehide Matsuhisa and Toshio Matsumoto : 副腎不全症状を呈し，診断に苦慮した両側副腎B細胞リンパ腫の1例, 第12回日本内分泌学会四国支部学術集会, Sep. 2012.
470.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Yusuke Arakawa, Hiroki Mori, Mami Kanamoto and Munehide Matsuhisa : 四国地区モデルとしての徳島県の膵島移植待機患者の現状と問題点, 第48回日本移植学会総会, Sep. 2012. (Keyword) 国内学会
471.	Itsuro Endo, Sumiko Yoshida, 倉橋清衛, Mizuho Kinouchi, Nanako Kataoka, Takeshi Kondo, 近藤絵里, Ken-ichi Aihara, Toshio Matsumoto, Akio Kuroda and Munehide Matsuhisa : Werner症候群に伴う糖尿病の治療経過, 第106回日本内科学会四国地方会, Jun. 2012.
472.	Ken-ichi Aihara, Sumiko Yoshida, 倉橋清衛, Takeshi Kondo, 近藤絵里, Nanako Kataoka, Itsuro Endo, Akio Kuroda, Munehide Matsuhisa and Toshio Matsumoto : インクレチン関連薬を用いた周術期血糖管理の有用性, 第106回日本内科学会四国地方会, Jun. 2012.
473.	安田哲行, 藤澤慶子, Mayumi Tsuji, 宮下和幸, 嵩龍一, 佐藤利幸, 岡田正規, 小島順子, 渡辺敏弘, 細谷砂美子, 金藤秀明, Munehide Matsuhisa, 下村伊一郎 and 中島弘 : 微侵襲食後高血糖モニタリングシステムの性能評価, 第55回日本糖尿病学会年次学術集会, May 2012.
474.	Munehide Matsuhisa and 河盛隆造 : DPP-阻害薬ビルダグリプチンのHbA1c変化と体重変化の関連性(VISION研究), 第55回日本糖尿病学会年次学術集会, May 2012.
475.	大橋博, Munehide Matsuhisa and 河盛隆造 : 高齢者の2型糖尿病患者でのDPP-4阻害薬ビルダグリプチンの有効性, 第55回日本糖尿病学会年次学術集会, May 2012.
476.	日吉徹, Munehide Matsuhisa and 河盛隆造 : グリコアルブミンによるDPP-4阻害薬ビルダグリプチンの有効性の評価, 第55回日本糖尿病学会年次学術集会, May 2012.
477.	島健二, 新谷保実, 福島泰江, Yoshihiko Noma, Munehide Matsuhisa, 小松まち子, 鶴尾美穂, 白神敦久, Yuichi Fujinaka, Hiroko Ishimoto and 播紀子 : 糖尿病死亡率ワーストワンからの脱却を目指してー糖尿病対策活動の成果ー, 第55回日本糖尿病学会年次学術集会, May 2012.
478.	管野一男, Munehide Matsuhisa and 河盛隆造 : DPP-4阻害薬ブルダグリプチンの血糖低下作用はスルホニル尿素薬間で差はない, 第55回日本糖尿病学会年次学術集会, May 2012.
479.	片上直人, 金藤秀明, 松岡孝昭, 高原充佳, 前田法一, 清水一紀, 大野敬三, 遅野井健, 川井紘一, 石橋不可止, 今村憲一, Atsunori kasiwagi, 河盛隆造, Munehide Matsuhisa, 船橋徹, 山﨑義光 and 下村伊一郎 : 2型糖尿病患者においてadiponectin遺伝子G276T多型は心血管疾患と関連する, 第55回日本糖尿病学会年次学術集会, May 2012.
480.	加藤健一郎, 竹下有美枝, 御簾博文, 太田嗣人, 徳山薫平, Munehide Matsuhisa, 長坂昌一郎, 金子周一 and 篁俊成 : 臓器特異的インスリン抵抗性(IR)指標の妥当性および肝病理像との関連, 第55回日本糖尿病学会年次学術集会, May 2012.
481.	鶴尾美穂, 寺澤敏秀, 木戸里佳, Sumiko Yoshida, Tomoyuki Yuasa, Takeshi Kondo, 笠松哲司, 近藤絵里, Mizuho Kinouchi, Akio Kuroda, Munehide Matsuhisa, Toshio Matsumoto and Masashi Akaike : 粥状動脈硬化病変を呈した高Lp(a)血症合併糖尿病の姉妹例, 第55回日本糖尿病学会年次学術集会, May 2012.
482.	坂本芙美枝, 片上直人, 高原充佳, 宮下和幸, 山本かをる, Akio Kuroda, 坂本賢哉, Munehide Matsuhisa, 小杉圭右, 金藤秀明 and 下村伊一郎 : 1型糖尿病におけるIMT進展に関連する因子の検討, 第55回日本糖尿病学会年次学術集会, May 2012.
483.	上野裕子, 堀筋富士子, 森岡隆子, 鶴尾美穂, Tomoyuki Yuasa, 木戸里佳, Sumiko Yoshida, Mizuho Kinouchi, Takeshi Kondo, 近藤絵里, 笠松哲司, Akio Kuroda, Munehide Matsuhisa, Toshio Matsumoto and 寺澤敏秀 : サイトローテーションシート(SLS)を使用したインスリン自己注射の指導, 第55回日本糖尿病学会年次学術集会, May 2012.
484.	秋田賢子, 鶴尾美穂, 木戸里佳, Sumiko Yoshida, 近藤絵里, Mizuho Kinouchi, Takeshi Kondo, 笠松哲司, Tomoyuki Yuasa, Akio Kuroda, Munehide Matsuhisa, Toshio Matsumoto and 寺澤敏秀 : カーボカウントを導入した高齢1型糖尿病の3例, 第55回日本糖尿病学会年次学術集会, May 2012.
485.	Miwa Yamaguchi, Yumiko Kotani, Akiko Matsumura, Ichiro Yokota, Shoji Kagami, Kokichi Arisawa, Akio Kuroda and Munehide Matsuhisa : 学校給食の副食糖質量の検討, 第55回日本糖尿病学会年次学術集会, May 2012.
486.	Akio Kuroda, 宮下和幸, 川嶋聡, 安田哲行, 松岡孝昭, 金藤秀明, 山﨑義光, 下村伊一郎 and Munehide Matsuhisa : 内因性インスリン分泌能残存と糖尿病合併症進展の関連についての検討, 第55回日本糖尿病学会年次学術集会, May 2012.
487.	Akio Kuroda and Munehide Matsuhisa : カーボカウント活用∼医師の立場から∼, 第55回日本糖尿病学会年次学術集会, May 2012.
488.	大黒由加里, Ken-ichi Aihara, Sumiko Yoshida, 近藤絵里, Takeshi Kondo, 倉橋清衛, Mizuho Kinouchi, Itsuro Endo, Nanako Kataoka, Akio Kuroda, Munehide Matsuhisa and Toshio Matsumoto : 摂食障害による著明な低K血症を呈した視床下部性ACTH分泌低下症の1例, 第85回日本内分泌学会学術総会, Apr. 2012.
489.	Munehide Matsuhisa : 病態に基づいた2型糖尿病のありかた, 第85回日本内分泌学会学術総会, Apr. 2012.
490.	Sumiko Yoshida, Ken-ichi Aihara, 近藤絵里, 倉橋清衛, Takeshi Kondo, Mizuho Kinouchi, Itsuro Endo, Toshio Matsumoto, Nanako Kataoka, Akio Kuroda and Munehide Matsuhisa : 糖尿病はHDLコレステロールによる血管内皮機改善効果を減弱させる, 第85回日本内分泌学会学術総会, Apr. 2012.
491.	Ken-ichi Aihara, Sumiko Yoshida, 近藤絵里, Takeshi Kondo, 倉橋清衛, Mizuho Kinouchi, Itsuro Endo, Nanako Kataoka, Akio Kuroda, Munehide Matsuhisa and Toshio Matsumoto : ヘパリンコファクターⅡは耐糖能制御因子である, 第85回日本内分泌学会学術総会, Apr. 2012.
492.	Sumiko Yoshida, Yuichi Fujinaka, Ken-ichi Aihara, 鈴木麗子, Mizuho Kinouchi, 近藤絵里, 安藝菜奈子, Itsuro Endo, Akio Kuroda, Munehide Matsuhisa and Toshio Matsumoto : 当院検診受診者における耐糖能異常の特徴, 第109回日本内科学会総会・講演会, Apr. 2012.
493.	立花綾香, 田岡志保, 荻野寛隆, 高橋真美子, Ken-ichi Aihara, Sumiko Yoshida, Itsuro Endo, Akio Kuroda, Munehide Matsuhisa, 福森智治 and Toshio Matsumoto : 低血圧で推移したvon Hippel-Lindau 病・褐色細胞腫の1手術例, 第21回臨床内分泌代謝Update in Hamamatsu, Jan. 2012.
494.	田岡志保, 立花綾香, 荻野寛隆, 高橋真美子, Ken-ichi Aihara, Sumiko Yoshida, 近藤絵里, 倉橋清衛, Itsuro Endo, Toshio Matsumoto, Nanako Kataoka, Akio Kuroda and Munehide Matsuhisa : 周術期血糖管理にリラグルチドが有用であった2型糖尿病患者の2例, 第21回臨床内分泌代謝Update in Hamamatsu, Jan. 2012.
495.	Miwa Yamaguchi, Yumiko Kotani, Akio Kuroda, Ichiro Yokota, Munehide Matsuhisa, Kokichi Arisawa and Shoji Kagami : 徳島市学校給食の副食糖質量の検討, 第15回日本病態栄養学会年次学術集会, Jan. 2012.
496.	Miwa Yamaguchi, Akiko Matsumura, Yumiko Kotani, Akio Kuroda, Ichiro Yokota, Munehide Matsuhisa, Kokichi Arisawa and Shoji Kagami : 外来栄養指導でカーボカウントの継続が見られた例, 第15回日本病態栄養学会年次学術集会, Jan. 2012.
497.	Rumi Katashima, 佐藤千穂, 丸笹美津子, 明石晃代, 高井繁美, 宮本登志子, 山上真樹子, Munehide Matsuhisa, Hiroshi Kitahata, Eiji Takeda, Hiro-omi Kanayama and Hiroaki Yanagawa : 徳島大学病院における臨床研究推進体制構築の試み, 第32回日本臨床薬理学会年会, Dec. 2011.
498.	Akio Kuroda, 新居沙央理, Sumiko Yoshida, 近藤絵里, Itsuro Endo, Ken-ichi Aihara, 松本友里, Nanako Kataoka, Toshio Matsumoto and Munehide Matsuhisa : 新たなインスリンポンプParadigm722によってカーボカウントのみで血糖管理が可能となった1症例, 第11回日本先進糖尿病治療研究会, Nov. 2011.
499.	木戸里佳, 鶴尾美穂, Akio Kuroda, Sumiko Yoshida, Tomoyuki Yuasa, 瀬尾浩二, 笠松哲司, Toshio Matsumoto, Munehide Matsuhisa and 寺沢敏秀 : カーボカウント併用CS11療法が有効であった高齢発症1型糖尿病症例, 日本糖尿病学会中国四国地方会第49回総会, Nov. 2011.
500.	新居沙央里, Akio Kuroda, Sumiko Yoshida, 近藤絵里, Itsuro Endo, Ken-ichi Aihara, 松本友里, Nanako Kataoka, Munehide Matsuhisa and Toshio Matsumoto : 新たなインスリンポンプParadigm722によりカーボカウントのみで血糖管理が可能となった1例, 日本糖尿病学会中国四国地方会第49回総会, Nov. 2011.
501.	Miwa Yamaguchi, Yumiko Kotani, Ichiro Yokota, Akio Kuroda, Munehide Matsuhisa, Kokichi Arisawa and Shoji Kagami : 学校給食の副食糖質量の検討, 日本糖尿病学会中国四国地方会第49回総会, Nov. 2011.
502.	堀筋富士子, 森岡隆子, 片田英子, 鶴尾美穂, 木戸里佳, Tomoyuki Yuasa, Akio Kuroda, Munehide Matsuhisa, Toshio Matsumoto and 寺沢敏秀 : サイトローテーションシート(SLS)を使用したインスリン自己注射の指導, 日本糖尿病学会中国四国地方会第49回総会, Nov. 2011.
503.	秋田賢子, 木戸里佳, 鶴尾美穂, Sumiko Yoshida, Mizuho Kinouchi, Tomoyuki Yuasa, Akio Kuroda, Munehide Matsuhisa, Toshio Matsumoto and 寺沢敏秀 : カーボカウントを導入した高齢1型糖尿病の3例, 日本糖尿病学会中国四国地方会第49回総会, Nov. 2011.
504.	Mizuho Kinouchi, Ken-ichi Aihara, Yuichi Fujinaka, 鈴木麗子, Sumiko Yoshida, 近藤絵里, Itsuro Endo, Akio Kuroda, Munehide Matsuhisa and Toshio Matsumoto : 内臓脂肪肥満とアルブミン尿の連関に関する検討, 日本糖尿病学会中国四国地方会第49回総会, Nov. 2011.
505.	鶴尾美穂, 寺沢敏秀, 木戸里佳, Tomoyuki Yuasa, Sumiko Yoshida, 笠松哲司, Akio Kuroda, Munehide Matsuhisa, Toshio Matsumoto and Masashi Akaike : 粥状動脈硬化病変を呈した糖尿病合併高Lp(a)血症の姉妹例, 日本糖尿病学会中国四国地方会第49回総会, Nov. 2011.
506.	鈴木麗子, 大和光, 菊恵木田, Ken-ichi Aihara, Itsuro Endo, Nanako Kataoka, 近藤絵里, Toshio Matsumoto, Akio Kuroda and Munehide Matsuhisa : フットケア外来におけるインスリン皮下硬結の実態調査, 日本糖尿病学会中国四国地方会第49回総会, Nov. 2011.
507.	Ken-ichi Aihara, Yuichi Fujinaka, 鈴木麗子, Mizuho Kinouchi, Sumiko Yoshida, 近藤絵里, Nanako Kataoka, 倉橋清衛, Itsuro Endo, Akio Kuroda, Munehide Matsuhisa and Toshio Matsumoto : 慢性腎臓病と内臓脂肪蓄積病態の連関, 第32回日本肥満学会, Sep. 2011.
508.	Sumiko Yoshida, Yuichi Fujinaka, Ken-ichi Aihara, 鈴木麗子, Mizuho Kinouchi, 近藤絵里, Nanako Kataoka, 倉橋清衛, Itsuro Endo, Akio Kuroda, Munehide Matsuhisa and Toshio Matsumoto : メタボリックシンドローム検診受診者における耐糖能異常の検討, 第32回日本肥満学会, Sep. 2011.
509.	Ken-ichi Aihara, Sumiko Yoshida, 近藤絵里, 倉橋清衛, Takeshi Kondo, Mizuho Kinouchi, Itsuro Endo, Toshio Matsumoto, Nanako Kataoka, Akio Kuroda and Munehide Matsuhisa : 慢性腎臓病におけるエイコサペンタエン酸の意義に関する臨床的検討, 第11回日本内分泌学会四国支部学術集会, Sep. 2011.
510.	井本逸勢, 鎌田正晴, 石本寛子, 野間喜彦, 白神敦久, 前田実知代 and Munehide Matsuhisa : 徳島県における健康保持増進体制-糖尿病の見地から-職場における健康づくりの事例(ITを利用した職場との連携)-徳島県の新しい糖尿病医療連携を目指す試み-, 第243回徳島医学会学術集会, Jul. 2011.
511.	Miwa Yamaguchi, Yumiko Kotani, Ichiro Yokota, Akio Kuroda, Munehide Matsuhisa and Shoji Kagami : 小児期発症1型糖尿病患者へのカーボカウント教育の試み, 小児思春期糖尿病学会, Jul. 2011.
512.	Munehide Matsuhisa : IMTを活用した糖尿病大血管症のリスク評価とバイオマーカの探索, 第54回日本糖尿病学会年次学術集会, May 2011.
513.	Munehide Matsuhisa : グリコアルブミンの新展開, 第54回日本糖尿病学会年次学術集会, May 2011.
514.	木戸里佳, Mizuho Kinouchi, Sumiko Yoshida, Tomoyuki Yuasa, 瀬尾浩二, 笠松哲司, Toshio Matsumoto, Munehide Matsuhisa, 鶴尾美穂 and 寺沢敏秀 : カーボカウント併用CSⅡ療法が用効であった高齢発症1型糖尿病の2症例, 第54回日本糖尿病学会年次学術集会, May 2011.
515.	森岡隆子, 上野裕子, 堀筋富士子, 澤井敏子, 藤島周子, 奥村滋子, 伊澤真弓, 片田英子, 秋田賢子, 木戸里佳, Sumiko Yoshida, Mizuho Kinouchi, 笠松哲司, Tomoyuki Yuasa, 鶴尾美穂, 寺沢敏秀, Munehide Matsuhisa and Toshio Matsumoto : インスリン治療を行っている高齢糖尿病患者の療養指導について, 第54回日本糖尿病学会年次学術集会, May 2011.
516.	片上直人, 金藤秀明, 松岡孝昭, 高原充佳, 今村憲市, 石橋不可止, 神田勤, 川井紘一, 遅野井健, Atsunori kasiwagi, 河盛隆造, Munehide Matsuhisa, 山崎義光 and 下村伊一郎 : 酸化ストレスに関連する遺伝子多型の集積は心筋梗塞に関連する, 第54回日本糖尿病学会年次学術集会, May 2011.
517.	坂本扶美枝, 片上直人, 高原充佳, Akio Kuroda, 安田哲行, 松岡孝昭, Munehide Matsuhisa, 金藤秀明 and 下村伊一郎 : 若年1型糖尿病におけるYKL-40測定の有用性についての検討, 第54回糖尿病学会年次学術集会, May 2011.
518.	Akio Kuroda and Munehide Matsuhisa : 1型糖尿病以外の糖尿病とカーボカウント, 第54回日本糖尿病学会年次学術集会, May 2011.
519.	Sumiko Yoshida, 大政暁, Ken-ichi Aihara, 倉橋清衛, Takeshi Kondo, Nanako Kataoka, Itsuro Endo, Yuichi Fujinaka, Munehide Matsuhisa and Toshio Matsumoto : 強化インスリン療法からGLP-1アナログ製剤少量投与に変更し，良好な血糖コントロールが得られた1例, 第104回日本内科学会四国地方会, May 2011.
520.	津川愛, Ken-ichi Aihara, Sumiko Yoshida, Itsuro Endo, Yuichi Fujinaka, Munehide Matsuhisa and Toshio Matsumoto : DPP-4阻害薬シタグリプチンの臨床効果の特徴に関する検討, 第84回日本内分泌学会学術総会, Apr. 2011.
521.	Yuichi Fujinaka, 倉橋清衛, Mizuho Kinouchi, Sumiko Yoshida, Nanako Kataoka, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto : トリロスタン投与により内分泌学的な寛解状態が得られた異所性ACTH症候群一例, 第84回日本内分泌学会学術総会, Apr. 2011.
522.	Munehide Matsuhisa : 糖尿病の病態探索, 第84回日本内分泌学会学術総会モーニングセッション, Apr. 2011.
523.	門田宗之, Yuichi Fujinaka, 廣野友理, 倉橋清衛, Mizuho Kinouchi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto : 低ナトリウム血症で発症したトルコ鞍部腫瘍の一例, 第20回臨床内分泌代謝Update, Jan. 2011.
524.	安積麻衣, Ken-ichi Aihara, Sumiko Yoshida, 倉橋清衛, Mizuho Kinouchi, Nanako Kataoka, Itsuro Endo, Yuichi Fujinaka, Toshio Matsumoto and Munehide Matsuhisa : 2型糖尿病患者の左室拡張障害に対する強化インスリン療法の効果, 第10回日本内分泌学会四国支部学術集会, Sep. 2010.
525.	Munehide Matsuhisa : 病態に基づく糖尿病治療, 第10回日本内分泌学会四国支部学術集会, Sep. 2010.
526.	高原充佳, 飯田修, 五郎川伸一, 池田雅彦, 久保田稔, 金藤秀明, Munehide Matsuhisa and 下村伊一郎 : 糖尿病を有する重症虚血肢患者における予後規定因子の検討, 第53回日本糖尿病学会年次学術集会, May 2010.
527.	片上直人, 金藤秀明, 松岡孝昭, 高原充佳, 清水一紀, 大野敬三, 石橋不可止, 遅野井健, Atsunori kasiwagi, 河盛隆造, 下村伊一郎, Munehide Matsuhisa and 山崎義光 : プラークの破綻・凝固線溶系に関連する遺伝子多型の集積は脳梗塞に関連する, 第53回日本糖尿病学会年次学術集会, May 2010.
528.	川嶋聡, 松岡孝昭, 金藤秀明, 加藤研, 山本かをる, 嵩龍一, 栩野義博, Munehide Matsuhisa and 下村伊一郎 : 糖尿病治療薬の膵β細胞与える効果の検討, 第53回日本糖尿病学会年次学術集会, May 2010.
529.	沖田考平, 岩橋博見, 岡内幸義, 小澤純二, 米田祥, 芳川篤志, 山岡正弥, 樫根晋, 中川靖彦, 北村哲宏, 福井健司, 岸田堅, 大月道夫, Munehide Matsuhisa, 山縣和也, 船橋徹, 今川彰久 and 下村伊一郎 : インスリン治療中の2型糖尿病患者におけるインスリン感受性;インスリン負荷試験の有用性について, 第53回日本糖尿病学会年次学術集会, May 2010.
530.	松岡孝昭, 金藤秀明, 川嶋聡, 山本かをる, 加藤研, 山本恒彦, 吉内和富, 宮埼純一, Munehide Matsuhisa and 下村伊一郎 : 膵β細胞機能維持におけるMafAの重要性, 第53回日本糖尿病学会年次学術集会, May 2010.
531.	山本かをる, 松岡孝昭, 金藤秀明, 嵩龍一, 川嶋聡, 吉内和富, 片上直人, 山本恒彦, Munehide Matsuhisa and 下村伊一郎 : MafAの転写活性に影響を与える因子の検討, 第53回日本糖尿病学会年次学術集会, May 2010.

Et cetera, Workshop:

1.	Munehide Matsuhisa : 測ることからはじめる糖尿病の予防と治療, HbA1c認知向上運動での講演,
2.	Yuu Tamaki, Munehide Matsuhisa, Hiroyasu Mori and Satoshi Taniguchi : IHEITIを活用したID-Linkと連携した糖尿病向けPHRの研究開発, 第8回全国ID-Link研究会, Nov. 2019.
3.	Hiroyasu Mori, Akio Kuroda, Michiko Araki, Reiko Suzuki, Mami Ohishi, Satoshi Taniguchi, Motoyuki Tamaki, Yuko Akehi, Hiroshi Sakaue, Kiyoe Kurahashi, Takeshi Kondo, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki and Munehide Matsuhisa : Advanced glycation end-products are a risk for muscle weakness in patients with type2 diabetes., American Diabetes Association 78th Scientific Sessions, Jun. 2017.
4.	Akio Kuroda, Satoshi Taniguchi, Akehi Yuko, Hiroyasu Mori, Motoyuki Tamaki, Suzuki Reiko, Hwa In and Munehide Matsuhisa : The comparison of glucose readings of continuous glucose monitoring and bedside artificial pancreas during glucose clamp study, American Diabetes Association 76th Scientific Sessions, Jun. 2016.
5.	Akio Kuroda, Satoshi Taniguchi, Akehi Yuko, Hiroyasu Mori, Motoyuki Tamaki, Suzuki Reiko, Hwa In and Munehide Matsuhisa : The comparison of glucose readings of continuous glucose monitoring and bedside artificial pancreas during glucose clamp study, Advanced Technologiies & Treatments for Diabetes, Feb. 2016.
6.	Munehide Matsuhisa : 理想の体液と老化した体液, 脳心血管抗加齢研究会梅田スカイビル, Nov. 2015.
7.	Munehide Matsuhisa : 知ることから始まるアンチエイジング医療, 日本抗加齢医学会専門医・指導士認定委員会講習会大阪カレッジキャピタルコングレコンベンションセンター, Nov. 2015.
8.	Munehide Matsuhisa : CGMiPRO2と人工膵臓STG-55との測定グルコース濃度の比較, 第15回日本先進糖尿病治療研究会メルパルク京都, Nov. 2015.
9.	Munehide Matsuhisa, M. Koyama, X. Cheng, M. Sumi, T. Hirose and groups JP 1 study EDITION : Sustained glycaemic control and less nocturnal hypoglycaemia with new insulin glargine 300 U/mL versus glargine 100 U/mL over 1 year in Japanese people with T1DM, 第51回欧州糖尿病学会口演, Sep. 2015.
10.	Munehide Matsuhisa : 糖尿病の病態理解の深化と治療の進歩, 第45回中国四国大学保健管理研究集会徳島大学大塚講堂, Aug. 2015.
11.	Akio Kuroda, Tenma Jin, Horie Toru, Hiroyasu Mori, Motoyuki Tamaki, Ken-ichi Aihara and Munehide Matsuhisa : Non-invasive measurement of skin autofluorescence as a beneficial surrogate marker for atherosclerosis in patients with type 2 diabetes., 第75回アメリカ糖尿病学会ポスター発表, Jun. 2015.
12.	Munehide Matsuhisa : 変貌する糖尿病病態の概念とその対策, 第10回クッキーテスト研究会, May 2013.
13.	Akio Kuroda and Munehide Matsuhisa : 予防から重症合併症の治療，そして先進治療まで院内外で広範なチーム医療を展開する, DM Trend Journal, Vol.6, No.23, 6-7, Mar. 2013.
14.	Munehide Matsuhisa : 日本糖尿病協会の現状について, 日本糖尿病協会徳島県支部交流会での講演, May 2012.
15.	Munehide Matsuhisa : 進言糖尿病対策に待ったなし, 厚生福祉, No.5872, 9, Jan. 2012.
16.	Sumiko Yoshida, 近藤絵里, 倉橋清衛, Mizuho Kinouchi, Nanako Kataoka, Itsuro Endo, Ken-ichi Aihara, Toshio Matsumoto, Akio Kuroda and Munehide Matsuhisa : 当科での1型糖尿病に対するインスリンポンプ療法導入経験, 第17回徳島内分泌研究会, Nov. 2011.
17.	Munehide Matsuhisa : 肝臓が悪い時の糖尿病の養生法, 第3回徳島市医師会糖尿病市民フォーラムでの講演, Jun. 2011.
18.	Munehide Matsuhisa and Akio Kuroda : 1型糖尿病診療のUp to Date, 第1回AWA DM.comでの講演, Apr. 2011.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

Efficacy of self-management personal health record for diabetes care integrated by internet of things and smart speaker: confirmatory study (Project/Area Number: 21K11623 )
Novel method utilizing bisulfite conversion with dual amplification-refractory mutation system polymerase chain reaction to detect circulating pancreatic beta cell cfDNA. (Project/Area Number: 18K07448 )
The effect of nutritional guidance by teleconference system for patients with type 2 diabetes using dietary energy density and AR (Project/Area Number: 16K12723 )
Detection of pancreatic beta cell DNA in the circulation utilizing epigenetic modification (Project/Area Number: 15K06910 )
Development of the diabetes oral health assessment tool for nurses to help the patients with diabetes with their oral health behaviors simply (Project/Area Number: 26463305 )
Is angiogenesis in regenerative medicine influenced by vascular preconditioning? (Project/Area Number: 26462360 )
Is angiogenesis in regenerative medicine influenced by perioperative management methods? -effect of hyperglycemia- (Project/Area Number: 23592292 )
Molecular mechanism for pancreatic beta-cell glucose toxicity (Project/Area Number: 21591135 )
Evaluation for significant role of Mafa under Type2 diabetic conditions (Project/Area Number: 21591133 )
Role of oxidative stress and the JNK pathway in diabetes (Project/Area Number: 17390263 )
糖尿病再生医療に向けた類β細胞化の標的となりうる組織幹細胞の同定と解析 (Project/Area Number: 15039222 )
Search by Researcher Number (60362737)

Professor : Matsuhisa, Munehide

Research

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Academic Paper (Unrefereed Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Et cetera, Workshop:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)